<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Teriflunomide for multiple sclerosis - He, D - 2016 | Cochrane Library</title> <meta content="Teriflunomide for multiple sclerosis - He, D - 2016 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009882.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Teriflunomide for multiple sclerosis - He, D - 2016 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009882.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD009882.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Teriflunomide for multiple sclerosis" name="citation_title"/> <meta content="Dian He" name="citation_author"/> <meta content="Affiliated Hospital of Guizhou Medical University" name="citation_author_institution"/> <meta content="Chao Zhang" name="citation_author"/> <meta content="Jinan No. 6 People's Hospital" name="citation_author_institution"/> <meta content="Xia Zhao" name="citation_author"/> <meta content="Jinan No. 6 People's Hospital" name="citation_author_institution"/> <meta content="Yifan Zhang" name="citation_author"/> <meta content="Affiliated Hospital of Guizhou Medical University" name="citation_author_institution"/> <meta content="Qingqing Dai" name="citation_author"/> <meta content="Affiliated Hospital of Guizhou Medical University" name="citation_author_institution"/> <meta content="Yuan Li" name="citation_author"/> <meta content="Affiliated Hospital of Guizhou Medical University" name="citation_author_institution"/> <meta content="Lan Chu" name="citation_author"/> <meta content="Affiliated Hospital of Guizhou Medical University" name="citation_author_institution"/> <meta content="chulan8999@yeah.net" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="3" name="citation_issue"/> <meta content="10.1002/14651858.CD009882.pub3" name="citation_doi"/> <meta content="2016" name="citation_date"/> <meta content="2016/03/22" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009882.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009882.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009882.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Crotonates [adverse effects, *therapeutic use]; Hydroxybutyrates; Immunologic Factors [adverse effects, therapeutic use]; Immunosuppressive Agents [adverse effects, *therapeutic use]; Interferon‐beta [therapeutic use]; Multiple Sclerosis, Chronic Progressive [*drug therapy]; Multiple Sclerosis, Relapsing‐Remitting [*drug therapy]; Nitriles; Randomized Controlled Trials as Topic; Toluidines [adverse effects, *therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009882.pub3&amp;doi=10.1002/14651858.CD009882.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009882.pub3&amp;doi=10.1002/14651858.CD009882.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009882.pub3&amp;doi=10.1002/14651858.CD009882.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009882.pub3&amp;doi=10.1002/14651858.CD009882.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009882.pub3&amp;doi=10.1002/14651858.CD009882.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009882.pub3&amp;doi=10.1002/14651858.CD009882.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009882.pub3&amp;doi=10.1002/14651858.CD009882.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009882.pub3&amp;doi=10.1002/14651858.CD009882.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009882.pub3&amp;doi=10.1002/14651858.CD009882.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009882.pub3&amp;doi=10.1002/14651858.CD009882.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009882.pub3&amp;doi=10.1002/14651858.CD009882.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009882.pub3&amp;doi=10.1002/14651858.CD009882.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009882.pub3&amp;doi=10.1002/14651858.CD009882.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009882.pub3&amp;doi=10.1002/14651858.CD009882.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009882.pub3&amp;doi=10.1002/14651858.CD009882.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009882.pub3&amp;doi=10.1002/14651858.CD009882.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009882.pub3&amp;doi=10.1002/14651858.CD009882.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009882.pub3&amp;doi=10.1002/14651858.CD009882.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009882.pub3&amp;doi=10.1002/14651858.CD009882.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009882.pub3&amp;doi=10.1002/14651858.CD009882.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009882.pub3&amp;doi=10.1002/14651858.CD009882.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009882.pub3&amp;doi=10.1002/14651858.CD009882.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009882.pub3&amp;doi=10.1002/14651858.CD009882.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="9nGOjNGw";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD009882\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD009882\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009882\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009882\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","hr","ja","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD009882.pub3",title:"Teriflunomide for multiple sclerosis",firstPublishedDate:"Mar 22, 2016 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Multiple Sclerosis and Rare Diseases of the CNS Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=9nGOjNGw&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009882.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD009882.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD009882.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD009882.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009882.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD009882.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD009882.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD009882.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD009882.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD009882.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Conclusiones de los autores&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Antecedentes&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Objetivos&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Métodos&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Discusión&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD009882.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD009882.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD009882.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD009882.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>4191 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD009882.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009882.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009882.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009882.pub3/full#CD009882-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009882.pub3/full#CD009882-sec-0081"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009882.pub3/full#CD009882-sec-0015"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009882.pub3/full#CD009882-sec-0016"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009882.pub3/full#CD009882-sec-0021"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009882.pub3/full#CD009882-sec-0022"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009882.pub3/full#CD009882-sec-0049"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009882.pub3/full#CD009882-sec-0075"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD009882.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009882.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009882.pub3/appendices#CD009882-sec-0085"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009882.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009882.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009882.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009882.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD009882.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD009882.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD009882.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2016 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD009882.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> <li aria-label="There has been an important change to the conclusions of the review." class="status-item up-to-date custom-tooltip" data-status="conclusionchanged" title="There has been an important change to the conclusions of the review."> <a class="btn secondary" href="information#history">Conclusions changed</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Teriflunomide for multiple sclerosis</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009882.pub3/information#CD009882-cr-0002">Dian He</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009882.pub3/information#CD009882-cr-0003">Chao Zhang</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009882.pub3/information#CD009882-cr-0004">Xia Zhao</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009882.pub3/information#CD009882-cr-0005">Yifan Zhang</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009882.pub3/information#CD009882-cr-0006">Qingqing Dai</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009882.pub3/information#CD009882-cr-0007">Yuan Li</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009882.pub3/information#CD009882-cr-0008"><i class="icon corresponding-author fa fa-envelope"></i>Lan Chu</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD009882.pub3/information/en#CD009882-sec-0089">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 22 March 2016 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD009882.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD009882.pub3">https://doi.org/10.1002/14651858.CD009882.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD009882-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009882-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009882-abs-0002">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD009882-abs-0008">فارسی</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD009882-abs-0001" lang="en"> <section id="CD009882-sec-0001"> <h3 class="title" id="CD009882-sec-0001">Background</h3> <p>This is an update of the Cochrane review "Teriflunomide for multiple sclerosis" (first published in <i>The Cochrane Library</i> 2012, Issue 12). </p> <p>Multiple sclerosis (MS) is a chronic immune‐mediated disease of the central nervous system. It is clinically characterized by recurrent relapses or progression, or both, often leading to severe neurological disability and a serious decline in quality of life. Disease‐modifying therapies (DMTs) for MS aim to prevent occurrence of relapses and disability progression. Teriflunomide is a pyrimidine synthesis inhibitor approved by both the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) as a DMT for adults with relapsing‐remitting MS (RRMS). </p> </section> <section id="CD009882-sec-0002"> <h3 class="title" id="CD009882-sec-0002">Objectives</h3> <p>To assess the absolute and comparative effectiveness and safety of teriflunomide as monotherapy or combination therapy versus placebo or other disease‐modifying drugs (DMDs) (interferon beta (IFNβ), glatiramer acetate, natalizumab, mitoxantrone, fingolimod, dimethyl fumarate, alemtuzumab) for modifying the disease course in people with MS. </p> </section> <section id="CD009882-sec-0003"> <h3 class="title" id="CD009882-sec-0003">Search methods</h3> <p>We searched the Cochrane Multiple Sclerosis and Rare Diseases of the CNS Group Specialised Trials Register (30 September 2015). We checked reference lists of published reviews and retrieved articles and searched reports (2004 to September 2015) from the MS societies in Europe and America. We also communicated with investigators participating in trials of teriflunomide and the pharmaceutical company, Sanofi‐Aventis. </p> </section> <section id="CD009882-sec-0004"> <h3 class="title" id="CD009882-sec-0004">Selection criteria</h3> <p>We included randomized, controlled, parallel‐group clinical trials with a length of follow‐up of one year or greater evaluating teriflunomide, as monotherapy or combination therapy, versus placebo or other approved DMDs for people with MS without restrictions regarding dose, administration frequency and duration of treatment. </p> </section> <section id="CD009882-sec-0005"> <h3 class="title" id="CD009882-sec-0005">Data collection and analysis</h3> <p>We used the standard methodological procedures of Cochrane. Two review authors independently assessed trial quality and extracted data. Disagreements were discussed and resolved by consensus among the review authors. We contacted the principal investigators of included studies for additional data or confirmation of data. </p> </section> <section id="CD009882-sec-0006"> <h3 class="title" id="CD009882-sec-0006">Main results</h3> <p>Five studies involving 3231 people evaluated the efficacy and safety of teriflunomide 7 mg and 14 mg, alone or with add‐on IFNβ, versus placebo or IFNβ‐1a for adults with relapsing forms of MS and an entry Expanded Disability Status Scale score of less than 5.5. </p> <p>Overall, there were obvious clinical heterogeneities due to diversities in study designs or interventions and methodological heterogeneities across studies. All studies had a high risk of detection bias for relapse assessment and a high risk of bias due to conflicts of interest. Among them, three studies additionally had a high risk of attrition bias due to a high dropout rate and two studies had an unclear risk of attrition bias. The studies of combination therapy with IFNβ (650 participants) and the study with IFNβ‐1a as controls (324 participants) also had a high risk for performance bias and a lack of power due to the limited sample. </p> <p>Two studies evaluated the benefit and the safety of teriflunomide as monotherapy versus placebo over a period of one year (1169 participants) or two years (1088 participants). A meta‐analysis was not conducted. Compared to placebo, administration of teriflunomide at a dose of 7 mg/day or 14 mg/day as monotherapy reduced the number of participants with at least one relapse over one year (risk ratio (RR) 0.72, 95% confidence interval (CI) 0.59 to 0.87, P value = 0.001 with 7 mg/day and RR 0.60, 95% CI 0.48 to 0.75, P value &lt; 0.00001 with 14 mg/day) or two years (RR 0.85, 95% CI 0.74 to 0.98, P value = 0.03 with 7 mg/day and RR 0.80, 95% CI 0.69 to 0.93, P value = 0.004 with 14 days). Only teriflunomide at a dose of 14 mg/day reduced the number of participants with disability progression over one year (RR 0.55, 95% CI 0.36 to 0.84, P value = 0.006) or two years (RR 0.74, 95% CI 0.56 to 0.96, P value = 0.02). When taking the effect of drop‐outs into consideration, the likely‐case scenario analyses still showed a benefit in reducing the number of participants with at least one relapse, but not for the number of participants with disability progression. Both doses also reduced the annualized relapse rate and the number of gadolinium‐enhancing T1‐weighted lesions over two years. Quality of evidence for relapse outcomes at one year or at two years was low, while for disability progression at one year or at two years was very low. </p> <p>When compared to IFNβ‐1a, teriflunomide at a dose of 14 mg/day had a similar efficacy to IFNβ‐1a in reducing the proportion of participants with at least one relapse over one year, while teriflunomide at a dose of 7 mg/day was inferior to IFNβ‐1a (RR 1.52, 95% CI 0.87 to 2.67, P value = 0.14; 215 participants with 14 mg/day and RR 2.74, 95% CI 1.66 to 4.53, P value &lt; 0.0001; 213 participants with 7 mg/day). However, the quality of evidence was very low. </p> <p>In terms of safety profile, the most common adverse events associated with teriflunomide were diarrhoea, nausea, hair thinning, elevated alanine aminotransferase, neutropenia and lymphopenia. These adverse events had a dose‐related effects and rarely led to treatment discontinuation. </p> </section> <section id="CD009882-sec-0007"> <h3 class="title" id="CD009882-sec-0007">Authors' conclusions</h3> <p>There was low‐quality evidence to support that teriflunomide at a dose of 7 mg/day or 14 mg/day as monotherapy reduces both the number of participants with at least one relapse and the annualized relapse rate over one year or two years of treatment in comparison with placebo. Only teriflunomide at a dose of 14 mg/day reduced the number of participants with disability progression and delayed the progression of disability over one year or two years, but the quality of the evidence was very low. The quality of available data was too low to evaluate the benefit teriflunomide as monotherapy versus IFNβ‐1a or as combination therapy with IFNβ. The common adverse effects were diarrhoea, nausea, hair thinning, elevated alanine aminotransferase, neutropenia and lymphopenia. These adverse effects were mostly mild‐to‐moderate in severity, but had a dose‐related effect. New studies of high quality and longer follow‐up are needed to evaluate the comparative benefit of teriflunomide on these outcomes and the safety in comparison with other DMTs. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD009882-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009882-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD009882-abs-0004">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD009882-abs-0006">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD009882-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/hr#CD009882-abs-0005">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ja#CD009882-abs-0007">日本語</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD009882-abs-0003" lang="en"> <h3>Teriflunomide modifies the disease course in people with multiple sclerosis</h3> <p><b>Background</b> </p> <p>Teriflunomide was first used in rheumatoid arthritis, and is known to possess both anti‐proliferative (inhibiting cell growth) and anti‐inflammatory (counteracting a local response to cellular injury) actions. In 2012, its use was approved for these characteristics by the US Food and Drug Administration for people with relapsing (with recurrent exacerbations of neurological symptoms) forms of multiple sclerosis (MS) and in 2013 also by the European Medicines Agency. </p> <p><b>Objectives</b> </p> <p>To assess the effectiveness and safety of two different doses of teriflunomide, alone or in combination with other medicines, for modifying the course of MS in people with the relapsing forms, with or without progression. </p> <p><b>Study characteristics</b> </p> <p>The review authors considered the effectiveness of teriflunomide mainly in terms of the number of participants with at least one relapse, the number of people with disability progression, the annualized rate of relapse (number of relapses per participant‐year) and the time to disability progression. They evaluated safety as the number of participants with side effects, number of participants with serious side effects, and number of participants who withdrew or dropped out from the study because of side effects at one year or two years. Among the pertinent literature, five studies met the inclusion criteria. They involved 3231 participants and evaluated the effectiveness and safety of teriflunomide alone or with another medicine called interferon‐β (IFNβ), versus placebo (a pretend medicine) or IFNβ‐1a. The evidence is current to September 2015. </p> <p><b>Key results</b> </p> <p>The authors found low‐quality evidence that both doses of teriflunomide reduced the occurrence of relapses after one year or two years of treatment, while there is very low‐quality evidence showing that the medicine prevented disability progression at one year or two years. High‐dose rather than low‐dose teriflunomide had a similar efficacy to IFNβ‐1a in reducing relapse at one year, but the quality of evidence was very low. As far as safety was concerned, the most commonly reported side effects were diarrhoea (frequent, loose stools), nausea (feeling sick), hair thinning, neutropenia (low levels of white blood cells called neutrophils, which fight off infection) and lymphopenia (low levels of white blood cells called lymphocytes, which fight off infection). In general, these side effects are mild to moderate, and do not usually lead to treatment being stopped, but higher dose is more prone to cause these side effects. </p> <p><b>Quality of evidence</b> </p> <p>The low/very low quality of the results is mainly due to the inadequate blinding of relapse assessment (assessors were aware of which treatment the person had received), the high dropout rate (people left the trial), disability progression confirmed in less than six months, the low number of participants, and the different length of treatments within the studies. The duration of the studies is a key point for a lifetime disease with chances of chronic treatments as MS, also suggesting the need of studies with a longer period of monitoring (follow‐up). The five studies included in this review were sponsored by pharmaceutical companies, and this is known as a potential source of conflict of interest and thus of bias. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD009882-sec-0081" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009882-sec-0081">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009882-sec-0121">Español</a> </li> </nav> </div> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD009882-sec-0081"></div> <h3 class="title" id="CD009882-sec-0082">Implications for practice</h3> <section id="CD009882-sec-0082"> <p>There was low‐quality evidence to support that teriflunomide at a dose of 7 mg and 14 mg orally once daily as monotherapy by direct comparison with placebo reduced both the annualized relapse rate and the number of participants with a relapse over one year and two years of treatment. Only teriflunomide at a dose of 14 mg/day as monotherapy reduced the number of participants with disability progression and delayed the progression of disability over one year or two years, but the quality of the evidence was very low. The quality of available data was too low to evaluate the benefit of teriflunomide as monotherapy versus interferon beta‐1a (IFNβ‐1a) or as combination therapy with interferon beta (IFNβ). The common adverse effects were diarrhoea, nausea, hair thinning, elevated alanine aminotransferase, neutropenia and lymphopenia. These adverse effects were mostly mild‐to‐moderate in severity, but had a dose‐related effect. </p> </section> <h3 class="title" id="CD009882-sec-0083">Implications for research</h3> <section id="CD009882-sec-0083"> <p>The ideal target of disease‐modifying therapy for multiple sclerosis (MS) is to prevent disability progression and improve quality of life, which are two key aspects generally needed to be considered when evaluating and deciding whether a disease‐modifying drug has superior benefit. MS is a chronic disease with a duration of decades that requires long‐term treatment. Therefore, new studies of high quality and longer follow‐up are needed to evaluate the comparative benefit of teriflunomide on these outcomes and safety in comparison with other disease‐modifying drugs. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD009882-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD009882-sec-0015"></div> <div class="table" id="CD009882-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Teriflunomide compared to placebo for multiple sclerosis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Teriflunomide compared to placebo for multiple sclerosis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with relapsing multiple sclerosis<br/> <b>Settings:</b> US, Austria, France, Canada, Germany, UK, Sweden, Netherlands, Turkey, Poland, Chile, Ukraine, China, Italy, Australia, etc.<br/> <b>Intervention:</b> teriflunomide at a dose of 14 mg orally once daily<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Teriflunomide</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of participants with at least 1 relapse at 1 year</b> <br/> Follow‐up: 1 year </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>394 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>237 per 1000</b> <br/> (189 to 296) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.60</b> <br/> (0.48 to 0.75) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>761<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>This outcome was considered low, because we considered there were very serious limitation in study design and execution. The bias that influenced the validity of the results for this outcome included: the high risks of bias due to unblinded assessments for relapse and conflicts of interest (sensitivity analysis according to a likely‐case scenario showed a robustness for the results of this outcome, we considered that the high attrition bias did not influence the robustness of the results on relapse). Therefore, we downgraded the quality of evidence for this outcome by 2 levels </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>The proportion of participants with at least 1 relapse at 2 years</b> <br/> Follow‐up: 2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>545 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>436 per 1000</b> <br/> (376 to 507) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.80</b> <br/> (0.69 to 0.93) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>722<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>This outcome was considered low, because we considered there were very serious limitation in study design and execution. The bias that influenced the validity of the results for this outcome included: the high risks of bias due to unblinded assessments for relapse and conflicts of interest. (Sensitivity analysis according to a likely‐case scenario showed a robustness for the results of this outcome, we considered that the unclear attrition bias did not influence the robustness of the results on relapse.) Therefore, we downgraded the quality of evidence for this outcome by 2 levels </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>The proportion of participants with disability progression at 1 year</b> <br/> Follow‐up: 1 year </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>142 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>78 per 1000</b> <br/> (51 to 119) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.55</b> <br/> (0.36 to 0.84) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>761<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>c,e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was considered very low based on the following reasons:</p> <p> <ul id="CD009882-list-0001"> <li> <p>we considered there were very serious limitation in study design and execution. The bias that influenced the validity of the results for this outcome included: the high risks of bias due to the high attrition bias and conflicts of interest. Sensitivity analysis according to a likely‐case scenario showed an unsteadiness for the results of this outcome, we considered that the high attrition bias influenced the robustness of the results on progression disability. Therefore, we downgraded the quality of evidence for this outcome by 2 levels </p> </li> <li> <p>This outcome was an indirect outcome because disability progression was confirmed at 3 months of follow‐up. We had serious doubts about directness. Therefore, we downgraded the quality of evidence for this outcome by 1 level </p> </li> </ul> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>The proportion of participants with disability progression at 2 years</b> <br/> Follow‐up: 2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>273 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>202 per 1000</b> <br/> (153 to 262) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.74</b> <br/> (0.56 to 0.96) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>722<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>d,e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was considered very low based on the following reasons:</p> <p> <ul id="CD009882-list-0002"> <li> <p>We considered there were very serious limitation in study design and execution. The bias that influenced the validity of the results for this outcome included: the high risks of bias due to unclear attrition bias and conflicts of interest. Sensitivity analysis according to a likely‐case scenario showed an unsteadiness for the results of this outcome, we considered that the unclear attrition bias influenced the robustness of the results on progression disability. Therefore, we downgraded the quality of evidence for this outcome by 2 levels </p> </li> <li> <p>This outcome was an indirect outcome because disability progression was confirmed at 3 months of follow‐up. We had serious doubts about directness. Therefore, we downgraded the quality of evidence for this outcome by 1 level </p> </li> </ul> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>The proportion of participants with diarrhoea at 2 years</b> <br/> Follow‐up: 2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>89 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>179 per 1000</b> <br/> (120 to 267) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.01</b> <br/> (1.35 to 3.00) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>718<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>f</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The follow‐up periods were diverse in <a href="./references#CD009882-bbs2-0001" title="ComiG , FreedmanMS , KapposL , MillerA , OlssonTP , WolinskyJS , et al. Effect of teriflunomide on lymphocyte and neutrophil counts in patients with relapsing multiple sclerosis: results from the TOWER study. Journal of the Neurological Sciences2013;333:e376. ConfavreuxC , O'ConnorP , ComiG , FreedmanMS , MillerAE , OlssonTP , et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet Neurology2014;13(3):247‐56. KapposL , ComiG , ConfavreuxC , FreedmanMS , MillerAE , OlssonTP , et al. The efficacy and safety of teriflunomide in patients with relapsing MS: results from TOWER, a phase Ⅲ, placebo‐controlled study. Multiple Sclerosis2012;18:50‐1. MillerA , KapposL , ComiG , ConfavreuxC , FreedmanM , OlssonT , et al. Teriflunomide efficacy and safety in patients with relapsing multiple sclerosis: results from tower, a second, pivotal, phase 3 placebo‐controlled study. Neurology. 2013; Vol. 80. MillerAE , MacdonellR , ComiG , FreedmanMS , KapposL , MaurerM , et al. Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study. Journal of Neurology2014;261(9):1781‐8. MosesH , FreedmanM , KapposL , MillerA , OlssonT , WolinskyJ , et al. Pre‐defined subgroups analyses of tower, a placebo‐controlled phase 3 trial of teriflunomide in patients with relapsing multiple sclerosis. Proceedings of the American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). O'ConnorP , LublinF , WolinskyJ , ComiG , ConfavreuxC , FreedmanM , et al. Teriflunomide reduces relapse‐related sequelae, hospitalizations and corticosteroid use: a post‐HOC analysis of the phase 3 TOWER study. Proceedings of The American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). ">Confavreux 2014</a> and <a href="./references#CD009882-bbs2-0004" title="ComiG , BenzerdjebH , WangL , TruffinetP , O'ConnorP . Effect of teriflunomide on lymphocyte and neutrophil levels in patients with relapsing multiple sclerosis: results from the TEMSO study. Journal of Neurological Science2013;333(Suppl 1):e376. ComiG , O'ConnorP , WolinskyJ , ConfavreuxC , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: safety outcomes with up to 4 years of follow‐Up. Multiple Sclerosis2011;17:S182‐3. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Long‐term safety and efficacy of teriflunomide in patients with relapsing forms of multiple sclerosis in the TEMSO extension trial. Multiple Sclerosis2013;19:225. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Safety and efficacy of teriflunomide for up to 9 years in relapsing forms of multiple sclerosis: Update of the TEMSO extension trial. Neurology2014; Vol. 82, issue Suppl 10:3‐150. FreedmanMS , DelhayJL , BenamorM . Gastrointestinal symptoms infrequently lead to discontinuation of teriflunomide therapy. Multiple Sclerosis2012;18:S13. MillerA , LublinF , O'ConnorP , TaniouC , Dive‐PoulettyC . Impact of relapses with sequelae on disability, health‐related quality of life, and fatigue in a population with relapsing forms of multiple sclerosis using data from TEMSO, a pivotal phase Ⅲ teriflunomide trial. Neurology2012;78:P07.082. MillerA , LublinF , O'ConnorP , WolinskyJ , ComiG , KapposL , et al. Effect of teriflunomide on relapses with sequelae and relapse leading to hospitalization in a population with relapsing forms of multiple sclerosis: results from the TEMSO study. Neurology2012;78:S30.003. MillerA , O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , et al. Efficacy of oral teriflunomide in multiple sclerosis with relapses: cognitive outcomes from a phase Ⅲ trial (TEMSO). Multiple Sclerosis2011;17:S182. MillerAE , O'ConnorP , WolinskyJS , ConfavreuxC , KapposL , OlssonTP , et al. Pre‐specified subgroup analyses of a placebo‐controlled phase Ⅲ trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis. Multiple Sclerosis2012;18(11):1625‐32. O'ConnorP , BriggsA , CaritaP , Bego‐Le‐BagousseG . Impact on health‐related quality of life of teriflunomide treatment by estimating utilities in patients with relapsing multiple sclerosis: results from TEMSO post hoc analysis. Journal of Neurology2012;259:S107. O'ConnorP , BurrellA , WangL , WeiL , CaritaP , ZhangQ . Effect of teriflunomide on longitudinal patterns of relapse and relapse‐related hospitalization in multiple sclerosis. Multiple Sclerosis2011;17:S414. O'ConnorP , LublinF , WolinskyJ , ComiG , KapposL , FreedmanM , et al. Effect of teriflunomide on relapses leading to healthcare resource use: results from the TEMSO study. Multiple Sclerosis2011;17:S95‐6. O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: clinical and MRI data 5 years after initial randomization. Multiple Sclerosis2011;17:S414‐5. O'ConnorP , WolinskyJS , ConfavreuxC , ComiG , KapposL , OlssonTP , et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. New England Journal of Medicine2011;365(14):1293‐303. O'ConnorPW , LublinFD , WolinskyJS , ConfavreuxC , ComiG , FreedmanMS , et al. Teriflunomide reduces relapse‐related neurological sequelae, hospitalizations and steroid use. Journal of Neurology2013;260(10):2472‐80. WolinksyJS , WangL , TruffinetP , NarayanaPA , NelsonF , O'ConnorP . Magnetic resonance imaging as a surrogate for clinical endpoints in multiple sclerosis. Multiple Sclerosis2012;18:470‐1. WolinskyJS , NarayanaPA , NelsonF , DattaS , O'ConnorP , ConfavreuxC , et al. Magnetic resonance imaging outcomes from a phase Ⅲ trial of teriflunomide. Multiple Sclerosis2013;19(10):1310‐9. ">O'Connor 2011</a> (at least 48 weeks (<a href="./references#CD009882-bbs2-0001" title="ComiG , FreedmanMS , KapposL , MillerA , OlssonTP , WolinskyJS , et al. Effect of teriflunomide on lymphocyte and neutrophil counts in patients with relapsing multiple sclerosis: results from the TOWER study. Journal of the Neurological Sciences2013;333:e376. ConfavreuxC , O'ConnorP , ComiG , FreedmanMS , MillerAE , OlssonTP , et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet Neurology2014;13(3):247‐56. KapposL , ComiG , ConfavreuxC , FreedmanMS , MillerAE , OlssonTP , et al. The efficacy and safety of teriflunomide in patients with relapsing MS: results from TOWER, a phase Ⅲ, placebo‐controlled study. Multiple Sclerosis2012;18:50‐1. MillerA , KapposL , ComiG , ConfavreuxC , FreedmanM , OlssonT , et al. Teriflunomide efficacy and safety in patients with relapsing multiple sclerosis: results from tower, a second, pivotal, phase 3 placebo‐controlled study. Neurology. 2013; Vol. 80. MillerAE , MacdonellR , ComiG , FreedmanMS , KapposL , MaurerM , et al. Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study. Journal of Neurology2014;261(9):1781‐8. MosesH , FreedmanM , KapposL , MillerA , OlssonT , WolinskyJ , et al. Pre‐defined subgroups analyses of tower, a placebo‐controlled phase 3 trial of teriflunomide in patients with relapsing multiple sclerosis. Proceedings of the American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). O'ConnorP , LublinF , WolinskyJ , ComiG , ConfavreuxC , FreedmanM , et al. Teriflunomide reduces relapse‐related sequelae, hospitalizations and corticosteroid use: a post‐HOC analysis of the phase 3 TOWER study. Proceedings of The American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). ">Confavreux 2014</a>) and 108 weeks (<a href="./references#CD009882-bbs2-0004" title="ComiG , BenzerdjebH , WangL , TruffinetP , O'ConnorP . Effect of teriflunomide on lymphocyte and neutrophil levels in patients with relapsing multiple sclerosis: results from the TEMSO study. Journal of Neurological Science2013;333(Suppl 1):e376. ComiG , O'ConnorP , WolinskyJ , ConfavreuxC , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: safety outcomes with up to 4 years of follow‐Up. Multiple Sclerosis2011;17:S182‐3. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Long‐term safety and efficacy of teriflunomide in patients with relapsing forms of multiple sclerosis in the TEMSO extension trial. Multiple Sclerosis2013;19:225. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Safety and efficacy of teriflunomide for up to 9 years in relapsing forms of multiple sclerosis: Update of the TEMSO extension trial. Neurology2014; Vol. 82, issue Suppl 10:3‐150. FreedmanMS , DelhayJL , BenamorM . Gastrointestinal symptoms infrequently lead to discontinuation of teriflunomide therapy. Multiple Sclerosis2012;18:S13. MillerA , LublinF , O'ConnorP , TaniouC , Dive‐PoulettyC . Impact of relapses with sequelae on disability, health‐related quality of life, and fatigue in a population with relapsing forms of multiple sclerosis using data from TEMSO, a pivotal phase Ⅲ teriflunomide trial. Neurology2012;78:P07.082. MillerA , LublinF , O'ConnorP , WolinskyJ , ComiG , KapposL , et al. Effect of teriflunomide on relapses with sequelae and relapse leading to hospitalization in a population with relapsing forms of multiple sclerosis: results from the TEMSO study. Neurology2012;78:S30.003. MillerA , O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , et al. Efficacy of oral teriflunomide in multiple sclerosis with relapses: cognitive outcomes from a phase Ⅲ trial (TEMSO). Multiple Sclerosis2011;17:S182. MillerAE , O'ConnorP , WolinskyJS , ConfavreuxC , KapposL , OlssonTP , et al. Pre‐specified subgroup analyses of a placebo‐controlled phase Ⅲ trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis. Multiple Sclerosis2012;18(11):1625‐32. O'ConnorP , BriggsA , CaritaP , Bego‐Le‐BagousseG . Impact on health‐related quality of life of teriflunomide treatment by estimating utilities in patients with relapsing multiple sclerosis: results from TEMSO post hoc analysis. Journal of Neurology2012;259:S107. O'ConnorP , BurrellA , WangL , WeiL , CaritaP , ZhangQ . Effect of teriflunomide on longitudinal patterns of relapse and relapse‐related hospitalization in multiple sclerosis. Multiple Sclerosis2011;17:S414. O'ConnorP , LublinF , WolinskyJ , ComiG , KapposL , FreedmanM , et al. Effect of teriflunomide on relapses leading to healthcare resource use: results from the TEMSO study. Multiple Sclerosis2011;17:S95‐6. O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: clinical and MRI data 5 years after initial randomization. Multiple Sclerosis2011;17:S414‐5. O'ConnorP , WolinskyJS , ConfavreuxC , ComiG , KapposL , OlssonTP , et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. New England Journal of Medicine2011;365(14):1293‐303. O'ConnorPW , LublinFD , WolinskyJS , ConfavreuxC , ComiG , FreedmanMS , et al. Teriflunomide reduces relapse‐related neurological sequelae, hospitalizations and steroid use. Journal of Neurology2013;260(10):2472‐80. WolinksyJS , WangL , TruffinetP , NarayanaPA , NelsonF , O'ConnorP . Magnetic resonance imaging as a surrogate for clinical endpoints in multiple sclerosis. Multiple Sclerosis2012;18:470‐1. WolinskyJS , NarayanaPA , NelsonF , DattaS , O'ConnorP , ConfavreuxC , et al. Magnetic resonance imaging outcomes from a phase Ⅲ trial of teriflunomide. Multiple Sclerosis2013;19(10):1310‐9. ">O'Connor 2011</a>)). Treatment duration of participants in <a href="./references#CD009882-bbs2-0001" title="ComiG , FreedmanMS , KapposL , MillerA , OlssonTP , WolinskyJS , et al. Effect of teriflunomide on lymphocyte and neutrophil counts in patients with relapsing multiple sclerosis: results from the TOWER study. Journal of the Neurological Sciences2013;333:e376. ConfavreuxC , O'ConnorP , ComiG , FreedmanMS , MillerAE , OlssonTP , et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet Neurology2014;13(3):247‐56. KapposL , ComiG , ConfavreuxC , FreedmanMS , MillerAE , OlssonTP , et al. The efficacy and safety of teriflunomide in patients with relapsing MS: results from TOWER, a phase Ⅲ, placebo‐controlled study. Multiple Sclerosis2012;18:50‐1. MillerA , KapposL , ComiG , ConfavreuxC , FreedmanM , OlssonT , et al. Teriflunomide efficacy and safety in patients with relapsing multiple sclerosis: results from tower, a second, pivotal, phase 3 placebo‐controlled study. Neurology. 2013; Vol. 80. MillerAE , MacdonellR , ComiG , FreedmanMS , KapposL , MaurerM , et al. Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study. Journal of Neurology2014;261(9):1781‐8. MosesH , FreedmanM , KapposL , MillerA , OlssonT , WolinskyJ , et al. Pre‐defined subgroups analyses of tower, a placebo‐controlled phase 3 trial of teriflunomide in patients with relapsing multiple sclerosis. Proceedings of the American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). O'ConnorP , LublinF , WolinskyJ , ComiG , ConfavreuxC , FreedmanM , et al. Teriflunomide reduces relapse‐related sequelae, hospitalizations and corticosteroid use: a post‐HOC analysis of the phase 3 TOWER study. Proceedings of The American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). ">Confavreux 2014</a> was variable, ending 48 weeks after the last participant was included (a maximum treatment duration of 173 weeks). Actually, the data on adverse events in <a href="./references#CD009882-bbs2-0001" title="ComiG , FreedmanMS , KapposL , MillerA , OlssonTP , WolinskyJS , et al. Effect of teriflunomide on lymphocyte and neutrophil counts in patients with relapsing multiple sclerosis: results from the TOWER study. Journal of the Neurological Sciences2013;333:e376. ConfavreuxC , O'ConnorP , ComiG , FreedmanMS , MillerAE , OlssonTP , et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet Neurology2014;13(3):247‐56. KapposL , ComiG , ConfavreuxC , FreedmanMS , MillerAE , OlssonTP , et al. The efficacy and safety of teriflunomide in patients with relapsing MS: results from TOWER, a phase Ⅲ, placebo‐controlled study. Multiple Sclerosis2012;18:50‐1. MillerA , KapposL , ComiG , ConfavreuxC , FreedmanM , OlssonT , et al. Teriflunomide efficacy and safety in patients with relapsing multiple sclerosis: results from tower, a second, pivotal, phase 3 placebo‐controlled study. Neurology. 2013; Vol. 80. MillerAE , MacdonellR , ComiG , FreedmanMS , KapposL , MaurerM , et al. Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study. Journal of Neurology2014;261(9):1781‐8. MosesH , FreedmanM , KapposL , MillerA , OlssonT , WolinskyJ , et al. Pre‐defined subgroups analyses of tower, a placebo‐controlled phase 3 trial of teriflunomide in patients with relapsing multiple sclerosis. Proceedings of the American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). O'ConnorP , LublinF , WolinskyJ , ComiG , ConfavreuxC , FreedmanM , et al. Teriflunomide reduces relapse‐related sequelae, hospitalizations and corticosteroid use: a post‐HOC analysis of the phase 3 TOWER study. Proceedings of The American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). ">Confavreux 2014</a> were not at 2 years. There was a heterogeneity in follow‐up period between the studies. Therefore, we did not combine the data on adverse events in <a href="./references#CD009882-bbs2-0001" title="ComiG , FreedmanMS , KapposL , MillerA , OlssonTP , WolinskyJS , et al. Effect of teriflunomide on lymphocyte and neutrophil counts in patients with relapsing multiple sclerosis: results from the TOWER study. Journal of the Neurological Sciences2013;333:e376. ConfavreuxC , O'ConnorP , ComiG , FreedmanMS , MillerAE , OlssonTP , et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet Neurology2014;13(3):247‐56. KapposL , ComiG , ConfavreuxC , FreedmanMS , MillerAE , OlssonTP , et al. The efficacy and safety of teriflunomide in patients with relapsing MS: results from TOWER, a phase Ⅲ, placebo‐controlled study. Multiple Sclerosis2012;18:50‐1. MillerA , KapposL , ComiG , ConfavreuxC , FreedmanM , OlssonT , et al. Teriflunomide efficacy and safety in patients with relapsing multiple sclerosis: results from tower, a second, pivotal, phase 3 placebo‐controlled study. Neurology. 2013; Vol. 80. MillerAE , MacdonellR , ComiG , FreedmanMS , KapposL , MaurerM , et al. Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study. Journal of Neurology2014;261(9):1781‐8. MosesH , FreedmanM , KapposL , MillerA , OlssonT , WolinskyJ , et al. Pre‐defined subgroups analyses of tower, a placebo‐controlled phase 3 trial of teriflunomide in patients with relapsing multiple sclerosis. Proceedings of the American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). O'ConnorP , LublinF , WolinskyJ , ComiG , ConfavreuxC , FreedmanM , et al. Teriflunomide reduces relapse‐related sequelae, hospitalizations and corticosteroid use: a post‐HOC analysis of the phase 3 TOWER study. Proceedings of The American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). ">Confavreux 2014</a> and <a href="./references#CD009882-bbs2-0004" title="ComiG , BenzerdjebH , WangL , TruffinetP , O'ConnorP . Effect of teriflunomide on lymphocyte and neutrophil levels in patients with relapsing multiple sclerosis: results from the TEMSO study. Journal of Neurological Science2013;333(Suppl 1):e376. ComiG , O'ConnorP , WolinskyJ , ConfavreuxC , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: safety outcomes with up to 4 years of follow‐Up. Multiple Sclerosis2011;17:S182‐3. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Long‐term safety and efficacy of teriflunomide in patients with relapsing forms of multiple sclerosis in the TEMSO extension trial. Multiple Sclerosis2013;19:225. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Safety and efficacy of teriflunomide for up to 9 years in relapsing forms of multiple sclerosis: Update of the TEMSO extension trial. Neurology2014; Vol. 82, issue Suppl 10:3‐150. FreedmanMS , DelhayJL , BenamorM . Gastrointestinal symptoms infrequently lead to discontinuation of teriflunomide therapy. Multiple Sclerosis2012;18:S13. MillerA , LublinF , O'ConnorP , TaniouC , Dive‐PoulettyC . Impact of relapses with sequelae on disability, health‐related quality of life, and fatigue in a population with relapsing forms of multiple sclerosis using data from TEMSO, a pivotal phase Ⅲ teriflunomide trial. Neurology2012;78:P07.082. MillerA , LublinF , O'ConnorP , WolinskyJ , ComiG , KapposL , et al. Effect of teriflunomide on relapses with sequelae and relapse leading to hospitalization in a population with relapsing forms of multiple sclerosis: results from the TEMSO study. Neurology2012;78:S30.003. MillerA , O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , et al. Efficacy of oral teriflunomide in multiple sclerosis with relapses: cognitive outcomes from a phase Ⅲ trial (TEMSO). Multiple Sclerosis2011;17:S182. MillerAE , O'ConnorP , WolinskyJS , ConfavreuxC , KapposL , OlssonTP , et al. Pre‐specified subgroup analyses of a placebo‐controlled phase Ⅲ trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis. Multiple Sclerosis2012;18(11):1625‐32. O'ConnorP , BriggsA , CaritaP , Bego‐Le‐BagousseG . Impact on health‐related quality of life of teriflunomide treatment by estimating utilities in patients with relapsing multiple sclerosis: results from TEMSO post hoc analysis. Journal of Neurology2012;259:S107. O'ConnorP , BurrellA , WangL , WeiL , CaritaP , ZhangQ . Effect of teriflunomide on longitudinal patterns of relapse and relapse‐related hospitalization in multiple sclerosis. Multiple Sclerosis2011;17:S414. O'ConnorP , LublinF , WolinskyJ , ComiG , KapposL , FreedmanM , et al. Effect of teriflunomide on relapses leading to healthcare resource use: results from the TEMSO study. Multiple Sclerosis2011;17:S95‐6. O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: clinical and MRI data 5 years after initial randomization. Multiple Sclerosis2011;17:S414‐5. O'ConnorP , WolinskyJS , ConfavreuxC , ComiG , KapposL , OlssonTP , et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. New England Journal of Medicine2011;365(14):1293‐303. O'ConnorPW , LublinFD , WolinskyJS , ConfavreuxC , ComiG , FreedmanMS , et al. Teriflunomide reduces relapse‐related neurological sequelae, hospitalizations and steroid use. Journal of Neurology2013;260(10):2472‐80. WolinksyJS , WangL , TruffinetP , NarayanaPA , NelsonF , O'ConnorP . Magnetic resonance imaging as a surrogate for clinical endpoints in multiple sclerosis. Multiple Sclerosis2012;18:470‐1. WolinskyJS , NarayanaPA , NelsonF , DattaS , O'ConnorP , ConfavreuxC , et al. Magnetic resonance imaging outcomes from a phase Ⅲ trial of teriflunomide. Multiple Sclerosis2013;19(10):1310‐9. ">O'Connor 2011</a> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>The proportion of participants with hair thinning at 2 years</b> <br/> Follow‐up: 2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>33 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>131 per 1000</b> <br/> (71 to 243) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 3.94</b> <br/> (2.13 to 7.30) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>718<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>f</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The follow‐up periods were diverse in <a href="./references#CD009882-bbs2-0001" title="ComiG , FreedmanMS , KapposL , MillerA , OlssonTP , WolinskyJS , et al. Effect of teriflunomide on lymphocyte and neutrophil counts in patients with relapsing multiple sclerosis: results from the TOWER study. Journal of the Neurological Sciences2013;333:e376. ConfavreuxC , O'ConnorP , ComiG , FreedmanMS , MillerAE , OlssonTP , et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet Neurology2014;13(3):247‐56. KapposL , ComiG , ConfavreuxC , FreedmanMS , MillerAE , OlssonTP , et al. The efficacy and safety of teriflunomide in patients with relapsing MS: results from TOWER, a phase Ⅲ, placebo‐controlled study. Multiple Sclerosis2012;18:50‐1. MillerA , KapposL , ComiG , ConfavreuxC , FreedmanM , OlssonT , et al. Teriflunomide efficacy and safety in patients with relapsing multiple sclerosis: results from tower, a second, pivotal, phase 3 placebo‐controlled study. Neurology. 2013; Vol. 80. MillerAE , MacdonellR , ComiG , FreedmanMS , KapposL , MaurerM , et al. Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study. Journal of Neurology2014;261(9):1781‐8. MosesH , FreedmanM , KapposL , MillerA , OlssonT , WolinskyJ , et al. Pre‐defined subgroups analyses of tower, a placebo‐controlled phase 3 trial of teriflunomide in patients with relapsing multiple sclerosis. Proceedings of the American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). O'ConnorP , LublinF , WolinskyJ , ComiG , ConfavreuxC , FreedmanM , et al. Teriflunomide reduces relapse‐related sequelae, hospitalizations and corticosteroid use: a post‐HOC analysis of the phase 3 TOWER study. Proceedings of The American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). ">Confavreux 2014</a> and <a href="./references#CD009882-bbs2-0004" title="ComiG , BenzerdjebH , WangL , TruffinetP , O'ConnorP . Effect of teriflunomide on lymphocyte and neutrophil levels in patients with relapsing multiple sclerosis: results from the TEMSO study. Journal of Neurological Science2013;333(Suppl 1):e376. ComiG , O'ConnorP , WolinskyJ , ConfavreuxC , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: safety outcomes with up to 4 years of follow‐Up. Multiple Sclerosis2011;17:S182‐3. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Long‐term safety and efficacy of teriflunomide in patients with relapsing forms of multiple sclerosis in the TEMSO extension trial. Multiple Sclerosis2013;19:225. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Safety and efficacy of teriflunomide for up to 9 years in relapsing forms of multiple sclerosis: Update of the TEMSO extension trial. Neurology2014; Vol. 82, issue Suppl 10:3‐150. FreedmanMS , DelhayJL , BenamorM . Gastrointestinal symptoms infrequently lead to discontinuation of teriflunomide therapy. Multiple Sclerosis2012;18:S13. MillerA , LublinF , O'ConnorP , TaniouC , Dive‐PoulettyC . Impact of relapses with sequelae on disability, health‐related quality of life, and fatigue in a population with relapsing forms of multiple sclerosis using data from TEMSO, a pivotal phase Ⅲ teriflunomide trial. Neurology2012;78:P07.082. MillerA , LublinF , O'ConnorP , WolinskyJ , ComiG , KapposL , et al. Effect of teriflunomide on relapses with sequelae and relapse leading to hospitalization in a population with relapsing forms of multiple sclerosis: results from the TEMSO study. Neurology2012;78:S30.003. MillerA , O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , et al. Efficacy of oral teriflunomide in multiple sclerosis with relapses: cognitive outcomes from a phase Ⅲ trial (TEMSO). Multiple Sclerosis2011;17:S182. MillerAE , O'ConnorP , WolinskyJS , ConfavreuxC , KapposL , OlssonTP , et al. Pre‐specified subgroup analyses of a placebo‐controlled phase Ⅲ trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis. Multiple Sclerosis2012;18(11):1625‐32. O'ConnorP , BriggsA , CaritaP , Bego‐Le‐BagousseG . Impact on health‐related quality of life of teriflunomide treatment by estimating utilities in patients with relapsing multiple sclerosis: results from TEMSO post hoc analysis. Journal of Neurology2012;259:S107. O'ConnorP , BurrellA , WangL , WeiL , CaritaP , ZhangQ . Effect of teriflunomide on longitudinal patterns of relapse and relapse‐related hospitalization in multiple sclerosis. Multiple Sclerosis2011;17:S414. O'ConnorP , LublinF , WolinskyJ , ComiG , KapposL , FreedmanM , et al. Effect of teriflunomide on relapses leading to healthcare resource use: results from the TEMSO study. Multiple Sclerosis2011;17:S95‐6. O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: clinical and MRI data 5 years after initial randomization. Multiple Sclerosis2011;17:S414‐5. O'ConnorP , WolinskyJS , ConfavreuxC , ComiG , KapposL , OlssonTP , et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. New England Journal of Medicine2011;365(14):1293‐303. O'ConnorPW , LublinFD , WolinskyJS , ConfavreuxC , ComiG , FreedmanMS , et al. Teriflunomide reduces relapse‐related neurological sequelae, hospitalizations and steroid use. Journal of Neurology2013;260(10):2472‐80. WolinksyJS , WangL , TruffinetP , NarayanaPA , NelsonF , O'ConnorP . Magnetic resonance imaging as a surrogate for clinical endpoints in multiple sclerosis. Multiple Sclerosis2012;18:470‐1. WolinskyJS , NarayanaPA , NelsonF , DattaS , O'ConnorP , ConfavreuxC , et al. Magnetic resonance imaging outcomes from a phase Ⅲ trial of teriflunomide. Multiple Sclerosis2013;19(10):1310‐9. ">O'Connor 2011</a> (at least 48 weeks (<a href="./references#CD009882-bbs2-0001" title="ComiG , FreedmanMS , KapposL , MillerA , OlssonTP , WolinskyJS , et al. Effect of teriflunomide on lymphocyte and neutrophil counts in patients with relapsing multiple sclerosis: results from the TOWER study. Journal of the Neurological Sciences2013;333:e376. ConfavreuxC , O'ConnorP , ComiG , FreedmanMS , MillerAE , OlssonTP , et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet Neurology2014;13(3):247‐56. KapposL , ComiG , ConfavreuxC , FreedmanMS , MillerAE , OlssonTP , et al. The efficacy and safety of teriflunomide in patients with relapsing MS: results from TOWER, a phase Ⅲ, placebo‐controlled study. Multiple Sclerosis2012;18:50‐1. MillerA , KapposL , ComiG , ConfavreuxC , FreedmanM , OlssonT , et al. Teriflunomide efficacy and safety in patients with relapsing multiple sclerosis: results from tower, a second, pivotal, phase 3 placebo‐controlled study. Neurology. 2013; Vol. 80. MillerAE , MacdonellR , ComiG , FreedmanMS , KapposL , MaurerM , et al. Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study. Journal of Neurology2014;261(9):1781‐8. MosesH , FreedmanM , KapposL , MillerA , OlssonT , WolinskyJ , et al. Pre‐defined subgroups analyses of tower, a placebo‐controlled phase 3 trial of teriflunomide in patients with relapsing multiple sclerosis. Proceedings of the American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). O'ConnorP , LublinF , WolinskyJ , ComiG , ConfavreuxC , FreedmanM , et al. Teriflunomide reduces relapse‐related sequelae, hospitalizations and corticosteroid use: a post‐HOC analysis of the phase 3 TOWER study. Proceedings of The American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). ">Confavreux 2014</a>) and 108 weeks (<a href="./references#CD009882-bbs2-0004" title="ComiG , BenzerdjebH , WangL , TruffinetP , O'ConnorP . Effect of teriflunomide on lymphocyte and neutrophil levels in patients with relapsing multiple sclerosis: results from the TEMSO study. Journal of Neurological Science2013;333(Suppl 1):e376. ComiG , O'ConnorP , WolinskyJ , ConfavreuxC , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: safety outcomes with up to 4 years of follow‐Up. Multiple Sclerosis2011;17:S182‐3. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Long‐term safety and efficacy of teriflunomide in patients with relapsing forms of multiple sclerosis in the TEMSO extension trial. Multiple Sclerosis2013;19:225. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Safety and efficacy of teriflunomide for up to 9 years in relapsing forms of multiple sclerosis: Update of the TEMSO extension trial. Neurology2014; Vol. 82, issue Suppl 10:3‐150. FreedmanMS , DelhayJL , BenamorM . Gastrointestinal symptoms infrequently lead to discontinuation of teriflunomide therapy. Multiple Sclerosis2012;18:S13. MillerA , LublinF , O'ConnorP , TaniouC , Dive‐PoulettyC . Impact of relapses with sequelae on disability, health‐related quality of life, and fatigue in a population with relapsing forms of multiple sclerosis using data from TEMSO, a pivotal phase Ⅲ teriflunomide trial. Neurology2012;78:P07.082. MillerA , LublinF , O'ConnorP , WolinskyJ , ComiG , KapposL , et al. Effect of teriflunomide on relapses with sequelae and relapse leading to hospitalization in a population with relapsing forms of multiple sclerosis: results from the TEMSO study. Neurology2012;78:S30.003. MillerA , O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , et al. Efficacy of oral teriflunomide in multiple sclerosis with relapses: cognitive outcomes from a phase Ⅲ trial (TEMSO). Multiple Sclerosis2011;17:S182. MillerAE , O'ConnorP , WolinskyJS , ConfavreuxC , KapposL , OlssonTP , et al. Pre‐specified subgroup analyses of a placebo‐controlled phase Ⅲ trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis. Multiple Sclerosis2012;18(11):1625‐32. O'ConnorP , BriggsA , CaritaP , Bego‐Le‐BagousseG . Impact on health‐related quality of life of teriflunomide treatment by estimating utilities in patients with relapsing multiple sclerosis: results from TEMSO post hoc analysis. Journal of Neurology2012;259:S107. O'ConnorP , BurrellA , WangL , WeiL , CaritaP , ZhangQ . Effect of teriflunomide on longitudinal patterns of relapse and relapse‐related hospitalization in multiple sclerosis. Multiple Sclerosis2011;17:S414. O'ConnorP , LublinF , WolinskyJ , ComiG , KapposL , FreedmanM , et al. Effect of teriflunomide on relapses leading to healthcare resource use: results from the TEMSO study. Multiple Sclerosis2011;17:S95‐6. O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: clinical and MRI data 5 years after initial randomization. Multiple Sclerosis2011;17:S414‐5. O'ConnorP , WolinskyJS , ConfavreuxC , ComiG , KapposL , OlssonTP , et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. New England Journal of Medicine2011;365(14):1293‐303. O'ConnorPW , LublinFD , WolinskyJS , ConfavreuxC , ComiG , FreedmanMS , et al. Teriflunomide reduces relapse‐related neurological sequelae, hospitalizations and steroid use. Journal of Neurology2013;260(10):2472‐80. WolinksyJS , WangL , TruffinetP , NarayanaPA , NelsonF , O'ConnorP . Magnetic resonance imaging as a surrogate for clinical endpoints in multiple sclerosis. Multiple Sclerosis2012;18:470‐1. WolinskyJS , NarayanaPA , NelsonF , DattaS , O'ConnorP , ConfavreuxC , et al. Magnetic resonance imaging outcomes from a phase Ⅲ trial of teriflunomide. Multiple Sclerosis2013;19(10):1310‐9. ">O'Connor 2011</a>)). Treatment duration of participants in <a href="./references#CD009882-bbs2-0001" title="ComiG , FreedmanMS , KapposL , MillerA , OlssonTP , WolinskyJS , et al. Effect of teriflunomide on lymphocyte and neutrophil counts in patients with relapsing multiple sclerosis: results from the TOWER study. Journal of the Neurological Sciences2013;333:e376. ConfavreuxC , O'ConnorP , ComiG , FreedmanMS , MillerAE , OlssonTP , et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet Neurology2014;13(3):247‐56. KapposL , ComiG , ConfavreuxC , FreedmanMS , MillerAE , OlssonTP , et al. The efficacy and safety of teriflunomide in patients with relapsing MS: results from TOWER, a phase Ⅲ, placebo‐controlled study. Multiple Sclerosis2012;18:50‐1. MillerA , KapposL , ComiG , ConfavreuxC , FreedmanM , OlssonT , et al. Teriflunomide efficacy and safety in patients with relapsing multiple sclerosis: results from tower, a second, pivotal, phase 3 placebo‐controlled study. Neurology. 2013; Vol. 80. MillerAE , MacdonellR , ComiG , FreedmanMS , KapposL , MaurerM , et al. Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study. Journal of Neurology2014;261(9):1781‐8. MosesH , FreedmanM , KapposL , MillerA , OlssonT , WolinskyJ , et al. Pre‐defined subgroups analyses of tower, a placebo‐controlled phase 3 trial of teriflunomide in patients with relapsing multiple sclerosis. Proceedings of the American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). O'ConnorP , LublinF , WolinskyJ , ComiG , ConfavreuxC , FreedmanM , et al. Teriflunomide reduces relapse‐related sequelae, hospitalizations and corticosteroid use: a post‐HOC analysis of the phase 3 TOWER study. Proceedings of The American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). ">Confavreux 2014</a> was variable, ending 48 weeks after the last participant was included (a maximum treatment duration of 173 weeks). Actually, the data on adverse events in <a href="./references#CD009882-bbs2-0001" title="ComiG , FreedmanMS , KapposL , MillerA , OlssonTP , WolinskyJS , et al. Effect of teriflunomide on lymphocyte and neutrophil counts in patients with relapsing multiple sclerosis: results from the TOWER study. Journal of the Neurological Sciences2013;333:e376. ConfavreuxC , O'ConnorP , ComiG , FreedmanMS , MillerAE , OlssonTP , et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet Neurology2014;13(3):247‐56. KapposL , ComiG , ConfavreuxC , FreedmanMS , MillerAE , OlssonTP , et al. The efficacy and safety of teriflunomide in patients with relapsing MS: results from TOWER, a phase Ⅲ, placebo‐controlled study. Multiple Sclerosis2012;18:50‐1. MillerA , KapposL , ComiG , ConfavreuxC , FreedmanM , OlssonT , et al. Teriflunomide efficacy and safety in patients with relapsing multiple sclerosis: results from tower, a second, pivotal, phase 3 placebo‐controlled study. Neurology. 2013; Vol. 80. MillerAE , MacdonellR , ComiG , FreedmanMS , KapposL , MaurerM , et al. Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study. Journal of Neurology2014;261(9):1781‐8. MosesH , FreedmanM , KapposL , MillerA , OlssonT , WolinskyJ , et al. Pre‐defined subgroups analyses of tower, a placebo‐controlled phase 3 trial of teriflunomide in patients with relapsing multiple sclerosis. Proceedings of the American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). O'ConnorP , LublinF , WolinskyJ , ComiG , ConfavreuxC , FreedmanM , et al. Teriflunomide reduces relapse‐related sequelae, hospitalizations and corticosteroid use: a post‐HOC analysis of the phase 3 TOWER study. Proceedings of The American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). ">Confavreux 2014</a> were not at 2 years. There was a heterogeneity in follow‐up period between the studies. Therefore, we did not combine the data on adverse events in <a href="./references#CD009882-bbs2-0001" title="ComiG , FreedmanMS , KapposL , MillerA , OlssonTP , WolinskyJS , et al. Effect of teriflunomide on lymphocyte and neutrophil counts in patients with relapsing multiple sclerosis: results from the TOWER study. Journal of the Neurological Sciences2013;333:e376. ConfavreuxC , O'ConnorP , ComiG , FreedmanMS , MillerAE , OlssonTP , et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet Neurology2014;13(3):247‐56. KapposL , ComiG , ConfavreuxC , FreedmanMS , MillerAE , OlssonTP , et al. The efficacy and safety of teriflunomide in patients with relapsing MS: results from TOWER, a phase Ⅲ, placebo‐controlled study. Multiple Sclerosis2012;18:50‐1. MillerA , KapposL , ComiG , ConfavreuxC , FreedmanM , OlssonT , et al. Teriflunomide efficacy and safety in patients with relapsing multiple sclerosis: results from tower, a second, pivotal, phase 3 placebo‐controlled study. Neurology. 2013; Vol. 80. MillerAE , MacdonellR , ComiG , FreedmanMS , KapposL , MaurerM , et al. Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study. Journal of Neurology2014;261(9):1781‐8. MosesH , FreedmanM , KapposL , MillerA , OlssonT , WolinskyJ , et al. Pre‐defined subgroups analyses of tower, a placebo‐controlled phase 3 trial of teriflunomide in patients with relapsing multiple sclerosis. Proceedings of the American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). O'ConnorP , LublinF , WolinskyJ , ComiG , ConfavreuxC , FreedmanM , et al. Teriflunomide reduces relapse‐related sequelae, hospitalizations and corticosteroid use: a post‐HOC analysis of the phase 3 TOWER study. Proceedings of The American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). ">Confavreux 2014</a> and <a href="./references#CD009882-bbs2-0004" title="ComiG , BenzerdjebH , WangL , TruffinetP , O'ConnorP . Effect of teriflunomide on lymphocyte and neutrophil levels in patients with relapsing multiple sclerosis: results from the TEMSO study. Journal of Neurological Science2013;333(Suppl 1):e376. ComiG , O'ConnorP , WolinskyJ , ConfavreuxC , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: safety outcomes with up to 4 years of follow‐Up. Multiple Sclerosis2011;17:S182‐3. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Long‐term safety and efficacy of teriflunomide in patients with relapsing forms of multiple sclerosis in the TEMSO extension trial. Multiple Sclerosis2013;19:225. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Safety and efficacy of teriflunomide for up to 9 years in relapsing forms of multiple sclerosis: Update of the TEMSO extension trial. Neurology2014; Vol. 82, issue Suppl 10:3‐150. FreedmanMS , DelhayJL , BenamorM . Gastrointestinal symptoms infrequently lead to discontinuation of teriflunomide therapy. Multiple Sclerosis2012;18:S13. MillerA , LublinF , O'ConnorP , TaniouC , Dive‐PoulettyC . Impact of relapses with sequelae on disability, health‐related quality of life, and fatigue in a population with relapsing forms of multiple sclerosis using data from TEMSO, a pivotal phase Ⅲ teriflunomide trial. Neurology2012;78:P07.082. MillerA , LublinF , O'ConnorP , WolinskyJ , ComiG , KapposL , et al. Effect of teriflunomide on relapses with sequelae and relapse leading to hospitalization in a population with relapsing forms of multiple sclerosis: results from the TEMSO study. Neurology2012;78:S30.003. MillerA , O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , et al. Efficacy of oral teriflunomide in multiple sclerosis with relapses: cognitive outcomes from a phase Ⅲ trial (TEMSO). Multiple Sclerosis2011;17:S182. MillerAE , O'ConnorP , WolinskyJS , ConfavreuxC , KapposL , OlssonTP , et al. Pre‐specified subgroup analyses of a placebo‐controlled phase Ⅲ trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis. Multiple Sclerosis2012;18(11):1625‐32. O'ConnorP , BriggsA , CaritaP , Bego‐Le‐BagousseG . Impact on health‐related quality of life of teriflunomide treatment by estimating utilities in patients with relapsing multiple sclerosis: results from TEMSO post hoc analysis. Journal of Neurology2012;259:S107. O'ConnorP , BurrellA , WangL , WeiL , CaritaP , ZhangQ . Effect of teriflunomide on longitudinal patterns of relapse and relapse‐related hospitalization in multiple sclerosis. Multiple Sclerosis2011;17:S414. O'ConnorP , LublinF , WolinskyJ , ComiG , KapposL , FreedmanM , et al. Effect of teriflunomide on relapses leading to healthcare resource use: results from the TEMSO study. Multiple Sclerosis2011;17:S95‐6. O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: clinical and MRI data 5 years after initial randomization. Multiple Sclerosis2011;17:S414‐5. O'ConnorP , WolinskyJS , ConfavreuxC , ComiG , KapposL , OlssonTP , et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. New England Journal of Medicine2011;365(14):1293‐303. O'ConnorPW , LublinFD , WolinskyJS , ConfavreuxC , ComiG , FreedmanMS , et al. Teriflunomide reduces relapse‐related neurological sequelae, hospitalizations and steroid use. Journal of Neurology2013;260(10):2472‐80. WolinksyJS , WangL , TruffinetP , NarayanaPA , NelsonF , O'ConnorP . Magnetic resonance imaging as a surrogate for clinical endpoints in multiple sclerosis. Multiple Sclerosis2012;18:470‐1. WolinskyJS , NarayanaPA , NelsonF , DattaS , O'ConnorP , ConfavreuxC , et al. Magnetic resonance imaging outcomes from a phase Ⅲ trial of teriflunomide. Multiple Sclerosis2013;19(10):1310‐9. ">O'Connor 2011</a> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>The proportion of participants with elevated ALT levels at 2 years</b> <br/> Follow‐up: 2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>67 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>143 per 1000</b> <br/> (90 to 226) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.14</b> <br/> (1.35 to 3.39) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>718<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>f</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The follow‐up periods were diverse in <a href="./references#CD009882-bbs2-0001" title="ComiG , FreedmanMS , KapposL , MillerA , OlssonTP , WolinskyJS , et al. Effect of teriflunomide on lymphocyte and neutrophil counts in patients with relapsing multiple sclerosis: results from the TOWER study. Journal of the Neurological Sciences2013;333:e376. ConfavreuxC , O'ConnorP , ComiG , FreedmanMS , MillerAE , OlssonTP , et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet Neurology2014;13(3):247‐56. KapposL , ComiG , ConfavreuxC , FreedmanMS , MillerAE , OlssonTP , et al. The efficacy and safety of teriflunomide in patients with relapsing MS: results from TOWER, a phase Ⅲ, placebo‐controlled study. Multiple Sclerosis2012;18:50‐1. MillerA , KapposL , ComiG , ConfavreuxC , FreedmanM , OlssonT , et al. Teriflunomide efficacy and safety in patients with relapsing multiple sclerosis: results from tower, a second, pivotal, phase 3 placebo‐controlled study. Neurology. 2013; Vol. 80. MillerAE , MacdonellR , ComiG , FreedmanMS , KapposL , MaurerM , et al. Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study. Journal of Neurology2014;261(9):1781‐8. MosesH , FreedmanM , KapposL , MillerA , OlssonT , WolinskyJ , et al. Pre‐defined subgroups analyses of tower, a placebo‐controlled phase 3 trial of teriflunomide in patients with relapsing multiple sclerosis. Proceedings of the American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). O'ConnorP , LublinF , WolinskyJ , ComiG , ConfavreuxC , FreedmanM , et al. Teriflunomide reduces relapse‐related sequelae, hospitalizations and corticosteroid use: a post‐HOC analysis of the phase 3 TOWER study. Proceedings of The American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). ">Confavreux 2014</a> and <a href="./references#CD009882-bbs2-0004" title="ComiG , BenzerdjebH , WangL , TruffinetP , O'ConnorP . Effect of teriflunomide on lymphocyte and neutrophil levels in patients with relapsing multiple sclerosis: results from the TEMSO study. Journal of Neurological Science2013;333(Suppl 1):e376. ComiG , O'ConnorP , WolinskyJ , ConfavreuxC , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: safety outcomes with up to 4 years of follow‐Up. Multiple Sclerosis2011;17:S182‐3. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Long‐term safety and efficacy of teriflunomide in patients with relapsing forms of multiple sclerosis in the TEMSO extension trial. Multiple Sclerosis2013;19:225. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Safety and efficacy of teriflunomide for up to 9 years in relapsing forms of multiple sclerosis: Update of the TEMSO extension trial. Neurology2014; Vol. 82, issue Suppl 10:3‐150. FreedmanMS , DelhayJL , BenamorM . Gastrointestinal symptoms infrequently lead to discontinuation of teriflunomide therapy. Multiple Sclerosis2012;18:S13. MillerA , LublinF , O'ConnorP , TaniouC , Dive‐PoulettyC . Impact of relapses with sequelae on disability, health‐related quality of life, and fatigue in a population with relapsing forms of multiple sclerosis using data from TEMSO, a pivotal phase Ⅲ teriflunomide trial. Neurology2012;78:P07.082. MillerA , LublinF , O'ConnorP , WolinskyJ , ComiG , KapposL , et al. Effect of teriflunomide on relapses with sequelae and relapse leading to hospitalization in a population with relapsing forms of multiple sclerosis: results from the TEMSO study. Neurology2012;78:S30.003. MillerA , O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , et al. Efficacy of oral teriflunomide in multiple sclerosis with relapses: cognitive outcomes from a phase Ⅲ trial (TEMSO). Multiple Sclerosis2011;17:S182. MillerAE , O'ConnorP , WolinskyJS , ConfavreuxC , KapposL , OlssonTP , et al. Pre‐specified subgroup analyses of a placebo‐controlled phase Ⅲ trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis. Multiple Sclerosis2012;18(11):1625‐32. O'ConnorP , BriggsA , CaritaP , Bego‐Le‐BagousseG . Impact on health‐related quality of life of teriflunomide treatment by estimating utilities in patients with relapsing multiple sclerosis: results from TEMSO post hoc analysis. Journal of Neurology2012;259:S107. O'ConnorP , BurrellA , WangL , WeiL , CaritaP , ZhangQ . Effect of teriflunomide on longitudinal patterns of relapse and relapse‐related hospitalization in multiple sclerosis. Multiple Sclerosis2011;17:S414. O'ConnorP , LublinF , WolinskyJ , ComiG , KapposL , FreedmanM , et al. Effect of teriflunomide on relapses leading to healthcare resource use: results from the TEMSO study. Multiple Sclerosis2011;17:S95‐6. O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: clinical and MRI data 5 years after initial randomization. Multiple Sclerosis2011;17:S414‐5. O'ConnorP , WolinskyJS , ConfavreuxC , ComiG , KapposL , OlssonTP , et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. New England Journal of Medicine2011;365(14):1293‐303. O'ConnorPW , LublinFD , WolinskyJS , ConfavreuxC , ComiG , FreedmanMS , et al. Teriflunomide reduces relapse‐related neurological sequelae, hospitalizations and steroid use. Journal of Neurology2013;260(10):2472‐80. WolinksyJS , WangL , TruffinetP , NarayanaPA , NelsonF , O'ConnorP . Magnetic resonance imaging as a surrogate for clinical endpoints in multiple sclerosis. Multiple Sclerosis2012;18:470‐1. WolinskyJS , NarayanaPA , NelsonF , DattaS , O'ConnorP , ConfavreuxC , et al. Magnetic resonance imaging outcomes from a phase Ⅲ trial of teriflunomide. Multiple Sclerosis2013;19(10):1310‐9. ">O'Connor 2011</a> (at least 48 weeks (<a href="./references#CD009882-bbs2-0001" title="ComiG , FreedmanMS , KapposL , MillerA , OlssonTP , WolinskyJS , et al. Effect of teriflunomide on lymphocyte and neutrophil counts in patients with relapsing multiple sclerosis: results from the TOWER study. Journal of the Neurological Sciences2013;333:e376. ConfavreuxC , O'ConnorP , ComiG , FreedmanMS , MillerAE , OlssonTP , et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet Neurology2014;13(3):247‐56. KapposL , ComiG , ConfavreuxC , FreedmanMS , MillerAE , OlssonTP , et al. The efficacy and safety of teriflunomide in patients with relapsing MS: results from TOWER, a phase Ⅲ, placebo‐controlled study. Multiple Sclerosis2012;18:50‐1. MillerA , KapposL , ComiG , ConfavreuxC , FreedmanM , OlssonT , et al. Teriflunomide efficacy and safety in patients with relapsing multiple sclerosis: results from tower, a second, pivotal, phase 3 placebo‐controlled study. Neurology. 2013; Vol. 80. MillerAE , MacdonellR , ComiG , FreedmanMS , KapposL , MaurerM , et al. Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study. Journal of Neurology2014;261(9):1781‐8. MosesH , FreedmanM , KapposL , MillerA , OlssonT , WolinskyJ , et al. Pre‐defined subgroups analyses of tower, a placebo‐controlled phase 3 trial of teriflunomide in patients with relapsing multiple sclerosis. Proceedings of the American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). O'ConnorP , LublinF , WolinskyJ , ComiG , ConfavreuxC , FreedmanM , et al. Teriflunomide reduces relapse‐related sequelae, hospitalizations and corticosteroid use: a post‐HOC analysis of the phase 3 TOWER study. Proceedings of The American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). ">Confavreux 2014</a>) and 108 weeks (<a href="./references#CD009882-bbs2-0004" title="ComiG , BenzerdjebH , WangL , TruffinetP , O'ConnorP . Effect of teriflunomide on lymphocyte and neutrophil levels in patients with relapsing multiple sclerosis: results from the TEMSO study. Journal of Neurological Science2013;333(Suppl 1):e376. ComiG , O'ConnorP , WolinskyJ , ConfavreuxC , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: safety outcomes with up to 4 years of follow‐Up. Multiple Sclerosis2011;17:S182‐3. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Long‐term safety and efficacy of teriflunomide in patients with relapsing forms of multiple sclerosis in the TEMSO extension trial. Multiple Sclerosis2013;19:225. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Safety and efficacy of teriflunomide for up to 9 years in relapsing forms of multiple sclerosis: Update of the TEMSO extension trial. Neurology2014; Vol. 82, issue Suppl 10:3‐150. FreedmanMS , DelhayJL , BenamorM . Gastrointestinal symptoms infrequently lead to discontinuation of teriflunomide therapy. Multiple Sclerosis2012;18:S13. MillerA , LublinF , O'ConnorP , TaniouC , Dive‐PoulettyC . Impact of relapses with sequelae on disability, health‐related quality of life, and fatigue in a population with relapsing forms of multiple sclerosis using data from TEMSO, a pivotal phase Ⅲ teriflunomide trial. Neurology2012;78:P07.082. MillerA , LublinF , O'ConnorP , WolinskyJ , ComiG , KapposL , et al. Effect of teriflunomide on relapses with sequelae and relapse leading to hospitalization in a population with relapsing forms of multiple sclerosis: results from the TEMSO study. Neurology2012;78:S30.003. MillerA , O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , et al. Efficacy of oral teriflunomide in multiple sclerosis with relapses: cognitive outcomes from a phase Ⅲ trial (TEMSO). Multiple Sclerosis2011;17:S182. MillerAE , O'ConnorP , WolinskyJS , ConfavreuxC , KapposL , OlssonTP , et al. Pre‐specified subgroup analyses of a placebo‐controlled phase Ⅲ trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis. Multiple Sclerosis2012;18(11):1625‐32. O'ConnorP , BriggsA , CaritaP , Bego‐Le‐BagousseG . Impact on health‐related quality of life of teriflunomide treatment by estimating utilities in patients with relapsing multiple sclerosis: results from TEMSO post hoc analysis. Journal of Neurology2012;259:S107. O'ConnorP , BurrellA , WangL , WeiL , CaritaP , ZhangQ . Effect of teriflunomide on longitudinal patterns of relapse and relapse‐related hospitalization in multiple sclerosis. Multiple Sclerosis2011;17:S414. O'ConnorP , LublinF , WolinskyJ , ComiG , KapposL , FreedmanM , et al. Effect of teriflunomide on relapses leading to healthcare resource use: results from the TEMSO study. Multiple Sclerosis2011;17:S95‐6. O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: clinical and MRI data 5 years after initial randomization. Multiple Sclerosis2011;17:S414‐5. O'ConnorP , WolinskyJS , ConfavreuxC , ComiG , KapposL , OlssonTP , et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. New England Journal of Medicine2011;365(14):1293‐303. O'ConnorPW , LublinFD , WolinskyJS , ConfavreuxC , ComiG , FreedmanMS , et al. Teriflunomide reduces relapse‐related neurological sequelae, hospitalizations and steroid use. Journal of Neurology2013;260(10):2472‐80. WolinksyJS , WangL , TruffinetP , NarayanaPA , NelsonF , O'ConnorP . Magnetic resonance imaging as a surrogate for clinical endpoints in multiple sclerosis. Multiple Sclerosis2012;18:470‐1. WolinskyJS , NarayanaPA , NelsonF , DattaS , O'ConnorP , ConfavreuxC , et al. Magnetic resonance imaging outcomes from a phase Ⅲ trial of teriflunomide. Multiple Sclerosis2013;19(10):1310‐9. ">O'Connor 2011</a>)). Treatment duration of participants in <a href="./references#CD009882-bbs2-0001" title="ComiG , FreedmanMS , KapposL , MillerA , OlssonTP , WolinskyJS , et al. Effect of teriflunomide on lymphocyte and neutrophil counts in patients with relapsing multiple sclerosis: results from the TOWER study. Journal of the Neurological Sciences2013;333:e376. ConfavreuxC , O'ConnorP , ComiG , FreedmanMS , MillerAE , OlssonTP , et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet Neurology2014;13(3):247‐56. KapposL , ComiG , ConfavreuxC , FreedmanMS , MillerAE , OlssonTP , et al. The efficacy and safety of teriflunomide in patients with relapsing MS: results from TOWER, a phase Ⅲ, placebo‐controlled study. Multiple Sclerosis2012;18:50‐1. MillerA , KapposL , ComiG , ConfavreuxC , FreedmanM , OlssonT , et al. Teriflunomide efficacy and safety in patients with relapsing multiple sclerosis: results from tower, a second, pivotal, phase 3 placebo‐controlled study. Neurology. 2013; Vol. 80. MillerAE , MacdonellR , ComiG , FreedmanMS , KapposL , MaurerM , et al. Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study. Journal of Neurology2014;261(9):1781‐8. MosesH , FreedmanM , KapposL , MillerA , OlssonT , WolinskyJ , et al. Pre‐defined subgroups analyses of tower, a placebo‐controlled phase 3 trial of teriflunomide in patients with relapsing multiple sclerosis. Proceedings of the American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). O'ConnorP , LublinF , WolinskyJ , ComiG , ConfavreuxC , FreedmanM , et al. Teriflunomide reduces relapse‐related sequelae, hospitalizations and corticosteroid use: a post‐HOC analysis of the phase 3 TOWER study. Proceedings of The American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). ">Confavreux 2014</a> was variable, ending 48 weeks after the last participant was included (a maximum treatment duration of 173 weeks). Actually, the data on adverse events in <a href="./references#CD009882-bbs2-0001" title="ComiG , FreedmanMS , KapposL , MillerA , OlssonTP , WolinskyJS , et al. Effect of teriflunomide on lymphocyte and neutrophil counts in patients with relapsing multiple sclerosis: results from the TOWER study. Journal of the Neurological Sciences2013;333:e376. ConfavreuxC , O'ConnorP , ComiG , FreedmanMS , MillerAE , OlssonTP , et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet Neurology2014;13(3):247‐56. KapposL , ComiG , ConfavreuxC , FreedmanMS , MillerAE , OlssonTP , et al. The efficacy and safety of teriflunomide in patients with relapsing MS: results from TOWER, a phase Ⅲ, placebo‐controlled study. Multiple Sclerosis2012;18:50‐1. MillerA , KapposL , ComiG , ConfavreuxC , FreedmanM , OlssonT , et al. Teriflunomide efficacy and safety in patients with relapsing multiple sclerosis: results from tower, a second, pivotal, phase 3 placebo‐controlled study. Neurology. 2013; Vol. 80. MillerAE , MacdonellR , ComiG , FreedmanMS , KapposL , MaurerM , et al. Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study. Journal of Neurology2014;261(9):1781‐8. MosesH , FreedmanM , KapposL , MillerA , OlssonT , WolinskyJ , et al. Pre‐defined subgroups analyses of tower, a placebo‐controlled phase 3 trial of teriflunomide in patients with relapsing multiple sclerosis. Proceedings of the American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). O'ConnorP , LublinF , WolinskyJ , ComiG , ConfavreuxC , FreedmanM , et al. Teriflunomide reduces relapse‐related sequelae, hospitalizations and corticosteroid use: a post‐HOC analysis of the phase 3 TOWER study. Proceedings of The American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). ">Confavreux 2014</a> were not at 2 years. There was a heterogeneity in follow‐up period between the studies. Therefore, we did not combine the data on adverse events in <a href="./references#CD009882-bbs2-0001" title="ComiG , FreedmanMS , KapposL , MillerA , OlssonTP , WolinskyJS , et al. Effect of teriflunomide on lymphocyte and neutrophil counts in patients with relapsing multiple sclerosis: results from the TOWER study. Journal of the Neurological Sciences2013;333:e376. ConfavreuxC , O'ConnorP , ComiG , FreedmanMS , MillerAE , OlssonTP , et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet Neurology2014;13(3):247‐56. KapposL , ComiG , ConfavreuxC , FreedmanMS , MillerAE , OlssonTP , et al. The efficacy and safety of teriflunomide in patients with relapsing MS: results from TOWER, a phase Ⅲ, placebo‐controlled study. Multiple Sclerosis2012;18:50‐1. MillerA , KapposL , ComiG , ConfavreuxC , FreedmanM , OlssonT , et al. Teriflunomide efficacy and safety in patients with relapsing multiple sclerosis: results from tower, a second, pivotal, phase 3 placebo‐controlled study. Neurology. 2013; Vol. 80. MillerAE , MacdonellR , ComiG , FreedmanMS , KapposL , MaurerM , et al. Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study. Journal of Neurology2014;261(9):1781‐8. MosesH , FreedmanM , KapposL , MillerA , OlssonT , WolinskyJ , et al. Pre‐defined subgroups analyses of tower, a placebo‐controlled phase 3 trial of teriflunomide in patients with relapsing multiple sclerosis. Proceedings of the American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). O'ConnorP , LublinF , WolinskyJ , ComiG , ConfavreuxC , FreedmanM , et al. Teriflunomide reduces relapse‐related sequelae, hospitalizations and corticosteroid use: a post‐HOC analysis of the phase 3 TOWER study. Proceedings of The American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). ">Confavreux 2014</a> and <a href="./references#CD009882-bbs2-0004" title="ComiG , BenzerdjebH , WangL , TruffinetP , O'ConnorP . Effect of teriflunomide on lymphocyte and neutrophil levels in patients with relapsing multiple sclerosis: results from the TEMSO study. Journal of Neurological Science2013;333(Suppl 1):e376. ComiG , O'ConnorP , WolinskyJ , ConfavreuxC , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: safety outcomes with up to 4 years of follow‐Up. Multiple Sclerosis2011;17:S182‐3. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Long‐term safety and efficacy of teriflunomide in patients with relapsing forms of multiple sclerosis in the TEMSO extension trial. Multiple Sclerosis2013;19:225. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Safety and efficacy of teriflunomide for up to 9 years in relapsing forms of multiple sclerosis: Update of the TEMSO extension trial. Neurology2014; Vol. 82, issue Suppl 10:3‐150. FreedmanMS , DelhayJL , BenamorM . Gastrointestinal symptoms infrequently lead to discontinuation of teriflunomide therapy. Multiple Sclerosis2012;18:S13. MillerA , LublinF , O'ConnorP , TaniouC , Dive‐PoulettyC . Impact of relapses with sequelae on disability, health‐related quality of life, and fatigue in a population with relapsing forms of multiple sclerosis using data from TEMSO, a pivotal phase Ⅲ teriflunomide trial. Neurology2012;78:P07.082. MillerA , LublinF , O'ConnorP , WolinskyJ , ComiG , KapposL , et al. Effect of teriflunomide on relapses with sequelae and relapse leading to hospitalization in a population with relapsing forms of multiple sclerosis: results from the TEMSO study. Neurology2012;78:S30.003. MillerA , O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , et al. Efficacy of oral teriflunomide in multiple sclerosis with relapses: cognitive outcomes from a phase Ⅲ trial (TEMSO). Multiple Sclerosis2011;17:S182. MillerAE , O'ConnorP , WolinskyJS , ConfavreuxC , KapposL , OlssonTP , et al. Pre‐specified subgroup analyses of a placebo‐controlled phase Ⅲ trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis. Multiple Sclerosis2012;18(11):1625‐32. O'ConnorP , BriggsA , CaritaP , Bego‐Le‐BagousseG . Impact on health‐related quality of life of teriflunomide treatment by estimating utilities in patients with relapsing multiple sclerosis: results from TEMSO post hoc analysis. Journal of Neurology2012;259:S107. O'ConnorP , BurrellA , WangL , WeiL , CaritaP , ZhangQ . Effect of teriflunomide on longitudinal patterns of relapse and relapse‐related hospitalization in multiple sclerosis. Multiple Sclerosis2011;17:S414. O'ConnorP , LublinF , WolinskyJ , ComiG , KapposL , FreedmanM , et al. Effect of teriflunomide on relapses leading to healthcare resource use: results from the TEMSO study. Multiple Sclerosis2011;17:S95‐6. O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: clinical and MRI data 5 years after initial randomization. Multiple Sclerosis2011;17:S414‐5. O'ConnorP , WolinskyJS , ConfavreuxC , ComiG , KapposL , OlssonTP , et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. New England Journal of Medicine2011;365(14):1293‐303. O'ConnorPW , LublinFD , WolinskyJS , ConfavreuxC , ComiG , FreedmanMS , et al. Teriflunomide reduces relapse‐related neurological sequelae, hospitalizations and steroid use. Journal of Neurology2013;260(10):2472‐80. WolinksyJS , WangL , TruffinetP , NarayanaPA , NelsonF , O'ConnorP . Magnetic resonance imaging as a surrogate for clinical endpoints in multiple sclerosis. Multiple Sclerosis2012;18:470‐1. WolinskyJS , NarayanaPA , NelsonF , DattaS , O'ConnorP , ConfavreuxC , et al. Magnetic resonance imaging outcomes from a phase Ⅲ trial of teriflunomide. Multiple Sclerosis2013;19(10):1310‐9. ">O'Connor 2011</a> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for <b>assumed risk</b> is the placebo group risk. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>ALT: a</b> lanine aminotransferase; <b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> <p>The assumed risk was defined as placebo group risk because only one study was evaluated.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> High risks of bias existed in <a href="./references#CD009882-bbs2-0001" title="ComiG , FreedmanMS , KapposL , MillerA , OlssonTP , WolinskyJS , et al. Effect of teriflunomide on lymphocyte and neutrophil counts in patients with relapsing multiple sclerosis: results from the TOWER study. Journal of the Neurological Sciences2013;333:e376. ConfavreuxC , O'ConnorP , ComiG , FreedmanMS , MillerAE , OlssonTP , et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet Neurology2014;13(3):247‐56. KapposL , ComiG , ConfavreuxC , FreedmanMS , MillerAE , OlssonTP , et al. The efficacy and safety of teriflunomide in patients with relapsing MS: results from TOWER, a phase Ⅲ, placebo‐controlled study. Multiple Sclerosis2012;18:50‐1. MillerA , KapposL , ComiG , ConfavreuxC , FreedmanM , OlssonT , et al. Teriflunomide efficacy and safety in patients with relapsing multiple sclerosis: results from tower, a second, pivotal, phase 3 placebo‐controlled study. Neurology. 2013; Vol. 80. MillerAE , MacdonellR , ComiG , FreedmanMS , KapposL , MaurerM , et al. Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study. Journal of Neurology2014;261(9):1781‐8. MosesH , FreedmanM , KapposL , MillerA , OlssonT , WolinskyJ , et al. Pre‐defined subgroups analyses of tower, a placebo‐controlled phase 3 trial of teriflunomide in patients with relapsing multiple sclerosis. Proceedings of the American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). O'ConnorP , LublinF , WolinskyJ , ComiG , ConfavreuxC , FreedmanM , et al. Teriflunomide reduces relapse‐related sequelae, hospitalizations and corticosteroid use: a post‐HOC analysis of the phase 3 TOWER study. Proceedings of The American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). ">Confavreux 2014</a> due to unblinded assessments for relapse and conflicts of interest. </p> <p><sup>b</sup> High risks of bias existed in <a href="./references#CD009882-bbs2-0004" title="ComiG , BenzerdjebH , WangL , TruffinetP , O'ConnorP . Effect of teriflunomide on lymphocyte and neutrophil levels in patients with relapsing multiple sclerosis: results from the TEMSO study. Journal of Neurological Science2013;333(Suppl 1):e376. ComiG , O'ConnorP , WolinskyJ , ConfavreuxC , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: safety outcomes with up to 4 years of follow‐Up. Multiple Sclerosis2011;17:S182‐3. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Long‐term safety and efficacy of teriflunomide in patients with relapsing forms of multiple sclerosis in the TEMSO extension trial. Multiple Sclerosis2013;19:225. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Safety and efficacy of teriflunomide for up to 9 years in relapsing forms of multiple sclerosis: Update of the TEMSO extension trial. Neurology2014; Vol. 82, issue Suppl 10:3‐150. FreedmanMS , DelhayJL , BenamorM . Gastrointestinal symptoms infrequently lead to discontinuation of teriflunomide therapy. Multiple Sclerosis2012;18:S13. MillerA , LublinF , O'ConnorP , TaniouC , Dive‐PoulettyC . Impact of relapses with sequelae on disability, health‐related quality of life, and fatigue in a population with relapsing forms of multiple sclerosis using data from TEMSO, a pivotal phase Ⅲ teriflunomide trial. Neurology2012;78:P07.082. MillerA , LublinF , O'ConnorP , WolinskyJ , ComiG , KapposL , et al. Effect of teriflunomide on relapses with sequelae and relapse leading to hospitalization in a population with relapsing forms of multiple sclerosis: results from the TEMSO study. Neurology2012;78:S30.003. MillerA , O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , et al. Efficacy of oral teriflunomide in multiple sclerosis with relapses: cognitive outcomes from a phase Ⅲ trial (TEMSO). Multiple Sclerosis2011;17:S182. MillerAE , O'ConnorP , WolinskyJS , ConfavreuxC , KapposL , OlssonTP , et al. Pre‐specified subgroup analyses of a placebo‐controlled phase Ⅲ trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis. Multiple Sclerosis2012;18(11):1625‐32. O'ConnorP , BriggsA , CaritaP , Bego‐Le‐BagousseG . Impact on health‐related quality of life of teriflunomide treatment by estimating utilities in patients with relapsing multiple sclerosis: results from TEMSO post hoc analysis. Journal of Neurology2012;259:S107. O'ConnorP , BurrellA , WangL , WeiL , CaritaP , ZhangQ . Effect of teriflunomide on longitudinal patterns of relapse and relapse‐related hospitalization in multiple sclerosis. Multiple Sclerosis2011;17:S414. O'ConnorP , LublinF , WolinskyJ , ComiG , KapposL , FreedmanM , et al. Effect of teriflunomide on relapses leading to healthcare resource use: results from the TEMSO study. Multiple Sclerosis2011;17:S95‐6. O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: clinical and MRI data 5 years after initial randomization. Multiple Sclerosis2011;17:S414‐5. O'ConnorP , WolinskyJS , ConfavreuxC , ComiG , KapposL , OlssonTP , et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. New England Journal of Medicine2011;365(14):1293‐303. O'ConnorPW , LublinFD , WolinskyJS , ConfavreuxC , ComiG , FreedmanMS , et al. Teriflunomide reduces relapse‐related neurological sequelae, hospitalizations and steroid use. Journal of Neurology2013;260(10):2472‐80. WolinksyJS , WangL , TruffinetP , NarayanaPA , NelsonF , O'ConnorP . Magnetic resonance imaging as a surrogate for clinical endpoints in multiple sclerosis. Multiple Sclerosis2012;18:470‐1. WolinskyJS , NarayanaPA , NelsonF , DattaS , O'ConnorP , ConfavreuxC , et al. Magnetic resonance imaging outcomes from a phase Ⅲ trial of teriflunomide. Multiple Sclerosis2013;19(10):1310‐9. ">O'Connor 2011</a> due to unblinded assessments for relapse and conflicts of interest. </p> <p><sup>c</sup> High risks of bias existed in <a href="./references#CD009882-bbs2-0001" title="ComiG , FreedmanMS , KapposL , MillerA , OlssonTP , WolinskyJS , et al. Effect of teriflunomide on lymphocyte and neutrophil counts in patients with relapsing multiple sclerosis: results from the TOWER study. Journal of the Neurological Sciences2013;333:e376. ConfavreuxC , O'ConnorP , ComiG , FreedmanMS , MillerAE , OlssonTP , et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet Neurology2014;13(3):247‐56. KapposL , ComiG , ConfavreuxC , FreedmanMS , MillerAE , OlssonTP , et al. The efficacy and safety of teriflunomide in patients with relapsing MS: results from TOWER, a phase Ⅲ, placebo‐controlled study. Multiple Sclerosis2012;18:50‐1. MillerA , KapposL , ComiG , ConfavreuxC , FreedmanM , OlssonT , et al. Teriflunomide efficacy and safety in patients with relapsing multiple sclerosis: results from tower, a second, pivotal, phase 3 placebo‐controlled study. Neurology. 2013; Vol. 80. MillerAE , MacdonellR , ComiG , FreedmanMS , KapposL , MaurerM , et al. Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study. Journal of Neurology2014;261(9):1781‐8. MosesH , FreedmanM , KapposL , MillerA , OlssonT , WolinskyJ , et al. Pre‐defined subgroups analyses of tower, a placebo‐controlled phase 3 trial of teriflunomide in patients with relapsing multiple sclerosis. Proceedings of the American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). O'ConnorP , LublinF , WolinskyJ , ComiG , ConfavreuxC , FreedmanM , et al. Teriflunomide reduces relapse‐related sequelae, hospitalizations and corticosteroid use: a post‐HOC analysis of the phase 3 TOWER study. Proceedings of The American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). ">Confavreux 2014</a> due to effects of the high attrition bias on progression disability and conflicts of interest. </p> <p><sup>d</sup> High risk of bias existed in <a href="./references#CD009882-bbs2-0004" title="ComiG , BenzerdjebH , WangL , TruffinetP , O'ConnorP . Effect of teriflunomide on lymphocyte and neutrophil levels in patients with relapsing multiple sclerosis: results from the TEMSO study. Journal of Neurological Science2013;333(Suppl 1):e376. ComiG , O'ConnorP , WolinskyJ , ConfavreuxC , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: safety outcomes with up to 4 years of follow‐Up. Multiple Sclerosis2011;17:S182‐3. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Long‐term safety and efficacy of teriflunomide in patients with relapsing forms of multiple sclerosis in the TEMSO extension trial. Multiple Sclerosis2013;19:225. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Safety and efficacy of teriflunomide for up to 9 years in relapsing forms of multiple sclerosis: Update of the TEMSO extension trial. Neurology2014; Vol. 82, issue Suppl 10:3‐150. FreedmanMS , DelhayJL , BenamorM . Gastrointestinal symptoms infrequently lead to discontinuation of teriflunomide therapy. Multiple Sclerosis2012;18:S13. MillerA , LublinF , O'ConnorP , TaniouC , Dive‐PoulettyC . Impact of relapses with sequelae on disability, health‐related quality of life, and fatigue in a population with relapsing forms of multiple sclerosis using data from TEMSO, a pivotal phase Ⅲ teriflunomide trial. Neurology2012;78:P07.082. MillerA , LublinF , O'ConnorP , WolinskyJ , ComiG , KapposL , et al. Effect of teriflunomide on relapses with sequelae and relapse leading to hospitalization in a population with relapsing forms of multiple sclerosis: results from the TEMSO study. Neurology2012;78:S30.003. MillerA , O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , et al. Efficacy of oral teriflunomide in multiple sclerosis with relapses: cognitive outcomes from a phase Ⅲ trial (TEMSO). Multiple Sclerosis2011;17:S182. MillerAE , O'ConnorP , WolinskyJS , ConfavreuxC , KapposL , OlssonTP , et al. Pre‐specified subgroup analyses of a placebo‐controlled phase Ⅲ trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis. Multiple Sclerosis2012;18(11):1625‐32. O'ConnorP , BriggsA , CaritaP , Bego‐Le‐BagousseG . Impact on health‐related quality of life of teriflunomide treatment by estimating utilities in patients with relapsing multiple sclerosis: results from TEMSO post hoc analysis. Journal of Neurology2012;259:S107. O'ConnorP , BurrellA , WangL , WeiL , CaritaP , ZhangQ . Effect of teriflunomide on longitudinal patterns of relapse and relapse‐related hospitalization in multiple sclerosis. Multiple Sclerosis2011;17:S414. O'ConnorP , LublinF , WolinskyJ , ComiG , KapposL , FreedmanM , et al. Effect of teriflunomide on relapses leading to healthcare resource use: results from the TEMSO study. Multiple Sclerosis2011;17:S95‐6. O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: clinical and MRI data 5 years after initial randomization. Multiple Sclerosis2011;17:S414‐5. O'ConnorP , WolinskyJS , ConfavreuxC , ComiG , KapposL , OlssonTP , et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. New England Journal of Medicine2011;365(14):1293‐303. O'ConnorPW , LublinFD , WolinskyJS , ConfavreuxC , ComiG , FreedmanMS , et al. Teriflunomide reduces relapse‐related neurological sequelae, hospitalizations and steroid use. Journal of Neurology2013;260(10):2472‐80. WolinksyJS , WangL , TruffinetP , NarayanaPA , NelsonF , O'ConnorP . Magnetic resonance imaging as a surrogate for clinical endpoints in multiple sclerosis. Multiple Sclerosis2012;18:470‐1. WolinskyJS , NarayanaPA , NelsonF , DattaS , O'ConnorP , ConfavreuxC , et al. Magnetic resonance imaging outcomes from a phase Ⅲ trial of teriflunomide. Multiple Sclerosis2013;19(10):1310‐9. ">O'Connor 2011</a> due to effects of the unclear attrition bias on progression disability and conflicts of interest. </p> <p><sup>e</sup> Serious indirectness existed in <a href="./references#CD009882-bbs2-0001" title="ComiG , FreedmanMS , KapposL , MillerA , OlssonTP , WolinskyJS , et al. Effect of teriflunomide on lymphocyte and neutrophil counts in patients with relapsing multiple sclerosis: results from the TOWER study. Journal of the Neurological Sciences2013;333:e376. ConfavreuxC , O'ConnorP , ComiG , FreedmanMS , MillerAE , OlssonTP , et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet Neurology2014;13(3):247‐56. KapposL , ComiG , ConfavreuxC , FreedmanMS , MillerAE , OlssonTP , et al. The efficacy and safety of teriflunomide in patients with relapsing MS: results from TOWER, a phase Ⅲ, placebo‐controlled study. Multiple Sclerosis2012;18:50‐1. MillerA , KapposL , ComiG , ConfavreuxC , FreedmanM , OlssonT , et al. Teriflunomide efficacy and safety in patients with relapsing multiple sclerosis: results from tower, a second, pivotal, phase 3 placebo‐controlled study. Neurology. 2013; Vol. 80. MillerAE , MacdonellR , ComiG , FreedmanMS , KapposL , MaurerM , et al. Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study. Journal of Neurology2014;261(9):1781‐8. MosesH , FreedmanM , KapposL , MillerA , OlssonT , WolinskyJ , et al. Pre‐defined subgroups analyses of tower, a placebo‐controlled phase 3 trial of teriflunomide in patients with relapsing multiple sclerosis. Proceedings of the American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). O'ConnorP , LublinF , WolinskyJ , ComiG , ConfavreuxC , FreedmanM , et al. Teriflunomide reduces relapse‐related sequelae, hospitalizations and corticosteroid use: a post‐HOC analysis of the phase 3 TOWER study. Proceedings of The American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). ">Confavreux 2014</a> or in <a href="./references#CD009882-bbs2-0004" title="ComiG , BenzerdjebH , WangL , TruffinetP , O'ConnorP . Effect of teriflunomide on lymphocyte and neutrophil levels in patients with relapsing multiple sclerosis: results from the TEMSO study. Journal of Neurological Science2013;333(Suppl 1):e376. ComiG , O'ConnorP , WolinskyJ , ConfavreuxC , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: safety outcomes with up to 4 years of follow‐Up. Multiple Sclerosis2011;17:S182‐3. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Long‐term safety and efficacy of teriflunomide in patients with relapsing forms of multiple sclerosis in the TEMSO extension trial. Multiple Sclerosis2013;19:225. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Safety and efficacy of teriflunomide for up to 9 years in relapsing forms of multiple sclerosis: Update of the TEMSO extension trial. Neurology2014; Vol. 82, issue Suppl 10:3‐150. FreedmanMS , DelhayJL , BenamorM . Gastrointestinal symptoms infrequently lead to discontinuation of teriflunomide therapy. Multiple Sclerosis2012;18:S13. MillerA , LublinF , O'ConnorP , TaniouC , Dive‐PoulettyC . Impact of relapses with sequelae on disability, health‐related quality of life, and fatigue in a population with relapsing forms of multiple sclerosis using data from TEMSO, a pivotal phase Ⅲ teriflunomide trial. Neurology2012;78:P07.082. MillerA , LublinF , O'ConnorP , WolinskyJ , ComiG , KapposL , et al. Effect of teriflunomide on relapses with sequelae and relapse leading to hospitalization in a population with relapsing forms of multiple sclerosis: results from the TEMSO study. Neurology2012;78:S30.003. MillerA , O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , et al. Efficacy of oral teriflunomide in multiple sclerosis with relapses: cognitive outcomes from a phase Ⅲ trial (TEMSO). Multiple Sclerosis2011;17:S182. MillerAE , O'ConnorP , WolinskyJS , ConfavreuxC , KapposL , OlssonTP , et al. Pre‐specified subgroup analyses of a placebo‐controlled phase Ⅲ trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis. Multiple Sclerosis2012;18(11):1625‐32. O'ConnorP , BriggsA , CaritaP , Bego‐Le‐BagousseG . Impact on health‐related quality of life of teriflunomide treatment by estimating utilities in patients with relapsing multiple sclerosis: results from TEMSO post hoc analysis. Journal of Neurology2012;259:S107. O'ConnorP , BurrellA , WangL , WeiL , CaritaP , ZhangQ . Effect of teriflunomide on longitudinal patterns of relapse and relapse‐related hospitalization in multiple sclerosis. Multiple Sclerosis2011;17:S414. O'ConnorP , LublinF , WolinskyJ , ComiG , KapposL , FreedmanM , et al. Effect of teriflunomide on relapses leading to healthcare resource use: results from the TEMSO study. Multiple Sclerosis2011;17:S95‐6. O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: clinical and MRI data 5 years after initial randomization. Multiple Sclerosis2011;17:S414‐5. O'ConnorP , WolinskyJS , ConfavreuxC , ComiG , KapposL , OlssonTP , et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. New England Journal of Medicine2011;365(14):1293‐303. O'ConnorPW , LublinFD , WolinskyJS , ConfavreuxC , ComiG , FreedmanMS , et al. Teriflunomide reduces relapse‐related neurological sequelae, hospitalizations and steroid use. Journal of Neurology2013;260(10):2472‐80. WolinksyJS , WangL , TruffinetP , NarayanaPA , NelsonF , O'ConnorP . Magnetic resonance imaging as a surrogate for clinical endpoints in multiple sclerosis. Multiple Sclerosis2012;18:470‐1. WolinskyJS , NarayanaPA , NelsonF , DattaS , O'ConnorP , ConfavreuxC , et al. Magnetic resonance imaging outcomes from a phase Ⅲ trial of teriflunomide. Multiple Sclerosis2013;19(10):1310‐9. ">O'Connor 2011</a> because disability progression was confirmed at 3 months of follow‐up. </p> <p><sup>f</sup> High risk of bias existed in <a href="./references#CD009882-bbs2-0004" title="ComiG , BenzerdjebH , WangL , TruffinetP , O'ConnorP . Effect of teriflunomide on lymphocyte and neutrophil levels in patients with relapsing multiple sclerosis: results from the TEMSO study. Journal of Neurological Science2013;333(Suppl 1):e376. ComiG , O'ConnorP , WolinskyJ , ConfavreuxC , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: safety outcomes with up to 4 years of follow‐Up. Multiple Sclerosis2011;17:S182‐3. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Long‐term safety and efficacy of teriflunomide in patients with relapsing forms of multiple sclerosis in the TEMSO extension trial. Multiple Sclerosis2013;19:225. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Safety and efficacy of teriflunomide for up to 9 years in relapsing forms of multiple sclerosis: Update of the TEMSO extension trial. Neurology2014; Vol. 82, issue Suppl 10:3‐150. FreedmanMS , DelhayJL , BenamorM . Gastrointestinal symptoms infrequently lead to discontinuation of teriflunomide therapy. Multiple Sclerosis2012;18:S13. MillerA , LublinF , O'ConnorP , TaniouC , Dive‐PoulettyC . Impact of relapses with sequelae on disability, health‐related quality of life, and fatigue in a population with relapsing forms of multiple sclerosis using data from TEMSO, a pivotal phase Ⅲ teriflunomide trial. Neurology2012;78:P07.082. MillerA , LublinF , O'ConnorP , WolinskyJ , ComiG , KapposL , et al. Effect of teriflunomide on relapses with sequelae and relapse leading to hospitalization in a population with relapsing forms of multiple sclerosis: results from the TEMSO study. Neurology2012;78:S30.003. MillerA , O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , et al. Efficacy of oral teriflunomide in multiple sclerosis with relapses: cognitive outcomes from a phase Ⅲ trial (TEMSO). Multiple Sclerosis2011;17:S182. MillerAE , O'ConnorP , WolinskyJS , ConfavreuxC , KapposL , OlssonTP , et al. Pre‐specified subgroup analyses of a placebo‐controlled phase Ⅲ trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis. Multiple Sclerosis2012;18(11):1625‐32. O'ConnorP , BriggsA , CaritaP , Bego‐Le‐BagousseG . Impact on health‐related quality of life of teriflunomide treatment by estimating utilities in patients with relapsing multiple sclerosis: results from TEMSO post hoc analysis. Journal of Neurology2012;259:S107. O'ConnorP , BurrellA , WangL , WeiL , CaritaP , ZhangQ . Effect of teriflunomide on longitudinal patterns of relapse and relapse‐related hospitalization in multiple sclerosis. Multiple Sclerosis2011;17:S414. O'ConnorP , LublinF , WolinskyJ , ComiG , KapposL , FreedmanM , et al. Effect of teriflunomide on relapses leading to healthcare resource use: results from the TEMSO study. Multiple Sclerosis2011;17:S95‐6. O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: clinical and MRI data 5 years after initial randomization. Multiple Sclerosis2011;17:S414‐5. O'ConnorP , WolinskyJS , ConfavreuxC , ComiG , KapposL , OlssonTP , et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. New England Journal of Medicine2011;365(14):1293‐303. O'ConnorPW , LublinFD , WolinskyJS , ConfavreuxC , ComiG , FreedmanMS , et al. Teriflunomide reduces relapse‐related neurological sequelae, hospitalizations and steroid use. Journal of Neurology2013;260(10):2472‐80. WolinksyJS , WangL , TruffinetP , NarayanaPA , NelsonF , O'ConnorP . Magnetic resonance imaging as a surrogate for clinical endpoints in multiple sclerosis. Multiple Sclerosis2012;18:470‐1. WolinskyJS , NarayanaPA , NelsonF , DattaS , O'ConnorP , ConfavreuxC , et al. Magnetic resonance imaging outcomes from a phase Ⅲ trial of teriflunomide. Multiple Sclerosis2013;19(10):1310‐9. ">O'Connor 2011</a> due to an unclear attrition bias and conflicts of interest. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD009882-sec-0016" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009882-sec-0016">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009882-sec-0097">Español</a> </li> </nav> </div> </div> <section class="background" lang="en"> <div class="section-header" id="CD009882-sec-0016"></div> <section id="CD009882-sec-0017"> <h3 class="title" id="CD009882-sec-0017">Description of the condition</h3> <p>Multiple sclerosis (MS) is a chronic immune‐mediated disease of the central nervous system. It is pathologically characterized by inflammation, demyelination, and axonal and neuronal loss. Clinically it is characterized by recurrent relapses or progression, or both, typically striking adults during the primary productive time of their lives and ultimately leading to severe neurological disability. </p> <p>In 1996, the clinical course of MS was characterized as relapsing‐remitting, primary progressive, secondary progressive or progressive relapsing. Initially, more than 80% of individuals with MS experience a relapsing‐remitting disease course (RRMS) characterized by clinical exacerbations of neurological symptoms followed by complete or incomplete remission (<a href="./references#CD009882-bbs2-0023" title="LublinFD , ReingoldSC . Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology1996;46:907‐11. ">Lublin 1996</a>). After 10 to 20 years, or median age of 39.1 years, about half of them gradually accumulate irreversible neurological deficits with or without clinical relapses (<a href="./references#CD009882-bbs2-0011" title="ConfavreuxC , VukusicS . Natural history of multiple sclerosis: a unifying concept. Brain2006;129(Pt 3):606‐16. ">Confavreux 2006</a>), which is known as secondary progressive MS (SPMS). Another 10% to 20% of individuals with MS are diagnosed with primary progressive MS (PPMS), clinically defined as a disease course without any clinical attacks or remission from onset (<a href="./references#CD009882-bbs2-0023" title="LublinFD , ReingoldSC . Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology1996;46:907‐11. ">Lublin 1996</a>). A significantly rarer form is progressive relapsing MS (PRMS), which initially presents as PPMS, however, during the course of the disease, these individuals develop true neurological exacerbations (<a href="./references#CD009882-bbs2-0040" title="TullmanMJ , OshinskyRJ , LublinFD , CutterGR . Clinical characteristics of progressive relapsing multiple sclerosis. Multiple Sclerosis2004;10(4):451‐4. ">Tullman 2004</a>). In 2013, the clinical course of MS was re‐defined. In the new revisions, clinically isolated syndrome was added, and PRMS was eliminated, from the clinical course descriptions. All forms of MS should be further subcategorized as either active or non‐active. Active MS is defined as the occurrence of clinical relapse or the presence of new T2 or gadolinium‐enhancing lesions over a specified period of time, preferably at least one year. An additional subcategory for people with progressive MS differentiates between people who have shown signs of disability progression over a given time period and people who have remained stable (<a href="./references#CD009882-bbs2-0024" title="LublinFD , ReingoldSC , CohenJA , CutterGR , SørensenPS , ThompsonAJ . Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology2014;83(3):278‐86. ">Lublin 2014a</a>; <a href="./references#CD009882-bbs2-0025" title="LublinFD . New multiple sclerosis phenotypic classification. European Neurology2014;72 Suppl:1‐5. ">Lublin 2014b</a>). </p> <p>MS causes a major socioeconomic burden, both for the individual and for society. Increased economic and quality of life (QoL) burden is associated with disease progression and relapses (<a href="./references#CD009882-bbs2-0020" title="KarampampaK , GustavssonA , MiltenburgerC , KindunduCM , SelchenDH . Treatment experience, burden, and unmet needs (TRIBUNE) in multiple sclerosis: the costs and utilities of MS patients in Canada. Journal of Population Therapeutics and Clinical Pharmacology2012;19(1):11‐25. ">Karampampa 2012</a>; <a href="./references#CD009882-bbs2-0030" title="O'ConnellK , KellySB , FogartyE , DugganM , BuckleyL , HutchinsonM , et al. Economic costs associated with an MS relapse. Multiple Sclerosis and Related Disorders2014;3(6):678‐83. ">O'Connell 2014</a>; <a href="./references#CD009882-bbs2-0032" title="PariséH , LalibertéF , LefebvreP , DuhMS , KimE , AgashivalaN , et al. Direct and indirect cost burden associated with multiple sclerosis relapses: excess costs of persons with MS and their spouse caregivers. Journal of the Neurological Sciences2013;330(1‐2):71‐7. ">Parisé 2013</a>). From a person's perspective, an MS relapse is associated with a significant increase in economic costs as well as a decline in health‐related quality of life (HRQoL) and functional ability (<a href="./references#CD009882-bbs2-0031" title="Oleen‐BurkeyM , Castelli‐HaleyJ , LageMJ , JohnsonKP . Burden of a multiple sclerosis relapse: the patients perspective. Patient2012;5(1):57‐69. ">Oleen‐Burkey 2012</a>). Effective treatment that reduces relapse frequency and prevents progression could have an impact both on costs and HRQoL, and may help to reduce the social burden of MS (<a href="./references#CD009882-bbs2-0020" title="KarampampaK , GustavssonA , MiltenburgerC , KindunduCM , SelchenDH . Treatment experience, burden, and unmet needs (TRIBUNE) in multiple sclerosis: the costs and utilities of MS patients in Canada. Journal of Population Therapeutics and Clinical Pharmacology2012;19(1):11‐25. ">Karampampa 2012</a>). </p> </section> <section id="CD009882-sec-0018"> <h3 class="title" id="CD009882-sec-0018">Description of the intervention</h3> <p>Teriflunomide, the active metabolite of leflunomide, is known to possess both anti‐proliferative and anti‐inflammatory actions. Data from human trials of leflunomide in rheumatoid arthritis showed that teriflunomide demonstrated linear pharmacokinetics over a dose range of 5 mg/day to 25 mg/day. The mean plasma half‐life is 15 days to 18 days and teriflunomide is extensively (greater than 99%) protein bound and exhibits linear protein binding at therapeutic concentrations. Clearance is via biliary and renal routes so administration of cholestyramine can be used to facilitate rapid elimination of teriflunomide from the circulation (<a href="./references#CD009882-bbs2-0038" title="TallantyreE , EvangelouN , ConstantinescuCS . Spotlight on teriflunomide. International MS Journal2008;15(2):62‐8. ">Tallantyre 2008</a>). Teriflunomide decreases disease severity and reduces inflammation, demyelination and axonal loss in a dose‐dependent manner in the Dark Agouti rat model of experimental autoimmune encephalomyelitis (EAE) (<a href="./references#CD009882-bbs2-0029" title="MerrillJE , HanakS , PuSF , LiangJ , DangC , Iglesias‐BregnaD , et al. Teriflunomide reduces behavioral, electrophysiological, and histopathological deficits in the Dark Agouti rat model of experimental autoimmune encephalomyelitis. Journal of Neurology2009;256(1):89‐103. ">Merrill 2009</a>). Teriflunomide (Aubagio®) was approved by the US Food and Drug Administration (FDA) in 2012 for people with relapsing forms of MS (7 mg or 14 mg orally once daily). In 2013, it was approved by the European Medicines Agency (EMA) for adults with RRMS (the recommended dose: 14 mg once a day). </p> </section> <section id="CD009882-sec-0019"> <h3 class="title" id="CD009882-sec-0019">How the intervention might work</h3> <p>Teriflunomide has an ability to non‐competitively and reversibly inhibit the mitochondrial enzyme dihydro‐orotate dehydrogenase (DHODH), a key cellular enzyme involved in the de novo synthesis of pyrimidine (<a href="./references#CD009882-bbs2-0008" title="BruneauJM , YeaCM , Spinella‐JaegleS , FudaliC , WoodwardK , RobsonPA , et al. Purification of human dihydro‐orotate dehydrogenase and its inhibition by A77 1726, the active metabolite of leflunomide. Biochemical Journal1998;336(Pt 2):299‐303. ">Bruneau 1998</a>; <a href="./references#CD009882-bbs2-0015" title="GreeneS , WatanabeK , Braatz‐TrulsonJ , LouL . Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent leflunomide. Biochemical Pharmacology1995;50(6):861‐7. ">Greene 1995</a>). By inhibiting DHODH and diminishing deoxyribonucleic acid (DNA) synthesis, teriflunomide has a cytostatic effect on proliferating B and T lymphocytes (<a href="./references#CD009882-bbs2-0010" title="CherwinskiHM , McCarleyD , SchatzmanR , DevensB , RansomJT . The immunosuppressant leflunomide inhibits lymphocyte progression through cell cycle by a novel mechanism. Journal of Pharmacology and Experimental Therapeutics1995;272(1):460‐8. ">Cherwinski 1995</a>). Teriflunomide also inhibits protein tyrosinekinase activity (<a href="./references#CD009882-bbs2-0044" title="XuX , WilliamsJW , GongH , FinneganA , ChongAS . Two activities of the immunosuppressive metabolite of leflunomide, A77 1726. Inhibition of pyrimidine nucleotide synthesis and protein tyrosine phosphorylation. Biochemical Pharmacology1996;52(4):527‐34. ">Xu 1996</a>), resulting in the reduction of T‐cell proliferation, T‐cell production of interferon gamma (IFN‐γ) and interleukin 2 (IL2), as well as B‐cell immunoglobulin (Ig)G1 production and inhibition of nuclear factor ĸB (NFĸB) (<a href="./references#CD009882-bbs2-0026" title="MannaSK , AggarwalBB . Immunosuppressive leflunomide metabolite (A77 1726) blocks TNF‐dependent nuclear factor‐kappa B activation and gene expression. Journal of Immunology1999;162(4):2095‐102. ">Manna 1999</a>; <a href="./references#CD009882-bbs2-0037" title="SiemaskoK , ChongAS , JäckHM , GongH , WilliamsJW , FinneganA . Inhibition of JAK3 and STAT6 tyrosine phosphorylation by the immunosuppressive drug leflunomide leads to a block in IgG1 production. Journal of Immunology1998;160(4):1581‐8. ">Siemasko 1998</a>; <a href="./references#CD009882-bbs2-0043" title="XuX , WilliamsJW , BremerEG , FinneganA , ChongAS . Inhibition of protein tyrosine phosphorylation in T cells by a novel immunosuppressive agent, leflunomide. Journal of Biological Chemistry1995;270(21):12398‐403. ">Xu 1995</a>). In addition, teriflunomide diminishes the ability of antigen‐presenting cells (APC) to activate T cells and for stimulated T cells to activate monocytes in vitro (<a href="./references#CD009882-bbs2-0046" title="ZeydaM , PoglitschM , GeyereggerR , SmolenJS , ZlabingerGJ , HörlWH , et al. Disruption of the interaction of T cells with antigen‐presenting cells by the active leflunomide metabolite teriflunomide: involvement of impaired integrin activation and immunologic synapse formation. Arthritis and Rheumatism2005;52(9):2730‐9. ">Zeyda 2005</a>), and inhibits interleukin 1 beta, matrix metalloproteinases (<a href="./references#CD009882-bbs2-0012" title="DeageV , BurgerD , DayerJM . Exposure of T lymphocytes to leflunomide but not to dexamethasone favors the production by monocytic cells of interleukin‐1 receptor antagonist and the tissue‐inhibitor of metalloproteinases‐1 over that of interleukin‐1beta and metalloproteinases. European Cytokine Network1998;9(4):663‐8. ">Deage 1998</a>), and cyclo‐oxygenase‐2 activity (<a href="./references#CD009882-bbs2-0018" title="HamiltonLC , VojnovicI , WarnerTD . A771726, the active metabolite of leflunomide, directly inhibits the activity of cyclo‐oxygenase‐2 in vitro and in vivo in a substrate‐sensitive manner. British Journal of Pharmacology1999;127(7):1589‐96. ">Hamilton 1999</a>). In EAE, teriflunomide reduces activation of myelin basic protein (MBP)‐specific T cells then reduces the production of IFN‐γ and chemotaxis (<a href="./references#CD009882-bbs2-0021" title="KornT , MagnusT , ToykaK , JungS . Modulation of effector cell functions in experimental autoimmune encephalomyelitis by leflunomide ‐ mechanisms independent of pyrimidine depletion. Journal of Leukocyte Biology2004;76:950‐60. ">Korn 2004</a>). </p> </section> <section id="CD009882-sec-0020"> <h3 class="title" id="CD009882-sec-0020">Why it is important to do this review</h3> <p>This is an update of the Cochrane review "Teriflunomide for multiple sclerosis" (first published in <i>The Cochrane Library</i> 2012 Issue 12). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD009882-sec-0021" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009882-sec-0021">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009882-sec-0102">Español</a> </li> </nav> </div> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD009882-sec-0021"></div> <p>To assess the absolute and comparative effectiveness and safety of teriflunomide as monotherapy or combination therapy versus placebo or other disease‐modifying drugs (DMDs) (interferon beta (IFNβ), glatiramer acetate, natalizumab, mitoxantrone, fingolimod, dimethyl fumarate, alemtuzumab) for modifying the disease course in people with MS. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD009882-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009882-sec-0022">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009882-sec-0103">Español</a> </li> </nav> </div> </div> <section class="methods" lang="en"> <div class="section-header" id="CD009882-sec-0022"></div> <section id="CD009882-sec-0023"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD009882-sec-0024"> <h4 class="title">Types of studies</h4> <p>All randomized, controlled, parallel‐group clinical trials (RCTs) evaluating teriflunomide, as monotherapy or combination therapy, versus placebo or any approved DMDs for people with MS. We excluded trials with a length of follow‐up shorter than one year. </p> </section> <section id="CD009882-sec-0025"> <h4 class="title">Types of participants</h4> <p>We included participants aged 18 years or older with definite diagnoses of MS according to Poser's (<a href="./references#CD009882-bbs2-0035" title="PoserCM , PatyDW , ScheinbergL , McDonaldWI , DavisFA , EbersGC , et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Annals of Neurology1983;13(3):227‐31. ">Poser 1983</a>) or Mc Donald's (<a href="./references#CD009882-bbs2-0028" title="McDonaldWI , CompstonA , EdanG , GoodkinD , HartungHP , LublinFD , et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Annals of Neurology2001;50(1):121‐7. ">McDonald 2001</a>; <a href="./references#CD009882-bbs2-0033" title='PolmanCH , ReingoldSC , EdanG , FilippiM , HartungHP , KapposL , et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Annals of Neurology2005;58(6):840‐6. '>Polman 2005</a>; <a href="./references#CD009882-bbs2-0034" title="PolmanCH , ReingoldSC , BanwellB , ClanetM , CohenJA , FilippiM , et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Annals of Neurology2011;69(2):292‐302. ">Polman 2011</a>) criteria, any clinical phenotypes categorized according to the classification of Lublin and Reingold (<a href="./references#CD009882-bbs2-0023" title="LublinFD , ReingoldSC . Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology1996;46:907‐11. ">Lublin 1996</a>), and an Expanded Disability Status Scale (EDSS) scores of 6.0 or lower. </p> </section> <section id="CD009882-sec-0026"> <h4 class="title">Types of interventions</h4> <section id="CD009882-sec-0027"> <h5 class="title">Experimental intervention</h5> <p>Treatment with teriflunomide orally, as monotherapy or combination therapy, without restrictions regarding dose, administration frequency and duration of treatment. </p> </section> <section id="CD009882-sec-0028"> <h5 class="title">Control intervention</h5> <p>Placebo or an approved DMDs.</p> </section> </section> <section id="CD009882-sec-0029"> <h4 class="title">Types of outcome measures</h4> <section id="CD009882-sec-0030"> <h5 class="title">Primary outcomes</h5> <section id="CD009882-sec-0031"> <h6 class="title">Efficacy</h6> <p> <ul id="CD009882-list-0003"> <li> <p>The proportion of participants with at least one relapse at one year or two years. Confirmed relapse was defined as the occurrence of new symptoms or worsening of previously stable or improving symptoms and signs not associated with fever or infection that occurred at least 30 days after the onset of a preceding relapse and lasted more than 24 hours. The relapse should be verified by the examining neurologist within seven days after its occurrence and be accompanied by an increase of at least half a point in the EDSS score or at least one point in two functional systems (excluding change in sphincteric or cerebral functions). </p> </li> </ul> <ul id="CD009882-list-0004"> <li> <p>The proportion of participants with disability progression as assessed by the EDSS (<a href="./references#CD009882-bbs2-0022" title="KurtzkeJF . Rating neurological impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology1983;33:1444‐52. ">Kurtzke 1983</a>) at one year or two years. Disability progression was defined as an increase in the EDSS score of at least 1.0 point in participants with a baseline score of 1.0 or higher or an increase of at least 1.5 points in participants with a baseline score of 0, with the increased score sustained for six months. We used the data where disability progression was confirmed in less than six months, however, we downgraded the study for indirectness of evidence when we performed the GRADE assessment. </p> </li> </ul> </p> </section> <section id="CD009882-sec-0032"> <h6 class="title">Safety</h6> <p> <ul id="CD009882-list-0005"> <li> <p>The number of participants with adverse events (AEs), number of participants with serious adverse events (SAEs), and number of participants who withdrew or dropped out from the study because of AEs at one year or two years. </p> </li> </ul> </p> </section> </section> <section id="CD009882-sec-0033"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD009882-list-0006"> <li> <p>The annualized relapse rate at one year or two years, defined as the mean number of confirmed relapses per participant adjusting for the duration of follow‐up to annualize it. </p> </li> </ul> <ul id="CD009882-list-0007"> <li> <p>The number of gadolinium‐enhancing T1‐weighted lesions at one year or two years. Lesions that persisted for more than four weeks were counted more than once. </p> </li> </ul> <ul id="CD009882-list-0008"> <li> <p>The time to disability progression at one year or two years.</p> </li> </ul> <ul id="CD009882-list-0009"> <li> <p>Changes in T1 hypointensity or magnetization transfer ratio of lesion damage at one year or two years. </p> </li> </ul> <ul id="CD009882-list-0010"> <li> <p>Mean change in HRQoL. The following scales were accepted: 36‐item Short Form (SF‐36) scores (<a href="./references#CD009882-bbs2-0042" title="WareJEJr , SherbourneCD . The MOS 36‐item short‐form health survey (SF‐36). I. Conceptual framework and item selection. Medical Care1992;30(6):473‐83. ">Ware 1992</a>), Multiple Sclerosis Quality of Life (MSQoL‐54) questionnaire scores (<a href="./references#CD009882-bbs2-0041" title="VickreyBG , HaysRD , HarooniR , MyersLW , EllisonGW . A health‐related quality of life measure for multiple sclerosis. Quality of Life Research1995;4(3):187‐206. ">Vickrey 1995</a>), Multiple Sclerosis Quality of Life Inventory (MSQLI) (<a href="./references#CD009882-bbs2-0014" title="FischerJS , LaRoccaNG , MillerDM , RitvoPG , AndrewsH , PatyD . Recent developments in the assessment of quality of life in multiple sclerosis (MS). Multiple Sclerosis1999;5(4):251‐9. ">Fischer 1999</a>), or Functional Assessment of Multiple Sclerosis (FAMS) (<a href="./references#CD009882-bbs2-0009" title="CellaDF , DineenK , ArnasonB , RederA , WebsterKA , KarabatsosG , et al. Validation of the functional assessment of multiple sclerosis quality of life instrument. Neurology1996;47(1):129‐39. ">Cella 1996</a>) at one year or two years. </p> </li> </ul> </p> </section> </section> </section> <section id="CD009882-sec-0034"> <h3 class="title">Search methods for identification of studies</h3> <p>We applied no language restrictions to the search.</p> <section id="CD009882-sec-0035"> <h4 class="title">Electronic searches</h4> <p>The Trials Search Co‐ordinator searched the Cochrane Multiple Sclerosis and Rare Diseases of the CNS Group Specialised Trials Register (30 September 2015), which, among other sources, contains trials from: </p> <p> <ul id="CD009882-list-0011"> <li> <p>the Cochrane Central Register of Controlled Trials (CENTRAL) (2015 Issue 9);</p> </li> </ul> <ul id="CD009882-list-0012"> <li> <p>MEDLINE (PubMed) (1966 to 30 September 2015);</p> </li> </ul> <ul id="CD009882-list-0013"> <li> <p>EMBASE (<a href="http://EMBASE.com" target="_blank">EMBASE.com</a>) (1974 to 30 September 2015); </p> </li> </ul> <ul id="CD009882-list-0014"> <li> <p>Cumulative Index to Nursing and Allied Health Literature (CINAHL) (EBSCOhost) (1981 to 30 September 2015); </p> </li> </ul> <ul id="CD009882-list-0015"> <li> <p>Latin American and Caribbean Health Science Information Database (LILACS) (Bireme) (1982 to 30 September 2015); </p> </li> </ul> <ul id="CD009882-list-0016"> <li> <p>Clinical trial registries (<a href="https://clinicaltrials.gov/ct2/home" target="_blank">clinicaltrials.gov</a>); </p> </li> </ul> <ul id="CD009882-list-0017"> <li> <p>World Health Organization (WHO) International Clinical Trials Registry Portal (<a href="http://apps.who.int/trialsearch/" target="_blank">apps.who.int/trialsearch/</a>). </p> </li> </ul> </p> <p>Information on the Trials Register and details of search strategies used to identify trials is in the 'Specialised Register' section within the Cochrane Multiple Sclerosis and Rare Diseases of the CNS Group's <a href="http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/MS/frame.html" target="_blank">module</a>. </p> <p><a href="./appendices#CD009882-sec-0086">Appendix 1</a> shows the keywords used to search for trials for this review. </p> </section> <section id="CD009882-sec-0036"> <h4 class="title">Searching other resources</h4> <p>We checked the reference lists of published reviews and retrieved articles for additional trials. We searched reports (2004 to September 2015) from the MS Societies (National Multiple Sclerosis Society (United States, United Kingdom)) (<a href="http://www.nationalmssociety.org" target="_blank">www.nationalmssociety.org</a>) and the Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS (<a href="http://www.ectrims.eu" target="_blank">www.ectrims.eu</a>) and Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS (<a href="http://www.actrims.org" target="_blank">www.actrims.org</a>)). We communicated with investigators participating in trials of teriflunomide. We also contacted the Sanofi‐Aventis company in an effort to identify further studies (<a href="http://en.sanofi.com" target="_blank">en.sanofi.com</a>). </p> </section> </section> <section id="CD009882-sec-0037"> <h3 class="title" id="CD009882-sec-0037">Data collection and analysis</h3> <section id="CD009882-sec-0038"> <h4 class="title">Selection of studies</h4> <p>Two review authors (DH and YZ) independently screened titles and abstracts of the citations retrieved by the literature search for inclusion or exclusion. We obtained the available full texts of potentially relevant studies for further assessment. We independently evaluated the eligibility of these studies (on the basis of information available in the published data) and listed papers that did not meet the inclusion criteria in the <a href="./references#CD009882-sec-0096" title="">Characteristics of excluded studies</a> table with the reasons for exclusion. We resolved any disagreement regarding inclusion by discussion or by referral to a third review author (LC) if necessary. </p> </section> <section id="CD009882-sec-0039"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (DH and YZ) independently extracted information and data from the selected trials using standardized forms, including information about eligibility criteria, methods<br/> (study design, total study duration, sequence generation, allocation sequence concealment, blinding and other concerns about bias), participants (total number, setting, diagnostic criteria, age, sex and country), interventions (total number of intervention groups and specific intervention) and outcomes (outcomes and time points, outcome definition and unit of measurement), results (number of participants allocated to each intervention group, sample size, missing participants and summary data for each intervention group) and funding source. Where the standard deviation was not reported, we calculated it from the standard error, confidence interval, t values or P values. We contacted the principal investigators of included studies to request additional data or confirmation of methodological aspects of the study. We discussed and resolved disagreements by consensus among the review authors. </p> </section> <section id="CD009882-sec-0040"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We assessed the risk of bias of the included studies using the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD009882-bbs2-0019" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). Two review authors (DH and YZ) independently evaluated each study using the 'Risk of bias' tool under the domains of sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective outcome and other biases. We judged a study to have a high risk of attrition bias if it had a dropout rate higher than 20%, or the reasons for drop‐outs were not balanced across intervention groups. We judged a study to be at high risk of bias if at least one of the seven domains was rated at high risk of bias. Conversely, we judged a study to be at low risk of bias if all key domains were rated at low risk of bias, unless one or more of the domains was reported at unclear risk of bias, in which case we judged the study to be at unclear risk of bias. </p> </section> <section id="CD009882-sec-0041"> <h4 class="title">Measures of treatment effect</h4> <p>We calculated the treatment effects of interventions based on the available data in the original studies using the Review Manager 5 analysis software (<a href="./references#CD009882-bbs2-0036" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2015. ">RevMan 2015</a>). For dichotomous outcomes, such as the proportion of participants with at least one relapse, disability worsening and at least one AE, we used the risk ratio (RR) as the measure of treatment effect. We also calculated the risk difference (RD) (also called the absolute risk reduction) and the number needed to treat for an additional beneficial outcome (NNTB) or the number needed to treat for an additional harmful outcome (NNTH) (NNTB = 1/RD). We used the rate ratio as the measure of treatment effect for count data, such as the numbers of relapses and new gadolinium‐enhancing T1‐weighted lesions. Changes in T1 hypointensity and magnetization transfer ratio of lesion damage were continuous outcomes and we used the mean difference (MD) as the measure of treatment effect. We treated the data on QoL scales as continuous because they were longer ordinal rating scales and had a reasonably large number of categories. Therefore, we used the MD for trials that used the same rating scale. The time to disability progression was a time‐to‐event outcome, we summarized such data using methods of survival analysis and expressed the treatment effect as a hazard ratio (HR). We calculated 95% CIs for each treatment effect. </p> </section> <section id="CD009882-sec-0042"> <h4 class="title">Unit of analysis issues</h4> <p>Most RCTs on teriflunomide for MS are multi‐arm studies with two experimental intervention groups (7 mg/day or 14 mg/day of teriflunomide) and a common control group, and involving repeated observations on participants. In future updates, where data are presented for each of the groups to which participants were randomized, we will create two pair‐wise comparisons of intervention groups to conduct independent meta‐analyses (high‐dose dimethyl fumarate group versus placebo group; low‐dose dimethyl fumarate group versus placebo group). Where outcomes are measured at multiple time points, we will define time frames to reflect short‐term (one year) and long‐term (two years) follow‐up. </p> </section> <section id="CD009882-sec-0043"> <h4 class="title">Dealing with missing data</h4> <p>We did not conduct meta‐analyses because of the clinical and methodological diversity across the included studies. We included intention‐to‐treat data. We analysed the available data when the missing data can be reasonably assumed to be missing at random, but for data not missing at random, we performed sensitivity analyses according to a likely‐case scenario analysis, in which we assumed that both participants who dropped out both in the experimental group and in the control group had poor outcomes. We addressed the potential impact of missing data on the findings of the review in the <a href="#CD009882-sec-0075">Discussion</a> section. </p> </section> <section id="CD009882-sec-0044"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed clinical heterogeneity by examining the characteristics of the studies and the similarity between the types of participants, interventions and outcomes. We also evaluated the variability in study design and risk of bias (methodological heterogeneity). We found obvious clinical and methodological heterogeneity across the included studies. If further data become available, we will evaluate statistical heterogeneity where clinical and methodological heterogeneity are not obvious across the included studies. When pooling trials in meta‐analyses, we will calculate the I<sup>2</sup> statistic in order to identify heterogeneity across studies. An I<sup>2</sup> value higher than 30% may indicate moderate heterogeneity (<a href="./references#CD009882-bbs2-0019" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). </p> </section> <section id="CD009882-sec-0045"> <h4 class="title">Assessment of reporting biases</h4> <p>The trials included in this review did not permit an assessment of publication bias. If we include a sufficient number of RCTs in meta‐analysis (10 or more RCTs) in future updates, we will examine potential publication bias using a funnel plot. For continuous outcomes, we will use the standard error as the vertical axis and MDs as the horizontal axis in funnel plots. For dichotomous outcomes, we will plot RRs on a logarithmic scale as the horizontal axis and use the standard error as the vertical axis. </p> </section> <section id="CD009882-sec-0046"> <h4 class="title">Data synthesis</h4> <p>We could not combine the outcome data because of the different study designs and interventions across studies; instead, we gave a descriptive summary of the results in the original studies. If we consider studies to be sufficiently clinically and methodologically similar in future updates, we will conduct formal meta‐analysis using Review Manager 5 software (<a href="./references#CD009882-bbs2-0036" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2015. ">RevMan 2015</a>). We will conduct separate analyses in which higher‐dose teriflunomide (14 mg once daily) and lower‐dose teriflunomide (7 mg once daily) are compared to placebo. We will examine one‐year and two‐year outcomes separately. If we consider that all studies in a meta‐analysis are likely to be estimating the same underlying treatment effect, then we will use a fixed‐effect model, otherwise we will use a random‐effects model for meta‐analysis. For dichotomous outcomes, we will use the Mantel‐Haenszel method (<a href="./references#CD009882-bbs2-0016" title="GreenlandS , RobinsJM . Estimation of a common effect parameter from sparse follow‐up data. Biometrics1985;41(1):55‐68. ">Greenland 1985</a>; <a href="./references#CD009882-bbs2-0027" title="MantelN , HaenszelW . Statistical aspects of the analysis of data from retrospective studies of disease. Journal of the National Cancer Institute1959;22(4):719‐48. ">Mantel 1959</a>). For continuous outcomes, we will use the inverse‐variance method (<a href="./references#CD009882-bbs2-0013" title="DerSimonianR , LairdN . Meta‐analysis in clinical trials. Controlled Clinical Trials1986;7(3):177‐88. ">DerSimonian 1986</a>). </p> </section> <section id="CD009882-sec-0047"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We could not carry out subgroup analysis because of the lack of data, but in future updates and if further data become available, we intend to undertake subgroup analyses according to: </p> <p> <ul id="CD009882-list-0018"> <li> <p>different types of MS (e.g. people with RRMS or people with progressive MS);</p> </li> <li> <p>baseline EDSS scores (e.g. 3.5 or lower, between 3.5 and 6);</p> </li> <li> <p>different duration of MS (e.g. five years, more than five years);</p> </li> <li> <p>risk of bias in included studies.</p> </li> </ul> </p> </section> <section id="CD009882-sec-0048"> <h4 class="title">Sensitivity analysis</h4> <p>We undertook sensitivity analyses to assess the robustness of our review results. We conducted sensitivity analyses according to a likely‐case scenario in order to assess the effect of study withdrawal on the primary outcomes. Based on the intention‐to‐treat principle, we included all randomly assigned participants (including those who did not receive study treatment) into sensitivity analysis. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD009882-sec-0049" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD009882-sec-0049"></div> <section id="CD009882-sec-0050"> <h3 class="title">Description of studies</h3> <p>See: <a href="./references#CD009882-sec-0095" title="">Characteristics of included studies</a>; <a href="./references#CD009882-sec-0096" title="">Characteristics of excluded studies</a> and Characteristics of ongoing studies. </p> <section id="CD009882-sec-0051"> <h4 class="title">Results of the search</h4> <p>In total, the search strategy retrieved 193 records after we removed duplicates. After screening of titles and abstracts, we selected seven studies reported in 42 articles provisionally and obtained the full papers for further assessment for eligibility. We excluded two studies (reported in 14 articles) due to a length of follow‐up shorter than one year or participants without a diagnosis of definite MS (<a href="./references#CD009882-bbs2-0006" title="ComiG , MillerAE , WolinskyJS , BenamorM , BauerD , TruffinetP , et al. The effect of teriflunomide on lymphocyte and neutrophil count in patients with a first clinical episode consistent with multiple sclerosis: results from the TOPIC study. European Journal of Neurology2014;21:127‐8. MillerA , WolinskyJ , KapposL , ComiG , FreedmanM , OlssonT , et al. TOPIC: efficacy and safety of once‐daily oral teriflunomide in patients with first clinical episode consistent with multiple sclerosis. Neurology. 2014; Vol. 82. MillerA , WolinskyJ , KapposL , ComiG , FreedmanMS , OlssonT , et al. TOPIC main outcomes: efficacy and safety of once‐daily oral teriflunomide in patients with clinically isolated syndrome. Multiple Sclerosis2013;19:25‐6. MillerAE , WolinskyJS , KapposL , ComiG , FreedmanMS , OlssonTP , et al. Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet Neurology2014;13(10):977‐86. TurnerB , BauerD , BenamorM , TruffinetP , MillerA . Teriflunomide in early stage MS: results from TOPIC. Journal of Neurology, Neurosurgery and Psychiatry2014;85:A40. WolinskyJS , ComiG , KapposL , BauerD , TruffinetP , MillerAE . Effect of teriflunomide on MRI activity in patients with early MS: outcomes from the phase 3 TOPIC study. European Journal of Neurology2014;21:103. WolinskyJS , TruffinetP , BauerD , MillerAE . Efficacy of teriflunomide in patients with early stage MS: analysis of the TOPIC study using 2010 McDonald diagnostic criteria. Multiple Sclerosis2014;20:109‐10. WolinskyJS , TruffinetP , BauerD , MillerAE . MRI outcomes in patients with early multiple sclerosis treated with teriflunomide: subgroup analyses from the TOPIC phase 3 study. Multiple Sclerosis2014;20:84. ">Miller 2014</a>; <a href="./references#CD009882-bbs2-0007" title="ConfavreuxC , LiDK , FreedmanMS , TruffinetP , BenzerdjebH , WangD , et al. Long‐term follow‐up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years. Multiple Sclerosis2012;18(9):1278‐89. ConfavreuxC , O'ConnorP , FreedmanM , BenzerdjebH , WangD , Bar‐OrA . Long term safety and tolerability of teriflunomide in multiple sclerosis: 9‐year follow‐up of a phase Ⅱ study. Multiple Sclerosis2011;17:S409‐10. JumahMA , LiDB , YamoutB , TruffinetP , DukovicD , O'ConnorPW . Long‐term clinical and magnetic resonance imaging outcomes from patients treated with teriflunomide: results from a phase 2 extension study. Multiple Sclerosis and Related Disorders2014;3:755‐56. LiD , O'ConnorP , ConfavreuxC , TruffinetP , WangD , TraboulseeA . Efficacy of teriflunomide in relapsing multiple sclerosis: phase Ⅱ extension study with 8‐year follow‐up. Multiple Sclerosis2011;17:S183‐4. LiDBK , TraboulseeAL , TruffinetP , DukovicD , O'ConnorPW . Long‐term MRI outcomes from patients treated with teriflunomide: results from a phase 2 extension study. Multiple Sclerosis2014;20:102‐3. O'ConnorPW , LiD , FreedmanMS , Bar‐OrA , RiceGP , ConfavreuxC , et al. A Phase Ⅱ study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology2006;66(6):894‐900. ">O'Connor 2006</a>). Five studies met the inclusion criteria (<a href="./references#CD009882-bbs2-0001" title="ComiG , FreedmanMS , KapposL , MillerA , OlssonTP , WolinskyJS , et al. Effect of teriflunomide on lymphocyte and neutrophil counts in patients with relapsing multiple sclerosis: results from the TOWER study. Journal of the Neurological Sciences2013;333:e376. ConfavreuxC , O'ConnorP , ComiG , FreedmanMS , MillerAE , OlssonTP , et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet Neurology2014;13(3):247‐56. KapposL , ComiG , ConfavreuxC , FreedmanMS , MillerAE , OlssonTP , et al. The efficacy and safety of teriflunomide in patients with relapsing MS: results from TOWER, a phase Ⅲ, placebo‐controlled study. Multiple Sclerosis2012;18:50‐1. MillerA , KapposL , ComiG , ConfavreuxC , FreedmanM , OlssonT , et al. Teriflunomide efficacy and safety in patients with relapsing multiple sclerosis: results from tower, a second, pivotal, phase 3 placebo‐controlled study. Neurology. 2013; Vol. 80. MillerAE , MacdonellR , ComiG , FreedmanMS , KapposL , MaurerM , et al. Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study. Journal of Neurology2014;261(9):1781‐8. MosesH , FreedmanM , KapposL , MillerA , OlssonT , WolinskyJ , et al. Pre‐defined subgroups analyses of tower, a placebo‐controlled phase 3 trial of teriflunomide in patients with relapsing multiple sclerosis. Proceedings of the American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). O'ConnorP , LublinF , WolinskyJ , ComiG , ConfavreuxC , FreedmanM , et al. Teriflunomide reduces relapse‐related sequelae, hospitalizations and corticosteroid use: a post‐HOC analysis of the phase 3 TOWER study. Proceedings of The American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). ">Confavreux 2014</a>; <a href="./references#CD009882-bbs2-0002" title="FreedmanMS , WolinskyJS , WamilB , ConfavreuxC , ComiG , KapposL , et al. Teriflunomide added to interferon‐β in relapsing multiple sclerosis: a randomized phase Ⅱ trial. Neurology2012;78(23):1877‐85. ">Freedman 2012</a>; <a href="./references#CD009882-bbs2-0003" title="NCT01252355 . Efficacy and Safety of Teriflunomide in Patients with Relapsing Multiple Sclerosis and Treated with Interferon‐beta (TERACLES). www.clinicaltrials.gov/ct2/show/results/NCT01252355 (accessed 12 January 2016). ">NCT01252355</a>; <a href="./references#CD009882-bbs2-0004" title="ComiG , BenzerdjebH , WangL , TruffinetP , O'ConnorP . Effect of teriflunomide on lymphocyte and neutrophil levels in patients with relapsing multiple sclerosis: results from the TEMSO study. Journal of Neurological Science2013;333(Suppl 1):e376. ComiG , O'ConnorP , WolinskyJ , ConfavreuxC , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: safety outcomes with up to 4 years of follow‐Up. Multiple Sclerosis2011;17:S182‐3. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Long‐term safety and efficacy of teriflunomide in patients with relapsing forms of multiple sclerosis in the TEMSO extension trial. Multiple Sclerosis2013;19:225. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Safety and efficacy of teriflunomide for up to 9 years in relapsing forms of multiple sclerosis: Update of the TEMSO extension trial. Neurology2014; Vol. 82, issue Suppl 10:3‐150. FreedmanMS , DelhayJL , BenamorM . Gastrointestinal symptoms infrequently lead to discontinuation of teriflunomide therapy. Multiple Sclerosis2012;18:S13. MillerA , LublinF , O'ConnorP , TaniouC , Dive‐PoulettyC . Impact of relapses with sequelae on disability, health‐related quality of life, and fatigue in a population with relapsing forms of multiple sclerosis using data from TEMSO, a pivotal phase Ⅲ teriflunomide trial. Neurology2012;78:P07.082. MillerA , LublinF , O'ConnorP , WolinskyJ , ComiG , KapposL , et al. Effect of teriflunomide on relapses with sequelae and relapse leading to hospitalization in a population with relapsing forms of multiple sclerosis: results from the TEMSO study. Neurology2012;78:S30.003. MillerA , O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , et al. Efficacy of oral teriflunomide in multiple sclerosis with relapses: cognitive outcomes from a phase Ⅲ trial (TEMSO). Multiple Sclerosis2011;17:S182. MillerAE , O'ConnorP , WolinskyJS , ConfavreuxC , KapposL , OlssonTP , et al. Pre‐specified subgroup analyses of a placebo‐controlled phase Ⅲ trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis. Multiple Sclerosis2012;18(11):1625‐32. O'ConnorP , BriggsA , CaritaP , Bego‐Le‐BagousseG . Impact on health‐related quality of life of teriflunomide treatment by estimating utilities in patients with relapsing multiple sclerosis: results from TEMSO post hoc analysis. Journal of Neurology2012;259:S107. O'ConnorP , BurrellA , WangL , WeiL , CaritaP , ZhangQ . Effect of teriflunomide on longitudinal patterns of relapse and relapse‐related hospitalization in multiple sclerosis. Multiple Sclerosis2011;17:S414. O'ConnorP , LublinF , WolinskyJ , ComiG , KapposL , FreedmanM , et al. Effect of teriflunomide on relapses leading to healthcare resource use: results from the TEMSO study. Multiple Sclerosis2011;17:S95‐6. O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: clinical and MRI data 5 years after initial randomization. Multiple Sclerosis2011;17:S414‐5. O'ConnorP , WolinskyJS , ConfavreuxC , ComiG , KapposL , OlssonTP , et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. New England Journal of Medicine2011;365(14):1293‐303. O'ConnorPW , LublinFD , WolinskyJS , ConfavreuxC , ComiG , FreedmanMS , et al. Teriflunomide reduces relapse‐related neurological sequelae, hospitalizations and steroid use. Journal of Neurology2013;260(10):2472‐80. WolinksyJS , WangL , TruffinetP , NarayanaPA , NelsonF , O'ConnorP . Magnetic resonance imaging as a surrogate for clinical endpoints in multiple sclerosis. Multiple Sclerosis2012;18:470‐1. WolinskyJS , NarayanaPA , NelsonF , DattaS , O'ConnorP , ConfavreuxC , et al. Magnetic resonance imaging outcomes from a phase Ⅲ trial of teriflunomide. Multiple Sclerosis2013;19(10):1310‐9. ">O'Connor 2011</a>; <a href="./references#CD009882-bbs2-0005" title="VermerschP , CzlonkowskaA , GrimaldiLM , ConfavreuxC , ComiG , KapposL , et al. A multicenter, randomized, parallel‐group, rater‐blinded study comparing the effectiveness and safety of teriflunomide and subcutaneous interferon beta‐1a in patients with relapsing multiple sclerosis. Multiple Sclerosis2012;18:S9‐10. VermerschP , CzlonkowskaA , GrimaldiLM , ConfavreuxC , ComiG , KapposL , et al. Evaluation of patient satisfaction from the TENERE study: a comparison of teriflunomide and subcutaneous interferon beta‐1a in patients with relapsing multiple sclerosis. Journal of Neurology2012;259:S38. VermerschP , CzlonkowskaA , GrimaldiLM , ConfavreuxC , ComiG , KapposL , et al. Teriflunomide versus subcutaneous interferon beta‐1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial. Multiple Sclerosis2014;20(6):705‐16. ">Vermersch 2014</a>) (reported in 28 articles, the results of <a href="./references#CD009882-bbs2-0003" title="NCT01252355 . Efficacy and Safety of Teriflunomide in Patients with Relapsing Multiple Sclerosis and Treated with Interferon‐beta (TERACLES). www.clinicaltrials.gov/ct2/show/results/NCT01252355 (accessed 12 January 2016). ">NCT01252355</a> were published on <a href="https://clinicaltrials.gov/ct2/home" target="_blank">clinicaltrials.gov</a>). We included the trials that we classified in ongoing studies in previous versions of this review (NCT00751881 and NCT01252355) in the current review (<a href="./references#CD009882-bbs2-0001" title="ComiG , FreedmanMS , KapposL , MillerA , OlssonTP , WolinskyJS , et al. Effect of teriflunomide on lymphocyte and neutrophil counts in patients with relapsing multiple sclerosis: results from the TOWER study. Journal of the Neurological Sciences2013;333:e376. ConfavreuxC , O'ConnorP , ComiG , FreedmanMS , MillerAE , OlssonTP , et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet Neurology2014;13(3):247‐56. KapposL , ComiG , ConfavreuxC , FreedmanMS , MillerAE , OlssonTP , et al. The efficacy and safety of teriflunomide in patients with relapsing MS: results from TOWER, a phase Ⅲ, placebo‐controlled study. Multiple Sclerosis2012;18:50‐1. MillerA , KapposL , ComiG , ConfavreuxC , FreedmanM , OlssonT , et al. Teriflunomide efficacy and safety in patients with relapsing multiple sclerosis: results from tower, a second, pivotal, phase 3 placebo‐controlled study. Neurology. 2013; Vol. 80. MillerAE , MacdonellR , ComiG , FreedmanMS , KapposL , MaurerM , et al. Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study. Journal of Neurology2014;261(9):1781‐8. MosesH , FreedmanM , KapposL , MillerA , OlssonT , WolinskyJ , et al. Pre‐defined subgroups analyses of tower, a placebo‐controlled phase 3 trial of teriflunomide in patients with relapsing multiple sclerosis. Proceedings of the American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). O'ConnorP , LublinF , WolinskyJ , ComiG , ConfavreuxC , FreedmanM , et al. Teriflunomide reduces relapse‐related sequelae, hospitalizations and corticosteroid use: a post‐HOC analysis of the phase 3 TOWER study. Proceedings of The American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). ">Confavreux 2014</a>; <a href="./references#CD009882-bbs2-0003" title="NCT01252355 . Efficacy and Safety of Teriflunomide in Patients with Relapsing Multiple Sclerosis and Treated with Interferon‐beta (TERACLES). www.clinicaltrials.gov/ct2/show/results/NCT01252355 (accessed 12 January 2016). ">NCT01252355</a>). See <a href="#CD009882-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD009882-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD009882-fig-0001" src="/cdsr/doi/10.1002/14651858.CD009882.pub3/media/CDSR/CD009882/image_n/nCD009882-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD009882-sec-0052"> <h4 class="title">Included studies</h4> <p>The review included five studies involving 3231 people (<a href="./references#CD009882-bbs2-0001" title="ComiG , FreedmanMS , KapposL , MillerA , OlssonTP , WolinskyJS , et al. Effect of teriflunomide on lymphocyte and neutrophil counts in patients with relapsing multiple sclerosis: results from the TOWER study. Journal of the Neurological Sciences2013;333:e376. ConfavreuxC , O'ConnorP , ComiG , FreedmanMS , MillerAE , OlssonTP , et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet Neurology2014;13(3):247‐56. KapposL , ComiG , ConfavreuxC , FreedmanMS , MillerAE , OlssonTP , et al. The efficacy and safety of teriflunomide in patients with relapsing MS: results from TOWER, a phase Ⅲ, placebo‐controlled study. Multiple Sclerosis2012;18:50‐1. MillerA , KapposL , ComiG , ConfavreuxC , FreedmanM , OlssonT , et al. Teriflunomide efficacy and safety in patients with relapsing multiple sclerosis: results from tower, a second, pivotal, phase 3 placebo‐controlled study. Neurology. 2013; Vol. 80. MillerAE , MacdonellR , ComiG , FreedmanMS , KapposL , MaurerM , et al. Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study. Journal of Neurology2014;261(9):1781‐8. MosesH , FreedmanM , KapposL , MillerA , OlssonT , WolinskyJ , et al. Pre‐defined subgroups analyses of tower, a placebo‐controlled phase 3 trial of teriflunomide in patients with relapsing multiple sclerosis. Proceedings of the American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). O'ConnorP , LublinF , WolinskyJ , ComiG , ConfavreuxC , FreedmanM , et al. Teriflunomide reduces relapse‐related sequelae, hospitalizations and corticosteroid use: a post‐HOC analysis of the phase 3 TOWER study. Proceedings of The American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). ">Confavreux 2014</a>; <a href="./references#CD009882-bbs2-0002" title="FreedmanMS , WolinskyJS , WamilB , ConfavreuxC , ComiG , KapposL , et al. Teriflunomide added to interferon‐β in relapsing multiple sclerosis: a randomized phase Ⅱ trial. Neurology2012;78(23):1877‐85. ">Freedman 2012</a>; <a href="./references#CD009882-bbs2-0003" title="NCT01252355 . Efficacy and Safety of Teriflunomide in Patients with Relapsing Multiple Sclerosis and Treated with Interferon‐beta (TERACLES). www.clinicaltrials.gov/ct2/show/results/NCT01252355 (accessed 12 January 2016). ">NCT01252355</a>; <a href="./references#CD009882-bbs2-0004" title="ComiG , BenzerdjebH , WangL , TruffinetP , O'ConnorP . Effect of teriflunomide on lymphocyte and neutrophil levels in patients with relapsing multiple sclerosis: results from the TEMSO study. Journal of Neurological Science2013;333(Suppl 1):e376. ComiG , O'ConnorP , WolinskyJ , ConfavreuxC , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: safety outcomes with up to 4 years of follow‐Up. Multiple Sclerosis2011;17:S182‐3. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Long‐term safety and efficacy of teriflunomide in patients with relapsing forms of multiple sclerosis in the TEMSO extension trial. Multiple Sclerosis2013;19:225. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Safety and efficacy of teriflunomide for up to 9 years in relapsing forms of multiple sclerosis: Update of the TEMSO extension trial. Neurology2014; Vol. 82, issue Suppl 10:3‐150. FreedmanMS , DelhayJL , BenamorM . Gastrointestinal symptoms infrequently lead to discontinuation of teriflunomide therapy. Multiple Sclerosis2012;18:S13. MillerA , LublinF , O'ConnorP , TaniouC , Dive‐PoulettyC . Impact of relapses with sequelae on disability, health‐related quality of life, and fatigue in a population with relapsing forms of multiple sclerosis using data from TEMSO, a pivotal phase Ⅲ teriflunomide trial. Neurology2012;78:P07.082. MillerA , LublinF , O'ConnorP , WolinskyJ , ComiG , KapposL , et al. Effect of teriflunomide on relapses with sequelae and relapse leading to hospitalization in a population with relapsing forms of multiple sclerosis: results from the TEMSO study. Neurology2012;78:S30.003. MillerA , O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , et al. Efficacy of oral teriflunomide in multiple sclerosis with relapses: cognitive outcomes from a phase Ⅲ trial (TEMSO). Multiple Sclerosis2011;17:S182. MillerAE , O'ConnorP , WolinskyJS , ConfavreuxC , KapposL , OlssonTP , et al. Pre‐specified subgroup analyses of a placebo‐controlled phase Ⅲ trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis. Multiple Sclerosis2012;18(11):1625‐32. O'ConnorP , BriggsA , CaritaP , Bego‐Le‐BagousseG . Impact on health‐related quality of life of teriflunomide treatment by estimating utilities in patients with relapsing multiple sclerosis: results from TEMSO post hoc analysis. Journal of Neurology2012;259:S107. O'ConnorP , BurrellA , WangL , WeiL , CaritaP , ZhangQ . Effect of teriflunomide on longitudinal patterns of relapse and relapse‐related hospitalization in multiple sclerosis. Multiple Sclerosis2011;17:S414. O'ConnorP , LublinF , WolinskyJ , ComiG , KapposL , FreedmanM , et al. Effect of teriflunomide on relapses leading to healthcare resource use: results from the TEMSO study. Multiple Sclerosis2011;17:S95‐6. O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: clinical and MRI data 5 years after initial randomization. Multiple Sclerosis2011;17:S414‐5. O'ConnorP , WolinskyJS , ConfavreuxC , ComiG , KapposL , OlssonTP , et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. New England Journal of Medicine2011;365(14):1293‐303. O'ConnorPW , LublinFD , WolinskyJS , ConfavreuxC , ComiG , FreedmanMS , et al. Teriflunomide reduces relapse‐related neurological sequelae, hospitalizations and steroid use. Journal of Neurology2013;260(10):2472‐80. WolinksyJS , WangL , TruffinetP , NarayanaPA , NelsonF , O'ConnorP . Magnetic resonance imaging as a surrogate for clinical endpoints in multiple sclerosis. Multiple Sclerosis2012;18:470‐1. WolinskyJS , NarayanaPA , NelsonF , DattaS , O'ConnorP , ConfavreuxC , et al. Magnetic resonance imaging outcomes from a phase Ⅲ trial of teriflunomide. Multiple Sclerosis2013;19(10):1310‐9. ">O'Connor 2011</a>; <a href="./references#CD009882-bbs2-0005" title="VermerschP , CzlonkowskaA , GrimaldiLM , ConfavreuxC , ComiG , KapposL , et al. A multicenter, randomized, parallel‐group, rater‐blinded study comparing the effectiveness and safety of teriflunomide and subcutaneous interferon beta‐1a in patients with relapsing multiple sclerosis. Multiple Sclerosis2012;18:S9‐10. VermerschP , CzlonkowskaA , GrimaldiLM , ConfavreuxC , ComiG , KapposL , et al. Evaluation of patient satisfaction from the TENERE study: a comparison of teriflunomide and subcutaneous interferon beta‐1a in patients with relapsing multiple sclerosis. Journal of Neurology2012;259:S38. VermerschP , CzlonkowskaA , GrimaldiLM , ConfavreuxC , ComiG , KapposL , et al. Teriflunomide versus subcutaneous interferon beta‐1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial. Multiple Sclerosis2014;20(6):705‐16. ">Vermersch 2014</a>). Among them, two studies evaluated the efficacy and safety of teriflunomide 7 mg/day or 14 mg/day versus placebo for 2257 adults with relapsing forms of MS (<a href="./references#CD009882-bbs2-0001" title="ComiG , FreedmanMS , KapposL , MillerA , OlssonTP , WolinskyJS , et al. Effect of teriflunomide on lymphocyte and neutrophil counts in patients with relapsing multiple sclerosis: results from the TOWER study. Journal of the Neurological Sciences2013;333:e376. ConfavreuxC , O'ConnorP , ComiG , FreedmanMS , MillerAE , OlssonTP , et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet Neurology2014;13(3):247‐56. KapposL , ComiG , ConfavreuxC , FreedmanMS , MillerAE , OlssonTP , et al. The efficacy and safety of teriflunomide in patients with relapsing MS: results from TOWER, a phase Ⅲ, placebo‐controlled study. Multiple Sclerosis2012;18:50‐1. MillerA , KapposL , ComiG , ConfavreuxC , FreedmanM , OlssonT , et al. Teriflunomide efficacy and safety in patients with relapsing multiple sclerosis: results from tower, a second, pivotal, phase 3 placebo‐controlled study. Neurology. 2013; Vol. 80. MillerAE , MacdonellR , ComiG , FreedmanMS , KapposL , MaurerM , et al. Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study. Journal of Neurology2014;261(9):1781‐8. MosesH , FreedmanM , KapposL , MillerA , OlssonT , WolinskyJ , et al. Pre‐defined subgroups analyses of tower, a placebo‐controlled phase 3 trial of teriflunomide in patients with relapsing multiple sclerosis. Proceedings of the American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). O'ConnorP , LublinF , WolinskyJ , ComiG , ConfavreuxC , FreedmanM , et al. Teriflunomide reduces relapse‐related sequelae, hospitalizations and corticosteroid use: a post‐HOC analysis of the phase 3 TOWER study. Proceedings of The American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). ">Confavreux 2014</a>; <a href="./references#CD009882-bbs2-0004" title="ComiG , BenzerdjebH , WangL , TruffinetP , O'ConnorP . Effect of teriflunomide on lymphocyte and neutrophil levels in patients with relapsing multiple sclerosis: results from the TEMSO study. Journal of Neurological Science2013;333(Suppl 1):e376. ComiG , O'ConnorP , WolinskyJ , ConfavreuxC , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: safety outcomes with up to 4 years of follow‐Up. Multiple Sclerosis2011;17:S182‐3. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Long‐term safety and efficacy of teriflunomide in patients with relapsing forms of multiple sclerosis in the TEMSO extension trial. Multiple Sclerosis2013;19:225. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Safety and efficacy of teriflunomide for up to 9 years in relapsing forms of multiple sclerosis: Update of the TEMSO extension trial. Neurology2014; Vol. 82, issue Suppl 10:3‐150. FreedmanMS , DelhayJL , BenamorM . Gastrointestinal symptoms infrequently lead to discontinuation of teriflunomide therapy. Multiple Sclerosis2012;18:S13. MillerA , LublinF , O'ConnorP , TaniouC , Dive‐PoulettyC . Impact of relapses with sequelae on disability, health‐related quality of life, and fatigue in a population with relapsing forms of multiple sclerosis using data from TEMSO, a pivotal phase Ⅲ teriflunomide trial. Neurology2012;78:P07.082. MillerA , LublinF , O'ConnorP , WolinskyJ , ComiG , KapposL , et al. Effect of teriflunomide on relapses with sequelae and relapse leading to hospitalization in a population with relapsing forms of multiple sclerosis: results from the TEMSO study. Neurology2012;78:S30.003. MillerA , O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , et al. Efficacy of oral teriflunomide in multiple sclerosis with relapses: cognitive outcomes from a phase Ⅲ trial (TEMSO). Multiple Sclerosis2011;17:S182. MillerAE , O'ConnorP , WolinskyJS , ConfavreuxC , KapposL , OlssonTP , et al. Pre‐specified subgroup analyses of a placebo‐controlled phase Ⅲ trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis. Multiple Sclerosis2012;18(11):1625‐32. O'ConnorP , BriggsA , CaritaP , Bego‐Le‐BagousseG . Impact on health‐related quality of life of teriflunomide treatment by estimating utilities in patients with relapsing multiple sclerosis: results from TEMSO post hoc analysis. Journal of Neurology2012;259:S107. O'ConnorP , BurrellA , WangL , WeiL , CaritaP , ZhangQ . Effect of teriflunomide on longitudinal patterns of relapse and relapse‐related hospitalization in multiple sclerosis. Multiple Sclerosis2011;17:S414. O'ConnorP , LublinF , WolinskyJ , ComiG , KapposL , FreedmanM , et al. Effect of teriflunomide on relapses leading to healthcare resource use: results from the TEMSO study. Multiple Sclerosis2011;17:S95‐6. O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: clinical and MRI data 5 years after initial randomization. Multiple Sclerosis2011;17:S414‐5. O'ConnorP , WolinskyJS , ConfavreuxC , ComiG , KapposL , OlssonTP , et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. New England Journal of Medicine2011;365(14):1293‐303. O'ConnorPW , LublinFD , WolinskyJS , ConfavreuxC , ComiG , FreedmanMS , et al. Teriflunomide reduces relapse‐related neurological sequelae, hospitalizations and steroid use. Journal of Neurology2013;260(10):2472‐80. WolinksyJS , WangL , TruffinetP , NarayanaPA , NelsonF , O'ConnorP . Magnetic resonance imaging as a surrogate for clinical endpoints in multiple sclerosis. Multiple Sclerosis2012;18:470‐1. WolinskyJS , NarayanaPA , NelsonF , DattaS , O'ConnorP , ConfavreuxC , et al. Magnetic resonance imaging outcomes from a phase Ⅲ trial of teriflunomide. Multiple Sclerosis2013;19(10):1310‐9. ">O'Connor 2011</a>). Two studies primarily evaluated the safety and tolerability of teriflunomide 7 mg/day or 14 mg/day with add‐on IFNβ versus placebo in 650 people with relapsing MS (<a href="./references#CD009882-bbs2-0002" title="FreedmanMS , WolinskyJS , WamilB , ConfavreuxC , ComiG , KapposL , et al. Teriflunomide added to interferon‐β in relapsing multiple sclerosis: a randomized phase Ⅱ trial. Neurology2012;78(23):1877‐85. ">Freedman 2012</a>; <a href="./references#CD009882-bbs2-0003" title="NCT01252355 . Efficacy and Safety of Teriflunomide in Patients with Relapsing Multiple Sclerosis and Treated with Interferon‐beta (TERACLES). www.clinicaltrials.gov/ct2/show/results/NCT01252355 (accessed 12 January 2016). ">NCT01252355</a>). One study evaluated the efficacy, safety and tolerability of teriflunomide 7 mg/day or 14 mg/day in comparison to IFNβ‐1a in 324 people with relapsing MS (<a href="./references#CD009882-bbs2-0005" title="VermerschP , CzlonkowskaA , GrimaldiLM , ConfavreuxC , ComiG , KapposL , et al. A multicenter, randomized, parallel‐group, rater‐blinded study comparing the effectiveness and safety of teriflunomide and subcutaneous interferon beta‐1a in patients with relapsing multiple sclerosis. Multiple Sclerosis2012;18:S9‐10. VermerschP , CzlonkowskaA , GrimaldiLM , ConfavreuxC , ComiG , KapposL , et al. Evaluation of patient satisfaction from the TENERE study: a comparison of teriflunomide and subcutaneous interferon beta‐1a in patients with relapsing multiple sclerosis. Journal of Neurology2012;259:S38. VermerschP , CzlonkowskaA , GrimaldiLM , ConfavreuxC , ComiG , KapposL , et al. Teriflunomide versus subcutaneous interferon beta‐1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial. Multiple Sclerosis2014;20(6):705‐16. ">Vermersch 2014</a>). </p> <section id="CD009882-sec-0053"> <h5 class="title">Characteristics of the study design</h5> <p><a href="./references#CD009882-bbs2-0001" title="ComiG , FreedmanMS , KapposL , MillerA , OlssonTP , WolinskyJS , et al. Effect of teriflunomide on lymphocyte and neutrophil counts in patients with relapsing multiple sclerosis: results from the TOWER study. Journal of the Neurological Sciences2013;333:e376. ConfavreuxC , O'ConnorP , ComiG , FreedmanMS , MillerAE , OlssonTP , et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet Neurology2014;13(3):247‐56. KapposL , ComiG , ConfavreuxC , FreedmanMS , MillerAE , OlssonTP , et al. The efficacy and safety of teriflunomide in patients with relapsing MS: results from TOWER, a phase Ⅲ, placebo‐controlled study. Multiple Sclerosis2012;18:50‐1. MillerA , KapposL , ComiG , ConfavreuxC , FreedmanM , OlssonT , et al. Teriflunomide efficacy and safety in patients with relapsing multiple sclerosis: results from tower, a second, pivotal, phase 3 placebo‐controlled study. Neurology. 2013; Vol. 80. MillerAE , MacdonellR , ComiG , FreedmanMS , KapposL , MaurerM , et al. Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study. Journal of Neurology2014;261(9):1781‐8. MosesH , FreedmanM , KapposL , MillerA , OlssonT , WolinskyJ , et al. Pre‐defined subgroups analyses of tower, a placebo‐controlled phase 3 trial of teriflunomide in patients with relapsing multiple sclerosis. Proceedings of the American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). O'ConnorP , LublinF , WolinskyJ , ComiG , ConfavreuxC , FreedmanM , et al. Teriflunomide reduces relapse‐related sequelae, hospitalizations and corticosteroid use: a post‐HOC analysis of the phase 3 TOWER study. Proceedings of The American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). ">Confavreux 2014</a> and <a href="./references#CD009882-bbs2-0004" title="ComiG , BenzerdjebH , WangL , TruffinetP , O'ConnorP . Effect of teriflunomide on lymphocyte and neutrophil levels in patients with relapsing multiple sclerosis: results from the TEMSO study. Journal of Neurological Science2013;333(Suppl 1):e376. ComiG , O'ConnorP , WolinskyJ , ConfavreuxC , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: safety outcomes with up to 4 years of follow‐Up. Multiple Sclerosis2011;17:S182‐3. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Long‐term safety and efficacy of teriflunomide in patients with relapsing forms of multiple sclerosis in the TEMSO extension trial. Multiple Sclerosis2013;19:225. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Safety and efficacy of teriflunomide for up to 9 years in relapsing forms of multiple sclerosis: Update of the TEMSO extension trial. Neurology2014; Vol. 82, issue Suppl 10:3‐150. FreedmanMS , DelhayJL , BenamorM . Gastrointestinal symptoms infrequently lead to discontinuation of teriflunomide therapy. Multiple Sclerosis2012;18:S13. MillerA , LublinF , O'ConnorP , TaniouC , Dive‐PoulettyC . Impact of relapses with sequelae on disability, health‐related quality of life, and fatigue in a population with relapsing forms of multiple sclerosis using data from TEMSO, a pivotal phase Ⅲ teriflunomide trial. Neurology2012;78:P07.082. MillerA , LublinF , O'ConnorP , WolinskyJ , ComiG , KapposL , et al. Effect of teriflunomide on relapses with sequelae and relapse leading to hospitalization in a population with relapsing forms of multiple sclerosis: results from the TEMSO study. Neurology2012;78:S30.003. MillerA , O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , et al. Efficacy of oral teriflunomide in multiple sclerosis with relapses: cognitive outcomes from a phase Ⅲ trial (TEMSO). Multiple Sclerosis2011;17:S182. MillerAE , O'ConnorP , WolinskyJS , ConfavreuxC , KapposL , OlssonTP , et al. Pre‐specified subgroup analyses of a placebo‐controlled phase Ⅲ trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis. Multiple Sclerosis2012;18(11):1625‐32. O'ConnorP , BriggsA , CaritaP , Bego‐Le‐BagousseG . Impact on health‐related quality of life of teriflunomide treatment by estimating utilities in patients with relapsing multiple sclerosis: results from TEMSO post hoc analysis. Journal of Neurology2012;259:S107. O'ConnorP , BurrellA , WangL , WeiL , CaritaP , ZhangQ . Effect of teriflunomide on longitudinal patterns of relapse and relapse‐related hospitalization in multiple sclerosis. Multiple Sclerosis2011;17:S414. O'ConnorP , LublinF , WolinskyJ , ComiG , KapposL , FreedmanM , et al. Effect of teriflunomide on relapses leading to healthcare resource use: results from the TEMSO study. Multiple Sclerosis2011;17:S95‐6. O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: clinical and MRI data 5 years after initial randomization. Multiple Sclerosis2011;17:S414‐5. O'ConnorP , WolinskyJS , ConfavreuxC , ComiG , KapposL , OlssonTP , et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. New England Journal of Medicine2011;365(14):1293‐303. O'ConnorPW , LublinFD , WolinskyJS , ConfavreuxC , ComiG , FreedmanMS , et al. Teriflunomide reduces relapse‐related neurological sequelae, hospitalizations and steroid use. Journal of Neurology2013;260(10):2472‐80. WolinksyJS , WangL , TruffinetP , NarayanaPA , NelsonF , O'ConnorP . Magnetic resonance imaging as a surrogate for clinical endpoints in multiple sclerosis. Multiple Sclerosis2012;18:470‐1. WolinskyJS , NarayanaPA , NelsonF , DattaS , O'ConnorP , ConfavreuxC , et al. Magnetic resonance imaging outcomes from a phase Ⅲ trial of teriflunomide. Multiple Sclerosis2013;19(10):1310‐9. ">O'Connor 2011</a> were randomized, double‐blind, placebo‐controlled, parallel‐group studies over at least 48 weeks (a maximum of 173 weeks) (<a href="./references#CD009882-bbs2-0001" title="ComiG , FreedmanMS , KapposL , MillerA , OlssonTP , WolinskyJS , et al. Effect of teriflunomide on lymphocyte and neutrophil counts in patients with relapsing multiple sclerosis: results from the TOWER study. Journal of the Neurological Sciences2013;333:e376. ConfavreuxC , O'ConnorP , ComiG , FreedmanMS , MillerAE , OlssonTP , et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet Neurology2014;13(3):247‐56. KapposL , ComiG , ConfavreuxC , FreedmanMS , MillerAE , OlssonTP , et al. The efficacy and safety of teriflunomide in patients with relapsing MS: results from TOWER, a phase Ⅲ, placebo‐controlled study. Multiple Sclerosis2012;18:50‐1. MillerA , KapposL , ComiG , ConfavreuxC , FreedmanM , OlssonT , et al. Teriflunomide efficacy and safety in patients with relapsing multiple sclerosis: results from tower, a second, pivotal, phase 3 placebo‐controlled study. Neurology. 2013; Vol. 80. MillerAE , MacdonellR , ComiG , FreedmanMS , KapposL , MaurerM , et al. Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study. Journal of Neurology2014;261(9):1781‐8. MosesH , FreedmanM , KapposL , MillerA , OlssonT , WolinskyJ , et al. Pre‐defined subgroups analyses of tower, a placebo‐controlled phase 3 trial of teriflunomide in patients with relapsing multiple sclerosis. Proceedings of the American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). O'ConnorP , LublinF , WolinskyJ , ComiG , ConfavreuxC , FreedmanM , et al. Teriflunomide reduces relapse‐related sequelae, hospitalizations and corticosteroid use: a post‐HOC analysis of the phase 3 TOWER study. Proceedings of The American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). ">Confavreux 2014</a>) and 108 weeks (<a href="./references#CD009882-bbs2-0004" title="ComiG , BenzerdjebH , WangL , TruffinetP , O'ConnorP . Effect of teriflunomide on lymphocyte and neutrophil levels in patients with relapsing multiple sclerosis: results from the TEMSO study. Journal of Neurological Science2013;333(Suppl 1):e376. ComiG , O'ConnorP , WolinskyJ , ConfavreuxC , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: safety outcomes with up to 4 years of follow‐Up. Multiple Sclerosis2011;17:S182‐3. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Long‐term safety and efficacy of teriflunomide in patients with relapsing forms of multiple sclerosis in the TEMSO extension trial. Multiple Sclerosis2013;19:225. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Safety and efficacy of teriflunomide for up to 9 years in relapsing forms of multiple sclerosis: Update of the TEMSO extension trial. Neurology2014; Vol. 82, issue Suppl 10:3‐150. FreedmanMS , DelhayJL , BenamorM . Gastrointestinal symptoms infrequently lead to discontinuation of teriflunomide therapy. Multiple Sclerosis2012;18:S13. MillerA , LublinF , O'ConnorP , TaniouC , Dive‐PoulettyC . Impact of relapses with sequelae on disability, health‐related quality of life, and fatigue in a population with relapsing forms of multiple sclerosis using data from TEMSO, a pivotal phase Ⅲ teriflunomide trial. Neurology2012;78:P07.082. MillerA , LublinF , O'ConnorP , WolinskyJ , ComiG , KapposL , et al. Effect of teriflunomide on relapses with sequelae and relapse leading to hospitalization in a population with relapsing forms of multiple sclerosis: results from the TEMSO study. Neurology2012;78:S30.003. MillerA , O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , et al. Efficacy of oral teriflunomide in multiple sclerosis with relapses: cognitive outcomes from a phase Ⅲ trial (TEMSO). Multiple Sclerosis2011;17:S182. MillerAE , O'ConnorP , WolinskyJS , ConfavreuxC , KapposL , OlssonTP , et al. Pre‐specified subgroup analyses of a placebo‐controlled phase Ⅲ trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis. Multiple Sclerosis2012;18(11):1625‐32. O'ConnorP , BriggsA , CaritaP , Bego‐Le‐BagousseG . Impact on health‐related quality of life of teriflunomide treatment by estimating utilities in patients with relapsing multiple sclerosis: results from TEMSO post hoc analysis. Journal of Neurology2012;259:S107. O'ConnorP , BurrellA , WangL , WeiL , CaritaP , ZhangQ . Effect of teriflunomide on longitudinal patterns of relapse and relapse‐related hospitalization in multiple sclerosis. Multiple Sclerosis2011;17:S414. O'ConnorP , LublinF , WolinskyJ , ComiG , KapposL , FreedmanM , et al. Effect of teriflunomide on relapses leading to healthcare resource use: results from the TEMSO study. Multiple Sclerosis2011;17:S95‐6. O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: clinical and MRI data 5 years after initial randomization. Multiple Sclerosis2011;17:S414‐5. O'ConnorP , WolinskyJS , ConfavreuxC , ComiG , KapposL , OlssonTP , et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. New England Journal of Medicine2011;365(14):1293‐303. O'ConnorPW , LublinFD , WolinskyJS , ConfavreuxC , ComiG , FreedmanMS , et al. Teriflunomide reduces relapse‐related neurological sequelae, hospitalizations and steroid use. Journal of Neurology2013;260(10):2472‐80. WolinksyJS , WangL , TruffinetP , NarayanaPA , NelsonF , O'ConnorP . Magnetic resonance imaging as a surrogate for clinical endpoints in multiple sclerosis. Multiple Sclerosis2012;18:470‐1. WolinskyJS , NarayanaPA , NelsonF , DattaS , O'ConnorP , ConfavreuxC , et al. Magnetic resonance imaging outcomes from a phase Ⅲ trial of teriflunomide. Multiple Sclerosis2013;19(10):1310‐9. ">O'Connor 2011</a>). <a href="./references#CD009882-bbs2-0002" title="FreedmanMS , WolinskyJS , WamilB , ConfavreuxC , ComiG , KapposL , et al. Teriflunomide added to interferon‐β in relapsing multiple sclerosis: a randomized phase Ⅱ trial. Neurology2012;78(23):1877‐85. ">Freedman 2012</a> was a randomized, placebo‐controlled, 24‐week double‐blind study followed by a 24‐week blinded extension. Participants completing 24 weeks of treatment who continued to meet the eligibility criteria could select to enter a 24‐week blinded extension during which participants continued to receive their originally assigned treatment regimen. <a href="./references#CD009882-bbs2-0003" title="NCT01252355 . Efficacy and Safety of Teriflunomide in Patients with Relapsing Multiple Sclerosis and Treated with Interferon‐beta (TERACLES). www.clinicaltrials.gov/ct2/show/results/NCT01252355 (accessed 12 January 2016). ">NCT01252355</a> was a randomized, double‐blind, placebo‐controlled, parallel‐group study over 24 weeks (a maximum of 108 weeks). <a href="./references#CD009882-bbs2-0005" title="VermerschP , CzlonkowskaA , GrimaldiLM , ConfavreuxC , ComiG , KapposL , et al. A multicenter, randomized, parallel‐group, rater‐blinded study comparing the effectiveness and safety of teriflunomide and subcutaneous interferon beta‐1a in patients with relapsing multiple sclerosis. Multiple Sclerosis2012;18:S9‐10. VermerschP , CzlonkowskaA , GrimaldiLM , ConfavreuxC , ComiG , KapposL , et al. Evaluation of patient satisfaction from the TENERE study: a comparison of teriflunomide and subcutaneous interferon beta‐1a in patients with relapsing multiple sclerosis. Journal of Neurology2012;259:S38. VermerschP , CzlonkowskaA , GrimaldiLM , ConfavreuxC , ComiG , KapposL , et al. Teriflunomide versus subcutaneous interferon beta‐1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial. Multiple Sclerosis2014;20(6):705‐16. ">Vermersch 2014</a> was an approved DMD‐controlled, parallel‐group, rater‐blinded study over at least 48 weeks (a maximum of 115 weeks). </p> </section> <section id="CD009882-sec-0054"> <h5 class="title">Characteristics of the participants</h5> <p>All participants had a diagnosis of definite MS according to McDonald's diagnostic criteria (<a href="./references#CD009882-bbs2-0028" title="McDonaldWI , CompstonA , EdanG , GoodkinD , HartungHP , LublinFD , et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Annals of Neurology2001;50(1):121‐7. ">McDonald 2001</a>; <a href="./references#CD009882-bbs2-0033" title='PolmanCH , ReingoldSC , EdanG , FilippiM , HartungHP , KapposL , et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Annals of Neurology2005;58(6):840‐6. '>Polman 2005</a>), an age ranging from 18 to 55 years and a relapsing clinical course with or without progression (RRMS, SPMS or PRMS). All participants had an entry score of 5.5 or lower on the EDSS and no relapse for at least 30 days before randomization. The participants in <a href="./references#CD009882-bbs2-0001" title="ComiG , FreedmanMS , KapposL , MillerA , OlssonTP , WolinskyJS , et al. Effect of teriflunomide on lymphocyte and neutrophil counts in patients with relapsing multiple sclerosis: results from the TOWER study. Journal of the Neurological Sciences2013;333:e376. ConfavreuxC , O'ConnorP , ComiG , FreedmanMS , MillerAE , OlssonTP , et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet Neurology2014;13(3):247‐56. KapposL , ComiG , ConfavreuxC , FreedmanMS , MillerAE , OlssonTP , et al. The efficacy and safety of teriflunomide in patients with relapsing MS: results from TOWER, a phase Ⅲ, placebo‐controlled study. Multiple Sclerosis2012;18:50‐1. MillerA , KapposL , ComiG , ConfavreuxC , FreedmanM , OlssonT , et al. Teriflunomide efficacy and safety in patients with relapsing multiple sclerosis: results from tower, a second, pivotal, phase 3 placebo‐controlled study. Neurology. 2013; Vol. 80. MillerAE , MacdonellR , ComiG , FreedmanMS , KapposL , MaurerM , et al. Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study. Journal of Neurology2014;261(9):1781‐8. MosesH , FreedmanM , KapposL , MillerA , OlssonT , WolinskyJ , et al. Pre‐defined subgroups analyses of tower, a placebo‐controlled phase 3 trial of teriflunomide in patients with relapsing multiple sclerosis. Proceedings of the American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). O'ConnorP , LublinF , WolinskyJ , ComiG , ConfavreuxC , FreedmanM , et al. Teriflunomide reduces relapse‐related sequelae, hospitalizations and corticosteroid use: a post‐HOC analysis of the phase 3 TOWER study. Proceedings of The American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). ">Confavreux 2014</a> and <a href="./references#CD009882-bbs2-0004" title="ComiG , BenzerdjebH , WangL , TruffinetP , O'ConnorP . Effect of teriflunomide on lymphocyte and neutrophil levels in patients with relapsing multiple sclerosis: results from the TEMSO study. Journal of Neurological Science2013;333(Suppl 1):e376. ComiG , O'ConnorP , WolinskyJ , ConfavreuxC , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: safety outcomes with up to 4 years of follow‐Up. Multiple Sclerosis2011;17:S182‐3. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Long‐term safety and efficacy of teriflunomide in patients with relapsing forms of multiple sclerosis in the TEMSO extension trial. Multiple Sclerosis2013;19:225. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Safety and efficacy of teriflunomide for up to 9 years in relapsing forms of multiple sclerosis: Update of the TEMSO extension trial. Neurology2014; Vol. 82, issue Suppl 10:3‐150. FreedmanMS , DelhayJL , BenamorM . Gastrointestinal symptoms infrequently lead to discontinuation of teriflunomide therapy. Multiple Sclerosis2012;18:S13. MillerA , LublinF , O'ConnorP , TaniouC , Dive‐PoulettyC . Impact of relapses with sequelae on disability, health‐related quality of life, and fatigue in a population with relapsing forms of multiple sclerosis using data from TEMSO, a pivotal phase Ⅲ teriflunomide trial. Neurology2012;78:P07.082. MillerA , LublinF , O'ConnorP , WolinskyJ , ComiG , KapposL , et al. Effect of teriflunomide on relapses with sequelae and relapse leading to hospitalization in a population with relapsing forms of multiple sclerosis: results from the TEMSO study. Neurology2012;78:S30.003. MillerA , O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , et al. Efficacy of oral teriflunomide in multiple sclerosis with relapses: cognitive outcomes from a phase Ⅲ trial (TEMSO). Multiple Sclerosis2011;17:S182. MillerAE , O'ConnorP , WolinskyJS , ConfavreuxC , KapposL , OlssonTP , et al. Pre‐specified subgroup analyses of a placebo‐controlled phase Ⅲ trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis. Multiple Sclerosis2012;18(11):1625‐32. O'ConnorP , BriggsA , CaritaP , Bego‐Le‐BagousseG . Impact on health‐related quality of life of teriflunomide treatment by estimating utilities in patients with relapsing multiple sclerosis: results from TEMSO post hoc analysis. Journal of Neurology2012;259:S107. O'ConnorP , BurrellA , WangL , WeiL , CaritaP , ZhangQ . Effect of teriflunomide on longitudinal patterns of relapse and relapse‐related hospitalization in multiple sclerosis. Multiple Sclerosis2011;17:S414. O'ConnorP , LublinF , WolinskyJ , ComiG , KapposL , FreedmanM , et al. Effect of teriflunomide on relapses leading to healthcare resource use: results from the TEMSO study. Multiple Sclerosis2011;17:S95‐6. O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: clinical and MRI data 5 years after initial randomization. Multiple Sclerosis2011;17:S414‐5. O'ConnorP , WolinskyJS , ConfavreuxC , ComiG , KapposL , OlssonTP , et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. New England Journal of Medicine2011;365(14):1293‐303. O'ConnorPW , LublinFD , WolinskyJS , ConfavreuxC , ComiG , FreedmanMS , et al. Teriflunomide reduces relapse‐related neurological sequelae, hospitalizations and steroid use. Journal of Neurology2013;260(10):2472‐80. WolinksyJS , WangL , TruffinetP , NarayanaPA , NelsonF , O'ConnorP . Magnetic resonance imaging as a surrogate for clinical endpoints in multiple sclerosis. Multiple Sclerosis2012;18:470‐1. WolinskyJS , NarayanaPA , NelsonF , DattaS , O'ConnorP , ConfavreuxC , et al. Magnetic resonance imaging outcomes from a phase Ⅲ trial of teriflunomide. Multiple Sclerosis2013;19(10):1310‐9. ">O'Connor 2011</a> had at least one relapse in the previous year or at least two clinical relapses in the previous two years. The participants in <a href="./references#CD009882-bbs2-0003" title="NCT01252355 . Efficacy and Safety of Teriflunomide in Patients with Relapsing Multiple Sclerosis and Treated with Interferon‐beta (TERACLES). www.clinicaltrials.gov/ct2/show/results/NCT01252355 (accessed 12 January 2016). ">NCT01252355</a> had disease activity in the one year prior to randomization and after first three months of IFNβ treatment. Baseline demographic and disease characteristics were well balanced among the groups in most studies except for <a href="./references#CD009882-bbs2-0005" title="VermerschP , CzlonkowskaA , GrimaldiLM , ConfavreuxC , ComiG , KapposL , et al. A multicenter, randomized, parallel‐group, rater‐blinded study comparing the effectiveness and safety of teriflunomide and subcutaneous interferon beta‐1a in patients with relapsing multiple sclerosis. Multiple Sclerosis2012;18:S9‐10. VermerschP , CzlonkowskaA , GrimaldiLM , ConfavreuxC , ComiG , KapposL , et al. Evaluation of patient satisfaction from the TENERE study: a comparison of teriflunomide and subcutaneous interferon beta‐1a in patients with relapsing multiple sclerosis. Journal of Neurology2012;259:S38. VermerschP , CzlonkowskaA , GrimaldiLM , ConfavreuxC , ComiG , KapposL , et al. Teriflunomide versus subcutaneous interferon beta‐1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial. Multiple Sclerosis2014;20(6):705‐16. ">Vermersch 2014</a>, in which DMD use in the past two years in the teriflunomide 14 mg/day group was lower than that in the IFNβ‐1a group. </p> </section> <section id="CD009882-sec-0055"> <h5 class="title">Characteristics of the interventions</h5> <p>Participants in <a href="./references#CD009882-bbs2-0001" title="ComiG , FreedmanMS , KapposL , MillerA , OlssonTP , WolinskyJS , et al. Effect of teriflunomide on lymphocyte and neutrophil counts in patients with relapsing multiple sclerosis: results from the TOWER study. Journal of the Neurological Sciences2013;333:e376. ConfavreuxC , O'ConnorP , ComiG , FreedmanMS , MillerAE , OlssonTP , et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet Neurology2014;13(3):247‐56. KapposL , ComiG , ConfavreuxC , FreedmanMS , MillerAE , OlssonTP , et al. The efficacy and safety of teriflunomide in patients with relapsing MS: results from TOWER, a phase Ⅲ, placebo‐controlled study. Multiple Sclerosis2012;18:50‐1. MillerA , KapposL , ComiG , ConfavreuxC , FreedmanM , OlssonT , et al. Teriflunomide efficacy and safety in patients with relapsing multiple sclerosis: results from tower, a second, pivotal, phase 3 placebo‐controlled study. Neurology. 2013; Vol. 80. MillerAE , MacdonellR , ComiG , FreedmanMS , KapposL , MaurerM , et al. Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study. Journal of Neurology2014;261(9):1781‐8. MosesH , FreedmanM , KapposL , MillerA , OlssonT , WolinskyJ , et al. Pre‐defined subgroups analyses of tower, a placebo‐controlled phase 3 trial of teriflunomide in patients with relapsing multiple sclerosis. Proceedings of the American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). O'ConnorP , LublinF , WolinskyJ , ComiG , ConfavreuxC , FreedmanM , et al. Teriflunomide reduces relapse‐related sequelae, hospitalizations and corticosteroid use: a post‐HOC analysis of the phase 3 TOWER study. Proceedings of The American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). ">Confavreux 2014</a> and <a href="./references#CD009882-bbs2-0004" title="ComiG , BenzerdjebH , WangL , TruffinetP , O'ConnorP . Effect of teriflunomide on lymphocyte and neutrophil levels in patients with relapsing multiple sclerosis: results from the TEMSO study. Journal of Neurological Science2013;333(Suppl 1):e376. ComiG , O'ConnorP , WolinskyJ , ConfavreuxC , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: safety outcomes with up to 4 years of follow‐Up. Multiple Sclerosis2011;17:S182‐3. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Long‐term safety and efficacy of teriflunomide in patients with relapsing forms of multiple sclerosis in the TEMSO extension trial. Multiple Sclerosis2013;19:225. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Safety and efficacy of teriflunomide for up to 9 years in relapsing forms of multiple sclerosis: Update of the TEMSO extension trial. Neurology2014; Vol. 82, issue Suppl 10:3‐150. FreedmanMS , DelhayJL , BenamorM . Gastrointestinal symptoms infrequently lead to discontinuation of teriflunomide therapy. Multiple Sclerosis2012;18:S13. MillerA , LublinF , O'ConnorP , TaniouC , Dive‐PoulettyC . Impact of relapses with sequelae on disability, health‐related quality of life, and fatigue in a population with relapsing forms of multiple sclerosis using data from TEMSO, a pivotal phase Ⅲ teriflunomide trial. Neurology2012;78:P07.082. MillerA , LublinF , O'ConnorP , WolinskyJ , ComiG , KapposL , et al. Effect of teriflunomide on relapses with sequelae and relapse leading to hospitalization in a population with relapsing forms of multiple sclerosis: results from the TEMSO study. Neurology2012;78:S30.003. MillerA , O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , et al. Efficacy of oral teriflunomide in multiple sclerosis with relapses: cognitive outcomes from a phase Ⅲ trial (TEMSO). Multiple Sclerosis2011;17:S182. MillerAE , O'ConnorP , WolinskyJS , ConfavreuxC , KapposL , OlssonTP , et al. Pre‐specified subgroup analyses of a placebo‐controlled phase Ⅲ trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis. Multiple Sclerosis2012;18(11):1625‐32. O'ConnorP , BriggsA , CaritaP , Bego‐Le‐BagousseG . Impact on health‐related quality of life of teriflunomide treatment by estimating utilities in patients with relapsing multiple sclerosis: results from TEMSO post hoc analysis. Journal of Neurology2012;259:S107. O'ConnorP , BurrellA , WangL , WeiL , CaritaP , ZhangQ . Effect of teriflunomide on longitudinal patterns of relapse and relapse‐related hospitalization in multiple sclerosis. Multiple Sclerosis2011;17:S414. O'ConnorP , LublinF , WolinskyJ , ComiG , KapposL , FreedmanM , et al. Effect of teriflunomide on relapses leading to healthcare resource use: results from the TEMSO study. Multiple Sclerosis2011;17:S95‐6. O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: clinical and MRI data 5 years after initial randomization. Multiple Sclerosis2011;17:S414‐5. O'ConnorP , WolinskyJS , ConfavreuxC , ComiG , KapposL , OlssonTP , et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. New England Journal of Medicine2011;365(14):1293‐303. O'ConnorPW , LublinFD , WolinskyJS , ConfavreuxC , ComiG , FreedmanMS , et al. Teriflunomide reduces relapse‐related neurological sequelae, hospitalizations and steroid use. Journal of Neurology2013;260(10):2472‐80. WolinksyJS , WangL , TruffinetP , NarayanaPA , NelsonF , O'ConnorP . Magnetic resonance imaging as a surrogate for clinical endpoints in multiple sclerosis. Multiple Sclerosis2012;18:470‐1. WolinskyJS , NarayanaPA , NelsonF , DattaS , O'ConnorP , ConfavreuxC , et al. Magnetic resonance imaging outcomes from a phase Ⅲ trial of teriflunomide. Multiple Sclerosis2013;19(10):1310‐9. ">O'Connor 2011</a> received oral teriflunomide 7 mg once daily or oral teriflunomide 14 mg once daily or a matching placebo for at least 48 weeks (core treatment period: 48 weeks to 152 weeks, a maximum of 173 weeks) (<a href="./references#CD009882-bbs2-0001" title="ComiG , FreedmanMS , KapposL , MillerA , OlssonTP , WolinskyJS , et al. Effect of teriflunomide on lymphocyte and neutrophil counts in patients with relapsing multiple sclerosis: results from the TOWER study. Journal of the Neurological Sciences2013;333:e376. ConfavreuxC , O'ConnorP , ComiG , FreedmanMS , MillerAE , OlssonTP , et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet Neurology2014;13(3):247‐56. KapposL , ComiG , ConfavreuxC , FreedmanMS , MillerAE , OlssonTP , et al. The efficacy and safety of teriflunomide in patients with relapsing MS: results from TOWER, a phase Ⅲ, placebo‐controlled study. Multiple Sclerosis2012;18:50‐1. MillerA , KapposL , ComiG , ConfavreuxC , FreedmanM , OlssonT , et al. Teriflunomide efficacy and safety in patients with relapsing multiple sclerosis: results from tower, a second, pivotal, phase 3 placebo‐controlled study. Neurology. 2013; Vol. 80. MillerAE , MacdonellR , ComiG , FreedmanMS , KapposL , MaurerM , et al. Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study. Journal of Neurology2014;261(9):1781‐8. MosesH , FreedmanM , KapposL , MillerA , OlssonT , WolinskyJ , et al. Pre‐defined subgroups analyses of tower, a placebo‐controlled phase 3 trial of teriflunomide in patients with relapsing multiple sclerosis. Proceedings of the American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). O'ConnorP , LublinF , WolinskyJ , ComiG , ConfavreuxC , FreedmanM , et al. Teriflunomide reduces relapse‐related sequelae, hospitalizations and corticosteroid use: a post‐HOC analysis of the phase 3 TOWER study. Proceedings of The American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). ">Confavreux 2014</a>) and 108 weeks (<a href="./references#CD009882-bbs2-0004" title="ComiG , BenzerdjebH , WangL , TruffinetP , O'ConnorP . Effect of teriflunomide on lymphocyte and neutrophil levels in patients with relapsing multiple sclerosis: results from the TEMSO study. Journal of Neurological Science2013;333(Suppl 1):e376. ComiG , O'ConnorP , WolinskyJ , ConfavreuxC , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: safety outcomes with up to 4 years of follow‐Up. Multiple Sclerosis2011;17:S182‐3. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Long‐term safety and efficacy of teriflunomide in patients with relapsing forms of multiple sclerosis in the TEMSO extension trial. Multiple Sclerosis2013;19:225. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Safety and efficacy of teriflunomide for up to 9 years in relapsing forms of multiple sclerosis: Update of the TEMSO extension trial. Neurology2014; Vol. 82, issue Suppl 10:3‐150. FreedmanMS , DelhayJL , BenamorM . Gastrointestinal symptoms infrequently lead to discontinuation of teriflunomide therapy. Multiple Sclerosis2012;18:S13. MillerA , LublinF , O'ConnorP , TaniouC , Dive‐PoulettyC . Impact of relapses with sequelae on disability, health‐related quality of life, and fatigue in a population with relapsing forms of multiple sclerosis using data from TEMSO, a pivotal phase Ⅲ teriflunomide trial. Neurology2012;78:P07.082. MillerA , LublinF , O'ConnorP , WolinskyJ , ComiG , KapposL , et al. Effect of teriflunomide on relapses with sequelae and relapse leading to hospitalization in a population with relapsing forms of multiple sclerosis: results from the TEMSO study. Neurology2012;78:S30.003. MillerA , O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , et al. Efficacy of oral teriflunomide in multiple sclerosis with relapses: cognitive outcomes from a phase Ⅲ trial (TEMSO). Multiple Sclerosis2011;17:S182. MillerAE , O'ConnorP , WolinskyJS , ConfavreuxC , KapposL , OlssonTP , et al. Pre‐specified subgroup analyses of a placebo‐controlled phase Ⅲ trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis. Multiple Sclerosis2012;18(11):1625‐32. O'ConnorP , BriggsA , CaritaP , Bego‐Le‐BagousseG . Impact on health‐related quality of life of teriflunomide treatment by estimating utilities in patients with relapsing multiple sclerosis: results from TEMSO post hoc analysis. Journal of Neurology2012;259:S107. O'ConnorP , BurrellA , WangL , WeiL , CaritaP , ZhangQ . Effect of teriflunomide on longitudinal patterns of relapse and relapse‐related hospitalization in multiple sclerosis. Multiple Sclerosis2011;17:S414. O'ConnorP , LublinF , WolinskyJ , ComiG , KapposL , FreedmanM , et al. Effect of teriflunomide on relapses leading to healthcare resource use: results from the TEMSO study. Multiple Sclerosis2011;17:S95‐6. O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: clinical and MRI data 5 years after initial randomization. Multiple Sclerosis2011;17:S414‐5. O'ConnorP , WolinskyJS , ConfavreuxC , ComiG , KapposL , OlssonTP , et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. New England Journal of Medicine2011;365(14):1293‐303. O'ConnorPW , LublinFD , WolinskyJS , ConfavreuxC , ComiG , FreedmanMS , et al. Teriflunomide reduces relapse‐related neurological sequelae, hospitalizations and steroid use. Journal of Neurology2013;260(10):2472‐80. WolinksyJS , WangL , TruffinetP , NarayanaPA , NelsonF , O'ConnorP . Magnetic resonance imaging as a surrogate for clinical endpoints in multiple sclerosis. Multiple Sclerosis2012;18:470‐1. WolinskyJS , NarayanaPA , NelsonF , DattaS , O'ConnorP , ConfavreuxC , et al. Magnetic resonance imaging outcomes from a phase Ⅲ trial of teriflunomide. Multiple Sclerosis2013;19(10):1310‐9. ">O'Connor 2011</a>). Participants in <a href="./references#CD009882-bbs2-0002" title="FreedmanMS , WolinskyJS , WamilB , ConfavreuxC , ComiG , KapposL , et al. Teriflunomide added to interferon‐β in relapsing multiple sclerosis: a randomized phase Ⅱ trial. Neurology2012;78(23):1877‐85. ">Freedman 2012</a> and <a href="./references#CD009882-bbs2-0003" title="NCT01252355 . Efficacy and Safety of Teriflunomide in Patients with Relapsing Multiple Sclerosis and Treated with Interferon‐beta (TERACLES). www.clinicaltrials.gov/ct2/show/results/NCT01252355 (accessed 12 January 2016). ">NCT01252355</a> received oral administration of 7 mg/day of teriflunomide added to IFNβ, 14 mg/day of teriflunomide added to IFNβ or matching placebo added to IFNβ for 48 weeks (<a href="./references#CD009882-bbs2-0002" title="FreedmanMS , WolinskyJS , WamilB , ConfavreuxC , ComiG , KapposL , et al. Teriflunomide added to interferon‐β in relapsing multiple sclerosis: a randomized phase Ⅱ trial. Neurology2012;78(23):1877‐85. ">Freedman 2012</a>) and at least 24 weeks (a maximum of 108 weeks) (<a href="./references#CD009882-bbs2-0003" title="NCT01252355 . Efficacy and Safety of Teriflunomide in Patients with Relapsing Multiple Sclerosis and Treated with Interferon‐beta (TERACLES). www.clinicaltrials.gov/ct2/show/results/NCT01252355 (accessed 12 January 2016). ">NCT01252355</a>). Participants in <a href="./references#CD009882-bbs2-0005" title="VermerschP , CzlonkowskaA , GrimaldiLM , ConfavreuxC , ComiG , KapposL , et al. A multicenter, randomized, parallel‐group, rater‐blinded study comparing the effectiveness and safety of teriflunomide and subcutaneous interferon beta‐1a in patients with relapsing multiple sclerosis. Multiple Sclerosis2012;18:S9‐10. VermerschP , CzlonkowskaA , GrimaldiLM , ConfavreuxC , ComiG , KapposL , et al. Evaluation of patient satisfaction from the TENERE study: a comparison of teriflunomide and subcutaneous interferon beta‐1a in patients with relapsing multiple sclerosis. Journal of Neurology2012;259:S38. VermerschP , CzlonkowskaA , GrimaldiLM , ConfavreuxC , ComiG , KapposL , et al. Teriflunomide versus subcutaneous interferon beta‐1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial. Multiple Sclerosis2014;20(6):705‐16. ">Vermersch 2014</a> received oral teriflunomide 7 mg once daily or oral teriflunomide 14 mg once daily or IFNβ‐1a 44 μg by subcutaneous injection three times per week for at least 48 weeks (a maximum of 115 weeks). </p> </section> <section id="CD009882-sec-0056"> <h5 class="title">Characteristics of the outcome measures</h5> <p>All studies reported the proportion of participants with at least one relapse. Two studies reported sustained disability progression, which was defined as an increase from baseline of at least 1.0 point in the EDSS score (or at least 0.5 points for participants with a baseline EDSS score greater than 5.5) that persisted for at least 12 weeks (<a href="./references#CD009882-bbs2-0001" title="ComiG , FreedmanMS , KapposL , MillerA , OlssonTP , WolinskyJS , et al. Effect of teriflunomide on lymphocyte and neutrophil counts in patients with relapsing multiple sclerosis: results from the TOWER study. Journal of the Neurological Sciences2013;333:e376. ConfavreuxC , O'ConnorP , ComiG , FreedmanMS , MillerAE , OlssonTP , et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet Neurology2014;13(3):247‐56. KapposL , ComiG , ConfavreuxC , FreedmanMS , MillerAE , OlssonTP , et al. The efficacy and safety of teriflunomide in patients with relapsing MS: results from TOWER, a phase Ⅲ, placebo‐controlled study. Multiple Sclerosis2012;18:50‐1. MillerA , KapposL , ComiG , ConfavreuxC , FreedmanM , OlssonT , et al. Teriflunomide efficacy and safety in patients with relapsing multiple sclerosis: results from tower, a second, pivotal, phase 3 placebo‐controlled study. Neurology. 2013; Vol. 80. MillerAE , MacdonellR , ComiG , FreedmanMS , KapposL , MaurerM , et al. Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study. Journal of Neurology2014;261(9):1781‐8. MosesH , FreedmanM , KapposL , MillerA , OlssonT , WolinskyJ , et al. Pre‐defined subgroups analyses of tower, a placebo‐controlled phase 3 trial of teriflunomide in patients with relapsing multiple sclerosis. Proceedings of the American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). O'ConnorP , LublinF , WolinskyJ , ComiG , ConfavreuxC , FreedmanM , et al. Teriflunomide reduces relapse‐related sequelae, hospitalizations and corticosteroid use: a post‐HOC analysis of the phase 3 TOWER study. Proceedings of The American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). ">Confavreux 2014</a>; <a href="./references#CD009882-bbs2-0004" title="ComiG , BenzerdjebH , WangL , TruffinetP , O'ConnorP . Effect of teriflunomide on lymphocyte and neutrophil levels in patients with relapsing multiple sclerosis: results from the TEMSO study. Journal of Neurological Science2013;333(Suppl 1):e376. ComiG , O'ConnorP , WolinskyJ , ConfavreuxC , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: safety outcomes with up to 4 years of follow‐Up. Multiple Sclerosis2011;17:S182‐3. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Long‐term safety and efficacy of teriflunomide in patients with relapsing forms of multiple sclerosis in the TEMSO extension trial. Multiple Sclerosis2013;19:225. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Safety and efficacy of teriflunomide for up to 9 years in relapsing forms of multiple sclerosis: Update of the TEMSO extension trial. Neurology2014; Vol. 82, issue Suppl 10:3‐150. FreedmanMS , DelhayJL , BenamorM . Gastrointestinal symptoms infrequently lead to discontinuation of teriflunomide therapy. Multiple Sclerosis2012;18:S13. MillerA , LublinF , O'ConnorP , TaniouC , Dive‐PoulettyC . Impact of relapses with sequelae on disability, health‐related quality of life, and fatigue in a population with relapsing forms of multiple sclerosis using data from TEMSO, a pivotal phase Ⅲ teriflunomide trial. Neurology2012;78:P07.082. MillerA , LublinF , O'ConnorP , WolinskyJ , ComiG , KapposL , et al. Effect of teriflunomide on relapses with sequelae and relapse leading to hospitalization in a population with relapsing forms of multiple sclerosis: results from the TEMSO study. Neurology2012;78:S30.003. MillerA , O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , et al. Efficacy of oral teriflunomide in multiple sclerosis with relapses: cognitive outcomes from a phase Ⅲ trial (TEMSO). Multiple Sclerosis2011;17:S182. MillerAE , O'ConnorP , WolinskyJS , ConfavreuxC , KapposL , OlssonTP , et al. Pre‐specified subgroup analyses of a placebo‐controlled phase Ⅲ trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis. Multiple Sclerosis2012;18(11):1625‐32. O'ConnorP , BriggsA , CaritaP , Bego‐Le‐BagousseG . Impact on health‐related quality of life of teriflunomide treatment by estimating utilities in patients with relapsing multiple sclerosis: results from TEMSO post hoc analysis. Journal of Neurology2012;259:S107. O'ConnorP , BurrellA , WangL , WeiL , CaritaP , ZhangQ . Effect of teriflunomide on longitudinal patterns of relapse and relapse‐related hospitalization in multiple sclerosis. Multiple Sclerosis2011;17:S414. O'ConnorP , LublinF , WolinskyJ , ComiG , KapposL , FreedmanM , et al. Effect of teriflunomide on relapses leading to healthcare resource use: results from the TEMSO study. Multiple Sclerosis2011;17:S95‐6. O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: clinical and MRI data 5 years after initial randomization. Multiple Sclerosis2011;17:S414‐5. O'ConnorP , WolinskyJS , ConfavreuxC , ComiG , KapposL , OlssonTP , et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. New England Journal of Medicine2011;365(14):1293‐303. O'ConnorPW , LublinFD , WolinskyJS , ConfavreuxC , ComiG , FreedmanMS , et al. Teriflunomide reduces relapse‐related neurological sequelae, hospitalizations and steroid use. Journal of Neurology2013;260(10):2472‐80. WolinksyJS , WangL , TruffinetP , NarayanaPA , NelsonF , O'ConnorP . Magnetic resonance imaging as a surrogate for clinical endpoints in multiple sclerosis. Multiple Sclerosis2012;18:470‐1. WolinskyJS , NarayanaPA , NelsonF , DattaS , O'ConnorP , ConfavreuxC , et al. Magnetic resonance imaging outcomes from a phase Ⅲ trial of teriflunomide. Multiple Sclerosis2013;19(10):1310‐9. ">O'Connor 2011</a>). All studies reported the number of participants with AEs, number of participants with SAEs and number of participants who withdrew or dropped out from the study because of AEs. </p> <p>All studies reported the annualized relapse rate. Three trials reported the number of gadolinium‐enhancing T1‐weighted lesions (<a href="./references#CD009882-bbs2-0002" title="FreedmanMS , WolinskyJS , WamilB , ConfavreuxC , ComiG , KapposL , et al. Teriflunomide added to interferon‐β in relapsing multiple sclerosis: a randomized phase Ⅱ trial. Neurology2012;78(23):1877‐85. ">Freedman 2012</a>; <a href="./references#CD009882-bbs2-0003" title="NCT01252355 . Efficacy and Safety of Teriflunomide in Patients with Relapsing Multiple Sclerosis and Treated with Interferon‐beta (TERACLES). www.clinicaltrials.gov/ct2/show/results/NCT01252355 (accessed 12 January 2016). ">NCT01252355</a>; <a href="./references#CD009882-bbs2-0004" title="ComiG , BenzerdjebH , WangL , TruffinetP , O'ConnorP . Effect of teriflunomide on lymphocyte and neutrophil levels in patients with relapsing multiple sclerosis: results from the TEMSO study. Journal of Neurological Science2013;333(Suppl 1):e376. ComiG , O'ConnorP , WolinskyJ , ConfavreuxC , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: safety outcomes with up to 4 years of follow‐Up. Multiple Sclerosis2011;17:S182‐3. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Long‐term safety and efficacy of teriflunomide in patients with relapsing forms of multiple sclerosis in the TEMSO extension trial. Multiple Sclerosis2013;19:225. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Safety and efficacy of teriflunomide for up to 9 years in relapsing forms of multiple sclerosis: Update of the TEMSO extension trial. Neurology2014; Vol. 82, issue Suppl 10:3‐150. FreedmanMS , DelhayJL , BenamorM . Gastrointestinal symptoms infrequently lead to discontinuation of teriflunomide therapy. Multiple Sclerosis2012;18:S13. MillerA , LublinF , O'ConnorP , TaniouC , Dive‐PoulettyC . Impact of relapses with sequelae on disability, health‐related quality of life, and fatigue in a population with relapsing forms of multiple sclerosis using data from TEMSO, a pivotal phase Ⅲ teriflunomide trial. Neurology2012;78:P07.082. MillerA , LublinF , O'ConnorP , WolinskyJ , ComiG , KapposL , et al. Effect of teriflunomide on relapses with sequelae and relapse leading to hospitalization in a population with relapsing forms of multiple sclerosis: results from the TEMSO study. Neurology2012;78:S30.003. MillerA , O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , et al. Efficacy of oral teriflunomide in multiple sclerosis with relapses: cognitive outcomes from a phase Ⅲ trial (TEMSO). Multiple Sclerosis2011;17:S182. MillerAE , O'ConnorP , WolinskyJS , ConfavreuxC , KapposL , OlssonTP , et al. Pre‐specified subgroup analyses of a placebo‐controlled phase Ⅲ trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis. Multiple Sclerosis2012;18(11):1625‐32. O'ConnorP , BriggsA , CaritaP , Bego‐Le‐BagousseG . Impact on health‐related quality of life of teriflunomide treatment by estimating utilities in patients with relapsing multiple sclerosis: results from TEMSO post hoc analysis. Journal of Neurology2012;259:S107. O'ConnorP , BurrellA , WangL , WeiL , CaritaP , ZhangQ . Effect of teriflunomide on longitudinal patterns of relapse and relapse‐related hospitalization in multiple sclerosis. Multiple Sclerosis2011;17:S414. O'ConnorP , LublinF , WolinskyJ , ComiG , KapposL , FreedmanM , et al. Effect of teriflunomide on relapses leading to healthcare resource use: results from the TEMSO study. Multiple Sclerosis2011;17:S95‐6. O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: clinical and MRI data 5 years after initial randomization. Multiple Sclerosis2011;17:S414‐5. O'ConnorP , WolinskyJS , ConfavreuxC , ComiG , KapposL , OlssonTP , et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. New England Journal of Medicine2011;365(14):1293‐303. O'ConnorPW , LublinFD , WolinskyJS , ConfavreuxC , ComiG , FreedmanMS , et al. Teriflunomide reduces relapse‐related neurological sequelae, hospitalizations and steroid use. Journal of Neurology2013;260(10):2472‐80. WolinksyJS , WangL , TruffinetP , NarayanaPA , NelsonF , O'ConnorP . Magnetic resonance imaging as a surrogate for clinical endpoints in multiple sclerosis. Multiple Sclerosis2012;18:470‐1. WolinskyJS , NarayanaPA , NelsonF , DattaS , O'ConnorP , ConfavreuxC , et al. Magnetic resonance imaging outcomes from a phase Ⅲ trial of teriflunomide. Multiple Sclerosis2013;19(10):1310‐9. ">O'Connor 2011</a>). Three trials reported the time to disability progression (<a href="./references#CD009882-bbs2-0001" title="ComiG , FreedmanMS , KapposL , MillerA , OlssonTP , WolinskyJS , et al. Effect of teriflunomide on lymphocyte and neutrophil counts in patients with relapsing multiple sclerosis: results from the TOWER study. Journal of the Neurological Sciences2013;333:e376. ConfavreuxC , O'ConnorP , ComiG , FreedmanMS , MillerAE , OlssonTP , et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet Neurology2014;13(3):247‐56. KapposL , ComiG , ConfavreuxC , FreedmanMS , MillerAE , OlssonTP , et al. The efficacy and safety of teriflunomide in patients with relapsing MS: results from TOWER, a phase Ⅲ, placebo‐controlled study. Multiple Sclerosis2012;18:50‐1. MillerA , KapposL , ComiG , ConfavreuxC , FreedmanM , OlssonT , et al. Teriflunomide efficacy and safety in patients with relapsing multiple sclerosis: results from tower, a second, pivotal, phase 3 placebo‐controlled study. Neurology. 2013; Vol. 80. MillerAE , MacdonellR , ComiG , FreedmanMS , KapposL , MaurerM , et al. Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study. Journal of Neurology2014;261(9):1781‐8. MosesH , FreedmanM , KapposL , MillerA , OlssonT , WolinskyJ , et al. Pre‐defined subgroups analyses of tower, a placebo‐controlled phase 3 trial of teriflunomide in patients with relapsing multiple sclerosis. Proceedings of the American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). O'ConnorP , LublinF , WolinskyJ , ComiG , ConfavreuxC , FreedmanM , et al. Teriflunomide reduces relapse‐related sequelae, hospitalizations and corticosteroid use: a post‐HOC analysis of the phase 3 TOWER study. Proceedings of The American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). ">Confavreux 2014</a>; <a href="./references#CD009882-bbs2-0003" title="NCT01252355 . Efficacy and Safety of Teriflunomide in Patients with Relapsing Multiple Sclerosis and Treated with Interferon‐beta (TERACLES). www.clinicaltrials.gov/ct2/show/results/NCT01252355 (accessed 12 January 2016). ">NCT01252355</a>; <a href="./references#CD009882-bbs2-0004" title="ComiG , BenzerdjebH , WangL , TruffinetP , O'ConnorP . Effect of teriflunomide on lymphocyte and neutrophil levels in patients with relapsing multiple sclerosis: results from the TEMSO study. Journal of Neurological Science2013;333(Suppl 1):e376. ComiG , O'ConnorP , WolinskyJ , ConfavreuxC , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: safety outcomes with up to 4 years of follow‐Up. Multiple Sclerosis2011;17:S182‐3. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Long‐term safety and efficacy of teriflunomide in patients with relapsing forms of multiple sclerosis in the TEMSO extension trial. Multiple Sclerosis2013;19:225. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Safety and efficacy of teriflunomide for up to 9 years in relapsing forms of multiple sclerosis: Update of the TEMSO extension trial. Neurology2014; Vol. 82, issue Suppl 10:3‐150. FreedmanMS , DelhayJL , BenamorM . Gastrointestinal symptoms infrequently lead to discontinuation of teriflunomide therapy. Multiple Sclerosis2012;18:S13. MillerA , LublinF , O'ConnorP , TaniouC , Dive‐PoulettyC . Impact of relapses with sequelae on disability, health‐related quality of life, and fatigue in a population with relapsing forms of multiple sclerosis using data from TEMSO, a pivotal phase Ⅲ teriflunomide trial. Neurology2012;78:P07.082. MillerA , LublinF , O'ConnorP , WolinskyJ , ComiG , KapposL , et al. Effect of teriflunomide on relapses with sequelae and relapse leading to hospitalization in a population with relapsing forms of multiple sclerosis: results from the TEMSO study. Neurology2012;78:S30.003. MillerA , O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , et al. Efficacy of oral teriflunomide in multiple sclerosis with relapses: cognitive outcomes from a phase Ⅲ trial (TEMSO). Multiple Sclerosis2011;17:S182. MillerAE , O'ConnorP , WolinskyJS , ConfavreuxC , KapposL , OlssonTP , et al. Pre‐specified subgroup analyses of a placebo‐controlled phase Ⅲ trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis. Multiple Sclerosis2012;18(11):1625‐32. O'ConnorP , BriggsA , CaritaP , Bego‐Le‐BagousseG . Impact on health‐related quality of life of teriflunomide treatment by estimating utilities in patients with relapsing multiple sclerosis: results from TEMSO post hoc analysis. Journal of Neurology2012;259:S107. O'ConnorP , BurrellA , WangL , WeiL , CaritaP , ZhangQ . Effect of teriflunomide on longitudinal patterns of relapse and relapse‐related hospitalization in multiple sclerosis. Multiple Sclerosis2011;17:S414. O'ConnorP , LublinF , WolinskyJ , ComiG , KapposL , FreedmanM , et al. Effect of teriflunomide on relapses leading to healthcare resource use: results from the TEMSO study. Multiple Sclerosis2011;17:S95‐6. O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: clinical and MRI data 5 years after initial randomization. Multiple Sclerosis2011;17:S414‐5. O'ConnorP , WolinskyJS , ConfavreuxC , ComiG , KapposL , OlssonTP , et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. New England Journal of Medicine2011;365(14):1293‐303. O'ConnorPW , LublinFD , WolinskyJS , ConfavreuxC , ComiG , FreedmanMS , et al. Teriflunomide reduces relapse‐related neurological sequelae, hospitalizations and steroid use. Journal of Neurology2013;260(10):2472‐80. WolinksyJS , WangL , TruffinetP , NarayanaPA , NelsonF , O'ConnorP . Magnetic resonance imaging as a surrogate for clinical endpoints in multiple sclerosis. Multiple Sclerosis2012;18:470‐1. WolinskyJS , NarayanaPA , NelsonF , DattaS , O'ConnorP , ConfavreuxC , et al. Magnetic resonance imaging outcomes from a phase Ⅲ trial of teriflunomide. Multiple Sclerosis2013;19(10):1310‐9. ">O'Connor 2011</a>). One trial reported changes in T1 hypointensity of lesion damage (<a href="./references#CD009882-bbs2-0004" title="ComiG , BenzerdjebH , WangL , TruffinetP , O'ConnorP . Effect of teriflunomide on lymphocyte and neutrophil levels in patients with relapsing multiple sclerosis: results from the TEMSO study. Journal of Neurological Science2013;333(Suppl 1):e376. ComiG , O'ConnorP , WolinskyJ , ConfavreuxC , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: safety outcomes with up to 4 years of follow‐Up. Multiple Sclerosis2011;17:S182‐3. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Long‐term safety and efficacy of teriflunomide in patients with relapsing forms of multiple sclerosis in the TEMSO extension trial. Multiple Sclerosis2013;19:225. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Safety and efficacy of teriflunomide for up to 9 years in relapsing forms of multiple sclerosis: Update of the TEMSO extension trial. Neurology2014; Vol. 82, issue Suppl 10:3‐150. FreedmanMS , DelhayJL , BenamorM . Gastrointestinal symptoms infrequently lead to discontinuation of teriflunomide therapy. Multiple Sclerosis2012;18:S13. MillerA , LublinF , O'ConnorP , TaniouC , Dive‐PoulettyC . Impact of relapses with sequelae on disability, health‐related quality of life, and fatigue in a population with relapsing forms of multiple sclerosis using data from TEMSO, a pivotal phase Ⅲ teriflunomide trial. Neurology2012;78:P07.082. MillerA , LublinF , O'ConnorP , WolinskyJ , ComiG , KapposL , et al. Effect of teriflunomide on relapses with sequelae and relapse leading to hospitalization in a population with relapsing forms of multiple sclerosis: results from the TEMSO study. Neurology2012;78:S30.003. MillerA , O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , et al. Efficacy of oral teriflunomide in multiple sclerosis with relapses: cognitive outcomes from a phase Ⅲ trial (TEMSO). Multiple Sclerosis2011;17:S182. MillerAE , O'ConnorP , WolinskyJS , ConfavreuxC , KapposL , OlssonTP , et al. Pre‐specified subgroup analyses of a placebo‐controlled phase Ⅲ trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis. Multiple Sclerosis2012;18(11):1625‐32. O'ConnorP , BriggsA , CaritaP , Bego‐Le‐BagousseG . Impact on health‐related quality of life of teriflunomide treatment by estimating utilities in patients with relapsing multiple sclerosis: results from TEMSO post hoc analysis. Journal of Neurology2012;259:S107. O'ConnorP , BurrellA , WangL , WeiL , CaritaP , ZhangQ . Effect of teriflunomide on longitudinal patterns of relapse and relapse‐related hospitalization in multiple sclerosis. Multiple Sclerosis2011;17:S414. O'ConnorP , LublinF , WolinskyJ , ComiG , KapposL , FreedmanM , et al. Effect of teriflunomide on relapses leading to healthcare resource use: results from the TEMSO study. Multiple Sclerosis2011;17:S95‐6. O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: clinical and MRI data 5 years after initial randomization. Multiple Sclerosis2011;17:S414‐5. O'ConnorP , WolinskyJS , ConfavreuxC , ComiG , KapposL , OlssonTP , et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. New England Journal of Medicine2011;365(14):1293‐303. O'ConnorPW , LublinFD , WolinskyJS , ConfavreuxC , ComiG , FreedmanMS , et al. Teriflunomide reduces relapse‐related neurological sequelae, hospitalizations and steroid use. Journal of Neurology2013;260(10):2472‐80. WolinksyJS , WangL , TruffinetP , NarayanaPA , NelsonF , O'ConnorP . Magnetic resonance imaging as a surrogate for clinical endpoints in multiple sclerosis. Multiple Sclerosis2012;18:470‐1. WolinskyJS , NarayanaPA , NelsonF , DattaS , O'ConnorP , ConfavreuxC , et al. Magnetic resonance imaging outcomes from a phase Ⅲ trial of teriflunomide. Multiple Sclerosis2013;19(10):1310‐9. ">O'Connor 2011</a>). Two trials reported mean change in QoL measured by SF‐36 scores (<a href="./references#CD009882-bbs2-0001" title="ComiG , FreedmanMS , KapposL , MillerA , OlssonTP , WolinskyJS , et al. Effect of teriflunomide on lymphocyte and neutrophil counts in patients with relapsing multiple sclerosis: results from the TOWER study. Journal of the Neurological Sciences2013;333:e376. ConfavreuxC , O'ConnorP , ComiG , FreedmanMS , MillerAE , OlssonTP , et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet Neurology2014;13(3):247‐56. KapposL , ComiG , ConfavreuxC , FreedmanMS , MillerAE , OlssonTP , et al. The efficacy and safety of teriflunomide in patients with relapsing MS: results from TOWER, a phase Ⅲ, placebo‐controlled study. Multiple Sclerosis2012;18:50‐1. MillerA , KapposL , ComiG , ConfavreuxC , FreedmanM , OlssonT , et al. Teriflunomide efficacy and safety in patients with relapsing multiple sclerosis: results from tower, a second, pivotal, phase 3 placebo‐controlled study. Neurology. 2013; Vol. 80. MillerAE , MacdonellR , ComiG , FreedmanMS , KapposL , MaurerM , et al. Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study. Journal of Neurology2014;261(9):1781‐8. MosesH , FreedmanM , KapposL , MillerA , OlssonT , WolinskyJ , et al. Pre‐defined subgroups analyses of tower, a placebo‐controlled phase 3 trial of teriflunomide in patients with relapsing multiple sclerosis. Proceedings of the American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). O'ConnorP , LublinF , WolinskyJ , ComiG , ConfavreuxC , FreedmanM , et al. Teriflunomide reduces relapse‐related sequelae, hospitalizations and corticosteroid use: a post‐HOC analysis of the phase 3 TOWER study. Proceedings of The American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). ">Confavreux 2014</a>; <a href="./references#CD009882-bbs2-0003" title="NCT01252355 . Efficacy and Safety of Teriflunomide in Patients with Relapsing Multiple Sclerosis and Treated with Interferon‐beta (TERACLES). www.clinicaltrials.gov/ct2/show/results/NCT01252355 (accessed 12 January 2016). ">NCT01252355</a>). None of the studies reported magnetization transfer ratio of lesion damage. One trial did not provide data at one year (<a href="./references#CD009882-bbs2-0004" title="ComiG , BenzerdjebH , WangL , TruffinetP , O'ConnorP . Effect of teriflunomide on lymphocyte and neutrophil levels in patients with relapsing multiple sclerosis: results from the TEMSO study. Journal of Neurological Science2013;333(Suppl 1):e376. ComiG , O'ConnorP , WolinskyJ , ConfavreuxC , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: safety outcomes with up to 4 years of follow‐Up. Multiple Sclerosis2011;17:S182‐3. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Long‐term safety and efficacy of teriflunomide in patients with relapsing forms of multiple sclerosis in the TEMSO extension trial. Multiple Sclerosis2013;19:225. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Safety and efficacy of teriflunomide for up to 9 years in relapsing forms of multiple sclerosis: Update of the TEMSO extension trial. Neurology2014; Vol. 82, issue Suppl 10:3‐150. FreedmanMS , DelhayJL , BenamorM . Gastrointestinal symptoms infrequently lead to discontinuation of teriflunomide therapy. Multiple Sclerosis2012;18:S13. MillerA , LublinF , O'ConnorP , TaniouC , Dive‐PoulettyC . Impact of relapses with sequelae on disability, health‐related quality of life, and fatigue in a population with relapsing forms of multiple sclerosis using data from TEMSO, a pivotal phase Ⅲ teriflunomide trial. Neurology2012;78:P07.082. MillerA , LublinF , O'ConnorP , WolinskyJ , ComiG , KapposL , et al. Effect of teriflunomide on relapses with sequelae and relapse leading to hospitalization in a population with relapsing forms of multiple sclerosis: results from the TEMSO study. Neurology2012;78:S30.003. MillerA , O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , et al. Efficacy of oral teriflunomide in multiple sclerosis with relapses: cognitive outcomes from a phase Ⅲ trial (TEMSO). Multiple Sclerosis2011;17:S182. MillerAE , O'ConnorP , WolinskyJS , ConfavreuxC , KapposL , OlssonTP , et al. Pre‐specified subgroup analyses of a placebo‐controlled phase Ⅲ trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis. Multiple Sclerosis2012;18(11):1625‐32. O'ConnorP , BriggsA , CaritaP , Bego‐Le‐BagousseG . Impact on health‐related quality of life of teriflunomide treatment by estimating utilities in patients with relapsing multiple sclerosis: results from TEMSO post hoc analysis. Journal of Neurology2012;259:S107. O'ConnorP , BurrellA , WangL , WeiL , CaritaP , ZhangQ . Effect of teriflunomide on longitudinal patterns of relapse and relapse‐related hospitalization in multiple sclerosis. Multiple Sclerosis2011;17:S414. O'ConnorP , LublinF , WolinskyJ , ComiG , KapposL , FreedmanM , et al. Effect of teriflunomide on relapses leading to healthcare resource use: results from the TEMSO study. Multiple Sclerosis2011;17:S95‐6. O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: clinical and MRI data 5 years after initial randomization. Multiple Sclerosis2011;17:S414‐5. O'ConnorP , WolinskyJS , ConfavreuxC , ComiG , KapposL , OlssonTP , et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. New England Journal of Medicine2011;365(14):1293‐303. O'ConnorPW , LublinFD , WolinskyJS , ConfavreuxC , ComiG , FreedmanMS , et al. Teriflunomide reduces relapse‐related neurological sequelae, hospitalizations and steroid use. Journal of Neurology2013;260(10):2472‐80. WolinksyJS , WangL , TruffinetP , NarayanaPA , NelsonF , O'ConnorP . Magnetic resonance imaging as a surrogate for clinical endpoints in multiple sclerosis. Multiple Sclerosis2012;18:470‐1. WolinskyJS , NarayanaPA , NelsonF , DattaS , O'ConnorP , ConfavreuxC , et al. Magnetic resonance imaging outcomes from a phase Ⅲ trial of teriflunomide. Multiple Sclerosis2013;19(10):1310‐9. ">O'Connor 2011</a>). </p> </section> </section> <section id="CD009882-sec-0057"> <h4 class="title">Excluded studies</h4> <p>We excluded two studies (reported in 14 articles) from this review; the reasons for their exclusion are listed in the <a href="./references#CD009882-sec-0096" title="">Characteristics of excluded studies</a> table. </p> </section> </section> <section id="CD009882-sec-0058"> <h3 class="title">Risk of bias in included studies</h3> <p>Further details of this assessment are available in the <a href="./references#CD009882-sec-0095" title="">Characteristics of included studies</a> table and are also presented in the 'Risk of bias' graph (<a href="#CD009882-fig-0002">Figure 2</a>) and 'Risk of bias' summary (<a href="#CD009882-fig-0003">Figure 3</a>). </p> <div class="figure" id="CD009882-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD009882-fig-0002" src="/cdsr/doi/10.1002/14651858.CD009882.pub3/media/CDSR/CD009882/image_n/nCD009882-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD009882-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD009882-fig-0003" src="/cdsr/doi/10.1002/14651858.CD009882.pub3/media/CDSR/CD009882/image_n/nCD009882-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD009882-sec-0059"> <h4 class="title">Allocation</h4> <p>In <a href="./references#CD009882-bbs2-0001" title="ComiG , FreedmanMS , KapposL , MillerA , OlssonTP , WolinskyJS , et al. Effect of teriflunomide on lymphocyte and neutrophil counts in patients with relapsing multiple sclerosis: results from the TOWER study. Journal of the Neurological Sciences2013;333:e376. ConfavreuxC , O'ConnorP , ComiG , FreedmanMS , MillerAE , OlssonTP , et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet Neurology2014;13(3):247‐56. KapposL , ComiG , ConfavreuxC , FreedmanMS , MillerAE , OlssonTP , et al. The efficacy and safety of teriflunomide in patients with relapsing MS: results from TOWER, a phase Ⅲ, placebo‐controlled study. Multiple Sclerosis2012;18:50‐1. MillerA , KapposL , ComiG , ConfavreuxC , FreedmanM , OlssonT , et al. Teriflunomide efficacy and safety in patients with relapsing multiple sclerosis: results from tower, a second, pivotal, phase 3 placebo‐controlled study. Neurology. 2013; Vol. 80. MillerAE , MacdonellR , ComiG , FreedmanMS , KapposL , MaurerM , et al. Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study. Journal of Neurology2014;261(9):1781‐8. MosesH , FreedmanM , KapposL , MillerA , OlssonT , WolinskyJ , et al. Pre‐defined subgroups analyses of tower, a placebo‐controlled phase 3 trial of teriflunomide in patients with relapsing multiple sclerosis. Proceedings of the American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). O'ConnorP , LublinF , WolinskyJ , ComiG , ConfavreuxC , FreedmanM , et al. Teriflunomide reduces relapse‐related sequelae, hospitalizations and corticosteroid use: a post‐HOC analysis of the phase 3 TOWER study. Proceedings of The American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). ">Confavreux 2014</a> and <a href="./references#CD009882-bbs2-0004" title="ComiG , BenzerdjebH , WangL , TruffinetP , O'ConnorP . Effect of teriflunomide on lymphocyte and neutrophil levels in patients with relapsing multiple sclerosis: results from the TEMSO study. Journal of Neurological Science2013;333(Suppl 1):e376. ComiG , O'ConnorP , WolinskyJ , ConfavreuxC , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: safety outcomes with up to 4 years of follow‐Up. Multiple Sclerosis2011;17:S182‐3. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Long‐term safety and efficacy of teriflunomide in patients with relapsing forms of multiple sclerosis in the TEMSO extension trial. Multiple Sclerosis2013;19:225. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Safety and efficacy of teriflunomide for up to 9 years in relapsing forms of multiple sclerosis: Update of the TEMSO extension trial. Neurology2014; Vol. 82, issue Suppl 10:3‐150. FreedmanMS , DelhayJL , BenamorM . Gastrointestinal symptoms infrequently lead to discontinuation of teriflunomide therapy. Multiple Sclerosis2012;18:S13. MillerA , LublinF , O'ConnorP , TaniouC , Dive‐PoulettyC . Impact of relapses with sequelae on disability, health‐related quality of life, and fatigue in a population with relapsing forms of multiple sclerosis using data from TEMSO, a pivotal phase Ⅲ teriflunomide trial. Neurology2012;78:P07.082. MillerA , LublinF , O'ConnorP , WolinskyJ , ComiG , KapposL , et al. Effect of teriflunomide on relapses with sequelae and relapse leading to hospitalization in a population with relapsing forms of multiple sclerosis: results from the TEMSO study. Neurology2012;78:S30.003. MillerA , O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , et al. Efficacy of oral teriflunomide in multiple sclerosis with relapses: cognitive outcomes from a phase Ⅲ trial (TEMSO). Multiple Sclerosis2011;17:S182. MillerAE , O'ConnorP , WolinskyJS , ConfavreuxC , KapposL , OlssonTP , et al. Pre‐specified subgroup analyses of a placebo‐controlled phase Ⅲ trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis. Multiple Sclerosis2012;18(11):1625‐32. O'ConnorP , BriggsA , CaritaP , Bego‐Le‐BagousseG . Impact on health‐related quality of life of teriflunomide treatment by estimating utilities in patients with relapsing multiple sclerosis: results from TEMSO post hoc analysis. Journal of Neurology2012;259:S107. O'ConnorP , BurrellA , WangL , WeiL , CaritaP , ZhangQ . Effect of teriflunomide on longitudinal patterns of relapse and relapse‐related hospitalization in multiple sclerosis. Multiple Sclerosis2011;17:S414. O'ConnorP , LublinF , WolinskyJ , ComiG , KapposL , FreedmanM , et al. Effect of teriflunomide on relapses leading to healthcare resource use: results from the TEMSO study. Multiple Sclerosis2011;17:S95‐6. O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: clinical and MRI data 5 years after initial randomization. Multiple Sclerosis2011;17:S414‐5. O'ConnorP , WolinskyJS , ConfavreuxC , ComiG , KapposL , OlssonTP , et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. New England Journal of Medicine2011;365(14):1293‐303. O'ConnorPW , LublinFD , WolinskyJS , ConfavreuxC , ComiG , FreedmanMS , et al. Teriflunomide reduces relapse‐related neurological sequelae, hospitalizations and steroid use. Journal of Neurology2013;260(10):2472‐80. WolinksyJS , WangL , TruffinetP , NarayanaPA , NelsonF , O'ConnorP . Magnetic resonance imaging as a surrogate for clinical endpoints in multiple sclerosis. Multiple Sclerosis2012;18:470‐1. WolinskyJS , NarayanaPA , NelsonF , DattaS , O'ConnorP , ConfavreuxC , et al. Magnetic resonance imaging outcomes from a phase Ⅲ trial of teriflunomide. Multiple Sclerosis2013;19(10):1310‐9. ">O'Connor 2011</a>, sequence generation and allocation concealment were adequate. Allocation sequence was generated by randomization number list (<a href="./references#CD009882-bbs2-0001" title="ComiG , FreedmanMS , KapposL , MillerA , OlssonTP , WolinskyJS , et al. Effect of teriflunomide on lymphocyte and neutrophil counts in patients with relapsing multiple sclerosis: results from the TOWER study. Journal of the Neurological Sciences2013;333:e376. ConfavreuxC , O'ConnorP , ComiG , FreedmanMS , MillerAE , OlssonTP , et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet Neurology2014;13(3):247‐56. KapposL , ComiG , ConfavreuxC , FreedmanMS , MillerAE , OlssonTP , et al. The efficacy and safety of teriflunomide in patients with relapsing MS: results from TOWER, a phase Ⅲ, placebo‐controlled study. Multiple Sclerosis2012;18:50‐1. MillerA , KapposL , ComiG , ConfavreuxC , FreedmanM , OlssonT , et al. Teriflunomide efficacy and safety in patients with relapsing multiple sclerosis: results from tower, a second, pivotal, phase 3 placebo‐controlled study. Neurology. 2013; Vol. 80. MillerAE , MacdonellR , ComiG , FreedmanMS , KapposL , MaurerM , et al. Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study. Journal of Neurology2014;261(9):1781‐8. MosesH , FreedmanM , KapposL , MillerA , OlssonT , WolinskyJ , et al. Pre‐defined subgroups analyses of tower, a placebo‐controlled phase 3 trial of teriflunomide in patients with relapsing multiple sclerosis. Proceedings of the American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). O'ConnorP , LublinF , WolinskyJ , ComiG , ConfavreuxC , FreedmanM , et al. Teriflunomide reduces relapse‐related sequelae, hospitalizations and corticosteroid use: a post‐HOC analysis of the phase 3 TOWER study. Proceedings of The American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). ">Confavreux 2014</a>) or a permuted‐block randomization schedule with stratification (<a href="./references#CD009882-bbs2-0004" title="ComiG , BenzerdjebH , WangL , TruffinetP , O'ConnorP . Effect of teriflunomide on lymphocyte and neutrophil levels in patients with relapsing multiple sclerosis: results from the TEMSO study. Journal of Neurological Science2013;333(Suppl 1):e376. ComiG , O'ConnorP , WolinskyJ , ConfavreuxC , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: safety outcomes with up to 4 years of follow‐Up. Multiple Sclerosis2011;17:S182‐3. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Long‐term safety and efficacy of teriflunomide in patients with relapsing forms of multiple sclerosis in the TEMSO extension trial. Multiple Sclerosis2013;19:225. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Safety and efficacy of teriflunomide for up to 9 years in relapsing forms of multiple sclerosis: Update of the TEMSO extension trial. Neurology2014; Vol. 82, issue Suppl 10:3‐150. FreedmanMS , DelhayJL , BenamorM . Gastrointestinal symptoms infrequently lead to discontinuation of teriflunomide therapy. Multiple Sclerosis2012;18:S13. MillerA , LublinF , O'ConnorP , TaniouC , Dive‐PoulettyC . Impact of relapses with sequelae on disability, health‐related quality of life, and fatigue in a population with relapsing forms of multiple sclerosis using data from TEMSO, a pivotal phase Ⅲ teriflunomide trial. Neurology2012;78:P07.082. MillerA , LublinF , O'ConnorP , WolinskyJ , ComiG , KapposL , et al. Effect of teriflunomide on relapses with sequelae and relapse leading to hospitalization in a population with relapsing forms of multiple sclerosis: results from the TEMSO study. Neurology2012;78:S30.003. MillerA , O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , et al. Efficacy of oral teriflunomide in multiple sclerosis with relapses: cognitive outcomes from a phase Ⅲ trial (TEMSO). Multiple Sclerosis2011;17:S182. MillerAE , O'ConnorP , WolinskyJS , ConfavreuxC , KapposL , OlssonTP , et al. Pre‐specified subgroup analyses of a placebo‐controlled phase Ⅲ trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis. Multiple Sclerosis2012;18(11):1625‐32. O'ConnorP , BriggsA , CaritaP , Bego‐Le‐BagousseG . Impact on health‐related quality of life of teriflunomide treatment by estimating utilities in patients with relapsing multiple sclerosis: results from TEMSO post hoc analysis. Journal of Neurology2012;259:S107. O'ConnorP , BurrellA , WangL , WeiL , CaritaP , ZhangQ . Effect of teriflunomide on longitudinal patterns of relapse and relapse‐related hospitalization in multiple sclerosis. Multiple Sclerosis2011;17:S414. O'ConnorP , LublinF , WolinskyJ , ComiG , KapposL , FreedmanM , et al. Effect of teriflunomide on relapses leading to healthcare resource use: results from the TEMSO study. Multiple Sclerosis2011;17:S95‐6. O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: clinical and MRI data 5 years after initial randomization. Multiple Sclerosis2011;17:S414‐5. O'ConnorP , WolinskyJS , ConfavreuxC , ComiG , KapposL , OlssonTP , et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. New England Journal of Medicine2011;365(14):1293‐303. O'ConnorPW , LublinFD , WolinskyJS , ConfavreuxC , ComiG , FreedmanMS , et al. Teriflunomide reduces relapse‐related neurological sequelae, hospitalizations and steroid use. Journal of Neurology2013;260(10):2472‐80. WolinksyJS , WangL , TruffinetP , NarayanaPA , NelsonF , O'ConnorP . Magnetic resonance imaging as a surrogate for clinical endpoints in multiple sclerosis. Multiple Sclerosis2012;18:470‐1. WolinskyJS , NarayanaPA , NelsonF , DattaS , O'ConnorP , ConfavreuxC , et al. Magnetic resonance imaging outcomes from a phase Ⅲ trial of teriflunomide. Multiple Sclerosis2013;19(10):1310‐9. ">O'Connor 2011</a>). Randomization was done centrally, via an interactive voice recognition system (IVRS) in both studies. In <a href="./references#CD009882-bbs2-0003" title="NCT01252355 . Efficacy and Safety of Teriflunomide in Patients with Relapsing Multiple Sclerosis and Treated with Interferon‐beta (TERACLES). www.clinicaltrials.gov/ct2/show/results/NCT01252355 (accessed 12 January 2016). ">NCT01252355</a>, sequence generation was probably made by software. Assignment to groups was done centrally using an IVRS. In <a href="./references#CD009882-bbs2-0002" title="FreedmanMS , WolinskyJS , WamilB , ConfavreuxC , ComiG , KapposL , et al. Teriflunomide added to interferon‐β in relapsing multiple sclerosis: a randomized phase Ⅱ trial. Neurology2012;78(23):1877‐85. ">Freedman 2012</a> and <a href="./references#CD009882-bbs2-0005" title="VermerschP , CzlonkowskaA , GrimaldiLM , ConfavreuxC , ComiG , KapposL , et al. A multicenter, randomized, parallel‐group, rater‐blinded study comparing the effectiveness and safety of teriflunomide and subcutaneous interferon beta‐1a in patients with relapsing multiple sclerosis. Multiple Sclerosis2012;18:S9‐10. VermerschP , CzlonkowskaA , GrimaldiLM , ConfavreuxC , ComiG , KapposL , et al. Evaluation of patient satisfaction from the TENERE study: a comparison of teriflunomide and subcutaneous interferon beta‐1a in patients with relapsing multiple sclerosis. Journal of Neurology2012;259:S38. VermerschP , CzlonkowskaA , GrimaldiLM , ConfavreuxC , ComiG , KapposL , et al. Teriflunomide versus subcutaneous interferon beta‐1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial. Multiple Sclerosis2014;20(6):705‐16. ">Vermersch 2014</a>, sequence generation was probably made by software, and central randomization was probably used. </p> </section> <section id="CD009882-sec-0060"> <h4 class="title">Blinding</h4> <p>In <a href="./references#CD009882-bbs2-0001" title="ComiG , FreedmanMS , KapposL , MillerA , OlssonTP , WolinskyJS , et al. Effect of teriflunomide on lymphocyte and neutrophil counts in patients with relapsing multiple sclerosis: results from the TOWER study. Journal of the Neurological Sciences2013;333:e376. ConfavreuxC , O'ConnorP , ComiG , FreedmanMS , MillerAE , OlssonTP , et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet Neurology2014;13(3):247‐56. KapposL , ComiG , ConfavreuxC , FreedmanMS , MillerAE , OlssonTP , et al. The efficacy and safety of teriflunomide in patients with relapsing MS: results from TOWER, a phase Ⅲ, placebo‐controlled study. Multiple Sclerosis2012;18:50‐1. MillerA , KapposL , ComiG , ConfavreuxC , FreedmanM , OlssonT , et al. Teriflunomide efficacy and safety in patients with relapsing multiple sclerosis: results from tower, a second, pivotal, phase 3 placebo‐controlled study. Neurology. 2013; Vol. 80. MillerAE , MacdonellR , ComiG , FreedmanMS , KapposL , MaurerM , et al. Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study. Journal of Neurology2014;261(9):1781‐8. MosesH , FreedmanM , KapposL , MillerA , OlssonT , WolinskyJ , et al. Pre‐defined subgroups analyses of tower, a placebo‐controlled phase 3 trial of teriflunomide in patients with relapsing multiple sclerosis. Proceedings of the American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). O'ConnorP , LublinF , WolinskyJ , ComiG , ConfavreuxC , FreedmanM , et al. Teriflunomide reduces relapse‐related sequelae, hospitalizations and corticosteroid use: a post‐HOC analysis of the phase 3 TOWER study. Proceedings of The American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). ">Confavreux 2014</a> and <a href="./references#CD009882-bbs2-0004" title="ComiG , BenzerdjebH , WangL , TruffinetP , O'ConnorP . Effect of teriflunomide on lymphocyte and neutrophil levels in patients with relapsing multiple sclerosis: results from the TEMSO study. Journal of Neurological Science2013;333(Suppl 1):e376. ComiG , O'ConnorP , WolinskyJ , ConfavreuxC , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: safety outcomes with up to 4 years of follow‐Up. Multiple Sclerosis2011;17:S182‐3. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Long‐term safety and efficacy of teriflunomide in patients with relapsing forms of multiple sclerosis in the TEMSO extension trial. Multiple Sclerosis2013;19:225. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Safety and efficacy of teriflunomide for up to 9 years in relapsing forms of multiple sclerosis: Update of the TEMSO extension trial. Neurology2014; Vol. 82, issue Suppl 10:3‐150. FreedmanMS , DelhayJL , BenamorM . Gastrointestinal symptoms infrequently lead to discontinuation of teriflunomide therapy. Multiple Sclerosis2012;18:S13. MillerA , LublinF , O'ConnorP , TaniouC , Dive‐PoulettyC . Impact of relapses with sequelae on disability, health‐related quality of life, and fatigue in a population with relapsing forms of multiple sclerosis using data from TEMSO, a pivotal phase Ⅲ teriflunomide trial. Neurology2012;78:P07.082. MillerA , LublinF , O'ConnorP , WolinskyJ , ComiG , KapposL , et al. Effect of teriflunomide on relapses with sequelae and relapse leading to hospitalization in a population with relapsing forms of multiple sclerosis: results from the TEMSO study. Neurology2012;78:S30.003. MillerA , O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , et al. Efficacy of oral teriflunomide in multiple sclerosis with relapses: cognitive outcomes from a phase Ⅲ trial (TEMSO). Multiple Sclerosis2011;17:S182. MillerAE , O'ConnorP , WolinskyJS , ConfavreuxC , KapposL , OlssonTP , et al. Pre‐specified subgroup analyses of a placebo‐controlled phase Ⅲ trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis. Multiple Sclerosis2012;18(11):1625‐32. O'ConnorP , BriggsA , CaritaP , Bego‐Le‐BagousseG . Impact on health‐related quality of life of teriflunomide treatment by estimating utilities in patients with relapsing multiple sclerosis: results from TEMSO post hoc analysis. Journal of Neurology2012;259:S107. O'ConnorP , BurrellA , WangL , WeiL , CaritaP , ZhangQ . Effect of teriflunomide on longitudinal patterns of relapse and relapse‐related hospitalization in multiple sclerosis. Multiple Sclerosis2011;17:S414. O'ConnorP , LublinF , WolinskyJ , ComiG , KapposL , FreedmanM , et al. Effect of teriflunomide on relapses leading to healthcare resource use: results from the TEMSO study. Multiple Sclerosis2011;17:S95‐6. O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: clinical and MRI data 5 years after initial randomization. Multiple Sclerosis2011;17:S414‐5. O'ConnorP , WolinskyJS , ConfavreuxC , ComiG , KapposL , OlssonTP , et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. New England Journal of Medicine2011;365(14):1293‐303. O'ConnorPW , LublinFD , WolinskyJS , ConfavreuxC , ComiG , FreedmanMS , et al. Teriflunomide reduces relapse‐related neurological sequelae, hospitalizations and steroid use. Journal of Neurology2013;260(10):2472‐80. WolinksyJS , WangL , TruffinetP , NarayanaPA , NelsonF , O'ConnorP . Magnetic resonance imaging as a surrogate for clinical endpoints in multiple sclerosis. Multiple Sclerosis2012;18:470‐1. WolinskyJS , NarayanaPA , NelsonF , DattaS , O'ConnorP , ConfavreuxC , et al. Magnetic resonance imaging outcomes from a phase Ⅲ trial of teriflunomide. Multiple Sclerosis2013;19(10):1310‐9. ">O'Connor 2011</a>, the treating neurologist who recorded adverse events was responsible for assessment of relapses, blinding of relapse assessment was probably not adequate. The risk of detection bias was high. Participants included in <a href="./references#CD009882-bbs2-0002" title="FreedmanMS , WolinskyJS , WamilB , ConfavreuxC , ComiG , KapposL , et al. Teriflunomide added to interferon‐β in relapsing multiple sclerosis: a randomized phase Ⅱ trial. Neurology2012;78(23):1877‐85. ">Freedman 2012</a> and <a href="./references#CD009882-bbs2-0003" title="NCT01252355 . Efficacy and Safety of Teriflunomide in Patients with Relapsing Multiple Sclerosis and Treated with Interferon‐beta (TERACLES). www.clinicaltrials.gov/ct2/show/results/NCT01252355 (accessed 12 January 2016). ">NCT01252355</a> received diverse regimens of IFNβ, they were not truly double‐blind, double‐dummy studies. The control (IFNβ‐1a) group was open‐label in <a href="./references#CD009882-bbs2-0005" title="VermerschP , CzlonkowskaA , GrimaldiLM , ConfavreuxC , ComiG , KapposL , et al. A multicenter, randomized, parallel‐group, rater‐blinded study comparing the effectiveness and safety of teriflunomide and subcutaneous interferon beta‐1a in patients with relapsing multiple sclerosis. Multiple Sclerosis2012;18:S9‐10. VermerschP , CzlonkowskaA , GrimaldiLM , ConfavreuxC , ComiG , KapposL , et al. Evaluation of patient satisfaction from the TENERE study: a comparison of teriflunomide and subcutaneous interferon beta‐1a in patients with relapsing multiple sclerosis. Journal of Neurology2012;259:S38. VermerschP , CzlonkowskaA , GrimaldiLM , ConfavreuxC , ComiG , KapposL , et al. Teriflunomide versus subcutaneous interferon beta‐1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial. Multiple Sclerosis2014;20(6):705‐16. ">Vermersch 2014</a>, it was not a truly double‐blind study. In addition, the treating neurologist who reported or managed adverse events was responsible for assessment of relapses in <a href="./references#CD009882-bbs2-0002" title="FreedmanMS , WolinskyJS , WamilB , ConfavreuxC , ComiG , KapposL , et al. Teriflunomide added to interferon‐β in relapsing multiple sclerosis: a randomized phase Ⅱ trial. Neurology2012;78(23):1877‐85. ">Freedman 2012</a>, <a href="./references#CD009882-bbs2-0003" title="NCT01252355 . Efficacy and Safety of Teriflunomide in Patients with Relapsing Multiple Sclerosis and Treated with Interferon‐beta (TERACLES). www.clinicaltrials.gov/ct2/show/results/NCT01252355 (accessed 12 January 2016). ">NCT01252355</a>, and <a href="./references#CD009882-bbs2-0005" title="VermerschP , CzlonkowskaA , GrimaldiLM , ConfavreuxC , ComiG , KapposL , et al. A multicenter, randomized, parallel‐group, rater‐blinded study comparing the effectiveness and safety of teriflunomide and subcutaneous interferon beta‐1a in patients with relapsing multiple sclerosis. Multiple Sclerosis2012;18:S9‐10. VermerschP , CzlonkowskaA , GrimaldiLM , ConfavreuxC , ComiG , KapposL , et al. Evaluation of patient satisfaction from the TENERE study: a comparison of teriflunomide and subcutaneous interferon beta‐1a in patients with relapsing multiple sclerosis. Journal of Neurology2012;259:S38. VermerschP , CzlonkowskaA , GrimaldiLM , ConfavreuxC , ComiG , KapposL , et al. Teriflunomide versus subcutaneous interferon beta‐1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial. Multiple Sclerosis2014;20(6):705‐16. ">Vermersch 2014</a>, blinding of relapse assessment was probably not adequate. The risks of performance bias and detection bias were high. </p> </section> <section id="CD009882-sec-0061"> <h4 class="title">Incomplete outcome data</h4> <p>Three studies had a high risk of attrition bias due to a high dropout rate of 29.8% (<a href="./references#CD009882-bbs2-0001" title="ComiG , FreedmanMS , KapposL , MillerA , OlssonTP , WolinskyJS , et al. Effect of teriflunomide on lymphocyte and neutrophil counts in patients with relapsing multiple sclerosis: results from the TOWER study. Journal of the Neurological Sciences2013;333:e376. ConfavreuxC , O'ConnorP , ComiG , FreedmanMS , MillerAE , OlssonTP , et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet Neurology2014;13(3):247‐56. KapposL , ComiG , ConfavreuxC , FreedmanMS , MillerAE , OlssonTP , et al. The efficacy and safety of teriflunomide in patients with relapsing MS: results from TOWER, a phase Ⅲ, placebo‐controlled study. Multiple Sclerosis2012;18:50‐1. MillerA , KapposL , ComiG , ConfavreuxC , FreedmanM , OlssonT , et al. Teriflunomide efficacy and safety in patients with relapsing multiple sclerosis: results from tower, a second, pivotal, phase 3 placebo‐controlled study. Neurology. 2013; Vol. 80. MillerAE , MacdonellR , ComiG , FreedmanMS , KapposL , MaurerM , et al. Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study. Journal of Neurology2014;261(9):1781‐8. MosesH , FreedmanM , KapposL , MillerA , OlssonT , WolinskyJ , et al. Pre‐defined subgroups analyses of tower, a placebo‐controlled phase 3 trial of teriflunomide in patients with relapsing multiple sclerosis. Proceedings of the American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). O'ConnorP , LublinF , WolinskyJ , ComiG , ConfavreuxC , FreedmanM , et al. Teriflunomide reduces relapse‐related sequelae, hospitalizations and corticosteroid use: a post‐HOC analysis of the phase 3 TOWER study. Proceedings of The American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). ">Confavreux 2014</a>), 36.4% (<a href="./references#CD009882-bbs2-0002" title="FreedmanMS , WolinskyJS , WamilB , ConfavreuxC , ComiG , KapposL , et al. Teriflunomide added to interferon‐β in relapsing multiple sclerosis: a randomized phase Ⅱ trial. Neurology2012;78(23):1877‐85. ">Freedman 2012</a>), and 100% (<a href="./references#CD009882-bbs2-0003" title="NCT01252355 . Efficacy and Safety of Teriflunomide in Patients with Relapsing Multiple Sclerosis and Treated with Interferon‐beta (TERACLES). www.clinicaltrials.gov/ct2/show/results/NCT01252355 (accessed 12 January 2016). ">NCT01252355</a>). There was an overall dropout rate of 20.1% in <a href="./references#CD009882-bbs2-0004" title="ComiG , BenzerdjebH , WangL , TruffinetP , O'ConnorP . Effect of teriflunomide on lymphocyte and neutrophil levels in patients with relapsing multiple sclerosis: results from the TEMSO study. Journal of Neurological Science2013;333(Suppl 1):e376. ComiG , O'ConnorP , WolinskyJ , ConfavreuxC , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: safety outcomes with up to 4 years of follow‐Up. Multiple Sclerosis2011;17:S182‐3. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Long‐term safety and efficacy of teriflunomide in patients with relapsing forms of multiple sclerosis in the TEMSO extension trial. Multiple Sclerosis2013;19:225. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Safety and efficacy of teriflunomide for up to 9 years in relapsing forms of multiple sclerosis: Update of the TEMSO extension trial. Neurology2014; Vol. 82, issue Suppl 10:3‐150. FreedmanMS , DelhayJL , BenamorM . Gastrointestinal symptoms infrequently lead to discontinuation of teriflunomide therapy. Multiple Sclerosis2012;18:S13. MillerA , LublinF , O'ConnorP , TaniouC , Dive‐PoulettyC . Impact of relapses with sequelae on disability, health‐related quality of life, and fatigue in a population with relapsing forms of multiple sclerosis using data from TEMSO, a pivotal phase Ⅲ teriflunomide trial. Neurology2012;78:P07.082. MillerA , LublinF , O'ConnorP , WolinskyJ , ComiG , KapposL , et al. Effect of teriflunomide on relapses with sequelae and relapse leading to hospitalization in a population with relapsing forms of multiple sclerosis: results from the TEMSO study. Neurology2012;78:S30.003. MillerA , O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , et al. Efficacy of oral teriflunomide in multiple sclerosis with relapses: cognitive outcomes from a phase Ⅲ trial (TEMSO). Multiple Sclerosis2011;17:S182. MillerAE , O'ConnorP , WolinskyJS , ConfavreuxC , KapposL , OlssonTP , et al. Pre‐specified subgroup analyses of a placebo‐controlled phase Ⅲ trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis. Multiple Sclerosis2012;18(11):1625‐32. O'ConnorP , BriggsA , CaritaP , Bego‐Le‐BagousseG . Impact on health‐related quality of life of teriflunomide treatment by estimating utilities in patients with relapsing multiple sclerosis: results from TEMSO post hoc analysis. Journal of Neurology2012;259:S107. O'ConnorP , BurrellA , WangL , WeiL , CaritaP , ZhangQ . Effect of teriflunomide on longitudinal patterns of relapse and relapse‐related hospitalization in multiple sclerosis. Multiple Sclerosis2011;17:S414. O'ConnorP , LublinF , WolinskyJ , ComiG , KapposL , FreedmanM , et al. Effect of teriflunomide on relapses leading to healthcare resource use: results from the TEMSO study. Multiple Sclerosis2011;17:S95‐6. O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: clinical and MRI data 5 years after initial randomization. Multiple Sclerosis2011;17:S414‐5. O'ConnorP , WolinskyJS , ConfavreuxC , ComiG , KapposL , OlssonTP , et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. New England Journal of Medicine2011;365(14):1293‐303. O'ConnorPW , LublinFD , WolinskyJS , ConfavreuxC , ComiG , FreedmanMS , et al. Teriflunomide reduces relapse‐related neurological sequelae, hospitalizations and steroid use. Journal of Neurology2013;260(10):2472‐80. WolinksyJS , WangL , TruffinetP , NarayanaPA , NelsonF , O'ConnorP . Magnetic resonance imaging as a surrogate for clinical endpoints in multiple sclerosis. Multiple Sclerosis2012;18:470‐1. WolinskyJS , NarayanaPA , NelsonF , DattaS , O'ConnorP , ConfavreuxC , et al. Magnetic resonance imaging outcomes from a phase Ⅲ trial of teriflunomide. Multiple Sclerosis2013;19(10):1310‐9. ">O'Connor 2011</a>, but there was no sufficient information to understand the reasons for study discontinuation and their balance among the groups. The risk of attrition bias was unclear. One study did not report the number and reasons of drop‐outs and the incomplete outcome data were unclear (<a href="./references#CD009882-bbs2-0005" title="VermerschP , CzlonkowskaA , GrimaldiLM , ConfavreuxC , ComiG , KapposL , et al. A multicenter, randomized, parallel‐group, rater‐blinded study comparing the effectiveness and safety of teriflunomide and subcutaneous interferon beta‐1a in patients with relapsing multiple sclerosis. Multiple Sclerosis2012;18:S9‐10. VermerschP , CzlonkowskaA , GrimaldiLM , ConfavreuxC , ComiG , KapposL , et al. Evaluation of patient satisfaction from the TENERE study: a comparison of teriflunomide and subcutaneous interferon beta‐1a in patients with relapsing multiple sclerosis. Journal of Neurology2012;259:S38. VermerschP , CzlonkowskaA , GrimaldiLM , ConfavreuxC , ComiG , KapposL , et al. Teriflunomide versus subcutaneous interferon beta‐1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial. Multiple Sclerosis2014;20(6):705‐16. ">Vermersch 2014</a>). </p> </section> <section id="CD009882-sec-0062"> <h4 class="title">Selective reporting</h4> <p>All studies reported all listed outcomes adequately.</p> </section> <section id="CD009882-sec-0063"> <h4 class="title">Other potential sources of bias</h4> <p>All studies were sponsored by Sanofi‐Aventis. In <a href="./references#CD009882-bbs2-0001" title="ComiG , FreedmanMS , KapposL , MillerA , OlssonTP , WolinskyJS , et al. Effect of teriflunomide on lymphocyte and neutrophil counts in patients with relapsing multiple sclerosis: results from the TOWER study. Journal of the Neurological Sciences2013;333:e376. ConfavreuxC , O'ConnorP , ComiG , FreedmanMS , MillerAE , OlssonTP , et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet Neurology2014;13(3):247‐56. KapposL , ComiG , ConfavreuxC , FreedmanMS , MillerAE , OlssonTP , et al. The efficacy and safety of teriflunomide in patients with relapsing MS: results from TOWER, a phase Ⅲ, placebo‐controlled study. Multiple Sclerosis2012;18:50‐1. MillerA , KapposL , ComiG , ConfavreuxC , FreedmanM , OlssonT , et al. Teriflunomide efficacy and safety in patients with relapsing multiple sclerosis: results from tower, a second, pivotal, phase 3 placebo‐controlled study. Neurology. 2013; Vol. 80. MillerAE , MacdonellR , ComiG , FreedmanMS , KapposL , MaurerM , et al. Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study. Journal of Neurology2014;261(9):1781‐8. MosesH , FreedmanM , KapposL , MillerA , OlssonT , WolinskyJ , et al. Pre‐defined subgroups analyses of tower, a placebo‐controlled phase 3 trial of teriflunomide in patients with relapsing multiple sclerosis. Proceedings of the American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). O'ConnorP , LublinF , WolinskyJ , ComiG , ConfavreuxC , FreedmanM , et al. Teriflunomide reduces relapse‐related sequelae, hospitalizations and corticosteroid use: a post‐HOC analysis of the phase 3 TOWER study. Proceedings of The American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). ">Confavreux 2014</a> and <a href="./references#CD009882-bbs2-0004" title="ComiG , BenzerdjebH , WangL , TruffinetP , O'ConnorP . Effect of teriflunomide on lymphocyte and neutrophil levels in patients with relapsing multiple sclerosis: results from the TEMSO study. Journal of Neurological Science2013;333(Suppl 1):e376. ComiG , O'ConnorP , WolinskyJ , ConfavreuxC , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: safety outcomes with up to 4 years of follow‐Up. Multiple Sclerosis2011;17:S182‐3. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Long‐term safety and efficacy of teriflunomide in patients with relapsing forms of multiple sclerosis in the TEMSO extension trial. Multiple Sclerosis2013;19:225. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Safety and efficacy of teriflunomide for up to 9 years in relapsing forms of multiple sclerosis: Update of the TEMSO extension trial. Neurology2014; Vol. 82, issue Suppl 10:3‐150. FreedmanMS , DelhayJL , BenamorM . Gastrointestinal symptoms infrequently lead to discontinuation of teriflunomide therapy. Multiple Sclerosis2012;18:S13. MillerA , LublinF , O'ConnorP , TaniouC , Dive‐PoulettyC . Impact of relapses with sequelae on disability, health‐related quality of life, and fatigue in a population with relapsing forms of multiple sclerosis using data from TEMSO, a pivotal phase Ⅲ teriflunomide trial. Neurology2012;78:P07.082. MillerA , LublinF , O'ConnorP , WolinskyJ , ComiG , KapposL , et al. Effect of teriflunomide on relapses with sequelae and relapse leading to hospitalization in a population with relapsing forms of multiple sclerosis: results from the TEMSO study. Neurology2012;78:S30.003. MillerA , O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , et al. Efficacy of oral teriflunomide in multiple sclerosis with relapses: cognitive outcomes from a phase Ⅲ trial (TEMSO). Multiple Sclerosis2011;17:S182. MillerAE , O'ConnorP , WolinskyJS , ConfavreuxC , KapposL , OlssonTP , et al. Pre‐specified subgroup analyses of a placebo‐controlled phase Ⅲ trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis. Multiple Sclerosis2012;18(11):1625‐32. O'ConnorP , BriggsA , CaritaP , Bego‐Le‐BagousseG . Impact on health‐related quality of life of teriflunomide treatment by estimating utilities in patients with relapsing multiple sclerosis: results from TEMSO post hoc analysis. Journal of Neurology2012;259:S107. O'ConnorP , BurrellA , WangL , WeiL , CaritaP , ZhangQ . Effect of teriflunomide on longitudinal patterns of relapse and relapse‐related hospitalization in multiple sclerosis. Multiple Sclerosis2011;17:S414. O'ConnorP , LublinF , WolinskyJ , ComiG , KapposL , FreedmanM , et al. Effect of teriflunomide on relapses leading to healthcare resource use: results from the TEMSO study. Multiple Sclerosis2011;17:S95‐6. O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: clinical and MRI data 5 years after initial randomization. Multiple Sclerosis2011;17:S414‐5. O'ConnorP , WolinskyJS , ConfavreuxC , ComiG , KapposL , OlssonTP , et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. New England Journal of Medicine2011;365(14):1293‐303. O'ConnorPW , LublinFD , WolinskyJS , ConfavreuxC , ComiG , FreedmanMS , et al. Teriflunomide reduces relapse‐related neurological sequelae, hospitalizations and steroid use. Journal of Neurology2013;260(10):2472‐80. WolinksyJS , WangL , TruffinetP , NarayanaPA , NelsonF , O'ConnorP . Magnetic resonance imaging as a surrogate for clinical endpoints in multiple sclerosis. Multiple Sclerosis2012;18:470‐1. WolinskyJS , NarayanaPA , NelsonF , DattaS , O'ConnorP , ConfavreuxC , et al. Magnetic resonance imaging outcomes from a phase Ⅲ trial of teriflunomide. Multiple Sclerosis2013;19(10):1310‐9. ">O'Connor 2011</a>, the sponsor analysed the data and some co‐authors were affiliated to Sanofi‐Aventis. In <a href="./references#CD009882-bbs2-0005" title="VermerschP , CzlonkowskaA , GrimaldiLM , ConfavreuxC , ComiG , KapposL , et al. A multicenter, randomized, parallel‐group, rater‐blinded study comparing the effectiveness and safety of teriflunomide and subcutaneous interferon beta‐1a in patients with relapsing multiple sclerosis. Multiple Sclerosis2012;18:S9‐10. VermerschP , CzlonkowskaA , GrimaldiLM , ConfavreuxC , ComiG , KapposL , et al. Evaluation of patient satisfaction from the TENERE study: a comparison of teriflunomide and subcutaneous interferon beta‐1a in patients with relapsing multiple sclerosis. Journal of Neurology2012;259:S38. VermerschP , CzlonkowskaA , GrimaldiLM , ConfavreuxC , ComiG , KapposL , et al. Teriflunomide versus subcutaneous interferon beta‐1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial. Multiple Sclerosis2014;20(6):705‐16. ">Vermersch 2014</a>, Sanofi‐Aventis funded editorial support. Conflicts of interest were obvious, and there was a high risk of bias in all studies. </p> </section> </section> <section id="CD009882-sec-0064"> <h3 class="title" id="CD009882-sec-0064">Effects of interventions</h3> <p>See: <a href="./full#CD009882-tbl-0001"><b>Summary of findings for the main comparison</b> Teriflunomide compared to placebo for multiple sclerosis</a> </p> <p>We did not conduct meta‐analyses because of the high risk of bias and clinical diversities of the included studies. The study designs in <a href="./references#CD009882-bbs2-0001" title="ComiG , FreedmanMS , KapposL , MillerA , OlssonTP , WolinskyJS , et al. Effect of teriflunomide on lymphocyte and neutrophil counts in patients with relapsing multiple sclerosis: results from the TOWER study. Journal of the Neurological Sciences2013;333:e376. ConfavreuxC , O'ConnorP , ComiG , FreedmanMS , MillerAE , OlssonTP , et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet Neurology2014;13(3):247‐56. KapposL , ComiG , ConfavreuxC , FreedmanMS , MillerAE , OlssonTP , et al. The efficacy and safety of teriflunomide in patients with relapsing MS: results from TOWER, a phase Ⅲ, placebo‐controlled study. Multiple Sclerosis2012;18:50‐1. MillerA , KapposL , ComiG , ConfavreuxC , FreedmanM , OlssonT , et al. Teriflunomide efficacy and safety in patients with relapsing multiple sclerosis: results from tower, a second, pivotal, phase 3 placebo‐controlled study. Neurology. 2013; Vol. 80. MillerAE , MacdonellR , ComiG , FreedmanMS , KapposL , MaurerM , et al. Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study. Journal of Neurology2014;261(9):1781‐8. MosesH , FreedmanM , KapposL , MillerA , OlssonT , WolinskyJ , et al. Pre‐defined subgroups analyses of tower, a placebo‐controlled phase 3 trial of teriflunomide in patients with relapsing multiple sclerosis. Proceedings of the American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). O'ConnorP , LublinF , WolinskyJ , ComiG , ConfavreuxC , FreedmanM , et al. Teriflunomide reduces relapse‐related sequelae, hospitalizations and corticosteroid use: a post‐HOC analysis of the phase 3 TOWER study. Proceedings of The American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). ">Confavreux 2014</a> and <a href="./references#CD009882-bbs2-0004" title="ComiG , BenzerdjebH , WangL , TruffinetP , O'ConnorP . Effect of teriflunomide on lymphocyte and neutrophil levels in patients with relapsing multiple sclerosis: results from the TEMSO study. Journal of Neurological Science2013;333(Suppl 1):e376. ComiG , O'ConnorP , WolinskyJ , ConfavreuxC , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: safety outcomes with up to 4 years of follow‐Up. Multiple Sclerosis2011;17:S182‐3. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Long‐term safety and efficacy of teriflunomide in patients with relapsing forms of multiple sclerosis in the TEMSO extension trial. Multiple Sclerosis2013;19:225. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Safety and efficacy of teriflunomide for up to 9 years in relapsing forms of multiple sclerosis: Update of the TEMSO extension trial. Neurology2014; Vol. 82, issue Suppl 10:3‐150. FreedmanMS , DelhayJL , BenamorM . Gastrointestinal symptoms infrequently lead to discontinuation of teriflunomide therapy. Multiple Sclerosis2012;18:S13. MillerA , LublinF , O'ConnorP , TaniouC , Dive‐PoulettyC . Impact of relapses with sequelae on disability, health‐related quality of life, and fatigue in a population with relapsing forms of multiple sclerosis using data from TEMSO, a pivotal phase Ⅲ teriflunomide trial. Neurology2012;78:P07.082. MillerA , LublinF , O'ConnorP , WolinskyJ , ComiG , KapposL , et al. Effect of teriflunomide on relapses with sequelae and relapse leading to hospitalization in a population with relapsing forms of multiple sclerosis: results from the TEMSO study. Neurology2012;78:S30.003. MillerA , O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , et al. Efficacy of oral teriflunomide in multiple sclerosis with relapses: cognitive outcomes from a phase Ⅲ trial (TEMSO). Multiple Sclerosis2011;17:S182. MillerAE , O'ConnorP , WolinskyJS , ConfavreuxC , KapposL , OlssonTP , et al. Pre‐specified subgroup analyses of a placebo‐controlled phase Ⅲ trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis. Multiple Sclerosis2012;18(11):1625‐32. O'ConnorP , BriggsA , CaritaP , Bego‐Le‐BagousseG . Impact on health‐related quality of life of teriflunomide treatment by estimating utilities in patients with relapsing multiple sclerosis: results from TEMSO post hoc analysis. Journal of Neurology2012;259:S107. O'ConnorP , BurrellA , WangL , WeiL , CaritaP , ZhangQ . Effect of teriflunomide on longitudinal patterns of relapse and relapse‐related hospitalization in multiple sclerosis. Multiple Sclerosis2011;17:S414. O'ConnorP , LublinF , WolinskyJ , ComiG , KapposL , FreedmanM , et al. Effect of teriflunomide on relapses leading to healthcare resource use: results from the TEMSO study. Multiple Sclerosis2011;17:S95‐6. O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: clinical and MRI data 5 years after initial randomization. Multiple Sclerosis2011;17:S414‐5. O'ConnorP , WolinskyJS , ConfavreuxC , ComiG , KapposL , OlssonTP , et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. New England Journal of Medicine2011;365(14):1293‐303. O'ConnorPW , LublinFD , WolinskyJS , ConfavreuxC , ComiG , FreedmanMS , et al. Teriflunomide reduces relapse‐related neurological sequelae, hospitalizations and steroid use. Journal of Neurology2013;260(10):2472‐80. WolinksyJS , WangL , TruffinetP , NarayanaPA , NelsonF , O'ConnorP . Magnetic resonance imaging as a surrogate for clinical endpoints in multiple sclerosis. Multiple Sclerosis2012;18:470‐1. WolinskyJS , NarayanaPA , NelsonF , DattaS , O'ConnorP , ConfavreuxC , et al. Magnetic resonance imaging outcomes from a phase Ⅲ trial of teriflunomide. Multiple Sclerosis2013;19(10):1310‐9. ">O'Connor 2011</a> were similar, however, the follow‐up periods were diverse (at least 48 weeks (<a href="./references#CD009882-bbs2-0001" title="ComiG , FreedmanMS , KapposL , MillerA , OlssonTP , WolinskyJS , et al. Effect of teriflunomide on lymphocyte and neutrophil counts in patients with relapsing multiple sclerosis: results from the TOWER study. Journal of the Neurological Sciences2013;333:e376. ConfavreuxC , O'ConnorP , ComiG , FreedmanMS , MillerAE , OlssonTP , et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet Neurology2014;13(3):247‐56. KapposL , ComiG , ConfavreuxC , FreedmanMS , MillerAE , OlssonTP , et al. The efficacy and safety of teriflunomide in patients with relapsing MS: results from TOWER, a phase Ⅲ, placebo‐controlled study. Multiple Sclerosis2012;18:50‐1. MillerA , KapposL , ComiG , ConfavreuxC , FreedmanM , OlssonT , et al. Teriflunomide efficacy and safety in patients with relapsing multiple sclerosis: results from tower, a second, pivotal, phase 3 placebo‐controlled study. Neurology. 2013; Vol. 80. MillerAE , MacdonellR , ComiG , FreedmanMS , KapposL , MaurerM , et al. Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study. Journal of Neurology2014;261(9):1781‐8. MosesH , FreedmanM , KapposL , MillerA , OlssonT , WolinskyJ , et al. Pre‐defined subgroups analyses of tower, a placebo‐controlled phase 3 trial of teriflunomide in patients with relapsing multiple sclerosis. Proceedings of the American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). O'ConnorP , LublinF , WolinskyJ , ComiG , ConfavreuxC , FreedmanM , et al. Teriflunomide reduces relapse‐related sequelae, hospitalizations and corticosteroid use: a post‐HOC analysis of the phase 3 TOWER study. Proceedings of The American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). ">Confavreux 2014</a>) and 108 weeks (<a href="./references#CD009882-bbs2-0004" title="ComiG , BenzerdjebH , WangL , TruffinetP , O'ConnorP . Effect of teriflunomide on lymphocyte and neutrophil levels in patients with relapsing multiple sclerosis: results from the TEMSO study. Journal of Neurological Science2013;333(Suppl 1):e376. ComiG , O'ConnorP , WolinskyJ , ConfavreuxC , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: safety outcomes with up to 4 years of follow‐Up. Multiple Sclerosis2011;17:S182‐3. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Long‐term safety and efficacy of teriflunomide in patients with relapsing forms of multiple sclerosis in the TEMSO extension trial. Multiple Sclerosis2013;19:225. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Safety and efficacy of teriflunomide for up to 9 years in relapsing forms of multiple sclerosis: Update of the TEMSO extension trial. Neurology2014; Vol. 82, issue Suppl 10:3‐150. FreedmanMS , DelhayJL , BenamorM . Gastrointestinal symptoms infrequently lead to discontinuation of teriflunomide therapy. Multiple Sclerosis2012;18:S13. MillerA , LublinF , O'ConnorP , TaniouC , Dive‐PoulettyC . Impact of relapses with sequelae on disability, health‐related quality of life, and fatigue in a population with relapsing forms of multiple sclerosis using data from TEMSO, a pivotal phase Ⅲ teriflunomide trial. Neurology2012;78:P07.082. MillerA , LublinF , O'ConnorP , WolinskyJ , ComiG , KapposL , et al. Effect of teriflunomide on relapses with sequelae and relapse leading to hospitalization in a population with relapsing forms of multiple sclerosis: results from the TEMSO study. Neurology2012;78:S30.003. MillerA , O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , et al. Efficacy of oral teriflunomide in multiple sclerosis with relapses: cognitive outcomes from a phase Ⅲ trial (TEMSO). Multiple Sclerosis2011;17:S182. MillerAE , O'ConnorP , WolinskyJS , ConfavreuxC , KapposL , OlssonTP , et al. Pre‐specified subgroup analyses of a placebo‐controlled phase Ⅲ trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis. Multiple Sclerosis2012;18(11):1625‐32. O'ConnorP , BriggsA , CaritaP , Bego‐Le‐BagousseG . Impact on health‐related quality of life of teriflunomide treatment by estimating utilities in patients with relapsing multiple sclerosis: results from TEMSO post hoc analysis. Journal of Neurology2012;259:S107. O'ConnorP , BurrellA , WangL , WeiL , CaritaP , ZhangQ . Effect of teriflunomide on longitudinal patterns of relapse and relapse‐related hospitalization in multiple sclerosis. Multiple Sclerosis2011;17:S414. O'ConnorP , LublinF , WolinskyJ , ComiG , KapposL , FreedmanM , et al. Effect of teriflunomide on relapses leading to healthcare resource use: results from the TEMSO study. Multiple Sclerosis2011;17:S95‐6. O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: clinical and MRI data 5 years after initial randomization. Multiple Sclerosis2011;17:S414‐5. O'ConnorP , WolinskyJS , ConfavreuxC , ComiG , KapposL , OlssonTP , et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. New England Journal of Medicine2011;365(14):1293‐303. O'ConnorPW , LublinFD , WolinskyJS , ConfavreuxC , ComiG , FreedmanMS , et al. Teriflunomide reduces relapse‐related neurological sequelae, hospitalizations and steroid use. Journal of Neurology2013;260(10):2472‐80. WolinksyJS , WangL , TruffinetP , NarayanaPA , NelsonF , O'ConnorP . Magnetic resonance imaging as a surrogate for clinical endpoints in multiple sclerosis. Multiple Sclerosis2012;18:470‐1. WolinskyJS , NarayanaPA , NelsonF , DattaS , O'ConnorP , ConfavreuxC , et al. Magnetic resonance imaging outcomes from a phase Ⅲ trial of teriflunomide. Multiple Sclerosis2013;19(10):1310‐9. ">O'Connor 2011</a>)). Treatment duration in <a href="./references#CD009882-bbs2-0001" title="ComiG , FreedmanMS , KapposL , MillerA , OlssonTP , WolinskyJS , et al. Effect of teriflunomide on lymphocyte and neutrophil counts in patients with relapsing multiple sclerosis: results from the TOWER study. Journal of the Neurological Sciences2013;333:e376. ConfavreuxC , O'ConnorP , ComiG , FreedmanMS , MillerAE , OlssonTP , et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet Neurology2014;13(3):247‐56. KapposL , ComiG , ConfavreuxC , FreedmanMS , MillerAE , OlssonTP , et al. The efficacy and safety of teriflunomide in patients with relapsing MS: results from TOWER, a phase Ⅲ, placebo‐controlled study. Multiple Sclerosis2012;18:50‐1. MillerA , KapposL , ComiG , ConfavreuxC , FreedmanM , OlssonT , et al. Teriflunomide efficacy and safety in patients with relapsing multiple sclerosis: results from tower, a second, pivotal, phase 3 placebo‐controlled study. Neurology. 2013; Vol. 80. MillerAE , MacdonellR , ComiG , FreedmanMS , KapposL , MaurerM , et al. Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study. Journal of Neurology2014;261(9):1781‐8. MosesH , FreedmanM , KapposL , MillerA , OlssonT , WolinskyJ , et al. Pre‐defined subgroups analyses of tower, a placebo‐controlled phase 3 trial of teriflunomide in patients with relapsing multiple sclerosis. Proceedings of the American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). O'ConnorP , LublinF , WolinskyJ , ComiG , ConfavreuxC , FreedmanM , et al. Teriflunomide reduces relapse‐related sequelae, hospitalizations and corticosteroid use: a post‐HOC analysis of the phase 3 TOWER study. Proceedings of The American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). ">Confavreux 2014</a> was variable, ending 48 weeks after the last participant was included (a maximum treatment duration of 173 weeks). Furthermore, the data at one year in <a href="./references#CD009882-bbs2-0004" title="ComiG , BenzerdjebH , WangL , TruffinetP , O'ConnorP . Effect of teriflunomide on lymphocyte and neutrophil levels in patients with relapsing multiple sclerosis: results from the TEMSO study. Journal of Neurological Science2013;333(Suppl 1):e376. ComiG , O'ConnorP , WolinskyJ , ConfavreuxC , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: safety outcomes with up to 4 years of follow‐Up. Multiple Sclerosis2011;17:S182‐3. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Long‐term safety and efficacy of teriflunomide in patients with relapsing forms of multiple sclerosis in the TEMSO extension trial. Multiple Sclerosis2013;19:225. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Safety and efficacy of teriflunomide for up to 9 years in relapsing forms of multiple sclerosis: Update of the TEMSO extension trial. Neurology2014; Vol. 82, issue Suppl 10:3‐150. FreedmanMS , DelhayJL , BenamorM . Gastrointestinal symptoms infrequently lead to discontinuation of teriflunomide therapy. Multiple Sclerosis2012;18:S13. MillerA , LublinF , O'ConnorP , TaniouC , Dive‐PoulettyC . Impact of relapses with sequelae on disability, health‐related quality of life, and fatigue in a population with relapsing forms of multiple sclerosis using data from TEMSO, a pivotal phase Ⅲ teriflunomide trial. Neurology2012;78:P07.082. MillerA , LublinF , O'ConnorP , WolinskyJ , ComiG , KapposL , et al. Effect of teriflunomide on relapses with sequelae and relapse leading to hospitalization in a population with relapsing forms of multiple sclerosis: results from the TEMSO study. Neurology2012;78:S30.003. MillerA , O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , et al. Efficacy of oral teriflunomide in multiple sclerosis with relapses: cognitive outcomes from a phase Ⅲ trial (TEMSO). Multiple Sclerosis2011;17:S182. MillerAE , O'ConnorP , WolinskyJS , ConfavreuxC , KapposL , OlssonTP , et al. Pre‐specified subgroup analyses of a placebo‐controlled phase Ⅲ trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis. Multiple Sclerosis2012;18(11):1625‐32. O'ConnorP , BriggsA , CaritaP , Bego‐Le‐BagousseG . Impact on health‐related quality of life of teriflunomide treatment by estimating utilities in patients with relapsing multiple sclerosis: results from TEMSO post hoc analysis. Journal of Neurology2012;259:S107. O'ConnorP , BurrellA , WangL , WeiL , CaritaP , ZhangQ . Effect of teriflunomide on longitudinal patterns of relapse and relapse‐related hospitalization in multiple sclerosis. Multiple Sclerosis2011;17:S414. O'ConnorP , LublinF , WolinskyJ , ComiG , KapposL , FreedmanM , et al. Effect of teriflunomide on relapses leading to healthcare resource use: results from the TEMSO study. Multiple Sclerosis2011;17:S95‐6. O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: clinical and MRI data 5 years after initial randomization. Multiple Sclerosis2011;17:S414‐5. O'ConnorP , WolinskyJS , ConfavreuxC , ComiG , KapposL , OlssonTP , et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. New England Journal of Medicine2011;365(14):1293‐303. O'ConnorPW , LublinFD , WolinskyJS , ConfavreuxC , ComiG , FreedmanMS , et al. Teriflunomide reduces relapse‐related neurological sequelae, hospitalizations and steroid use. Journal of Neurology2013;260(10):2472‐80. WolinksyJS , WangL , TruffinetP , NarayanaPA , NelsonF , O'ConnorP . Magnetic resonance imaging as a surrogate for clinical endpoints in multiple sclerosis. Multiple Sclerosis2012;18:470‐1. WolinskyJS , NarayanaPA , NelsonF , DattaS , O'ConnorP , ConfavreuxC , et al. Magnetic resonance imaging outcomes from a phase Ⅲ trial of teriflunomide. Multiple Sclerosis2013;19(10):1310‐9. ">O'Connor 2011</a> were unavailable. The study designs in <a href="./references#CD009882-bbs2-0002" title="FreedmanMS , WolinskyJS , WamilB , ConfavreuxC , ComiG , KapposL , et al. Teriflunomide added to interferon‐β in relapsing multiple sclerosis: a randomized phase Ⅱ trial. Neurology2012;78(23):1877‐85. ">Freedman 2012</a> and <a href="./references#CD009882-bbs2-0003" title="NCT01252355 . Efficacy and Safety of Teriflunomide in Patients with Relapsing Multiple Sclerosis and Treated with Interferon‐beta (TERACLES). www.clinicaltrials.gov/ct2/show/results/NCT01252355 (accessed 12 January 2016). ">NCT01252355</a> were also similar, but the follow‐up periods were diverse (48 weeks (<a href="./references#CD009882-bbs2-0002" title="FreedmanMS , WolinskyJS , WamilB , ConfavreuxC , ComiG , KapposL , et al. Teriflunomide added to interferon‐β in relapsing multiple sclerosis: a randomized phase Ⅱ trial. Neurology2012;78(23):1877‐85. ">Freedman 2012</a>) and at least 24 weeks (<a href="./references#CD009882-bbs2-0003" title="NCT01252355 . Efficacy and Safety of Teriflunomide in Patients with Relapsing Multiple Sclerosis and Treated with Interferon‐beta (TERACLES). www.clinicaltrials.gov/ct2/show/results/NCT01252355 (accessed 12 January 2016). ">NCT01252355</a>)). Treatment duration in <a href="./references#CD009882-bbs2-0003" title="NCT01252355 . Efficacy and Safety of Teriflunomide in Patients with Relapsing Multiple Sclerosis and Treated with Interferon‐beta (TERACLES). www.clinicaltrials.gov/ct2/show/results/NCT01252355 (accessed 12 January 2016). ">NCT01252355</a> was variable (24 weeks to 108 weeks). Consequently, we could only calculate the treatment effects of interventions based on the available data in the original studies. </p> <section id="CD009882-sec-0065"> <h4 class="title">Primary outcomes</h4> <section id="CD009882-sec-0066"> <h5 class="title">Efficacy: proportion of participants with at least one relapse at one year or two years </h5> <p>All studies reported proportion of participants with at least one relapse at one year or two years. </p> <p><a href="./references#CD009882-bbs2-0001" title="ComiG , FreedmanMS , KapposL , MillerA , OlssonTP , WolinskyJS , et al. Effect of teriflunomide on lymphocyte and neutrophil counts in patients with relapsing multiple sclerosis: results from the TOWER study. Journal of the Neurological Sciences2013;333:e376. ConfavreuxC , O'ConnorP , ComiG , FreedmanMS , MillerAE , OlssonTP , et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet Neurology2014;13(3):247‐56. KapposL , ComiG , ConfavreuxC , FreedmanMS , MillerAE , OlssonTP , et al. The efficacy and safety of teriflunomide in patients with relapsing MS: results from TOWER, a phase Ⅲ, placebo‐controlled study. Multiple Sclerosis2012;18:50‐1. MillerA , KapposL , ComiG , ConfavreuxC , FreedmanM , OlssonT , et al. Teriflunomide efficacy and safety in patients with relapsing multiple sclerosis: results from tower, a second, pivotal, phase 3 placebo‐controlled study. Neurology. 2013; Vol. 80. MillerAE , MacdonellR , ComiG , FreedmanMS , KapposL , MaurerM , et al. Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study. Journal of Neurology2014;261(9):1781‐8. MosesH , FreedmanM , KapposL , MillerA , OlssonT , WolinskyJ , et al. Pre‐defined subgroups analyses of tower, a placebo‐controlled phase 3 trial of teriflunomide in patients with relapsing multiple sclerosis. Proceedings of the American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). O'ConnorP , LublinF , WolinskyJ , ComiG , ConfavreuxC , FreedmanM , et al. Teriflunomide reduces relapse‐related sequelae, hospitalizations and corticosteroid use: a post‐HOC analysis of the phase 3 TOWER study. Proceedings of The American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). ">Confavreux 2014</a> reported the proportion of participants with at least one relapse at one year of follow‐up were 28.10% with low‐dose teriflunomide, 23.70% with high‐dose teriflunomide and 39.40% with placebo, and the RD was 11.30% with low‐dose teriflunomide and 15.70% with high‐dose teriflunomide. Compared to placebo, the results showed low dose of teriflunomide as monotherapy reduced the number of participants with at least one relapse at one year of follow‐up (RR 0.72, 95% CI 0.59 to 0.87, P value = 0.001; 797 participants) and the NNTB was 9, which means that they needed to treat nine participants with low‐dose teriflunomide to prevent one participant relapsing during the one years of follow‐up. Similarly, high dose of teriflunomide as monotherapy also reduced the number of participants with at least one relapse at one year of follow‐up (RR 0.60, 95% CI 0.48 to 0.75, P value &lt; 0.00001; 761 participants) and the NNTB was 6, which means that they needed to treat six participants with high‐dose teriflunomide to prevent one participant relapsing during the one year of follow‐up. Assuming participants who withdrew from study both in experimental groups and control group had a relapse, the likely‐case scenario analyses showed both doses of teriflunomide reduced the number of participants with at least one relapse at one year of follow‐up (low dose: RR 0.83, 95% CI 0.75 to 0.93, P value = 0.0008, 797 participants; high dose: RR 0.79, 95% CI 0.70 to 0.88, P value &lt; 0.0001, 761 participants). </p> <p>Similarly, at two years of follow‐up in <a href="./references#CD009882-bbs2-0004" title="ComiG , BenzerdjebH , WangL , TruffinetP , O'ConnorP . Effect of teriflunomide on lymphocyte and neutrophil levels in patients with relapsing multiple sclerosis: results from the TEMSO study. Journal of Neurological Science2013;333(Suppl 1):e376. ComiG , O'ConnorP , WolinskyJ , ConfavreuxC , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: safety outcomes with up to 4 years of follow‐Up. Multiple Sclerosis2011;17:S182‐3. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Long‐term safety and efficacy of teriflunomide in patients with relapsing forms of multiple sclerosis in the TEMSO extension trial. Multiple Sclerosis2013;19:225. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Safety and efficacy of teriflunomide for up to 9 years in relapsing forms of multiple sclerosis: Update of the TEMSO extension trial. Neurology2014; Vol. 82, issue Suppl 10:3‐150. FreedmanMS , DelhayJL , BenamorM . Gastrointestinal symptoms infrequently lead to discontinuation of teriflunomide therapy. Multiple Sclerosis2012;18:S13. MillerA , LublinF , O'ConnorP , TaniouC , Dive‐PoulettyC . Impact of relapses with sequelae on disability, health‐related quality of life, and fatigue in a population with relapsing forms of multiple sclerosis using data from TEMSO, a pivotal phase Ⅲ teriflunomide trial. Neurology2012;78:P07.082. MillerA , LublinF , O'ConnorP , WolinskyJ , ComiG , KapposL , et al. Effect of teriflunomide on relapses with sequelae and relapse leading to hospitalization in a population with relapsing forms of multiple sclerosis: results from the TEMSO study. Neurology2012;78:S30.003. MillerA , O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , et al. Efficacy of oral teriflunomide in multiple sclerosis with relapses: cognitive outcomes from a phase Ⅲ trial (TEMSO). Multiple Sclerosis2011;17:S182. MillerAE , O'ConnorP , WolinskyJS , ConfavreuxC , KapposL , OlssonTP , et al. Pre‐specified subgroup analyses of a placebo‐controlled phase Ⅲ trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis. Multiple Sclerosis2012;18(11):1625‐32. O'ConnorP , BriggsA , CaritaP , Bego‐Le‐BagousseG . Impact on health‐related quality of life of teriflunomide treatment by estimating utilities in patients with relapsing multiple sclerosis: results from TEMSO post hoc analysis. Journal of Neurology2012;259:S107. O'ConnorP , BurrellA , WangL , WeiL , CaritaP , ZhangQ . Effect of teriflunomide on longitudinal patterns of relapse and relapse‐related hospitalization in multiple sclerosis. Multiple Sclerosis2011;17:S414. O'ConnorP , LublinF , WolinskyJ , ComiG , KapposL , FreedmanM , et al. Effect of teriflunomide on relapses leading to healthcare resource use: results from the TEMSO study. Multiple Sclerosis2011;17:S95‐6. O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: clinical and MRI data 5 years after initial randomization. Multiple Sclerosis2011;17:S414‐5. O'ConnorP , WolinskyJS , ConfavreuxC , ComiG , KapposL , OlssonTP , et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. New England Journal of Medicine2011;365(14):1293‐303. O'ConnorPW , LublinFD , WolinskyJS , ConfavreuxC , ComiG , FreedmanMS , et al. Teriflunomide reduces relapse‐related neurological sequelae, hospitalizations and steroid use. Journal of Neurology2013;260(10):2472‐80. WolinksyJS , WangL , TruffinetP , NarayanaPA , NelsonF , O'ConnorP . Magnetic resonance imaging as a surrogate for clinical endpoints in multiple sclerosis. Multiple Sclerosis2012;18:470‐1. WolinskyJS , NarayanaPA , NelsonF , DattaS , O'ConnorP , ConfavreuxC , et al. Magnetic resonance imaging outcomes from a phase Ⅲ trial of teriflunomide. Multiple Sclerosis2013;19(10):1310‐9. ">O'Connor 2011</a>, compared to placebo, both doses of teriflunomide as monotherapy reduced the number of participants with at least one relapse at two years of follow‐up (low dose: RR 0.85, 95% CI 0.74 to 0.98, P value = 0.03; 729 participants; high dose: RR 0.80, 95% CI 0.69 to 0.93, P value = 0.004; 722 participants). The proportion of participants with at least one relapse at two years of follow‐up were 46.30% with low‐dose teriflunomide, 43.50% with high‐dose teriflunomide and 54.40% with placebo, and the RD was 8.10% with low‐dose teriflunomide and 10.90% with high‐dose teriflunomide, corresponding to an NNTB of 12 with low‐dose teriflunomide and 9 with high‐dose teriflunomide, which means that they needed to treat 12 participants with low‐dose teriflunomide, and nine participants with high‐dose teriflunomide to prevent one participant relapsing during the two years of follow‐up. When taking the effect of drop‐outs into consideration, the likely‐case scenario analyses still showed a benefit in reducing the number of participants with at least one relapse for both doses of teriflunomide (low dose: RR 0.88, 95% CI 0.80 to 0.97, P value = 0.008; 729 participants; high dose: RR 0.87, 95% CI 0.79 to 0.96, P value = 0.005; 722 participants). </p> <p><a href="./references#CD009882-bbs2-0002" title="FreedmanMS , WolinskyJS , WamilB , ConfavreuxC , ComiG , KapposL , et al. Teriflunomide added to interferon‐β in relapsing multiple sclerosis: a randomized phase Ⅱ trial. Neurology2012;78(23):1877‐85. ">Freedman 2012</a> showed neither doses of teriflunomide added to IFNβ were superior to placebo added to IFNβ concerning the proportion of participants with at least one relapse at one year of follow‐up (low dose: RR 1.08, 95% CI 0.45 to 2.59, P value = 0.86; 79 participants; high dose: RR 0.79, 95% CI 0.30 to 2.07, P value = 0.63; 80 participants). However, <a href="./references#CD009882-bbs2-0003" title="NCT01252355 . Efficacy and Safety of Teriflunomide in Patients with Relapsing Multiple Sclerosis and Treated with Interferon‐beta (TERACLES). www.clinicaltrials.gov/ct2/show/results/NCT01252355 (accessed 12 January 2016). ">NCT01252355</a> showed opposite results, both doses of teriflunomide added to IFNβ were superior to placebo added to IFNβ concerning the proportion of participants with at least one relapse at one year of follow‐up (low dose: RR 0.60, 95% CI 0.42 to 0.87, P value = 0.007; 353 participants; high dose: RR 0.58, 95% CI 0.40 to 0.84, P value = 0.004; 354 participants). When administrated as monotherapy for 48 weeks to 115 weeks in <a href="./references#CD009882-bbs2-0005" title="VermerschP , CzlonkowskaA , GrimaldiLM , ConfavreuxC , ComiG , KapposL , et al. A multicenter, randomized, parallel‐group, rater‐blinded study comparing the effectiveness and safety of teriflunomide and subcutaneous interferon beta‐1a in patients with relapsing multiple sclerosis. Multiple Sclerosis2012;18:S9‐10. VermerschP , CzlonkowskaA , GrimaldiLM , ConfavreuxC , ComiG , KapposL , et al. Evaluation of patient satisfaction from the TENERE study: a comparison of teriflunomide and subcutaneous interferon beta‐1a in patients with relapsing multiple sclerosis. Journal of Neurology2012;259:S38. VermerschP , CzlonkowskaA , GrimaldiLM , ConfavreuxC , ComiG , KapposL , et al. Teriflunomide versus subcutaneous interferon beta‐1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial. Multiple Sclerosis2014;20(6):705‐16. ">Vermersch 2014</a>, low dose of teriflunomide was inferior to IFNβ‐1a on the proportion of participants with at least one relapse (RR 2.74, 95% CI 1.66 to 4.53, P value &lt; 0.0001; 213 participants), but there was no difference in reducing the number of participants with at least one relapse for high dose of teriflunomide (RR 1.52, 95% CI 0.87 to 2.67, P value = 0.14; 215 participants). </p> </section> <section id="CD009882-sec-0067"> <h5 class="title">Efficacy: proportion of participants with disability progression</h5> <p><a href="./references#CD009882-bbs2-0001" title="ComiG , FreedmanMS , KapposL , MillerA , OlssonTP , WolinskyJS , et al. Effect of teriflunomide on lymphocyte and neutrophil counts in patients with relapsing multiple sclerosis: results from the TOWER study. Journal of the Neurological Sciences2013;333:e376. ConfavreuxC , O'ConnorP , ComiG , FreedmanMS , MillerAE , OlssonTP , et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet Neurology2014;13(3):247‐56. KapposL , ComiG , ConfavreuxC , FreedmanMS , MillerAE , OlssonTP , et al. The efficacy and safety of teriflunomide in patients with relapsing MS: results from TOWER, a phase Ⅲ, placebo‐controlled study. Multiple Sclerosis2012;18:50‐1. MillerA , KapposL , ComiG , ConfavreuxC , FreedmanM , OlssonT , et al. Teriflunomide efficacy and safety in patients with relapsing multiple sclerosis: results from tower, a second, pivotal, phase 3 placebo‐controlled study. Neurology. 2013; Vol. 80. MillerAE , MacdonellR , ComiG , FreedmanMS , KapposL , MaurerM , et al. Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study. Journal of Neurology2014;261(9):1781‐8. MosesH , FreedmanM , KapposL , MillerA , OlssonT , WolinskyJ , et al. Pre‐defined subgroups analyses of tower, a placebo‐controlled phase 3 trial of teriflunomide in patients with relapsing multiple sclerosis. Proceedings of the American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). O'ConnorP , LublinF , WolinskyJ , ComiG , ConfavreuxC , FreedmanM , et al. Teriflunomide reduces relapse‐related sequelae, hospitalizations and corticosteroid use: a post‐HOC analysis of the phase 3 TOWER study. Proceedings of The American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). ">Confavreux 2014</a> reported the proportions of participants with progression of disability at one year of follow‐up were 12.10% with low‐dose teriflunomide, 7.80% with high‐dose teriflunomide and 14.20% with placebo, and the RD was 2.10% with low‐dose teriflunomide and 6.40% with high‐dose teriflunomide. Compared to placebo, the results showed high dose of teriflunomide as monotherapy reduced the number of participants with disability progression at one year of follow‐up (RR 0.55, 95% CI 0.36 to 0.84, P value = 0.006; 761 participants), and the NNTB was 16, which means that they needed to treat 16 participants with high‐dose teriflunomide to prevent one participant having disability progression during the one year of follow‐up. However, there was no difference for low dose of teriflunomide in disability progression at one year of follow‐up (RR 0.85, 95% CI 0.59 to 1.22, P value = 0.37; 797 participants). When taking the effect of drop‐outs into consideration, the likely‐case scenario analysis showed neither dose of teriflunomide reduced the number of participants with disability progression at one year of follow‐up (low dose: RR 0.94, 95% CI 0.80 to 1.11, P value = 0.47; 797 participants; high dose: RR 0.88, 95% CI 0.74 to 1.04, P value = 0.14; 761 participants). </p> <p><a href="./references#CD009882-bbs2-0004" title="ComiG , BenzerdjebH , WangL , TruffinetP , O'ConnorP . Effect of teriflunomide on lymphocyte and neutrophil levels in patients with relapsing multiple sclerosis: results from the TEMSO study. Journal of Neurological Science2013;333(Suppl 1):e376. ComiG , O'ConnorP , WolinskyJ , ConfavreuxC , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: safety outcomes with up to 4 years of follow‐Up. Multiple Sclerosis2011;17:S182‐3. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Long‐term safety and efficacy of teriflunomide in patients with relapsing forms of multiple sclerosis in the TEMSO extension trial. Multiple Sclerosis2013;19:225. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Safety and efficacy of teriflunomide for up to 9 years in relapsing forms of multiple sclerosis: Update of the TEMSO extension trial. Neurology2014; Vol. 82, issue Suppl 10:3‐150. FreedmanMS , DelhayJL , BenamorM . Gastrointestinal symptoms infrequently lead to discontinuation of teriflunomide therapy. Multiple Sclerosis2012;18:S13. MillerA , LublinF , O'ConnorP , TaniouC , Dive‐PoulettyC . Impact of relapses with sequelae on disability, health‐related quality of life, and fatigue in a population with relapsing forms of multiple sclerosis using data from TEMSO, a pivotal phase Ⅲ teriflunomide trial. Neurology2012;78:P07.082. MillerA , LublinF , O'ConnorP , WolinskyJ , ComiG , KapposL , et al. Effect of teriflunomide on relapses with sequelae and relapse leading to hospitalization in a population with relapsing forms of multiple sclerosis: results from the TEMSO study. Neurology2012;78:S30.003. MillerA , O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , et al. Efficacy of oral teriflunomide in multiple sclerosis with relapses: cognitive outcomes from a phase Ⅲ trial (TEMSO). Multiple Sclerosis2011;17:S182. MillerAE , O'ConnorP , WolinskyJS , ConfavreuxC , KapposL , OlssonTP , et al. Pre‐specified subgroup analyses of a placebo‐controlled phase Ⅲ trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis. Multiple Sclerosis2012;18(11):1625‐32. O'ConnorP , BriggsA , CaritaP , Bego‐Le‐BagousseG . Impact on health‐related quality of life of teriflunomide treatment by estimating utilities in patients with relapsing multiple sclerosis: results from TEMSO post hoc analysis. Journal of Neurology2012;259:S107. O'ConnorP , BurrellA , WangL , WeiL , CaritaP , ZhangQ . Effect of teriflunomide on longitudinal patterns of relapse and relapse‐related hospitalization in multiple sclerosis. Multiple Sclerosis2011;17:S414. O'ConnorP , LublinF , WolinskyJ , ComiG , KapposL , FreedmanM , et al. Effect of teriflunomide on relapses leading to healthcare resource use: results from the TEMSO study. Multiple Sclerosis2011;17:S95‐6. O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: clinical and MRI data 5 years after initial randomization. Multiple Sclerosis2011;17:S414‐5. O'ConnorP , WolinskyJS , ConfavreuxC , ComiG , KapposL , OlssonTP , et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. New England Journal of Medicine2011;365(14):1293‐303. O'ConnorPW , LublinFD , WolinskyJS , ConfavreuxC , ComiG , FreedmanMS , et al. Teriflunomide reduces relapse‐related neurological sequelae, hospitalizations and steroid use. Journal of Neurology2013;260(10):2472‐80. WolinksyJS , WangL , TruffinetP , NarayanaPA , NelsonF , O'ConnorP . Magnetic resonance imaging as a surrogate for clinical endpoints in multiple sclerosis. Multiple Sclerosis2012;18:470‐1. WolinskyJS , NarayanaPA , NelsonF , DattaS , O'ConnorP , ConfavreuxC , et al. Magnetic resonance imaging outcomes from a phase Ⅲ trial of teriflunomide. Multiple Sclerosis2013;19(10):1310‐9. ">O'Connor 2011</a> reported the risk of disability progression at two years of follow‐up was 21.70% with low‐dose teriflunomide and 20.20% with high‐dose teriflunomide lower than that in participants receiving placebo (27.3%). The RD was 5.60% with low‐dose teriflunomide and 7.10% with high‐dose teriflunomide. Compared to placebo, the results showed high dose of teriflunomide as monotherapy reduced the proportion of participants with disability progression at two years of follow‐up (RR 0.74, 95% CI 0.56 to 0.96, P value = 0.02; 722 participants), and the NNTB was 14, which means that they needed to treat 14 participants with high‐dose teriflunomide to prevent one participant against disability progression during the two years of follow‐up. However, there was no difference for low dose of teriflunomide (RR 0.79, 95% CI 0.61 to 1.02, P value = 0.08; 729 participants). However, the likely‐case scenario analysis showed neither dose of teriflunomide reduced the number of participants with disability progression at two years of follow‐up (low dose: RR 0.89, 95% CI 0.75 to 1.06, P value = 0.20; 729 participants; high dose: RR 0.92, 95% CI 0.77 to 1.09, P value = 0.32; 722 participants). </p> </section> <section id="CD009882-sec-0068"> <h5 class="title">Safety</h5> <p><a href="./references#CD009882-bbs2-0001" title="ComiG , FreedmanMS , KapposL , MillerA , OlssonTP , WolinskyJS , et al. Effect of teriflunomide on lymphocyte and neutrophil counts in patients with relapsing multiple sclerosis: results from the TOWER study. Journal of the Neurological Sciences2013;333:e376. ConfavreuxC , O'ConnorP , ComiG , FreedmanMS , MillerAE , OlssonTP , et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet Neurology2014;13(3):247‐56. KapposL , ComiG , ConfavreuxC , FreedmanMS , MillerAE , OlssonTP , et al. The efficacy and safety of teriflunomide in patients with relapsing MS: results from TOWER, a phase Ⅲ, placebo‐controlled study. Multiple Sclerosis2012;18:50‐1. MillerA , KapposL , ComiG , ConfavreuxC , FreedmanM , OlssonT , et al. Teriflunomide efficacy and safety in patients with relapsing multiple sclerosis: results from tower, a second, pivotal, phase 3 placebo‐controlled study. Neurology. 2013; Vol. 80. MillerAE , MacdonellR , ComiG , FreedmanMS , KapposL , MaurerM , et al. Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study. Journal of Neurology2014;261(9):1781‐8. MosesH , FreedmanM , KapposL , MillerA , OlssonT , WolinskyJ , et al. Pre‐defined subgroups analyses of tower, a placebo‐controlled phase 3 trial of teriflunomide in patients with relapsing multiple sclerosis. Proceedings of the American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). O'ConnorP , LublinF , WolinskyJ , ComiG , ConfavreuxC , FreedmanM , et al. Teriflunomide reduces relapse‐related sequelae, hospitalizations and corticosteroid use: a post‐HOC analysis of the phase 3 TOWER study. Proceedings of The American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). ">Confavreux 2014</a> reported the safety of teriflunomide as monotherapy after the core treatment period of 48 weeks to 152 weeks. Compared to placebo, there was no difference for both doses of teriflunomide in the incidence of AEs (low dose: RR 1.01, 95% CI 0.95 to 1.08, P value = 0.71; 794 participants; high dose: RR 1.04, 95% CI 0.98 to 1.10, P value = 0.23; 756 participants) or SAEs (low dose: RR 1.04, 95% CI 0.72 to 1.51, P value = 0.83; high dose: RR 0.97, 95% CI 0.66 to 1.43, P value = 0.88). However, the incidence of AEs leading to discontinuation of the study medication in both teriflunomide groups was higher than that in the placebo group (low dose: RR 2.08, 95% CI 1.31 to 3.30, P value = 0.002; NNTH 15; high dose: RR 2.51, 95% CI 1.59 to 3.95, P value &lt; 0.0001; NNTH 11). The most common AEs with an increased incidence in both teriflunomide groups included hair thinning (low dose: RR 2.33, 95% CI 1.35 to 4.01, P value = 0.002; NNTH 17; high dose: RR 3.05, 95% CI 1.79 to 5.19, P value &lt; 0.0001; NNTH 11), neutropenia (low dose: RR 2.48, 95% CI 1.26 to 4.90, P value = 0.009; NNTH 24; high dose: RR 3.30, 95% CI 1.70 to 6.40, P value = 0.0004; NNTH 15), neutrophil counts less than 1.5 x 10<sup>9</sup>/L (low dose: RR 1.85, 95% CI 1.18 to 2.90, P value = 0.008; NNTH 18; high dose: RR 2.47, 95% CI 1.60 to 3.82, P value &lt; 0.001; NNTH 10), lymphocyte counts less than 0.8 x 10<sup>9</sup>/L (low dose: RR 1.82, 95% CI 1.18 to 2.80, P value = 0.007; NNTH 17; high dose: RR 1.78, 95% CI 1.14 to 2.77, P value = 0.01; NNTH 18), and elevated alanine aminotransferase (ALT) levels greater than one time the upper limit of the normal range (low dose: RR 1.30, 95% CI 1.11 to 1.53, P value = 0.001; NNTH 9; high dose: RR 1.44, 95% CI 1.23 to 1.68, P value &lt; 0.00001; NNTH 6). </p> <p>There was a similar incidence of elevated ALT levels three times or greater the upper limit of the normal range and neutrophil counts less than 0.5 x 10<sup>9</sup>/L between the placebo group and the teriflunomide groups. Elevated ALT and lymphocyte counts less than 0.5 x 10<sup>9</sup>/L occurred at higher frequency with high‐dose teriflunomide compared to placebo (elevated ALT: RR 1.69, 95% CI 1.11 to 2.56, P value = 0.01; NNTH 18; elevated lymphocyte count: RR 11.42, 95% CI 1.48 to 87.98, P value = 0.02; NNTH 59), but there was no difference for low‐dose teriflunomide. In addition, diarrhoea was more common with low‐dose teriflunomide rather than high‐dose teriflunomide (RR 1.65, 95% CI 1.06 to 2.57, P value = 0.03). The proportion of other AEs most commonly reported in teriflunomide groups, such as headache, fatigue, nausea, nasopharyngitis, upper respiratory tract infection, back pain and urinary tract infection, were not higher than in the placebo group. The AEs leading to treatment discontinuation mainly included elevated ALT levels (3% with low‐dose teriflunomide and 2% with high‐dose teriflunomide), neutropenia (1% with low‐dose teriflunomide and 2% with high‐dose teriflunomide), hair thinning (2% with high‐dose teriflunomide) and diarrhoea (1% in both teriflunomide groups). There were 18 pregnancies in 14 female participants and four female partners of male participants. Of the 14 female participants, 10 elected to have induced abortions and four pregnancies resulted in healthy babies (one in the placebo group, two in the low‐dose teriflunomide group and one in the high‐dose teriflunomide group). Of the four pregnancies in partners of male participants, one woman elected to have an induced abortion and three pregnancies resulted in healthy babies (all in the low‐dose teriflunomide group). </p> <p><a href="./references#CD009882-bbs2-0004" title="ComiG , BenzerdjebH , WangL , TruffinetP , O'ConnorP . Effect of teriflunomide on lymphocyte and neutrophil levels in patients with relapsing multiple sclerosis: results from the TEMSO study. Journal of Neurological Science2013;333(Suppl 1):e376. ComiG , O'ConnorP , WolinskyJ , ConfavreuxC , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: safety outcomes with up to 4 years of follow‐Up. Multiple Sclerosis2011;17:S182‐3. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Long‐term safety and efficacy of teriflunomide in patients with relapsing forms of multiple sclerosis in the TEMSO extension trial. Multiple Sclerosis2013;19:225. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Safety and efficacy of teriflunomide for up to 9 years in relapsing forms of multiple sclerosis: Update of the TEMSO extension trial. Neurology2014; Vol. 82, issue Suppl 10:3‐150. FreedmanMS , DelhayJL , BenamorM . Gastrointestinal symptoms infrequently lead to discontinuation of teriflunomide therapy. Multiple Sclerosis2012;18:S13. MillerA , LublinF , O'ConnorP , TaniouC , Dive‐PoulettyC . Impact of relapses with sequelae on disability, health‐related quality of life, and fatigue in a population with relapsing forms of multiple sclerosis using data from TEMSO, a pivotal phase Ⅲ teriflunomide trial. Neurology2012;78:P07.082. MillerA , LublinF , O'ConnorP , WolinskyJ , ComiG , KapposL , et al. Effect of teriflunomide on relapses with sequelae and relapse leading to hospitalization in a population with relapsing forms of multiple sclerosis: results from the TEMSO study. Neurology2012;78:S30.003. MillerA , O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , et al. Efficacy of oral teriflunomide in multiple sclerosis with relapses: cognitive outcomes from a phase Ⅲ trial (TEMSO). Multiple Sclerosis2011;17:S182. MillerAE , O'ConnorP , WolinskyJS , ConfavreuxC , KapposL , OlssonTP , et al. Pre‐specified subgroup analyses of a placebo‐controlled phase Ⅲ trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis. Multiple Sclerosis2012;18(11):1625‐32. O'ConnorP , BriggsA , CaritaP , Bego‐Le‐BagousseG . Impact on health‐related quality of life of teriflunomide treatment by estimating utilities in patients with relapsing multiple sclerosis: results from TEMSO post hoc analysis. Journal of Neurology2012;259:S107. O'ConnorP , BurrellA , WangL , WeiL , CaritaP , ZhangQ . Effect of teriflunomide on longitudinal patterns of relapse and relapse‐related hospitalization in multiple sclerosis. Multiple Sclerosis2011;17:S414. O'ConnorP , LublinF , WolinskyJ , ComiG , KapposL , FreedmanM , et al. Effect of teriflunomide on relapses leading to healthcare resource use: results from the TEMSO study. Multiple Sclerosis2011;17:S95‐6. O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: clinical and MRI data 5 years after initial randomization. Multiple Sclerosis2011;17:S414‐5. O'ConnorP , WolinskyJS , ConfavreuxC , ComiG , KapposL , OlssonTP , et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. New England Journal of Medicine2011;365(14):1293‐303. O'ConnorPW , LublinFD , WolinskyJS , ConfavreuxC , ComiG , FreedmanMS , et al. Teriflunomide reduces relapse‐related neurological sequelae, hospitalizations and steroid use. Journal of Neurology2013;260(10):2472‐80. WolinksyJS , WangL , TruffinetP , NarayanaPA , NelsonF , O'ConnorP . Magnetic resonance imaging as a surrogate for clinical endpoints in multiple sclerosis. Multiple Sclerosis2012;18:470‐1. WolinskyJS , NarayanaPA , NelsonF , DattaS , O'ConnorP , ConfavreuxC , et al. Magnetic resonance imaging outcomes from a phase Ⅲ trial of teriflunomide. Multiple Sclerosis2013;19(10):1310‐9. ">O'Connor 2011</a> reported the safety of teriflunomide as monotherapy at two years of follow‐up. Compared to placebo, there was no difference for both doses of teriflunomide in the incidence of AEs (low dose: RR 1.02, 95% CI 0.97 to 1.07, P value = 0.49; 728 participants; high dose: RR 1.04, 95% CI 0.99 to 1.09, P value = 0.16; 718 participants), SAEs (low dose: RR 1.11, 95% CI 0.76 to 1.60, P value = 0.59; high dose: RR 1.25, 95% CI 0.87 to 1.79, P value = 0.23) and AEs leading to discontinuation of the study medication (low dose: RR 1.21, 95% CI 0.76 to 1.94, P value = 0.41; high dose: RR 1.35, 95% CI 0.86 to 2.14, P value = 0.20). The most common adverse events with an increased incidence in both teriflunomide groups included diarrhoea (low dose: RR 1.65, 95% CI 1.09 to 2.49, P value = 0.02; NNTH 17; high dose: RR 2.01, 95% CI 1.35 to 3.00, P value = 0.0006; NNTH 11), hair thinning or decreased hair density (low dose: RR 3.10, 95% CI 1.65 to 5.83, P value = 0.0005; NNTH 14; high dose: RR 3.94, 95% CI 2.13 to 7.30, P value &lt; 0.0001; NNTH 10), elevated ALT levels (low dose: RR 1.79, 95% CI 1.11 to 2.89, P value = 0.02; NNTH 19; high dose: RR 2.14, 95% CI 1.35 to 3.39, P value = 0.001; NNTH 13). The incidence of nausea in high‐dose teriflunomide group rather than in low‐dose teriflunomide group was higher than that in placebo group (low dose: RR 1.24, 95% CI 0.76 to 2.03, P value = 0.39; high dose: RR 1.90, 95% CI 1.21 to 2.98, P value = 0.006; NNTH 15). The incidence of elevated ALT levels one times or greater the upper limit of the normal range in both doses was higher than that in placebo group (low dose: RR 2.61, 95% CI 1.23 to 5.53, P value = 0.01; NNTH 6; high dose: RR 3.24, 95% CI 1.56 to 6.75, P value = 0.002; NNTH 5), but there was no difference for both doses of teriflunomide in the incidence of elevated ALT levels three times or greater the upper limit of the normal range. These events rarely led to discontinuation of the study medication: diarrhoea (0.3% in both teriflunomide groups), nausea (0.3% with low‐dose), hair thinning or decreased hair density (0.5% with low‐dose and 1.4% with high‐dose). The proportion of other AEs (10% or greater) most commonly reported in any teriflunomide group, such as nasopharyngitis, headache, fatigue, influenza, back pain and urinary tract infection, occurred with a similar frequency in the placebo group. Mean reductions in neutrophil and lymphocyte counts from baseline values were small in magnitude (1.0 x 10<sup>9</sup>/L or less for neutrophil counts and 0.3 x 10<sup>9</sup>/L or less for lymphocyte counts) but were slightly more marked with high‐dose teriflunomide than with low‐dose teriflunomide or placebo. Moderate neutropenia (defined as a neutrophil count of less than 0.9 x 10<sup>9</sup>/L) developed in three participants receiving teriflunomide. Eleven pregnancies occurred, leading to four spontaneous abortions (one in the placebo group and three in the high‐dose teriflunomide group), six induced abortions (five in the low‐dose teriflunomide group and one in the high‐dose teriflunomide group). One participant in the high‐dose teriflunomide group (treated for 31 days of the pregnancy) delivered a healthy baby with no reported health concerns after two years. </p> <p><a href="./references#CD009882-bbs2-0005" title="VermerschP , CzlonkowskaA , GrimaldiLM , ConfavreuxC , ComiG , KapposL , et al. A multicenter, randomized, parallel‐group, rater‐blinded study comparing the effectiveness and safety of teriflunomide and subcutaneous interferon beta‐1a in patients with relapsing multiple sclerosis. Multiple Sclerosis2012;18:S9‐10. VermerschP , CzlonkowskaA , GrimaldiLM , ConfavreuxC , ComiG , KapposL , et al. Evaluation of patient satisfaction from the TENERE study: a comparison of teriflunomide and subcutaneous interferon beta‐1a in patients with relapsing multiple sclerosis. Journal of Neurology2012;259:S38. VermerschP , CzlonkowskaA , GrimaldiLM , ConfavreuxC , ComiG , KapposL , et al. Teriflunomide versus subcutaneous interferon beta‐1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial. Multiple Sclerosis2014;20(6):705‐16. ">Vermersch 2014</a> reported the safety of teriflunomide as monotherapy after the core treatment period of 48 weeks to 115 weeks. Compared to IFNβ‐1a, there was no difference for both doses of teriflunomide in the incidence of AEs (low dose: RR 0.97, 95% CI 0.92 to 1.04, P value = 0.43; 211 participants; high dose: RR 0.97, 95% CI 0.90 to 1.03, P value = 0.29; 211 participants) or SAEs (low dose: RR 1.57, 95% CI 0.64 to 3.84, P value = 0.32; high dose: RR 0.79, 95% CI 0.27 to 2.26, P value = 0.66). However, the incidence of AEs leading to discontinuation in the IFNβ group was higher than those in the teriflunomide groups (low dose: RR 0.38, 95% CI 0.18 to 0.78, P value = 0.008; high dose: RR 0.50, 95% CI 0.26 to 0.96, P value = 0.04). The most commonly reported AEs (10% or greater) in either teriflunomide group were nasopharyngitis, headache, paraesthesia, diarrhoea, hair thinning, back pain and elevated ALT levels. Among these AEs, the incidence of diarrhoea in both teriflunomide groups was higher than that in the IFNβ‐1a group (low dose: RR 2.87, 95% CI 1.36 to 6.07, P value = 0.006; high dose: RR 2.64, 95% CI 1.24 to 5.63, P value = 0.01). Compared to IFNβ‐1a, hair thinning was more common with high‐dose teriflunomide rather than low‐dose teriflunomide (RR 20.20, 95% CI 2.77 to 147.14, P value = 0.003). However, elevated ALT levels occurred with a lower frequency in the teriflunomide groups (low dose: RR 0.36, 95% CI 0.19 to 0.65, P value = 0.0009; high dose: RR 0.33, 95% CI 0.17 to 0.61, P value = 0.0005). In addition, influenza‐like illness was reported more frequently with IFNβ‐1a than with teriflunomide (low dose: RR 0.07, 95% CI 0.03 to 0.18, P value &lt; 0.00001; high dose: RR 0.05, 95% CI 0.02 to 0.16, P value &lt; 0.00001). There was a similar incidence of other AEs between the IFNβ‐1a group and teriflunomide groups. </p> <p><a href="./references#CD009882-bbs2-0002" title="FreedmanMS , WolinskyJS , WamilB , ConfavreuxC , ComiG , KapposL , et al. Teriflunomide added to interferon‐β in relapsing multiple sclerosis: a randomized phase Ⅱ trial. Neurology2012;78(23):1877‐85. ">Freedman 2012</a> reported the safety of teriflunomide added to IFNβ at one year of follow‐up. Compared to placebo added to IFNβ, there was no difference for either dose of teriflunomide in the incidence of AEs (low dose: RR 1.11, 95% CI 0.96 to 1.29, P value = 0.17; 78 participants; high dose: RR 1.02, 95% CI 0.85 to 1.21, P value = 0.85; 79 participants), SAEs (low dose: RR 2.22, 95% CI 0.43 to 11.40, P value = 0.34; high dose: RR 0.54, 95% CI 0.05 to 5.71, P value = 0.61) and AEs leading to discontinuation (low dose: RR 1.66, 95% CI 0.29 to 9.40, P value = 0.57; high dose: RR 1.62, 95% CI 0.29 to 9.16, P value = 0.59). The most commonly reported AEs (10% or greater) in either teriflunomide group were elevated ALT levels, headache, decreased lymphocyte counts, nasopharyngitis, nausea, fatigue, decreased neutrophil counts, hypertension, back pain, vomiting, diarrhoea and urinary tract infection. However, these AEs occurred with a similar frequency in the IFNβ group. </p> <p><a href="./references#CD009882-bbs2-0003" title="NCT01252355 . Efficacy and Safety of Teriflunomide in Patients with Relapsing Multiple Sclerosis and Treated with Interferon‐beta (TERACLES). www.clinicaltrials.gov/ct2/show/results/NCT01252355 (accessed 12 January 2016). ">NCT01252355</a> reported the safety of teriflunomide added to IFNβ after the treatment period of 28 weeks to 108 weeks. Compared to placebo added to IFNβ, the incidences of AEs in both teriflunomide groups were higher than those in the placebo group (low dose: RR 1.15, 95% CI 1.01 to 1.31, P value = 0.03; 354 participants; high dose: RR 1.16, 95% CI 1.02 to 1.31, P value = 0.02; 353 participants). However, there was no difference for either dose of teriflunomide in the incidence of SAEs (low dose: RR 1.59, 95% CI 0.68 to 3.74, P value = 0.29; high dose: RR 1.72, 95% CI 0.74 to 4.00, P value = 0.21). The incidence of AEs leading to discontinuation with high‐dose teriflunomide rather than with low‐dose teriflunomide was higher than that in the placebo group (low dose: RR 1.74, 95% CI 0.79 to 3.83, P value = 0.17; high dose: RR 2.40, 95% CI 1.14 to 5.07, P value = 0.02). There was no difference for either dose of teriflunomide in the incidence of elevated ALT levels three times or greater the upper limit of the normal range (low dose: RR 1.46, 95% CI 0.53 to 4.01, P value = 0.47; high dose: RR 1.47, 95% CI 0.53 to 4.03, P value = 0.46). </p> </section> </section> <section id="CD009882-sec-0069"> <h4 class="title">Secondary outcomes</h4> <section id="CD009882-sec-0070"> <h5 class="title">Annualized relapse rate</h5> <p>All studies reported the annualized relapse rate. <a href="./references#CD009882-bbs2-0001" title="ComiG , FreedmanMS , KapposL , MillerA , OlssonTP , WolinskyJS , et al. Effect of teriflunomide on lymphocyte and neutrophil counts in patients with relapsing multiple sclerosis: results from the TOWER study. Journal of the Neurological Sciences2013;333:e376. ConfavreuxC , O'ConnorP , ComiG , FreedmanMS , MillerAE , OlssonTP , et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet Neurology2014;13(3):247‐56. KapposL , ComiG , ConfavreuxC , FreedmanMS , MillerAE , OlssonTP , et al. The efficacy and safety of teriflunomide in patients with relapsing MS: results from TOWER, a phase Ⅲ, placebo‐controlled study. Multiple Sclerosis2012;18:50‐1. MillerA , KapposL , ComiG , ConfavreuxC , FreedmanM , OlssonT , et al. Teriflunomide efficacy and safety in patients with relapsing multiple sclerosis: results from tower, a second, pivotal, phase 3 placebo‐controlled study. Neurology. 2013; Vol. 80. MillerAE , MacdonellR , ComiG , FreedmanMS , KapposL , MaurerM , et al. Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study. Journal of Neurology2014;261(9):1781‐8. MosesH , FreedmanM , KapposL , MillerA , OlssonT , WolinskyJ , et al. Pre‐defined subgroups analyses of tower, a placebo‐controlled phase 3 trial of teriflunomide in patients with relapsing multiple sclerosis. Proceedings of the American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). O'ConnorP , LublinF , WolinskyJ , ComiG , ConfavreuxC , FreedmanM , et al. Teriflunomide reduces relapse‐related sequelae, hospitalizations and corticosteroid use: a post‐HOC analysis of the phase 3 TOWER study. Proceedings of The American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). ">Confavreux 2014</a> reported annualized relapse rate after the core treatment period of 48 weeks to 152 weeks (low dose: annualized relapse rate 0.39, 95% CI 0.33 to 0.46; 407 participants; high dose: annualized relapse rate 0.32, 95% CI 0.27 to 0.38; 370 participants; placebo: annualized relapse rate 0.50, 95% CI 0.43 to 0.58; 388 participants), but we could not calculate the total number of relapses and standard errors due to the variable duration of follow‐up, consequently we could not calculate the rate ratio. However, the authors reported the RRs on annualized relapse rate, showing both doses of teriflunomide as monotherapy reduced annualized relapse rate during the follow‐up period of 48 weeks to 132 weeks (low dose: RR 0.78, 95% CI 0.63 to 0.96, P value = 0.0183; 797 participants; high dose: RR 0.64, 95% CI 0.51 to 0.79, P value = 0.0001; 761 participants). </p> <p>There were similar results at two years of follow‐up in <a href="./references#CD009882-bbs2-0004" title="ComiG , BenzerdjebH , WangL , TruffinetP , O'ConnorP . Effect of teriflunomide on lymphocyte and neutrophil levels in patients with relapsing multiple sclerosis: results from the TEMSO study. Journal of Neurological Science2013;333(Suppl 1):e376. ComiG , O'ConnorP , WolinskyJ , ConfavreuxC , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: safety outcomes with up to 4 years of follow‐Up. Multiple Sclerosis2011;17:S182‐3. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Long‐term safety and efficacy of teriflunomide in patients with relapsing forms of multiple sclerosis in the TEMSO extension trial. Multiple Sclerosis2013;19:225. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Safety and efficacy of teriflunomide for up to 9 years in relapsing forms of multiple sclerosis: Update of the TEMSO extension trial. Neurology2014; Vol. 82, issue Suppl 10:3‐150. FreedmanMS , DelhayJL , BenamorM . Gastrointestinal symptoms infrequently lead to discontinuation of teriflunomide therapy. Multiple Sclerosis2012;18:S13. MillerA , LublinF , O'ConnorP , TaniouC , Dive‐PoulettyC . Impact of relapses with sequelae on disability, health‐related quality of life, and fatigue in a population with relapsing forms of multiple sclerosis using data from TEMSO, a pivotal phase Ⅲ teriflunomide trial. Neurology2012;78:P07.082. MillerA , LublinF , O'ConnorP , WolinskyJ , ComiG , KapposL , et al. Effect of teriflunomide on relapses with sequelae and relapse leading to hospitalization in a population with relapsing forms of multiple sclerosis: results from the TEMSO study. Neurology2012;78:S30.003. MillerA , O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , et al. Efficacy of oral teriflunomide in multiple sclerosis with relapses: cognitive outcomes from a phase Ⅲ trial (TEMSO). Multiple Sclerosis2011;17:S182. MillerAE , O'ConnorP , WolinskyJS , ConfavreuxC , KapposL , OlssonTP , et al. Pre‐specified subgroup analyses of a placebo‐controlled phase Ⅲ trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis. Multiple Sclerosis2012;18(11):1625‐32. O'ConnorP , BriggsA , CaritaP , Bego‐Le‐BagousseG . Impact on health‐related quality of life of teriflunomide treatment by estimating utilities in patients with relapsing multiple sclerosis: results from TEMSO post hoc analysis. Journal of Neurology2012;259:S107. O'ConnorP , BurrellA , WangL , WeiL , CaritaP , ZhangQ . Effect of teriflunomide on longitudinal patterns of relapse and relapse‐related hospitalization in multiple sclerosis. Multiple Sclerosis2011;17:S414. O'ConnorP , LublinF , WolinskyJ , ComiG , KapposL , FreedmanM , et al. Effect of teriflunomide on relapses leading to healthcare resource use: results from the TEMSO study. Multiple Sclerosis2011;17:S95‐6. O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: clinical and MRI data 5 years after initial randomization. Multiple Sclerosis2011;17:S414‐5. O'ConnorP , WolinskyJS , ConfavreuxC , ComiG , KapposL , OlssonTP , et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. New England Journal of Medicine2011;365(14):1293‐303. O'ConnorPW , LublinFD , WolinskyJS , ConfavreuxC , ComiG , FreedmanMS , et al. Teriflunomide reduces relapse‐related neurological sequelae, hospitalizations and steroid use. Journal of Neurology2013;260(10):2472‐80. WolinksyJS , WangL , TruffinetP , NarayanaPA , NelsonF , O'ConnorP . Magnetic resonance imaging as a surrogate for clinical endpoints in multiple sclerosis. Multiple Sclerosis2012;18:470‐1. WolinskyJS , NarayanaPA , NelsonF , DattaS , O'ConnorP , ConfavreuxC , et al. Magnetic resonance imaging outcomes from a phase Ⅲ trial of teriflunomide. Multiple Sclerosis2013;19(10):1310‐9. ">O'Connor 2011</a> (low dose: rate ratio 0.69, 95% CI 0.59 to 0.81, P value &lt; 0.00001; 729 participants; high dose: rate ratio 0.69, 95% CI 0.59 to 0.80, P value &lt; 0.00001; 722 participants). </p> <p><a href="./references#CD009882-bbs2-0002" title="FreedmanMS , WolinskyJS , WamilB , ConfavreuxC , ComiG , KapposL , et al. Teriflunomide added to interferon‐β in relapsing multiple sclerosis: a randomized phase Ⅱ trial. Neurology2012;78(23):1877‐85. ">Freedman 2012</a> showed neither doses of teriflunomide added to IFNβ were superior to placebo added to IFNβ concerning annualized relapse rate at one year of follow‐up (low dose: rate ratio 0.42, 95% CI 0.15 to 1.16, P value = 0.10; 79 participants; high dose: rate ratio 0.67, 95% CI 0.29 to 1.54, P value = 0.35; 80 participants). </p> <p><a href="./references#CD009882-bbs2-0003" title="NCT01252355 . Efficacy and Safety of Teriflunomide in Patients with Relapsing Multiple Sclerosis and Treated with Interferon‐beta (TERACLES). www.clinicaltrials.gov/ct2/show/results/NCT01252355 (accessed 12 January 2016). ">NCT01252355</a> reported only the data of annualized relapse rate after the treatment duration of 24 weeks to 108 weeks (low dose: annualized relapse rate 0.242, 95% CI 0.152 to 0.386; 178 participants; high dose: annualized relapse rate 0.238, 95% CI 0.162 to 0.351; 179 participants; placebo: annualized relapse rate 0.298, 95% CI 0.206 to 0.432; 175 participants). Therefore, we could not calculate the total number of relapses and the standard error due to the variable duration of follow‐up, consequently we could not calculate the rate ratio. </p> <p><a href="./references#CD009882-bbs2-0005" title="VermerschP , CzlonkowskaA , GrimaldiLM , ConfavreuxC , ComiG , KapposL , et al. A multicenter, randomized, parallel‐group, rater‐blinded study comparing the effectiveness and safety of teriflunomide and subcutaneous interferon beta‐1a in patients with relapsing multiple sclerosis. Multiple Sclerosis2012;18:S9‐10. VermerschP , CzlonkowskaA , GrimaldiLM , ConfavreuxC , ComiG , KapposL , et al. Evaluation of patient satisfaction from the TENERE study: a comparison of teriflunomide and subcutaneous interferon beta‐1a in patients with relapsing multiple sclerosis. Journal of Neurology2012;259:S38. VermerschP , CzlonkowskaA , GrimaldiLM , ConfavreuxC , ComiG , KapposL , et al. Teriflunomide versus subcutaneous interferon beta‐1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial. Multiple Sclerosis2014;20(6):705‐16. ">Vermersch 2014</a> reported the data of annualized relapse rate after the treatment period of 48 weeks to 115 weeks (low dose: annualized relapse rate 0.41, 95% CI 0.27 to 0.64; 109 participants; high dose: annualized relapse rate 0.26, 95% CI 0.15 to 0.44; 111 participants; IFNβ‐1a: annualized relapse rate 0.22, 95% CI 0.11 to 0.42; 104 participants). However, we could not calculate the total number of relapses and the standard error due to the variable duration of follow‐up, consequently we could not calculate the rate ratio. However, the authors reported the RR on annualized relapse rate, showing that low‐dose teriflunomide was inferior to IFNβ‐1a on annualized relapse rate (RR 1.90, 95% CI 1.05 to 3.43, P value = 0.03; 213 participants), but there was no difference in reducing annualized relapse rate for high‐dose teriflunomide (RR 1.20, 95% CI 0.62 to 2.30, P value = 0.59; 215 participants). </p> </section> <section id="CD009882-sec-0071"> <h5 class="title">Number of gadolinium‐enhancing T1‐weighted lesions</h5> <p>Three studies reported the number of gadolinium‐enhancing T1‐weighted lesions (<a href="./references#CD009882-bbs2-0002" title="FreedmanMS , WolinskyJS , WamilB , ConfavreuxC , ComiG , KapposL , et al. Teriflunomide added to interferon‐β in relapsing multiple sclerosis: a randomized phase Ⅱ trial. Neurology2012;78(23):1877‐85. ">Freedman 2012</a>; <a href="./references#CD009882-bbs2-0003" title="NCT01252355 . Efficacy and Safety of Teriflunomide in Patients with Relapsing Multiple Sclerosis and Treated with Interferon‐beta (TERACLES). www.clinicaltrials.gov/ct2/show/results/NCT01252355 (accessed 12 January 2016). ">NCT01252355</a>; <a href="./references#CD009882-bbs2-0004" title="ComiG , BenzerdjebH , WangL , TruffinetP , O'ConnorP . Effect of teriflunomide on lymphocyte and neutrophil levels in patients with relapsing multiple sclerosis: results from the TEMSO study. Journal of Neurological Science2013;333(Suppl 1):e376. ComiG , O'ConnorP , WolinskyJ , ConfavreuxC , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: safety outcomes with up to 4 years of follow‐Up. Multiple Sclerosis2011;17:S182‐3. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Long‐term safety and efficacy of teriflunomide in patients with relapsing forms of multiple sclerosis in the TEMSO extension trial. Multiple Sclerosis2013;19:225. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Safety and efficacy of teriflunomide for up to 9 years in relapsing forms of multiple sclerosis: Update of the TEMSO extension trial. Neurology2014; Vol. 82, issue Suppl 10:3‐150. FreedmanMS , DelhayJL , BenamorM . Gastrointestinal symptoms infrequently lead to discontinuation of teriflunomide therapy. Multiple Sclerosis2012;18:S13. MillerA , LublinF , O'ConnorP , TaniouC , Dive‐PoulettyC . Impact of relapses with sequelae on disability, health‐related quality of life, and fatigue in a population with relapsing forms of multiple sclerosis using data from TEMSO, a pivotal phase Ⅲ teriflunomide trial. Neurology2012;78:P07.082. MillerA , LublinF , O'ConnorP , WolinskyJ , ComiG , KapposL , et al. Effect of teriflunomide on relapses with sequelae and relapse leading to hospitalization in a population with relapsing forms of multiple sclerosis: results from the TEMSO study. Neurology2012;78:S30.003. MillerA , O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , et al. Efficacy of oral teriflunomide in multiple sclerosis with relapses: cognitive outcomes from a phase Ⅲ trial (TEMSO). Multiple Sclerosis2011;17:S182. MillerAE , O'ConnorP , WolinskyJS , ConfavreuxC , KapposL , OlssonTP , et al. Pre‐specified subgroup analyses of a placebo‐controlled phase Ⅲ trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis. Multiple Sclerosis2012;18(11):1625‐32. O'ConnorP , BriggsA , CaritaP , Bego‐Le‐BagousseG . Impact on health‐related quality of life of teriflunomide treatment by estimating utilities in patients with relapsing multiple sclerosis: results from TEMSO post hoc analysis. Journal of Neurology2012;259:S107. O'ConnorP , BurrellA , WangL , WeiL , CaritaP , ZhangQ . Effect of teriflunomide on longitudinal patterns of relapse and relapse‐related hospitalization in multiple sclerosis. Multiple Sclerosis2011;17:S414. O'ConnorP , LublinF , WolinskyJ , ComiG , KapposL , FreedmanM , et al. Effect of teriflunomide on relapses leading to healthcare resource use: results from the TEMSO study. Multiple Sclerosis2011;17:S95‐6. O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: clinical and MRI data 5 years after initial randomization. Multiple Sclerosis2011;17:S414‐5. O'ConnorP , WolinskyJS , ConfavreuxC , ComiG , KapposL , OlssonTP , et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. New England Journal of Medicine2011;365(14):1293‐303. O'ConnorPW , LublinFD , WolinskyJS , ConfavreuxC , ComiG , FreedmanMS , et al. Teriflunomide reduces relapse‐related neurological sequelae, hospitalizations and steroid use. Journal of Neurology2013;260(10):2472‐80. WolinksyJS , WangL , TruffinetP , NarayanaPA , NelsonF , O'ConnorP . Magnetic resonance imaging as a surrogate for clinical endpoints in multiple sclerosis. Multiple Sclerosis2012;18:470‐1. WolinskyJS , NarayanaPA , NelsonF , DattaS , O'ConnorP , ConfavreuxC , et al. Magnetic resonance imaging outcomes from a phase Ⅲ trial of teriflunomide. Multiple Sclerosis2013;19(10):1310‐9. ">O'Connor 2011</a>). </p> <p>Compared to placebo, the results of <a href="./references#CD009882-bbs2-0004" title="ComiG , BenzerdjebH , WangL , TruffinetP , O'ConnorP . Effect of teriflunomide on lymphocyte and neutrophil levels in patients with relapsing multiple sclerosis: results from the TEMSO study. Journal of Neurological Science2013;333(Suppl 1):e376. ComiG , O'ConnorP , WolinskyJ , ConfavreuxC , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: safety outcomes with up to 4 years of follow‐Up. Multiple Sclerosis2011;17:S182‐3. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Long‐term safety and efficacy of teriflunomide in patients with relapsing forms of multiple sclerosis in the TEMSO extension trial. Multiple Sclerosis2013;19:225. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Safety and efficacy of teriflunomide for up to 9 years in relapsing forms of multiple sclerosis: Update of the TEMSO extension trial. Neurology2014; Vol. 82, issue Suppl 10:3‐150. FreedmanMS , DelhayJL , BenamorM . Gastrointestinal symptoms infrequently lead to discontinuation of teriflunomide therapy. Multiple Sclerosis2012;18:S13. MillerA , LublinF , O'ConnorP , TaniouC , Dive‐PoulettyC . Impact of relapses with sequelae on disability, health‐related quality of life, and fatigue in a population with relapsing forms of multiple sclerosis using data from TEMSO, a pivotal phase Ⅲ teriflunomide trial. Neurology2012;78:P07.082. MillerA , LublinF , O'ConnorP , WolinskyJ , ComiG , KapposL , et al. Effect of teriflunomide on relapses with sequelae and relapse leading to hospitalization in a population with relapsing forms of multiple sclerosis: results from the TEMSO study. Neurology2012;78:S30.003. MillerA , O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , et al. Efficacy of oral teriflunomide in multiple sclerosis with relapses: cognitive outcomes from a phase Ⅲ trial (TEMSO). Multiple Sclerosis2011;17:S182. MillerAE , O'ConnorP , WolinskyJS , ConfavreuxC , KapposL , OlssonTP , et al. Pre‐specified subgroup analyses of a placebo‐controlled phase Ⅲ trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis. Multiple Sclerosis2012;18(11):1625‐32. O'ConnorP , BriggsA , CaritaP , Bego‐Le‐BagousseG . Impact on health‐related quality of life of teriflunomide treatment by estimating utilities in patients with relapsing multiple sclerosis: results from TEMSO post hoc analysis. Journal of Neurology2012;259:S107. O'ConnorP , BurrellA , WangL , WeiL , CaritaP , ZhangQ . Effect of teriflunomide on longitudinal patterns of relapse and relapse‐related hospitalization in multiple sclerosis. Multiple Sclerosis2011;17:S414. O'ConnorP , LublinF , WolinskyJ , ComiG , KapposL , FreedmanM , et al. Effect of teriflunomide on relapses leading to healthcare resource use: results from the TEMSO study. Multiple Sclerosis2011;17:S95‐6. O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: clinical and MRI data 5 years after initial randomization. Multiple Sclerosis2011;17:S414‐5. O'ConnorP , WolinskyJS , ConfavreuxC , ComiG , KapposL , OlssonTP , et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. New England Journal of Medicine2011;365(14):1293‐303. O'ConnorPW , LublinFD , WolinskyJS , ConfavreuxC , ComiG , FreedmanMS , et al. Teriflunomide reduces relapse‐related neurological sequelae, hospitalizations and steroid use. Journal of Neurology2013;260(10):2472‐80. WolinksyJS , WangL , TruffinetP , NarayanaPA , NelsonF , O'ConnorP . Magnetic resonance imaging as a surrogate for clinical endpoints in multiple sclerosis. Multiple Sclerosis2012;18:470‐1. WolinskyJS , NarayanaPA , NelsonF , DattaS , O'ConnorP , ConfavreuxC , et al. Magnetic resonance imaging outcomes from a phase Ⅲ trial of teriflunomide. Multiple Sclerosis2013;19(10):1310‐9. ">O'Connor 2011</a> showed both doses of teriflunomide as monotherapy reduced the number of gadolinium‐enhancing T1‐weighted lesions at two years of follow‐up (low dose: rate ratio 0.43, 95% CI 0.37 to 0.51, P value &lt; 0.00001; 729 participants; high dose: rate ratio 0.19, 95% CI 0.15 to 0.24, P value &lt; 0.00001; 722 participants). </p> <p><a href="./references#CD009882-bbs2-0002" title="FreedmanMS , WolinskyJS , WamilB , ConfavreuxC , ComiG , KapposL , et al. Teriflunomide added to interferon‐β in relapsing multiple sclerosis: a randomized phase Ⅱ trial. Neurology2012;78(23):1877‐85. ">Freedman 2012</a> showed neither dose of teriflunomide added to IF‐β was superior to placebo added to IFNβ concerning the number of gadolinium‐enhancing T1‐weighted lesions at one year of follow‐up (low dose: rate ratio 0.67, 95% CI 0.29 to 1.55, P value = 0.35; 79 participants; high dose: rate ratio 0.42, 95% CI 0.16 to 1.09, P value = 0.08; 80 participants). </p> <p><a href="./references#CD009882-bbs2-0003" title="NCT01252355 . Efficacy and Safety of Teriflunomide in Patients with Relapsing Multiple Sclerosis and Treated with Interferon‐beta (TERACLES). www.clinicaltrials.gov/ct2/show/results/NCT01252355 (accessed 12 January 2016). ">NCT01252355</a> reported only the data of the number of gadolinium‐enhancing T1‐weighted lesions after the treatment period of 24 weeks to 108 weeks (low dose: 0.257, 95% CI 0.127 to 0.523; 142 participants; high dose: 0.158, 95% CI 0.070 to 0.360; 151 participants; placebo: 0.542, 95% CI 0.344 to 0.855; 151 participants). We could not calculate the annualized relapse rate due to the variable duration of follow‐up, consequently we could not calculate the rate ratio. </p> </section> <section id="CD009882-sec-0072"> <h5 class="title">Time to disability progression</h5> <p>Three studies reported the time to disability progression (<a href="./references#CD009882-bbs2-0001" title="ComiG , FreedmanMS , KapposL , MillerA , OlssonTP , WolinskyJS , et al. Effect of teriflunomide on lymphocyte and neutrophil counts in patients with relapsing multiple sclerosis: results from the TOWER study. Journal of the Neurological Sciences2013;333:e376. ConfavreuxC , O'ConnorP , ComiG , FreedmanMS , MillerAE , OlssonTP , et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet Neurology2014;13(3):247‐56. KapposL , ComiG , ConfavreuxC , FreedmanMS , MillerAE , OlssonTP , et al. The efficacy and safety of teriflunomide in patients with relapsing MS: results from TOWER, a phase Ⅲ, placebo‐controlled study. Multiple Sclerosis2012;18:50‐1. MillerA , KapposL , ComiG , ConfavreuxC , FreedmanM , OlssonT , et al. Teriflunomide efficacy and safety in patients with relapsing multiple sclerosis: results from tower, a second, pivotal, phase 3 placebo‐controlled study. Neurology. 2013; Vol. 80. MillerAE , MacdonellR , ComiG , FreedmanMS , KapposL , MaurerM , et al. Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study. Journal of Neurology2014;261(9):1781‐8. MosesH , FreedmanM , KapposL , MillerA , OlssonT , WolinskyJ , et al. Pre‐defined subgroups analyses of tower, a placebo‐controlled phase 3 trial of teriflunomide in patients with relapsing multiple sclerosis. Proceedings of the American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). O'ConnorP , LublinF , WolinskyJ , ComiG , ConfavreuxC , FreedmanM , et al. Teriflunomide reduces relapse‐related sequelae, hospitalizations and corticosteroid use: a post‐HOC analysis of the phase 3 TOWER study. Proceedings of The American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). ">Confavreux 2014</a>; <a href="./references#CD009882-bbs2-0003" title="NCT01252355 . Efficacy and Safety of Teriflunomide in Patients with Relapsing Multiple Sclerosis and Treated with Interferon‐beta (TERACLES). www.clinicaltrials.gov/ct2/show/results/NCT01252355 (accessed 12 January 2016). ">NCT01252355</a>; <a href="./references#CD009882-bbs2-0004" title="ComiG , BenzerdjebH , WangL , TruffinetP , O'ConnorP . Effect of teriflunomide on lymphocyte and neutrophil levels in patients with relapsing multiple sclerosis: results from the TEMSO study. Journal of Neurological Science2013;333(Suppl 1):e376. ComiG , O'ConnorP , WolinskyJ , ConfavreuxC , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: safety outcomes with up to 4 years of follow‐Up. Multiple Sclerosis2011;17:S182‐3. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Long‐term safety and efficacy of teriflunomide in patients with relapsing forms of multiple sclerosis in the TEMSO extension trial. Multiple Sclerosis2013;19:225. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Safety and efficacy of teriflunomide for up to 9 years in relapsing forms of multiple sclerosis: Update of the TEMSO extension trial. Neurology2014; Vol. 82, issue Suppl 10:3‐150. FreedmanMS , DelhayJL , BenamorM . Gastrointestinal symptoms infrequently lead to discontinuation of teriflunomide therapy. Multiple Sclerosis2012;18:S13. MillerA , LublinF , O'ConnorP , TaniouC , Dive‐PoulettyC . Impact of relapses with sequelae on disability, health‐related quality of life, and fatigue in a population with relapsing forms of multiple sclerosis using data from TEMSO, a pivotal phase Ⅲ teriflunomide trial. Neurology2012;78:P07.082. MillerA , LublinF , O'ConnorP , WolinskyJ , ComiG , KapposL , et al. Effect of teriflunomide on relapses with sequelae and relapse leading to hospitalization in a population with relapsing forms of multiple sclerosis: results from the TEMSO study. Neurology2012;78:S30.003. MillerA , O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , et al. Efficacy of oral teriflunomide in multiple sclerosis with relapses: cognitive outcomes from a phase Ⅲ trial (TEMSO). Multiple Sclerosis2011;17:S182. MillerAE , O'ConnorP , WolinskyJS , ConfavreuxC , KapposL , OlssonTP , et al. Pre‐specified subgroup analyses of a placebo‐controlled phase Ⅲ trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis. Multiple Sclerosis2012;18(11):1625‐32. O'ConnorP , BriggsA , CaritaP , Bego‐Le‐BagousseG . Impact on health‐related quality of life of teriflunomide treatment by estimating utilities in patients with relapsing multiple sclerosis: results from TEMSO post hoc analysis. Journal of Neurology2012;259:S107. O'ConnorP , BurrellA , WangL , WeiL , CaritaP , ZhangQ . Effect of teriflunomide on longitudinal patterns of relapse and relapse‐related hospitalization in multiple sclerosis. Multiple Sclerosis2011;17:S414. O'ConnorP , LublinF , WolinskyJ , ComiG , KapposL , FreedmanM , et al. Effect of teriflunomide on relapses leading to healthcare resource use: results from the TEMSO study. Multiple Sclerosis2011;17:S95‐6. O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: clinical and MRI data 5 years after initial randomization. Multiple Sclerosis2011;17:S414‐5. O'ConnorP , WolinskyJS , ConfavreuxC , ComiG , KapposL , OlssonTP , et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. New England Journal of Medicine2011;365(14):1293‐303. O'ConnorPW , LublinFD , WolinskyJS , ConfavreuxC , ComiG , FreedmanMS , et al. Teriflunomide reduces relapse‐related neurological sequelae, hospitalizations and steroid use. Journal of Neurology2013;260(10):2472‐80. WolinksyJS , WangL , TruffinetP , NarayanaPA , NelsonF , O'ConnorP . Magnetic resonance imaging as a surrogate for clinical endpoints in multiple sclerosis. Multiple Sclerosis2012;18:470‐1. WolinskyJS , NarayanaPA , NelsonF , DattaS , O'ConnorP , ConfavreuxC , et al. Magnetic resonance imaging outcomes from a phase Ⅲ trial of teriflunomide. Multiple Sclerosis2013;19(10):1310‐9. ">O'Connor 2011</a>). </p> <p>Compared to placebo, the results of <a href="./references#CD009882-bbs2-0001" title="ComiG , FreedmanMS , KapposL , MillerA , OlssonTP , WolinskyJS , et al. Effect of teriflunomide on lymphocyte and neutrophil counts in patients with relapsing multiple sclerosis: results from the TOWER study. Journal of the Neurological Sciences2013;333:e376. ConfavreuxC , O'ConnorP , ComiG , FreedmanMS , MillerAE , OlssonTP , et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet Neurology2014;13(3):247‐56. KapposL , ComiG , ConfavreuxC , FreedmanMS , MillerAE , OlssonTP , et al. The efficacy and safety of teriflunomide in patients with relapsing MS: results from TOWER, a phase Ⅲ, placebo‐controlled study. Multiple Sclerosis2012;18:50‐1. MillerA , KapposL , ComiG , ConfavreuxC , FreedmanM , OlssonT , et al. Teriflunomide efficacy and safety in patients with relapsing multiple sclerosis: results from tower, a second, pivotal, phase 3 placebo‐controlled study. Neurology. 2013; Vol. 80. MillerAE , MacdonellR , ComiG , FreedmanMS , KapposL , MaurerM , et al. Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study. Journal of Neurology2014;261(9):1781‐8. MosesH , FreedmanM , KapposL , MillerA , OlssonT , WolinskyJ , et al. Pre‐defined subgroups analyses of tower, a placebo‐controlled phase 3 trial of teriflunomide in patients with relapsing multiple sclerosis. Proceedings of the American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). O'ConnorP , LublinF , WolinskyJ , ComiG , ConfavreuxC , FreedmanM , et al. Teriflunomide reduces relapse‐related sequelae, hospitalizations and corticosteroid use: a post‐HOC analysis of the phase 3 TOWER study. Proceedings of The American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). ">Confavreux 2014</a> showed high‐dose teriflunomide as monotherapy delayed the progression of disability after the core treatment period of 48 weeks to 152 weeks (HR 0.68, 95% CI 0.47 to 1.00, P value = 0.04; 758 participants), but there was no difference in delaying the progression of disability for low‐dose teriflunomide (HR 0.95, 95% CI 0.68 to 1.35, P value = 0.76; 795 participants). </p> <p>The results of <a href="./references#CD009882-bbs2-0004" title="ComiG , BenzerdjebH , WangL , TruffinetP , O'ConnorP . Effect of teriflunomide on lymphocyte and neutrophil levels in patients with relapsing multiple sclerosis: results from the TEMSO study. Journal of Neurological Science2013;333(Suppl 1):e376. ComiG , O'ConnorP , WolinskyJ , ConfavreuxC , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: safety outcomes with up to 4 years of follow‐Up. Multiple Sclerosis2011;17:S182‐3. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Long‐term safety and efficacy of teriflunomide in patients with relapsing forms of multiple sclerosis in the TEMSO extension trial. Multiple Sclerosis2013;19:225. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Safety and efficacy of teriflunomide for up to 9 years in relapsing forms of multiple sclerosis: Update of the TEMSO extension trial. Neurology2014; Vol. 82, issue Suppl 10:3‐150. FreedmanMS , DelhayJL , BenamorM . Gastrointestinal symptoms infrequently lead to discontinuation of teriflunomide therapy. Multiple Sclerosis2012;18:S13. MillerA , LublinF , O'ConnorP , TaniouC , Dive‐PoulettyC . Impact of relapses with sequelae on disability, health‐related quality of life, and fatigue in a population with relapsing forms of multiple sclerosis using data from TEMSO, a pivotal phase Ⅲ teriflunomide trial. Neurology2012;78:P07.082. MillerA , LublinF , O'ConnorP , WolinskyJ , ComiG , KapposL , et al. Effect of teriflunomide on relapses with sequelae and relapse leading to hospitalization in a population with relapsing forms of multiple sclerosis: results from the TEMSO study. Neurology2012;78:S30.003. MillerA , O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , et al. Efficacy of oral teriflunomide in multiple sclerosis with relapses: cognitive outcomes from a phase Ⅲ trial (TEMSO). Multiple Sclerosis2011;17:S182. MillerAE , O'ConnorP , WolinskyJS , ConfavreuxC , KapposL , OlssonTP , et al. Pre‐specified subgroup analyses of a placebo‐controlled phase Ⅲ trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis. Multiple Sclerosis2012;18(11):1625‐32. O'ConnorP , BriggsA , CaritaP , Bego‐Le‐BagousseG . Impact on health‐related quality of life of teriflunomide treatment by estimating utilities in patients with relapsing multiple sclerosis: results from TEMSO post hoc analysis. Journal of Neurology2012;259:S107. O'ConnorP , BurrellA , WangL , WeiL , CaritaP , ZhangQ . Effect of teriflunomide on longitudinal patterns of relapse and relapse‐related hospitalization in multiple sclerosis. Multiple Sclerosis2011;17:S414. O'ConnorP , LublinF , WolinskyJ , ComiG , KapposL , FreedmanM , et al. Effect of teriflunomide on relapses leading to healthcare resource use: results from the TEMSO study. Multiple Sclerosis2011;17:S95‐6. O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: clinical and MRI data 5 years after initial randomization. Multiple Sclerosis2011;17:S414‐5. O'ConnorP , WolinskyJS , ConfavreuxC , ComiG , KapposL , OlssonTP , et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. New England Journal of Medicine2011;365(14):1293‐303. O'ConnorPW , LublinFD , WolinskyJS , ConfavreuxC , ComiG , FreedmanMS , et al. Teriflunomide reduces relapse‐related neurological sequelae, hospitalizations and steroid use. Journal of Neurology2013;260(10):2472‐80. WolinksyJS , WangL , TruffinetP , NarayanaPA , NelsonF , O'ConnorP . Magnetic resonance imaging as a surrogate for clinical endpoints in multiple sclerosis. Multiple Sclerosis2012;18:470‐1. WolinskyJS , NarayanaPA , NelsonF , DattaS , O'ConnorP , ConfavreuxC , et al. Magnetic resonance imaging outcomes from a phase Ⅲ trial of teriflunomide. Multiple Sclerosis2013;19(10):1310‐9. ">O'Connor 2011</a> showed high‐dose teriflunomide as monotherapy delayed the progression of disability at two years of follow‐up (HR 0.70, 95% CI 0.51 to 0.96, P value = 0.03; 721 participants), but there was no difference in delaying the progression of disability for low‐dose teriflunomide (HR 0.76, 95% CI 0.56 to 1.05, P value = 0.08; 728 participants). </p> <p>Data of the time to disability progression in <a href="./references#CD009882-bbs2-0003" title="NCT01252355 . Efficacy and Safety of Teriflunomide in Patients with Relapsing Multiple Sclerosis and Treated with Interferon‐beta (TERACLES). www.clinicaltrials.gov/ct2/show/results/NCT01252355 (accessed 12 January 2016). ">NCT01252355</a> were insufficient because of early study termination and were not reported in the original publication. </p> </section> <section id="CD009882-sec-0073"> <h5 class="title">Changes in T1 hypointensity or magnetization transfer ratio of lesion damage</h5> <p>One study reported changes in T1 hypointensity lesion damage (<a href="./references#CD009882-bbs2-0004" title="ComiG , BenzerdjebH , WangL , TruffinetP , O'ConnorP . Effect of teriflunomide on lymphocyte and neutrophil levels in patients with relapsing multiple sclerosis: results from the TEMSO study. Journal of Neurological Science2013;333(Suppl 1):e376. ComiG , O'ConnorP , WolinskyJ , ConfavreuxC , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: safety outcomes with up to 4 years of follow‐Up. Multiple Sclerosis2011;17:S182‐3. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Long‐term safety and efficacy of teriflunomide in patients with relapsing forms of multiple sclerosis in the TEMSO extension trial. Multiple Sclerosis2013;19:225. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Safety and efficacy of teriflunomide for up to 9 years in relapsing forms of multiple sclerosis: Update of the TEMSO extension trial. Neurology2014; Vol. 82, issue Suppl 10:3‐150. FreedmanMS , DelhayJL , BenamorM . Gastrointestinal symptoms infrequently lead to discontinuation of teriflunomide therapy. Multiple Sclerosis2012;18:S13. MillerA , LublinF , O'ConnorP , TaniouC , Dive‐PoulettyC . Impact of relapses with sequelae on disability, health‐related quality of life, and fatigue in a population with relapsing forms of multiple sclerosis using data from TEMSO, a pivotal phase Ⅲ teriflunomide trial. Neurology2012;78:P07.082. MillerA , LublinF , O'ConnorP , WolinskyJ , ComiG , KapposL , et al. Effect of teriflunomide on relapses with sequelae and relapse leading to hospitalization in a population with relapsing forms of multiple sclerosis: results from the TEMSO study. Neurology2012;78:S30.003. MillerA , O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , et al. Efficacy of oral teriflunomide in multiple sclerosis with relapses: cognitive outcomes from a phase Ⅲ trial (TEMSO). Multiple Sclerosis2011;17:S182. MillerAE , O'ConnorP , WolinskyJS , ConfavreuxC , KapposL , OlssonTP , et al. Pre‐specified subgroup analyses of a placebo‐controlled phase Ⅲ trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis. Multiple Sclerosis2012;18(11):1625‐32. O'ConnorP , BriggsA , CaritaP , Bego‐Le‐BagousseG . Impact on health‐related quality of life of teriflunomide treatment by estimating utilities in patients with relapsing multiple sclerosis: results from TEMSO post hoc analysis. Journal of Neurology2012;259:S107. O'ConnorP , BurrellA , WangL , WeiL , CaritaP , ZhangQ . Effect of teriflunomide on longitudinal patterns of relapse and relapse‐related hospitalization in multiple sclerosis. Multiple Sclerosis2011;17:S414. O'ConnorP , LublinF , WolinskyJ , ComiG , KapposL , FreedmanM , et al. Effect of teriflunomide on relapses leading to healthcare resource use: results from the TEMSO study. Multiple Sclerosis2011;17:S95‐6. O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: clinical and MRI data 5 years after initial randomization. Multiple Sclerosis2011;17:S414‐5. O'ConnorP , WolinskyJS , ConfavreuxC , ComiG , KapposL , OlssonTP , et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. New England Journal of Medicine2011;365(14):1293‐303. O'ConnorPW , LublinFD , WolinskyJS , ConfavreuxC , ComiG , FreedmanMS , et al. Teriflunomide reduces relapse‐related neurological sequelae, hospitalizations and steroid use. Journal of Neurology2013;260(10):2472‐80. WolinksyJS , WangL , TruffinetP , NarayanaPA , NelsonF , O'ConnorP . Magnetic resonance imaging as a surrogate for clinical endpoints in multiple sclerosis. Multiple Sclerosis2012;18:470‐1. WolinskyJS , NarayanaPA , NelsonF , DattaS , O'ConnorP , ConfavreuxC , et al. Magnetic resonance imaging outcomes from a phase Ⅲ trial of teriflunomide. Multiple Sclerosis2013;19(10):1310‐9. ">O'Connor 2011</a>). The results showed high‐dose teriflunomide as monotherapy, compared to placebo, reduced the volume of hypointense lesions on T1‐weighted images at two years (MD ‐0.20, 95% CI ‐0.35 to ‐0.05, P value = 0.009, 728 participants). However, there was no difference for low‐dose teriflunomide (MD ‐0.03, 95% CI ‐0.19 to 0.13, P value = 0.71; 721 participants). </p> <p>None of the studies reported magnetization transfer ratio of lesion damage.</p> </section> <section id="CD009882-sec-0074"> <h5 class="title">Change in health‐related quality of life</h5> <p>Two studies reported change in QoL measured by SF‐36 scores (<a href="./references#CD009882-bbs2-0001" title="ComiG , FreedmanMS , KapposL , MillerA , OlssonTP , WolinskyJS , et al. Effect of teriflunomide on lymphocyte and neutrophil counts in patients with relapsing multiple sclerosis: results from the TOWER study. Journal of the Neurological Sciences2013;333:e376. ConfavreuxC , O'ConnorP , ComiG , FreedmanMS , MillerAE , OlssonTP , et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet Neurology2014;13(3):247‐56. KapposL , ComiG , ConfavreuxC , FreedmanMS , MillerAE , OlssonTP , et al. The efficacy and safety of teriflunomide in patients with relapsing MS: results from TOWER, a phase Ⅲ, placebo‐controlled study. Multiple Sclerosis2012;18:50‐1. MillerA , KapposL , ComiG , ConfavreuxC , FreedmanM , OlssonT , et al. Teriflunomide efficacy and safety in patients with relapsing multiple sclerosis: results from tower, a second, pivotal, phase 3 placebo‐controlled study. Neurology. 2013; Vol. 80. MillerAE , MacdonellR , ComiG , FreedmanMS , KapposL , MaurerM , et al. Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study. Journal of Neurology2014;261(9):1781‐8. MosesH , FreedmanM , KapposL , MillerA , OlssonT , WolinskyJ , et al. Pre‐defined subgroups analyses of tower, a placebo‐controlled phase 3 trial of teriflunomide in patients with relapsing multiple sclerosis. Proceedings of the American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). O'ConnorP , LublinF , WolinskyJ , ComiG , ConfavreuxC , FreedmanM , et al. Teriflunomide reduces relapse‐related sequelae, hospitalizations and corticosteroid use: a post‐HOC analysis of the phase 3 TOWER study. Proceedings of The American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). ">Confavreux 2014</a>; <a href="./references#CD009882-bbs2-0003" title="NCT01252355 . Efficacy and Safety of Teriflunomide in Patients with Relapsing Multiple Sclerosis and Treated with Interferon‐beta (TERACLES). www.clinicaltrials.gov/ct2/show/results/NCT01252355 (accessed 12 January 2016). ">NCT01252355</a>). </p> <p><a href="./references#CD009882-bbs2-0001" title="ComiG , FreedmanMS , KapposL , MillerA , OlssonTP , WolinskyJS , et al. Effect of teriflunomide on lymphocyte and neutrophil counts in patients with relapsing multiple sclerosis: results from the TOWER study. Journal of the Neurological Sciences2013;333:e376. ConfavreuxC , O'ConnorP , ComiG , FreedmanMS , MillerAE , OlssonTP , et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet Neurology2014;13(3):247‐56. KapposL , ComiG , ConfavreuxC , FreedmanMS , MillerAE , OlssonTP , et al. The efficacy and safety of teriflunomide in patients with relapsing MS: results from TOWER, a phase Ⅲ, placebo‐controlled study. Multiple Sclerosis2012;18:50‐1. MillerA , KapposL , ComiG , ConfavreuxC , FreedmanM , OlssonT , et al. Teriflunomide efficacy and safety in patients with relapsing multiple sclerosis: results from tower, a second, pivotal, phase 3 placebo‐controlled study. Neurology. 2013; Vol. 80. MillerAE , MacdonellR , ComiG , FreedmanMS , KapposL , MaurerM , et al. Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study. Journal of Neurology2014;261(9):1781‐8. MosesH , FreedmanM , KapposL , MillerA , OlssonT , WolinskyJ , et al. Pre‐defined subgroups analyses of tower, a placebo‐controlled phase 3 trial of teriflunomide in patients with relapsing multiple sclerosis. Proceedings of the American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). O'ConnorP , LublinF , WolinskyJ , ComiG , ConfavreuxC , FreedmanM , et al. Teriflunomide reduces relapse‐related sequelae, hospitalizations and corticosteroid use: a post‐HOC analysis of the phase 3 TOWER study. Proceedings of The American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). ">Confavreux 2014</a> found that compared to placebo, there was no difference for teriflunomide as monotherapy in change of SF‐36 physical health summary score and in SF‐36 mental health summary score at 48 weeks (low dose: physical health: MD 0.68, 95% CI ‐0.44 to 1.80, P value = 0.24 and mental health: MD 0.88, 95% CI ‐0.72 to 2.48, P value = 0.28; 797 participants; high dose: physical health: MD 0.97, 95% CI ‐0.18 to 2.12, P value = 0.10 and mental health: MD 1.48, 95% CI ‐0.18 to 3.14, P value = 0.08; 761 participants). </p> <p>Data of change in QoL measured by SF‐36 scores in <a href="./references#CD009882-bbs2-0003" title="NCT01252355 . Efficacy and Safety of Teriflunomide in Patients with Relapsing Multiple Sclerosis and Treated with Interferon‐beta (TERACLES). www.clinicaltrials.gov/ct2/show/results/NCT01252355 (accessed 12 January 2016). ">NCT01252355</a> were insufficient because of early study termination and were not reported in the original publication. </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD009882-sec-0075" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009882-sec-0075">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009882-sec-0115">Español</a> </li> </nav> </div> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD009882-sec-0075"></div> <section id="CD009882-sec-0076"> <h3 class="title" id="CD009882-sec-0076">Summary of main results</h3> <p>This systematic review included five RCTs involving 3231 adults with relapsing MS. All participants had a score of less than 5.5 on the EDSS and a relapsing clinical course with or without progression (RRMS, SPMS or PRMS). Two studies were large‐scale RCTs in which participants had disease activity with at least one relapse in the previous year or at least two clinical relapses in the previous two years. These two studies primarily evaluated the benefit of teriflunomide at a dose of 7 mg/day or 14 mg/day as monotherapy versus placebo in respect of relapse, disability worsening and safety over at least 48 weeks (a maximum of 173 weeks) (<a href="./references#CD009882-bbs2-0001" title="ComiG , FreedmanMS , KapposL , MillerA , OlssonTP , WolinskyJS , et al. Effect of teriflunomide on lymphocyte and neutrophil counts in patients with relapsing multiple sclerosis: results from the TOWER study. Journal of the Neurological Sciences2013;333:e376. ConfavreuxC , O'ConnorP , ComiG , FreedmanMS , MillerAE , OlssonTP , et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet Neurology2014;13(3):247‐56. KapposL , ComiG , ConfavreuxC , FreedmanMS , MillerAE , OlssonTP , et al. The efficacy and safety of teriflunomide in patients with relapsing MS: results from TOWER, a phase Ⅲ, placebo‐controlled study. Multiple Sclerosis2012;18:50‐1. MillerA , KapposL , ComiG , ConfavreuxC , FreedmanM , OlssonT , et al. Teriflunomide efficacy and safety in patients with relapsing multiple sclerosis: results from tower, a second, pivotal, phase 3 placebo‐controlled study. Neurology. 2013; Vol. 80. MillerAE , MacdonellR , ComiG , FreedmanMS , KapposL , MaurerM , et al. Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study. Journal of Neurology2014;261(9):1781‐8. MosesH , FreedmanM , KapposL , MillerA , OlssonT , WolinskyJ , et al. Pre‐defined subgroups analyses of tower, a placebo‐controlled phase 3 trial of teriflunomide in patients with relapsing multiple sclerosis. Proceedings of the American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). O'ConnorP , LublinF , WolinskyJ , ComiG , ConfavreuxC , FreedmanM , et al. Teriflunomide reduces relapse‐related sequelae, hospitalizations and corticosteroid use: a post‐HOC analysis of the phase 3 TOWER study. Proceedings of The American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). ">Confavreux 2014</a>) or two years (<a href="./references#CD009882-bbs2-0004" title="ComiG , BenzerdjebH , WangL , TruffinetP , O'ConnorP . Effect of teriflunomide on lymphocyte and neutrophil levels in patients with relapsing multiple sclerosis: results from the TEMSO study. Journal of Neurological Science2013;333(Suppl 1):e376. ComiG , O'ConnorP , WolinskyJ , ConfavreuxC , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: safety outcomes with up to 4 years of follow‐Up. Multiple Sclerosis2011;17:S182‐3. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Long‐term safety and efficacy of teriflunomide in patients with relapsing forms of multiple sclerosis in the TEMSO extension trial. Multiple Sclerosis2013;19:225. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Safety and efficacy of teriflunomide for up to 9 years in relapsing forms of multiple sclerosis: Update of the TEMSO extension trial. Neurology2014; Vol. 82, issue Suppl 10:3‐150. FreedmanMS , DelhayJL , BenamorM . Gastrointestinal symptoms infrequently lead to discontinuation of teriflunomide therapy. Multiple Sclerosis2012;18:S13. MillerA , LublinF , O'ConnorP , TaniouC , Dive‐PoulettyC . Impact of relapses with sequelae on disability, health‐related quality of life, and fatigue in a population with relapsing forms of multiple sclerosis using data from TEMSO, a pivotal phase Ⅲ teriflunomide trial. Neurology2012;78:P07.082. MillerA , LublinF , O'ConnorP , WolinskyJ , ComiG , KapposL , et al. Effect of teriflunomide on relapses with sequelae and relapse leading to hospitalization in a population with relapsing forms of multiple sclerosis: results from the TEMSO study. Neurology2012;78:S30.003. MillerA , O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , et al. Efficacy of oral teriflunomide in multiple sclerosis with relapses: cognitive outcomes from a phase Ⅲ trial (TEMSO). Multiple Sclerosis2011;17:S182. MillerAE , O'ConnorP , WolinskyJS , ConfavreuxC , KapposL , OlssonTP , et al. Pre‐specified subgroup analyses of a placebo‐controlled phase Ⅲ trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis. Multiple Sclerosis2012;18(11):1625‐32. O'ConnorP , BriggsA , CaritaP , Bego‐Le‐BagousseG . Impact on health‐related quality of life of teriflunomide treatment by estimating utilities in patients with relapsing multiple sclerosis: results from TEMSO post hoc analysis. Journal of Neurology2012;259:S107. O'ConnorP , BurrellA , WangL , WeiL , CaritaP , ZhangQ . Effect of teriflunomide on longitudinal patterns of relapse and relapse‐related hospitalization in multiple sclerosis. Multiple Sclerosis2011;17:S414. O'ConnorP , LublinF , WolinskyJ , ComiG , KapposL , FreedmanM , et al. Effect of teriflunomide on relapses leading to healthcare resource use: results from the TEMSO study. Multiple Sclerosis2011;17:S95‐6. O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: clinical and MRI data 5 years after initial randomization. Multiple Sclerosis2011;17:S414‐5. O'ConnorP , WolinskyJS , ConfavreuxC , ComiG , KapposL , OlssonTP , et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. New England Journal of Medicine2011;365(14):1293‐303. O'ConnorPW , LublinFD , WolinskyJS , ConfavreuxC , ComiG , FreedmanMS , et al. Teriflunomide reduces relapse‐related neurological sequelae, hospitalizations and steroid use. Journal of Neurology2013;260(10):2472‐80. WolinksyJS , WangL , TruffinetP , NarayanaPA , NelsonF , O'ConnorP . Magnetic resonance imaging as a surrogate for clinical endpoints in multiple sclerosis. Multiple Sclerosis2012;18:470‐1. WolinskyJS , NarayanaPA , NelsonF , DattaS , O'ConnorP , ConfavreuxC , et al. Magnetic resonance imaging outcomes from a phase Ⅲ trial of teriflunomide. Multiple Sclerosis2013;19(10):1310‐9. ">O'Connor 2011</a>). The other three studies mainly evaluated the efficacy on relapse and the safety and tolerability of teriflunomide 7 mg/day or 14 mg/day with add‐on IFNβ versus placebo over 48 weeks (<a href="./references#CD009882-bbs2-0002" title="FreedmanMS , WolinskyJS , WamilB , ConfavreuxC , ComiG , KapposL , et al. Teriflunomide added to interferon‐β in relapsing multiple sclerosis: a randomized phase Ⅱ trial. Neurology2012;78(23):1877‐85. ">Freedman 2012</a>) or at least 24 weeks (a maximum of 108 weeks) (<a href="./references#CD009882-bbs2-0003" title="NCT01252355 . Efficacy and Safety of Teriflunomide in Patients with Relapsing Multiple Sclerosis and Treated with Interferon‐beta (TERACLES). www.clinicaltrials.gov/ct2/show/results/NCT01252355 (accessed 12 January 2016). ">NCT01252355</a>), or teriflunomide 7 mg/day or 14 mg/day alone versus IFNβ‐1a (<a href="./references#CD009882-bbs2-0005" title="VermerschP , CzlonkowskaA , GrimaldiLM , ConfavreuxC , ComiG , KapposL , et al. A multicenter, randomized, parallel‐group, rater‐blinded study comparing the effectiveness and safety of teriflunomide and subcutaneous interferon beta‐1a in patients with relapsing multiple sclerosis. Multiple Sclerosis2012;18:S9‐10. VermerschP , CzlonkowskaA , GrimaldiLM , ConfavreuxC , ComiG , KapposL , et al. Evaluation of patient satisfaction from the TENERE study: a comparison of teriflunomide and subcutaneous interferon beta‐1a in patients with relapsing multiple sclerosis. Journal of Neurology2012;259:S38. VermerschP , CzlonkowskaA , GrimaldiLM , ConfavreuxC , ComiG , KapposL , et al. Teriflunomide versus subcutaneous interferon beta‐1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial. Multiple Sclerosis2014;20(6):705‐16. ">Vermersch 2014</a>) at least 48 weeks (a maximum of 115 weeks). The study design and interventions of the five studies were diverse. There were obvious clinical heterogeneities due to the diversities in study designs or interventions and methodological heterogeneities across studies. All studies had a high risk of detection bias for relapse assessment and a high risk of bias due to conflicts of interest. Among them, <a href="./references#CD009882-bbs2-0001" title="ComiG , FreedmanMS , KapposL , MillerA , OlssonTP , WolinskyJS , et al. Effect of teriflunomide on lymphocyte and neutrophil counts in patients with relapsing multiple sclerosis: results from the TOWER study. Journal of the Neurological Sciences2013;333:e376. ConfavreuxC , O'ConnorP , ComiG , FreedmanMS , MillerAE , OlssonTP , et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet Neurology2014;13(3):247‐56. KapposL , ComiG , ConfavreuxC , FreedmanMS , MillerAE , OlssonTP , et al. The efficacy and safety of teriflunomide in patients with relapsing MS: results from TOWER, a phase Ⅲ, placebo‐controlled study. Multiple Sclerosis2012;18:50‐1. MillerA , KapposL , ComiG , ConfavreuxC , FreedmanM , OlssonT , et al. Teriflunomide efficacy and safety in patients with relapsing multiple sclerosis: results from tower, a second, pivotal, phase 3 placebo‐controlled study. Neurology. 2013; Vol. 80. MillerAE , MacdonellR , ComiG , FreedmanMS , KapposL , MaurerM , et al. Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study. Journal of Neurology2014;261(9):1781‐8. MosesH , FreedmanM , KapposL , MillerA , OlssonT , WolinskyJ , et al. Pre‐defined subgroups analyses of tower, a placebo‐controlled phase 3 trial of teriflunomide in patients with relapsing multiple sclerosis. Proceedings of the American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). O'ConnorP , LublinF , WolinskyJ , ComiG , ConfavreuxC , FreedmanM , et al. Teriflunomide reduces relapse‐related sequelae, hospitalizations and corticosteroid use: a post‐HOC analysis of the phase 3 TOWER study. Proceedings of The American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). ">Confavreux 2014</a>, <a href="./references#CD009882-bbs2-0002" title="FreedmanMS , WolinskyJS , WamilB , ConfavreuxC , ComiG , KapposL , et al. Teriflunomide added to interferon‐β in relapsing multiple sclerosis: a randomized phase Ⅱ trial. Neurology2012;78(23):1877‐85. ">Freedman 2012</a>, and <a href="./references#CD009882-bbs2-0003" title="NCT01252355 . Efficacy and Safety of Teriflunomide in Patients with Relapsing Multiple Sclerosis and Treated with Interferon‐beta (TERACLES). www.clinicaltrials.gov/ct2/show/results/NCT01252355 (accessed 12 January 2016). ">NCT01252355</a> had a high risk of attrition bias due to a high dropout rate (29.8% (<a href="./references#CD009882-bbs2-0001" title="ComiG , FreedmanMS , KapposL , MillerA , OlssonTP , WolinskyJS , et al. Effect of teriflunomide on lymphocyte and neutrophil counts in patients with relapsing multiple sclerosis: results from the TOWER study. Journal of the Neurological Sciences2013;333:e376. ConfavreuxC , O'ConnorP , ComiG , FreedmanMS , MillerAE , OlssonTP , et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet Neurology2014;13(3):247‐56. KapposL , ComiG , ConfavreuxC , FreedmanMS , MillerAE , OlssonTP , et al. The efficacy and safety of teriflunomide in patients with relapsing MS: results from TOWER, a phase Ⅲ, placebo‐controlled study. Multiple Sclerosis2012;18:50‐1. MillerA , KapposL , ComiG , ConfavreuxC , FreedmanM , OlssonT , et al. Teriflunomide efficacy and safety in patients with relapsing multiple sclerosis: results from tower, a second, pivotal, phase 3 placebo‐controlled study. Neurology. 2013; Vol. 80. MillerAE , MacdonellR , ComiG , FreedmanMS , KapposL , MaurerM , et al. Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study. Journal of Neurology2014;261(9):1781‐8. MosesH , FreedmanM , KapposL , MillerA , OlssonT , WolinskyJ , et al. Pre‐defined subgroups analyses of tower, a placebo‐controlled phase 3 trial of teriflunomide in patients with relapsing multiple sclerosis. Proceedings of the American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). O'ConnorP , LublinF , WolinskyJ , ComiG , ConfavreuxC , FreedmanM , et al. Teriflunomide reduces relapse‐related sequelae, hospitalizations and corticosteroid use: a post‐HOC analysis of the phase 3 TOWER study. Proceedings of The American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). ">Confavreux 2014</a>), 36.4% (<a href="./references#CD009882-bbs2-0002" title="FreedmanMS , WolinskyJS , WamilB , ConfavreuxC , ComiG , KapposL , et al. Teriflunomide added to interferon‐β in relapsing multiple sclerosis: a randomized phase Ⅱ trial. Neurology2012;78(23):1877‐85. ">Freedman 2012</a>) and 100% (<a href="./references#CD009882-bbs2-0003" title="NCT01252355 . Efficacy and Safety of Teriflunomide in Patients with Relapsing Multiple Sclerosis and Treated with Interferon‐beta (TERACLES). www.clinicaltrials.gov/ct2/show/results/NCT01252355 (accessed 12 January 2016). ">NCT01252355</a>). <a href="./references#CD009882-bbs2-0004" title="ComiG , BenzerdjebH , WangL , TruffinetP , O'ConnorP . Effect of teriflunomide on lymphocyte and neutrophil levels in patients with relapsing multiple sclerosis: results from the TEMSO study. Journal of Neurological Science2013;333(Suppl 1):e376. ComiG , O'ConnorP , WolinskyJ , ConfavreuxC , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: safety outcomes with up to 4 years of follow‐Up. Multiple Sclerosis2011;17:S182‐3. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Long‐term safety and efficacy of teriflunomide in patients with relapsing forms of multiple sclerosis in the TEMSO extension trial. Multiple Sclerosis2013;19:225. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Safety and efficacy of teriflunomide for up to 9 years in relapsing forms of multiple sclerosis: Update of the TEMSO extension trial. Neurology2014; Vol. 82, issue Suppl 10:3‐150. FreedmanMS , DelhayJL , BenamorM . Gastrointestinal symptoms infrequently lead to discontinuation of teriflunomide therapy. Multiple Sclerosis2012;18:S13. MillerA , LublinF , O'ConnorP , TaniouC , Dive‐PoulettyC . Impact of relapses with sequelae on disability, health‐related quality of life, and fatigue in a population with relapsing forms of multiple sclerosis using data from TEMSO, a pivotal phase Ⅲ teriflunomide trial. Neurology2012;78:P07.082. MillerA , LublinF , O'ConnorP , WolinskyJ , ComiG , KapposL , et al. Effect of teriflunomide on relapses with sequelae and relapse leading to hospitalization in a population with relapsing forms of multiple sclerosis: results from the TEMSO study. Neurology2012;78:S30.003. MillerA , O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , et al. Efficacy of oral teriflunomide in multiple sclerosis with relapses: cognitive outcomes from a phase Ⅲ trial (TEMSO). Multiple Sclerosis2011;17:S182. MillerAE , O'ConnorP , WolinskyJS , ConfavreuxC , KapposL , OlssonTP , et al. Pre‐specified subgroup analyses of a placebo‐controlled phase Ⅲ trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis. Multiple Sclerosis2012;18(11):1625‐32. O'ConnorP , BriggsA , CaritaP , Bego‐Le‐BagousseG . Impact on health‐related quality of life of teriflunomide treatment by estimating utilities in patients with relapsing multiple sclerosis: results from TEMSO post hoc analysis. Journal of Neurology2012;259:S107. O'ConnorP , BurrellA , WangL , WeiL , CaritaP , ZhangQ . Effect of teriflunomide on longitudinal patterns of relapse and relapse‐related hospitalization in multiple sclerosis. Multiple Sclerosis2011;17:S414. O'ConnorP , LublinF , WolinskyJ , ComiG , KapposL , FreedmanM , et al. Effect of teriflunomide on relapses leading to healthcare resource use: results from the TEMSO study. Multiple Sclerosis2011;17:S95‐6. O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: clinical and MRI data 5 years after initial randomization. Multiple Sclerosis2011;17:S414‐5. O'ConnorP , WolinskyJS , ConfavreuxC , ComiG , KapposL , OlssonTP , et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. New England Journal of Medicine2011;365(14):1293‐303. O'ConnorPW , LublinFD , WolinskyJS , ConfavreuxC , ComiG , FreedmanMS , et al. Teriflunomide reduces relapse‐related neurological sequelae, hospitalizations and steroid use. Journal of Neurology2013;260(10):2472‐80. WolinksyJS , WangL , TruffinetP , NarayanaPA , NelsonF , O'ConnorP . Magnetic resonance imaging as a surrogate for clinical endpoints in multiple sclerosis. Multiple Sclerosis2012;18:470‐1. WolinskyJS , NarayanaPA , NelsonF , DattaS , O'ConnorP , ConfavreuxC , et al. Magnetic resonance imaging outcomes from a phase Ⅲ trial of teriflunomide. Multiple Sclerosis2013;19(10):1310‐9. ">O'Connor 2011</a> and <a href="./references#CD009882-bbs2-0005" title="VermerschP , CzlonkowskaA , GrimaldiLM , ConfavreuxC , ComiG , KapposL , et al. A multicenter, randomized, parallel‐group, rater‐blinded study comparing the effectiveness and safety of teriflunomide and subcutaneous interferon beta‐1a in patients with relapsing multiple sclerosis. Multiple Sclerosis2012;18:S9‐10. VermerschP , CzlonkowskaA , GrimaldiLM , ConfavreuxC , ComiG , KapposL , et al. Evaluation of patient satisfaction from the TENERE study: a comparison of teriflunomide and subcutaneous interferon beta‐1a in patients with relapsing multiple sclerosis. Journal of Neurology2012;259:S38. VermerschP , CzlonkowskaA , GrimaldiLM , ConfavreuxC , ComiG , KapposL , et al. Teriflunomide versus subcutaneous interferon beta‐1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial. Multiple Sclerosis2014;20(6):705‐16. ">Vermersch 2014</a> had an unclear risk of attrition bias. <a href="./references#CD009882-bbs2-0002" title="FreedmanMS , WolinskyJS , WamilB , ConfavreuxC , ComiG , KapposL , et al. Teriflunomide added to interferon‐β in relapsing multiple sclerosis: a randomized phase Ⅱ trial. Neurology2012;78(23):1877‐85. ">Freedman 2012</a>, <a href="./references#CD009882-bbs2-0003" title="NCT01252355 . Efficacy and Safety of Teriflunomide in Patients with Relapsing Multiple Sclerosis and Treated with Interferon‐beta (TERACLES). www.clinicaltrials.gov/ct2/show/results/NCT01252355 (accessed 12 January 2016). ">NCT01252355</a>, and <a href="./references#CD009882-bbs2-0005" title="VermerschP , CzlonkowskaA , GrimaldiLM , ConfavreuxC , ComiG , KapposL , et al. A multicenter, randomized, parallel‐group, rater‐blinded study comparing the effectiveness and safety of teriflunomide and subcutaneous interferon beta‐1a in patients with relapsing multiple sclerosis. Multiple Sclerosis2012;18:S9‐10. VermerschP , CzlonkowskaA , GrimaldiLM , ConfavreuxC , ComiG , KapposL , et al. Evaluation of patient satisfaction from the TENERE study: a comparison of teriflunomide and subcutaneous interferon beta‐1a in patients with relapsing multiple sclerosis. Journal of Neurology2012;259:S38. VermerschP , CzlonkowskaA , GrimaldiLM , ConfavreuxC , ComiG , KapposL , et al. Teriflunomide versus subcutaneous interferon beta‐1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial. Multiple Sclerosis2014;20(6):705‐16. ">Vermersch 2014</a>had a high risk for performance bias and a lack of power due to the limited sample. The data at one year in <a href="./references#CD009882-bbs2-0004" title="ComiG , BenzerdjebH , WangL , TruffinetP , O'ConnorP . Effect of teriflunomide on lymphocyte and neutrophil levels in patients with relapsing multiple sclerosis: results from the TEMSO study. Journal of Neurological Science2013;333(Suppl 1):e376. ComiG , O'ConnorP , WolinskyJ , ConfavreuxC , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: safety outcomes with up to 4 years of follow‐Up. Multiple Sclerosis2011;17:S182‐3. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Long‐term safety and efficacy of teriflunomide in patients with relapsing forms of multiple sclerosis in the TEMSO extension trial. Multiple Sclerosis2013;19:225. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Safety and efficacy of teriflunomide for up to 9 years in relapsing forms of multiple sclerosis: Update of the TEMSO extension trial. Neurology2014; Vol. 82, issue Suppl 10:3‐150. FreedmanMS , DelhayJL , BenamorM . Gastrointestinal symptoms infrequently lead to discontinuation of teriflunomide therapy. Multiple Sclerosis2012;18:S13. MillerA , LublinF , O'ConnorP , TaniouC , Dive‐PoulettyC . Impact of relapses with sequelae on disability, health‐related quality of life, and fatigue in a population with relapsing forms of multiple sclerosis using data from TEMSO, a pivotal phase Ⅲ teriflunomide trial. Neurology2012;78:P07.082. MillerA , LublinF , O'ConnorP , WolinskyJ , ComiG , KapposL , et al. Effect of teriflunomide on relapses with sequelae and relapse leading to hospitalization in a population with relapsing forms of multiple sclerosis: results from the TEMSO study. Neurology2012;78:S30.003. MillerA , O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , et al. Efficacy of oral teriflunomide in multiple sclerosis with relapses: cognitive outcomes from a phase Ⅲ trial (TEMSO). Multiple Sclerosis2011;17:S182. MillerAE , O'ConnorP , WolinskyJS , ConfavreuxC , KapposL , OlssonTP , et al. Pre‐specified subgroup analyses of a placebo‐controlled phase Ⅲ trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis. Multiple Sclerosis2012;18(11):1625‐32. O'ConnorP , BriggsA , CaritaP , Bego‐Le‐BagousseG . Impact on health‐related quality of life of teriflunomide treatment by estimating utilities in patients with relapsing multiple sclerosis: results from TEMSO post hoc analysis. Journal of Neurology2012;259:S107. O'ConnorP , BurrellA , WangL , WeiL , CaritaP , ZhangQ . Effect of teriflunomide on longitudinal patterns of relapse and relapse‐related hospitalization in multiple sclerosis. Multiple Sclerosis2011;17:S414. O'ConnorP , LublinF , WolinskyJ , ComiG , KapposL , FreedmanM , et al. Effect of teriflunomide on relapses leading to healthcare resource use: results from the TEMSO study. Multiple Sclerosis2011;17:S95‐6. O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: clinical and MRI data 5 years after initial randomization. Multiple Sclerosis2011;17:S414‐5. O'ConnorP , WolinskyJS , ConfavreuxC , ComiG , KapposL , OlssonTP , et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. New England Journal of Medicine2011;365(14):1293‐303. O'ConnorPW , LublinFD , WolinskyJS , ConfavreuxC , ComiG , FreedmanMS , et al. Teriflunomide reduces relapse‐related neurological sequelae, hospitalizations and steroid use. Journal of Neurology2013;260(10):2472‐80. WolinksyJS , WangL , TruffinetP , NarayanaPA , NelsonF , O'ConnorP . Magnetic resonance imaging as a surrogate for clinical endpoints in multiple sclerosis. Multiple Sclerosis2012;18:470‐1. WolinskyJS , NarayanaPA , NelsonF , DattaS , O'ConnorP , ConfavreuxC , et al. Magnetic resonance imaging outcomes from a phase Ⅲ trial of teriflunomide. Multiple Sclerosis2013;19(10):1310‐9. ">O'Connor 2011</a> were not available. As a result, we could not conduct meta‐analyses. We calculated the treatment effects of interventions based on the available data in the original studies. </p> <p>Compared to placebo, administration of teriflunomide at a dose of 7 mg/day or 14 mg/day as monotherapy reduced the number of participants with relapse by one year or by two years, as well as the annualized relapse rate by two years. Both doses of teriflunomide as monotherapy reduced the number of gadolinium‐enhancing T1‐weighted lesions by two years, However, only teriflunomide at a dose of 14 mg/day as monotherapy significantly reduced the number of participants with disability progression and delayed the progression of disability by one year and two years. High dose rather than low dose of teriflunomide as monotherapy reduced the volume of hypointense lesions on T1‐weighted images by two years. Neither doses of teriflunomide improved QoL measured by SF‐36 scores by one year. When taking the effect of drop‐outs into consideration, the likely‐case scenario analyses still showed a benefit in reducing the number of participants with relapse, but not for the number of participants with disability progression. When administrated as combination therapy with IFNβ for one year, neither doses of teriflunomide added to IFNβ were superior to placebo added to IFNβ concerning annualized relapse rate and the number of gadolinium‐enhancing T1‐weighted lesions. When compared to IFNβ‐1a, low‐dose teriflunomide was inferior to IFNβ‐1a in respect of the annualized relapse rate and the number of participants with relapse, but there was no difference for high‐dose teriflunomide. </p> <p>Overall, the risks for AEs and SAEs in participants receiving teriflunomide were similar to those in participants receiving placebo both at one year and two years of follow‐up. However, the risks for study drug discontinuation due to AEs were increased by both doses of teriflunomide administration at one year of follow‐up, but not at two years of follow‐up. The most common<br/> AEs associated with teriflunomide included diarrhoea, nausea, hair thinning, elevated ALT levels, neutropenia and lymphopenia. These AEs rarely led to discontinuation of the study medication, but did have a dose‐related effect. </p> </section> <section id="CD009882-sec-0077"> <h3 class="title" id="CD009882-sec-0077">Overall completeness and applicability of evidence</h3> <p>In this review, we excluded one RCT due to length of follow‐up shorter than one year. Generally, DMT for MS needs an adequate administration duration and follow‐up to determine the benefit and safety outcomes accurately. A minimum duration of administration of one year, pre‐defined in the criteria of types of interventions, was a reasonable treatment length that partly avoided the inclusion of misleading evidence. We did not perform meta‐analyses due to the diversities in the study design and interventions. Two large‐scale RCTs contributed to the main evidence for this review. The evidence was only applicable to adults with relapsing MS, who had a score of less than 5.5 on the EDSS and disease activity with at least one relapse in the previous year or at least two clinical relapses in the previous two years. </p> </section> <section id="CD009882-sec-0078"> <h3 class="title" id="CD009882-sec-0078">Quality of the evidence</h3> <p>We included five RCTs in this review, involving 3231 adults with relapsing MS to evaluate mainly the benefit and safety of two doses of teriflunomide (7 mg/day and 14 mg/day) as monotherapy or combination therapy with IFNβ by direct comparison with placebo or IFNβ‐1a. Overall, there were obvious clinical heterogeneities due to the diversities in study designs or interventions and methodological heterogeneities across studies. All studies had a high risk of detection bias for relapse assessment and a high risk of bias due to conflicts of interest. Among them, three studies also had a high risk of attrition bias due to a high dropout rate and two studies had an unclear risk of attrition bias. Generally, the higher the ratio of participants with missing data to participants with events, the greater potential there is for bias, especially for the high frequency of events. The potential impact of missing continuous outcomes increases with the proportion of participants with missing data. In addition, the studies of combination therapy with IFNβ and the study with IFNβ‐1a as controls also had a high risk of performance bias and a lack of power due to the limited sample. The evidence in this review was mainly derived from the two large‐scale RCTs, in which the high risk of bias lead to low‐quality evidence for the results of relapse. The results of disability progression were also subjected to a serious indirectness of evidence because disability progression was confirmed in less than six months in both studies. The evidence for disability progression was very low. </p> </section> <section id="CD009882-sec-0079"> <h3 class="title" id="CD009882-sec-0079">Potential biases in the review process</h3> <p>An extensive and comprehensive search was undertaken to limit bias in the review process. The two review authors' independent assessments of the eligibility of studies for inclusion in this review and extraction of data minimized the potential for additional bias beyond that detailed in the 'Risk of bias' tables. The review authors had no conflicts of interest. </p> </section> <section id="CD009882-sec-0080"> <h3 class="title" id="CD009882-sec-0080">Agreements and disagreements with other studies or reviews</h3> <p>There are three network meta‐analyses that compared the benefit or acceptability of teriflunomide and other DMDs by mixed treatment comparison (<a href="./references#CD009882-bbs2-0017" title="HadjigeorgiouGM , DoxaniC , MiligkosM , ZiakasP , BakalosG , PapadimitriouD , et al. A network meta‐analysis of randomized controlled trials for comparing the effectiveness and safety profile of treatments with marketing authorization for relapsing multiple sclerosis. Journal of Clinical Pharmacy and Therapeutics2013;38(6):433‐9. ">Hadjigeorgiou 2013</a>; <a href="./references#CD009882-bbs2-0039" title="TramacereI , DelGiovaneC , SalantiG , D'AmicoR , FilippiniG . Immunomodulators and immunosuppressants for relapsing‐remitting multiple sclerosis: a network meta‐analysis. Cochrane Database of Systematic Reviews2015, Issue 9. [DOI: 10.1002/14651858.CD011381] ">Tramacere 2015</a>; <a href="./references#CD009882-bbs2-0045" title="ZagmuttFJ , CarrollCA . Meta‐analysis of adverse events in recent randomized clinical trials for dimethyl fumarate, glatiramer acetate and teriflunomide for the treatment of relapsing forms of multiple sclerosis. International Journal of Neuroscience2015;125(11):798‐807. ">Zagmutt 2015</a>). We have found no other systematic review on teriflunomide for MS that used only direct head‐to‐head comparisons. In this systematic review, our extensive and comprehensive search found only one RCT comparing teriflunomide to other DMDs, and it was very low‐quality. There was a lack of evidence to show the comparative benefit and safety of teriflunomide in comparison with other DMDs. As with the results of the network meta‐analyses, this systematic review also emphasized the need for randomized trials of direct comparisons between teriflunomide and other active agents. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD009882-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009882.pub3/media/CDSR/CD009882/urn:x-wiley:14651858:media:CD009882:CD009882-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009882.pub3/media/CDSR/CD009882/image_t/tCD009882-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD009882-fig-0001" src="/cdsr/doi/10.1002/14651858.CD009882.pub3/media/CDSR/CD009882/image_n/nCD009882-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009882.pub3/full#CD009882-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009882.pub3/media/CDSR/CD009882/image_n/nCD009882-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009882-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009882.pub3/media/CDSR/CD009882/urn:x-wiley:14651858:media:CD009882:CD009882-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009882.pub3/media/CDSR/CD009882/image_t/tCD009882-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD009882-fig-0002" src="/cdsr/doi/10.1002/14651858.CD009882.pub3/media/CDSR/CD009882/image_n/nCD009882-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009882.pub3/full#CD009882-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009882.pub3/media/CDSR/CD009882/image_n/nCD009882-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009882-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009882.pub3/media/CDSR/CD009882/urn:x-wiley:14651858:media:CD009882:CD009882-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009882.pub3/media/CDSR/CD009882/image_t/tCD009882-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD009882-fig-0003" src="/cdsr/doi/10.1002/14651858.CD009882.pub3/media/CDSR/CD009882/image_n/nCD009882-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009882.pub3/full#CD009882-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009882.pub3/media/CDSR/CD009882/image_n/nCD009882-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD009882-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Teriflunomide compared to placebo for multiple sclerosis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Teriflunomide compared to placebo for multiple sclerosis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with relapsing multiple sclerosis<br/> <b>Settings:</b> US, Austria, France, Canada, Germany, UK, Sweden, Netherlands, Turkey, Poland, Chile, Ukraine, China, Italy, Australia, etc.<br/> <b>Intervention:</b> teriflunomide at a dose of 14 mg orally once daily<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Teriflunomide</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of participants with at least 1 relapse at 1 year</b> <br/> Follow‐up: 1 year </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>394 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>237 per 1000</b> <br/> (189 to 296) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.60</b> <br/> (0.48 to 0.75) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>761<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>This outcome was considered low, because we considered there were very serious limitation in study design and execution. The bias that influenced the validity of the results for this outcome included: the high risks of bias due to unblinded assessments for relapse and conflicts of interest (sensitivity analysis according to a likely‐case scenario showed a robustness for the results of this outcome, we considered that the high attrition bias did not influence the robustness of the results on relapse). Therefore, we downgraded the quality of evidence for this outcome by 2 levels </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>The proportion of participants with at least 1 relapse at 2 years</b> <br/> Follow‐up: 2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>545 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>436 per 1000</b> <br/> (376 to 507) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.80</b> <br/> (0.69 to 0.93) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>722<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>This outcome was considered low, because we considered there were very serious limitation in study design and execution. The bias that influenced the validity of the results for this outcome included: the high risks of bias due to unblinded assessments for relapse and conflicts of interest. (Sensitivity analysis according to a likely‐case scenario showed a robustness for the results of this outcome, we considered that the unclear attrition bias did not influence the robustness of the results on relapse.) Therefore, we downgraded the quality of evidence for this outcome by 2 levels </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>The proportion of participants with disability progression at 1 year</b> <br/> Follow‐up: 1 year </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>142 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>78 per 1000</b> <br/> (51 to 119) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.55</b> <br/> (0.36 to 0.84) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>761<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>c,e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was considered very low based on the following reasons:</p> <p> <ul id="CD009882-list-0001"> <li> <p>we considered there were very serious limitation in study design and execution. The bias that influenced the validity of the results for this outcome included: the high risks of bias due to the high attrition bias and conflicts of interest. Sensitivity analysis according to a likely‐case scenario showed an unsteadiness for the results of this outcome, we considered that the high attrition bias influenced the robustness of the results on progression disability. Therefore, we downgraded the quality of evidence for this outcome by 2 levels </p> </li> <li> <p>This outcome was an indirect outcome because disability progression was confirmed at 3 months of follow‐up. We had serious doubts about directness. Therefore, we downgraded the quality of evidence for this outcome by 1 level </p> </li> </ul> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>The proportion of participants with disability progression at 2 years</b> <br/> Follow‐up: 2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>273 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>202 per 1000</b> <br/> (153 to 262) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.74</b> <br/> (0.56 to 0.96) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>722<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>d,e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was considered very low based on the following reasons:</p> <p> <ul id="CD009882-list-0002"> <li> <p>We considered there were very serious limitation in study design and execution. The bias that influenced the validity of the results for this outcome included: the high risks of bias due to unclear attrition bias and conflicts of interest. Sensitivity analysis according to a likely‐case scenario showed an unsteadiness for the results of this outcome, we considered that the unclear attrition bias influenced the robustness of the results on progression disability. Therefore, we downgraded the quality of evidence for this outcome by 2 levels </p> </li> <li> <p>This outcome was an indirect outcome because disability progression was confirmed at 3 months of follow‐up. We had serious doubts about directness. Therefore, we downgraded the quality of evidence for this outcome by 1 level </p> </li> </ul> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>The proportion of participants with diarrhoea at 2 years</b> <br/> Follow‐up: 2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>89 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>179 per 1000</b> <br/> (120 to 267) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.01</b> <br/> (1.35 to 3.00) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>718<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>f</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The follow‐up periods were diverse in <a href="./references#CD009882-bbs2-0001" title="ComiG , FreedmanMS , KapposL , MillerA , OlssonTP , WolinskyJS , et al. Effect of teriflunomide on lymphocyte and neutrophil counts in patients with relapsing multiple sclerosis: results from the TOWER study. Journal of the Neurological Sciences2013;333:e376. ConfavreuxC , O'ConnorP , ComiG , FreedmanMS , MillerAE , OlssonTP , et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet Neurology2014;13(3):247‐56. KapposL , ComiG , ConfavreuxC , FreedmanMS , MillerAE , OlssonTP , et al. The efficacy and safety of teriflunomide in patients with relapsing MS: results from TOWER, a phase Ⅲ, placebo‐controlled study. Multiple Sclerosis2012;18:50‐1. MillerA , KapposL , ComiG , ConfavreuxC , FreedmanM , OlssonT , et al. Teriflunomide efficacy and safety in patients with relapsing multiple sclerosis: results from tower, a second, pivotal, phase 3 placebo‐controlled study. Neurology. 2013; Vol. 80. MillerAE , MacdonellR , ComiG , FreedmanMS , KapposL , MaurerM , et al. Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study. Journal of Neurology2014;261(9):1781‐8. MosesH , FreedmanM , KapposL , MillerA , OlssonT , WolinskyJ , et al. Pre‐defined subgroups analyses of tower, a placebo‐controlled phase 3 trial of teriflunomide in patients with relapsing multiple sclerosis. Proceedings of the American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). O'ConnorP , LublinF , WolinskyJ , ComiG , ConfavreuxC , FreedmanM , et al. Teriflunomide reduces relapse‐related sequelae, hospitalizations and corticosteroid use: a post‐HOC analysis of the phase 3 TOWER study. Proceedings of The American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). ">Confavreux 2014</a> and <a href="./references#CD009882-bbs2-0004" title="ComiG , BenzerdjebH , WangL , TruffinetP , O'ConnorP . Effect of teriflunomide on lymphocyte and neutrophil levels in patients with relapsing multiple sclerosis: results from the TEMSO study. Journal of Neurological Science2013;333(Suppl 1):e376. ComiG , O'ConnorP , WolinskyJ , ConfavreuxC , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: safety outcomes with up to 4 years of follow‐Up. Multiple Sclerosis2011;17:S182‐3. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Long‐term safety and efficacy of teriflunomide in patients with relapsing forms of multiple sclerosis in the TEMSO extension trial. Multiple Sclerosis2013;19:225. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Safety and efficacy of teriflunomide for up to 9 years in relapsing forms of multiple sclerosis: Update of the TEMSO extension trial. Neurology2014; Vol. 82, issue Suppl 10:3‐150. FreedmanMS , DelhayJL , BenamorM . Gastrointestinal symptoms infrequently lead to discontinuation of teriflunomide therapy. Multiple Sclerosis2012;18:S13. MillerA , LublinF , O'ConnorP , TaniouC , Dive‐PoulettyC . Impact of relapses with sequelae on disability, health‐related quality of life, and fatigue in a population with relapsing forms of multiple sclerosis using data from TEMSO, a pivotal phase Ⅲ teriflunomide trial. Neurology2012;78:P07.082. MillerA , LublinF , O'ConnorP , WolinskyJ , ComiG , KapposL , et al. Effect of teriflunomide on relapses with sequelae and relapse leading to hospitalization in a population with relapsing forms of multiple sclerosis: results from the TEMSO study. Neurology2012;78:S30.003. MillerA , O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , et al. Efficacy of oral teriflunomide in multiple sclerosis with relapses: cognitive outcomes from a phase Ⅲ trial (TEMSO). Multiple Sclerosis2011;17:S182. MillerAE , O'ConnorP , WolinskyJS , ConfavreuxC , KapposL , OlssonTP , et al. Pre‐specified subgroup analyses of a placebo‐controlled phase Ⅲ trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis. Multiple Sclerosis2012;18(11):1625‐32. O'ConnorP , BriggsA , CaritaP , Bego‐Le‐BagousseG . Impact on health‐related quality of life of teriflunomide treatment by estimating utilities in patients with relapsing multiple sclerosis: results from TEMSO post hoc analysis. Journal of Neurology2012;259:S107. O'ConnorP , BurrellA , WangL , WeiL , CaritaP , ZhangQ . Effect of teriflunomide on longitudinal patterns of relapse and relapse‐related hospitalization in multiple sclerosis. Multiple Sclerosis2011;17:S414. O'ConnorP , LublinF , WolinskyJ , ComiG , KapposL , FreedmanM , et al. Effect of teriflunomide on relapses leading to healthcare resource use: results from the TEMSO study. Multiple Sclerosis2011;17:S95‐6. O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: clinical and MRI data 5 years after initial randomization. Multiple Sclerosis2011;17:S414‐5. O'ConnorP , WolinskyJS , ConfavreuxC , ComiG , KapposL , OlssonTP , et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. New England Journal of Medicine2011;365(14):1293‐303. O'ConnorPW , LublinFD , WolinskyJS , ConfavreuxC , ComiG , FreedmanMS , et al. Teriflunomide reduces relapse‐related neurological sequelae, hospitalizations and steroid use. Journal of Neurology2013;260(10):2472‐80. WolinksyJS , WangL , TruffinetP , NarayanaPA , NelsonF , O'ConnorP . Magnetic resonance imaging as a surrogate for clinical endpoints in multiple sclerosis. Multiple Sclerosis2012;18:470‐1. WolinskyJS , NarayanaPA , NelsonF , DattaS , O'ConnorP , ConfavreuxC , et al. Magnetic resonance imaging outcomes from a phase Ⅲ trial of teriflunomide. Multiple Sclerosis2013;19(10):1310‐9. ">O'Connor 2011</a> (at least 48 weeks (<a href="./references#CD009882-bbs2-0001" title="ComiG , FreedmanMS , KapposL , MillerA , OlssonTP , WolinskyJS , et al. Effect of teriflunomide on lymphocyte and neutrophil counts in patients with relapsing multiple sclerosis: results from the TOWER study. Journal of the Neurological Sciences2013;333:e376. ConfavreuxC , O'ConnorP , ComiG , FreedmanMS , MillerAE , OlssonTP , et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet Neurology2014;13(3):247‐56. KapposL , ComiG , ConfavreuxC , FreedmanMS , MillerAE , OlssonTP , et al. The efficacy and safety of teriflunomide in patients with relapsing MS: results from TOWER, a phase Ⅲ, placebo‐controlled study. Multiple Sclerosis2012;18:50‐1. MillerA , KapposL , ComiG , ConfavreuxC , FreedmanM , OlssonT , et al. Teriflunomide efficacy and safety in patients with relapsing multiple sclerosis: results from tower, a second, pivotal, phase 3 placebo‐controlled study. Neurology. 2013; Vol. 80. MillerAE , MacdonellR , ComiG , FreedmanMS , KapposL , MaurerM , et al. Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study. Journal of Neurology2014;261(9):1781‐8. MosesH , FreedmanM , KapposL , MillerA , OlssonT , WolinskyJ , et al. Pre‐defined subgroups analyses of tower, a placebo‐controlled phase 3 trial of teriflunomide in patients with relapsing multiple sclerosis. Proceedings of the American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). O'ConnorP , LublinF , WolinskyJ , ComiG , ConfavreuxC , FreedmanM , et al. Teriflunomide reduces relapse‐related sequelae, hospitalizations and corticosteroid use: a post‐HOC analysis of the phase 3 TOWER study. Proceedings of The American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). ">Confavreux 2014</a>) and 108 weeks (<a href="./references#CD009882-bbs2-0004" title="ComiG , BenzerdjebH , WangL , TruffinetP , O'ConnorP . Effect of teriflunomide on lymphocyte and neutrophil levels in patients with relapsing multiple sclerosis: results from the TEMSO study. Journal of Neurological Science2013;333(Suppl 1):e376. ComiG , O'ConnorP , WolinskyJ , ConfavreuxC , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: safety outcomes with up to 4 years of follow‐Up. Multiple Sclerosis2011;17:S182‐3. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Long‐term safety and efficacy of teriflunomide in patients with relapsing forms of multiple sclerosis in the TEMSO extension trial. Multiple Sclerosis2013;19:225. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Safety and efficacy of teriflunomide for up to 9 years in relapsing forms of multiple sclerosis: Update of the TEMSO extension trial. Neurology2014; Vol. 82, issue Suppl 10:3‐150. FreedmanMS , DelhayJL , BenamorM . Gastrointestinal symptoms infrequently lead to discontinuation of teriflunomide therapy. Multiple Sclerosis2012;18:S13. MillerA , LublinF , O'ConnorP , TaniouC , Dive‐PoulettyC . Impact of relapses with sequelae on disability, health‐related quality of life, and fatigue in a population with relapsing forms of multiple sclerosis using data from TEMSO, a pivotal phase Ⅲ teriflunomide trial. Neurology2012;78:P07.082. MillerA , LublinF , O'ConnorP , WolinskyJ , ComiG , KapposL , et al. Effect of teriflunomide on relapses with sequelae and relapse leading to hospitalization in a population with relapsing forms of multiple sclerosis: results from the TEMSO study. Neurology2012;78:S30.003. MillerA , O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , et al. Efficacy of oral teriflunomide in multiple sclerosis with relapses: cognitive outcomes from a phase Ⅲ trial (TEMSO). Multiple Sclerosis2011;17:S182. MillerAE , O'ConnorP , WolinskyJS , ConfavreuxC , KapposL , OlssonTP , et al. Pre‐specified subgroup analyses of a placebo‐controlled phase Ⅲ trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis. Multiple Sclerosis2012;18(11):1625‐32. O'ConnorP , BriggsA , CaritaP , Bego‐Le‐BagousseG . Impact on health‐related quality of life of teriflunomide treatment by estimating utilities in patients with relapsing multiple sclerosis: results from TEMSO post hoc analysis. Journal of Neurology2012;259:S107. O'ConnorP , BurrellA , WangL , WeiL , CaritaP , ZhangQ . Effect of teriflunomide on longitudinal patterns of relapse and relapse‐related hospitalization in multiple sclerosis. Multiple Sclerosis2011;17:S414. O'ConnorP , LublinF , WolinskyJ , ComiG , KapposL , FreedmanM , et al. Effect of teriflunomide on relapses leading to healthcare resource use: results from the TEMSO study. Multiple Sclerosis2011;17:S95‐6. O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: clinical and MRI data 5 years after initial randomization. Multiple Sclerosis2011;17:S414‐5. O'ConnorP , WolinskyJS , ConfavreuxC , ComiG , KapposL , OlssonTP , et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. New England Journal of Medicine2011;365(14):1293‐303. O'ConnorPW , LublinFD , WolinskyJS , ConfavreuxC , ComiG , FreedmanMS , et al. Teriflunomide reduces relapse‐related neurological sequelae, hospitalizations and steroid use. Journal of Neurology2013;260(10):2472‐80. WolinksyJS , WangL , TruffinetP , NarayanaPA , NelsonF , O'ConnorP . Magnetic resonance imaging as a surrogate for clinical endpoints in multiple sclerosis. Multiple Sclerosis2012;18:470‐1. WolinskyJS , NarayanaPA , NelsonF , DattaS , O'ConnorP , ConfavreuxC , et al. Magnetic resonance imaging outcomes from a phase Ⅲ trial of teriflunomide. Multiple Sclerosis2013;19(10):1310‐9. ">O'Connor 2011</a>)). Treatment duration of participants in <a href="./references#CD009882-bbs2-0001" title="ComiG , FreedmanMS , KapposL , MillerA , OlssonTP , WolinskyJS , et al. Effect of teriflunomide on lymphocyte and neutrophil counts in patients with relapsing multiple sclerosis: results from the TOWER study. Journal of the Neurological Sciences2013;333:e376. ConfavreuxC , O'ConnorP , ComiG , FreedmanMS , MillerAE , OlssonTP , et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet Neurology2014;13(3):247‐56. KapposL , ComiG , ConfavreuxC , FreedmanMS , MillerAE , OlssonTP , et al. The efficacy and safety of teriflunomide in patients with relapsing MS: results from TOWER, a phase Ⅲ, placebo‐controlled study. Multiple Sclerosis2012;18:50‐1. MillerA , KapposL , ComiG , ConfavreuxC , FreedmanM , OlssonT , et al. Teriflunomide efficacy and safety in patients with relapsing multiple sclerosis: results from tower, a second, pivotal, phase 3 placebo‐controlled study. Neurology. 2013; Vol. 80. MillerAE , MacdonellR , ComiG , FreedmanMS , KapposL , MaurerM , et al. Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study. Journal of Neurology2014;261(9):1781‐8. MosesH , FreedmanM , KapposL , MillerA , OlssonT , WolinskyJ , et al. Pre‐defined subgroups analyses of tower, a placebo‐controlled phase 3 trial of teriflunomide in patients with relapsing multiple sclerosis. Proceedings of the American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). O'ConnorP , LublinF , WolinskyJ , ComiG , ConfavreuxC , FreedmanM , et al. Teriflunomide reduces relapse‐related sequelae, hospitalizations and corticosteroid use: a post‐HOC analysis of the phase 3 TOWER study. Proceedings of The American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). ">Confavreux 2014</a> was variable, ending 48 weeks after the last participant was included (a maximum treatment duration of 173 weeks). Actually, the data on adverse events in <a href="./references#CD009882-bbs2-0001" title="ComiG , FreedmanMS , KapposL , MillerA , OlssonTP , WolinskyJS , et al. Effect of teriflunomide on lymphocyte and neutrophil counts in patients with relapsing multiple sclerosis: results from the TOWER study. Journal of the Neurological Sciences2013;333:e376. ConfavreuxC , O'ConnorP , ComiG , FreedmanMS , MillerAE , OlssonTP , et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet Neurology2014;13(3):247‐56. KapposL , ComiG , ConfavreuxC , FreedmanMS , MillerAE , OlssonTP , et al. The efficacy and safety of teriflunomide in patients with relapsing MS: results from TOWER, a phase Ⅲ, placebo‐controlled study. Multiple Sclerosis2012;18:50‐1. MillerA , KapposL , ComiG , ConfavreuxC , FreedmanM , OlssonT , et al. Teriflunomide efficacy and safety in patients with relapsing multiple sclerosis: results from tower, a second, pivotal, phase 3 placebo‐controlled study. Neurology. 2013; Vol. 80. MillerAE , MacdonellR , ComiG , FreedmanMS , KapposL , MaurerM , et al. Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study. Journal of Neurology2014;261(9):1781‐8. MosesH , FreedmanM , KapposL , MillerA , OlssonT , WolinskyJ , et al. Pre‐defined subgroups analyses of tower, a placebo‐controlled phase 3 trial of teriflunomide in patients with relapsing multiple sclerosis. Proceedings of the American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). O'ConnorP , LublinF , WolinskyJ , ComiG , ConfavreuxC , FreedmanM , et al. Teriflunomide reduces relapse‐related sequelae, hospitalizations and corticosteroid use: a post‐HOC analysis of the phase 3 TOWER study. Proceedings of The American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). ">Confavreux 2014</a> were not at 2 years. There was a heterogeneity in follow‐up period between the studies. Therefore, we did not combine the data on adverse events in <a href="./references#CD009882-bbs2-0001" title="ComiG , FreedmanMS , KapposL , MillerA , OlssonTP , WolinskyJS , et al. Effect of teriflunomide on lymphocyte and neutrophil counts in patients with relapsing multiple sclerosis: results from the TOWER study. Journal of the Neurological Sciences2013;333:e376. ConfavreuxC , O'ConnorP , ComiG , FreedmanMS , MillerAE , OlssonTP , et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet Neurology2014;13(3):247‐56. KapposL , ComiG , ConfavreuxC , FreedmanMS , MillerAE , OlssonTP , et al. The efficacy and safety of teriflunomide in patients with relapsing MS: results from TOWER, a phase Ⅲ, placebo‐controlled study. Multiple Sclerosis2012;18:50‐1. MillerA , KapposL , ComiG , ConfavreuxC , FreedmanM , OlssonT , et al. Teriflunomide efficacy and safety in patients with relapsing multiple sclerosis: results from tower, a second, pivotal, phase 3 placebo‐controlled study. Neurology. 2013; Vol. 80. MillerAE , MacdonellR , ComiG , FreedmanMS , KapposL , MaurerM , et al. Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study. Journal of Neurology2014;261(9):1781‐8. MosesH , FreedmanM , KapposL , MillerA , OlssonT , WolinskyJ , et al. Pre‐defined subgroups analyses of tower, a placebo‐controlled phase 3 trial of teriflunomide in patients with relapsing multiple sclerosis. Proceedings of the American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). O'ConnorP , LublinF , WolinskyJ , ComiG , ConfavreuxC , FreedmanM , et al. Teriflunomide reduces relapse‐related sequelae, hospitalizations and corticosteroid use: a post‐HOC analysis of the phase 3 TOWER study. Proceedings of The American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). ">Confavreux 2014</a> and <a href="./references#CD009882-bbs2-0004" title="ComiG , BenzerdjebH , WangL , TruffinetP , O'ConnorP . Effect of teriflunomide on lymphocyte and neutrophil levels in patients with relapsing multiple sclerosis: results from the TEMSO study. Journal of Neurological Science2013;333(Suppl 1):e376. ComiG , O'ConnorP , WolinskyJ , ConfavreuxC , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: safety outcomes with up to 4 years of follow‐Up. Multiple Sclerosis2011;17:S182‐3. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Long‐term safety and efficacy of teriflunomide in patients with relapsing forms of multiple sclerosis in the TEMSO extension trial. Multiple Sclerosis2013;19:225. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Safety and efficacy of teriflunomide for up to 9 years in relapsing forms of multiple sclerosis: Update of the TEMSO extension trial. Neurology2014; Vol. 82, issue Suppl 10:3‐150. FreedmanMS , DelhayJL , BenamorM . Gastrointestinal symptoms infrequently lead to discontinuation of teriflunomide therapy. Multiple Sclerosis2012;18:S13. MillerA , LublinF , O'ConnorP , TaniouC , Dive‐PoulettyC . Impact of relapses with sequelae on disability, health‐related quality of life, and fatigue in a population with relapsing forms of multiple sclerosis using data from TEMSO, a pivotal phase Ⅲ teriflunomide trial. Neurology2012;78:P07.082. MillerA , LublinF , O'ConnorP , WolinskyJ , ComiG , KapposL , et al. Effect of teriflunomide on relapses with sequelae and relapse leading to hospitalization in a population with relapsing forms of multiple sclerosis: results from the TEMSO study. Neurology2012;78:S30.003. MillerA , O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , et al. Efficacy of oral teriflunomide in multiple sclerosis with relapses: cognitive outcomes from a phase Ⅲ trial (TEMSO). Multiple Sclerosis2011;17:S182. MillerAE , O'ConnorP , WolinskyJS , ConfavreuxC , KapposL , OlssonTP , et al. Pre‐specified subgroup analyses of a placebo‐controlled phase Ⅲ trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis. Multiple Sclerosis2012;18(11):1625‐32. O'ConnorP , BriggsA , CaritaP , Bego‐Le‐BagousseG . Impact on health‐related quality of life of teriflunomide treatment by estimating utilities in patients with relapsing multiple sclerosis: results from TEMSO post hoc analysis. Journal of Neurology2012;259:S107. O'ConnorP , BurrellA , WangL , WeiL , CaritaP , ZhangQ . Effect of teriflunomide on longitudinal patterns of relapse and relapse‐related hospitalization in multiple sclerosis. Multiple Sclerosis2011;17:S414. O'ConnorP , LublinF , WolinskyJ , ComiG , KapposL , FreedmanM , et al. Effect of teriflunomide on relapses leading to healthcare resource use: results from the TEMSO study. Multiple Sclerosis2011;17:S95‐6. O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: clinical and MRI data 5 years after initial randomization. Multiple Sclerosis2011;17:S414‐5. O'ConnorP , WolinskyJS , ConfavreuxC , ComiG , KapposL , OlssonTP , et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. New England Journal of Medicine2011;365(14):1293‐303. O'ConnorPW , LublinFD , WolinskyJS , ConfavreuxC , ComiG , FreedmanMS , et al. Teriflunomide reduces relapse‐related neurological sequelae, hospitalizations and steroid use. Journal of Neurology2013;260(10):2472‐80. WolinksyJS , WangL , TruffinetP , NarayanaPA , NelsonF , O'ConnorP . Magnetic resonance imaging as a surrogate for clinical endpoints in multiple sclerosis. Multiple Sclerosis2012;18:470‐1. WolinskyJS , NarayanaPA , NelsonF , DattaS , O'ConnorP , ConfavreuxC , et al. Magnetic resonance imaging outcomes from a phase Ⅲ trial of teriflunomide. Multiple Sclerosis2013;19(10):1310‐9. ">O'Connor 2011</a> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>The proportion of participants with hair thinning at 2 years</b> <br/> Follow‐up: 2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>33 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>131 per 1000</b> <br/> (71 to 243) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 3.94</b> <br/> (2.13 to 7.30) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>718<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>f</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The follow‐up periods were diverse in <a href="./references#CD009882-bbs2-0001" title="ComiG , FreedmanMS , KapposL , MillerA , OlssonTP , WolinskyJS , et al. Effect of teriflunomide on lymphocyte and neutrophil counts in patients with relapsing multiple sclerosis: results from the TOWER study. Journal of the Neurological Sciences2013;333:e376. ConfavreuxC , O'ConnorP , ComiG , FreedmanMS , MillerAE , OlssonTP , et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet Neurology2014;13(3):247‐56. KapposL , ComiG , ConfavreuxC , FreedmanMS , MillerAE , OlssonTP , et al. The efficacy and safety of teriflunomide in patients with relapsing MS: results from TOWER, a phase Ⅲ, placebo‐controlled study. Multiple Sclerosis2012;18:50‐1. MillerA , KapposL , ComiG , ConfavreuxC , FreedmanM , OlssonT , et al. Teriflunomide efficacy and safety in patients with relapsing multiple sclerosis: results from tower, a second, pivotal, phase 3 placebo‐controlled study. Neurology. 2013; Vol. 80. MillerAE , MacdonellR , ComiG , FreedmanMS , KapposL , MaurerM , et al. Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study. Journal of Neurology2014;261(9):1781‐8. MosesH , FreedmanM , KapposL , MillerA , OlssonT , WolinskyJ , et al. Pre‐defined subgroups analyses of tower, a placebo‐controlled phase 3 trial of teriflunomide in patients with relapsing multiple sclerosis. Proceedings of the American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). O'ConnorP , LublinF , WolinskyJ , ComiG , ConfavreuxC , FreedmanM , et al. Teriflunomide reduces relapse‐related sequelae, hospitalizations and corticosteroid use: a post‐HOC analysis of the phase 3 TOWER study. Proceedings of The American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). ">Confavreux 2014</a> and <a href="./references#CD009882-bbs2-0004" title="ComiG , BenzerdjebH , WangL , TruffinetP , O'ConnorP . Effect of teriflunomide on lymphocyte and neutrophil levels in patients with relapsing multiple sclerosis: results from the TEMSO study. Journal of Neurological Science2013;333(Suppl 1):e376. ComiG , O'ConnorP , WolinskyJ , ConfavreuxC , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: safety outcomes with up to 4 years of follow‐Up. Multiple Sclerosis2011;17:S182‐3. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Long‐term safety and efficacy of teriflunomide in patients with relapsing forms of multiple sclerosis in the TEMSO extension trial. Multiple Sclerosis2013;19:225. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Safety and efficacy of teriflunomide for up to 9 years in relapsing forms of multiple sclerosis: Update of the TEMSO extension trial. Neurology2014; Vol. 82, issue Suppl 10:3‐150. FreedmanMS , DelhayJL , BenamorM . Gastrointestinal symptoms infrequently lead to discontinuation of teriflunomide therapy. Multiple Sclerosis2012;18:S13. MillerA , LublinF , O'ConnorP , TaniouC , Dive‐PoulettyC . Impact of relapses with sequelae on disability, health‐related quality of life, and fatigue in a population with relapsing forms of multiple sclerosis using data from TEMSO, a pivotal phase Ⅲ teriflunomide trial. Neurology2012;78:P07.082. MillerA , LublinF , O'ConnorP , WolinskyJ , ComiG , KapposL , et al. Effect of teriflunomide on relapses with sequelae and relapse leading to hospitalization in a population with relapsing forms of multiple sclerosis: results from the TEMSO study. Neurology2012;78:S30.003. MillerA , O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , et al. Efficacy of oral teriflunomide in multiple sclerosis with relapses: cognitive outcomes from a phase Ⅲ trial (TEMSO). Multiple Sclerosis2011;17:S182. MillerAE , O'ConnorP , WolinskyJS , ConfavreuxC , KapposL , OlssonTP , et al. Pre‐specified subgroup analyses of a placebo‐controlled phase Ⅲ trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis. Multiple Sclerosis2012;18(11):1625‐32. O'ConnorP , BriggsA , CaritaP , Bego‐Le‐BagousseG . Impact on health‐related quality of life of teriflunomide treatment by estimating utilities in patients with relapsing multiple sclerosis: results from TEMSO post hoc analysis. Journal of Neurology2012;259:S107. O'ConnorP , BurrellA , WangL , WeiL , CaritaP , ZhangQ . Effect of teriflunomide on longitudinal patterns of relapse and relapse‐related hospitalization in multiple sclerosis. Multiple Sclerosis2011;17:S414. O'ConnorP , LublinF , WolinskyJ , ComiG , KapposL , FreedmanM , et al. Effect of teriflunomide on relapses leading to healthcare resource use: results from the TEMSO study. Multiple Sclerosis2011;17:S95‐6. O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: clinical and MRI data 5 years after initial randomization. Multiple Sclerosis2011;17:S414‐5. O'ConnorP , WolinskyJS , ConfavreuxC , ComiG , KapposL , OlssonTP , et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. New England Journal of Medicine2011;365(14):1293‐303. O'ConnorPW , LublinFD , WolinskyJS , ConfavreuxC , ComiG , FreedmanMS , et al. Teriflunomide reduces relapse‐related neurological sequelae, hospitalizations and steroid use. Journal of Neurology2013;260(10):2472‐80. WolinksyJS , WangL , TruffinetP , NarayanaPA , NelsonF , O'ConnorP . Magnetic resonance imaging as a surrogate for clinical endpoints in multiple sclerosis. Multiple Sclerosis2012;18:470‐1. WolinskyJS , NarayanaPA , NelsonF , DattaS , O'ConnorP , ConfavreuxC , et al. Magnetic resonance imaging outcomes from a phase Ⅲ trial of teriflunomide. Multiple Sclerosis2013;19(10):1310‐9. ">O'Connor 2011</a> (at least 48 weeks (<a href="./references#CD009882-bbs2-0001" title="ComiG , FreedmanMS , KapposL , MillerA , OlssonTP , WolinskyJS , et al. Effect of teriflunomide on lymphocyte and neutrophil counts in patients with relapsing multiple sclerosis: results from the TOWER study. Journal of the Neurological Sciences2013;333:e376. ConfavreuxC , O'ConnorP , ComiG , FreedmanMS , MillerAE , OlssonTP , et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet Neurology2014;13(3):247‐56. KapposL , ComiG , ConfavreuxC , FreedmanMS , MillerAE , OlssonTP , et al. The efficacy and safety of teriflunomide in patients with relapsing MS: results from TOWER, a phase Ⅲ, placebo‐controlled study. Multiple Sclerosis2012;18:50‐1. MillerA , KapposL , ComiG , ConfavreuxC , FreedmanM , OlssonT , et al. Teriflunomide efficacy and safety in patients with relapsing multiple sclerosis: results from tower, a second, pivotal, phase 3 placebo‐controlled study. Neurology. 2013; Vol. 80. MillerAE , MacdonellR , ComiG , FreedmanMS , KapposL , MaurerM , et al. Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study. Journal of Neurology2014;261(9):1781‐8. MosesH , FreedmanM , KapposL , MillerA , OlssonT , WolinskyJ , et al. Pre‐defined subgroups analyses of tower, a placebo‐controlled phase 3 trial of teriflunomide in patients with relapsing multiple sclerosis. Proceedings of the American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). O'ConnorP , LublinF , WolinskyJ , ComiG , ConfavreuxC , FreedmanM , et al. Teriflunomide reduces relapse‐related sequelae, hospitalizations and corticosteroid use: a post‐HOC analysis of the phase 3 TOWER study. Proceedings of The American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). ">Confavreux 2014</a>) and 108 weeks (<a href="./references#CD009882-bbs2-0004" title="ComiG , BenzerdjebH , WangL , TruffinetP , O'ConnorP . Effect of teriflunomide on lymphocyte and neutrophil levels in patients with relapsing multiple sclerosis: results from the TEMSO study. Journal of Neurological Science2013;333(Suppl 1):e376. ComiG , O'ConnorP , WolinskyJ , ConfavreuxC , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: safety outcomes with up to 4 years of follow‐Up. Multiple Sclerosis2011;17:S182‐3. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Long‐term safety and efficacy of teriflunomide in patients with relapsing forms of multiple sclerosis in the TEMSO extension trial. Multiple Sclerosis2013;19:225. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Safety and efficacy of teriflunomide for up to 9 years in relapsing forms of multiple sclerosis: Update of the TEMSO extension trial. Neurology2014; Vol. 82, issue Suppl 10:3‐150. FreedmanMS , DelhayJL , BenamorM . Gastrointestinal symptoms infrequently lead to discontinuation of teriflunomide therapy. Multiple Sclerosis2012;18:S13. MillerA , LublinF , O'ConnorP , TaniouC , Dive‐PoulettyC . Impact of relapses with sequelae on disability, health‐related quality of life, and fatigue in a population with relapsing forms of multiple sclerosis using data from TEMSO, a pivotal phase Ⅲ teriflunomide trial. Neurology2012;78:P07.082. MillerA , LublinF , O'ConnorP , WolinskyJ , ComiG , KapposL , et al. Effect of teriflunomide on relapses with sequelae and relapse leading to hospitalization in a population with relapsing forms of multiple sclerosis: results from the TEMSO study. Neurology2012;78:S30.003. MillerA , O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , et al. Efficacy of oral teriflunomide in multiple sclerosis with relapses: cognitive outcomes from a phase Ⅲ trial (TEMSO). Multiple Sclerosis2011;17:S182. MillerAE , O'ConnorP , WolinskyJS , ConfavreuxC , KapposL , OlssonTP , et al. Pre‐specified subgroup analyses of a placebo‐controlled phase Ⅲ trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis. Multiple Sclerosis2012;18(11):1625‐32. O'ConnorP , BriggsA , CaritaP , Bego‐Le‐BagousseG . Impact on health‐related quality of life of teriflunomide treatment by estimating utilities in patients with relapsing multiple sclerosis: results from TEMSO post hoc analysis. Journal of Neurology2012;259:S107. O'ConnorP , BurrellA , WangL , WeiL , CaritaP , ZhangQ . Effect of teriflunomide on longitudinal patterns of relapse and relapse‐related hospitalization in multiple sclerosis. Multiple Sclerosis2011;17:S414. O'ConnorP , LublinF , WolinskyJ , ComiG , KapposL , FreedmanM , et al. Effect of teriflunomide on relapses leading to healthcare resource use: results from the TEMSO study. Multiple Sclerosis2011;17:S95‐6. O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: clinical and MRI data 5 years after initial randomization. Multiple Sclerosis2011;17:S414‐5. O'ConnorP , WolinskyJS , ConfavreuxC , ComiG , KapposL , OlssonTP , et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. New England Journal of Medicine2011;365(14):1293‐303. O'ConnorPW , LublinFD , WolinskyJS , ConfavreuxC , ComiG , FreedmanMS , et al. Teriflunomide reduces relapse‐related neurological sequelae, hospitalizations and steroid use. Journal of Neurology2013;260(10):2472‐80. WolinksyJS , WangL , TruffinetP , NarayanaPA , NelsonF , O'ConnorP . Magnetic resonance imaging as a surrogate for clinical endpoints in multiple sclerosis. Multiple Sclerosis2012;18:470‐1. WolinskyJS , NarayanaPA , NelsonF , DattaS , O'ConnorP , ConfavreuxC , et al. Magnetic resonance imaging outcomes from a phase Ⅲ trial of teriflunomide. Multiple Sclerosis2013;19(10):1310‐9. ">O'Connor 2011</a>)). Treatment duration of participants in <a href="./references#CD009882-bbs2-0001" title="ComiG , FreedmanMS , KapposL , MillerA , OlssonTP , WolinskyJS , et al. Effect of teriflunomide on lymphocyte and neutrophil counts in patients with relapsing multiple sclerosis: results from the TOWER study. Journal of the Neurological Sciences2013;333:e376. ConfavreuxC , O'ConnorP , ComiG , FreedmanMS , MillerAE , OlssonTP , et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet Neurology2014;13(3):247‐56. KapposL , ComiG , ConfavreuxC , FreedmanMS , MillerAE , OlssonTP , et al. The efficacy and safety of teriflunomide in patients with relapsing MS: results from TOWER, a phase Ⅲ, placebo‐controlled study. Multiple Sclerosis2012;18:50‐1. MillerA , KapposL , ComiG , ConfavreuxC , FreedmanM , OlssonT , et al. Teriflunomide efficacy and safety in patients with relapsing multiple sclerosis: results from tower, a second, pivotal, phase 3 placebo‐controlled study. Neurology. 2013; Vol. 80. MillerAE , MacdonellR , ComiG , FreedmanMS , KapposL , MaurerM , et al. Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study. Journal of Neurology2014;261(9):1781‐8. MosesH , FreedmanM , KapposL , MillerA , OlssonT , WolinskyJ , et al. Pre‐defined subgroups analyses of tower, a placebo‐controlled phase 3 trial of teriflunomide in patients with relapsing multiple sclerosis. Proceedings of the American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). O'ConnorP , LublinF , WolinskyJ , ComiG , ConfavreuxC , FreedmanM , et al. Teriflunomide reduces relapse‐related sequelae, hospitalizations and corticosteroid use: a post‐HOC analysis of the phase 3 TOWER study. Proceedings of The American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). ">Confavreux 2014</a> was variable, ending 48 weeks after the last participant was included (a maximum treatment duration of 173 weeks). Actually, the data on adverse events in <a href="./references#CD009882-bbs2-0001" title="ComiG , FreedmanMS , KapposL , MillerA , OlssonTP , WolinskyJS , et al. Effect of teriflunomide on lymphocyte and neutrophil counts in patients with relapsing multiple sclerosis: results from the TOWER study. Journal of the Neurological Sciences2013;333:e376. ConfavreuxC , O'ConnorP , ComiG , FreedmanMS , MillerAE , OlssonTP , et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet Neurology2014;13(3):247‐56. KapposL , ComiG , ConfavreuxC , FreedmanMS , MillerAE , OlssonTP , et al. The efficacy and safety of teriflunomide in patients with relapsing MS: results from TOWER, a phase Ⅲ, placebo‐controlled study. Multiple Sclerosis2012;18:50‐1. MillerA , KapposL , ComiG , ConfavreuxC , FreedmanM , OlssonT , et al. Teriflunomide efficacy and safety in patients with relapsing multiple sclerosis: results from tower, a second, pivotal, phase 3 placebo‐controlled study. Neurology. 2013; Vol. 80. MillerAE , MacdonellR , ComiG , FreedmanMS , KapposL , MaurerM , et al. Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study. Journal of Neurology2014;261(9):1781‐8. MosesH , FreedmanM , KapposL , MillerA , OlssonT , WolinskyJ , et al. Pre‐defined subgroups analyses of tower, a placebo‐controlled phase 3 trial of teriflunomide in patients with relapsing multiple sclerosis. Proceedings of the American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). O'ConnorP , LublinF , WolinskyJ , ComiG , ConfavreuxC , FreedmanM , et al. Teriflunomide reduces relapse‐related sequelae, hospitalizations and corticosteroid use: a post‐HOC analysis of the phase 3 TOWER study. Proceedings of The American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). ">Confavreux 2014</a> were not at 2 years. There was a heterogeneity in follow‐up period between the studies. Therefore, we did not combine the data on adverse events in <a href="./references#CD009882-bbs2-0001" title="ComiG , FreedmanMS , KapposL , MillerA , OlssonTP , WolinskyJS , et al. Effect of teriflunomide on lymphocyte and neutrophil counts in patients with relapsing multiple sclerosis: results from the TOWER study. Journal of the Neurological Sciences2013;333:e376. ConfavreuxC , O'ConnorP , ComiG , FreedmanMS , MillerAE , OlssonTP , et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet Neurology2014;13(3):247‐56. KapposL , ComiG , ConfavreuxC , FreedmanMS , MillerAE , OlssonTP , et al. The efficacy and safety of teriflunomide in patients with relapsing MS: results from TOWER, a phase Ⅲ, placebo‐controlled study. Multiple Sclerosis2012;18:50‐1. MillerA , KapposL , ComiG , ConfavreuxC , FreedmanM , OlssonT , et al. Teriflunomide efficacy and safety in patients with relapsing multiple sclerosis: results from tower, a second, pivotal, phase 3 placebo‐controlled study. Neurology. 2013; Vol. 80. MillerAE , MacdonellR , ComiG , FreedmanMS , KapposL , MaurerM , et al. Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study. Journal of Neurology2014;261(9):1781‐8. MosesH , FreedmanM , KapposL , MillerA , OlssonT , WolinskyJ , et al. Pre‐defined subgroups analyses of tower, a placebo‐controlled phase 3 trial of teriflunomide in patients with relapsing multiple sclerosis. Proceedings of the American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). O'ConnorP , LublinF , WolinskyJ , ComiG , ConfavreuxC , FreedmanM , et al. Teriflunomide reduces relapse‐related sequelae, hospitalizations and corticosteroid use: a post‐HOC analysis of the phase 3 TOWER study. Proceedings of The American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). ">Confavreux 2014</a> and <a href="./references#CD009882-bbs2-0004" title="ComiG , BenzerdjebH , WangL , TruffinetP , O'ConnorP . Effect of teriflunomide on lymphocyte and neutrophil levels in patients with relapsing multiple sclerosis: results from the TEMSO study. Journal of Neurological Science2013;333(Suppl 1):e376. ComiG , O'ConnorP , WolinskyJ , ConfavreuxC , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: safety outcomes with up to 4 years of follow‐Up. Multiple Sclerosis2011;17:S182‐3. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Long‐term safety and efficacy of teriflunomide in patients with relapsing forms of multiple sclerosis in the TEMSO extension trial. Multiple Sclerosis2013;19:225. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Safety and efficacy of teriflunomide for up to 9 years in relapsing forms of multiple sclerosis: Update of the TEMSO extension trial. Neurology2014; Vol. 82, issue Suppl 10:3‐150. FreedmanMS , DelhayJL , BenamorM . Gastrointestinal symptoms infrequently lead to discontinuation of teriflunomide therapy. Multiple Sclerosis2012;18:S13. MillerA , LublinF , O'ConnorP , TaniouC , Dive‐PoulettyC . Impact of relapses with sequelae on disability, health‐related quality of life, and fatigue in a population with relapsing forms of multiple sclerosis using data from TEMSO, a pivotal phase Ⅲ teriflunomide trial. Neurology2012;78:P07.082. MillerA , LublinF , O'ConnorP , WolinskyJ , ComiG , KapposL , et al. Effect of teriflunomide on relapses with sequelae and relapse leading to hospitalization in a population with relapsing forms of multiple sclerosis: results from the TEMSO study. Neurology2012;78:S30.003. MillerA , O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , et al. Efficacy of oral teriflunomide in multiple sclerosis with relapses: cognitive outcomes from a phase Ⅲ trial (TEMSO). Multiple Sclerosis2011;17:S182. MillerAE , O'ConnorP , WolinskyJS , ConfavreuxC , KapposL , OlssonTP , et al. Pre‐specified subgroup analyses of a placebo‐controlled phase Ⅲ trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis. Multiple Sclerosis2012;18(11):1625‐32. O'ConnorP , BriggsA , CaritaP , Bego‐Le‐BagousseG . Impact on health‐related quality of life of teriflunomide treatment by estimating utilities in patients with relapsing multiple sclerosis: results from TEMSO post hoc analysis. Journal of Neurology2012;259:S107. O'ConnorP , BurrellA , WangL , WeiL , CaritaP , ZhangQ . Effect of teriflunomide on longitudinal patterns of relapse and relapse‐related hospitalization in multiple sclerosis. Multiple Sclerosis2011;17:S414. O'ConnorP , LublinF , WolinskyJ , ComiG , KapposL , FreedmanM , et al. Effect of teriflunomide on relapses leading to healthcare resource use: results from the TEMSO study. Multiple Sclerosis2011;17:S95‐6. O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: clinical and MRI data 5 years after initial randomization. Multiple Sclerosis2011;17:S414‐5. O'ConnorP , WolinskyJS , ConfavreuxC , ComiG , KapposL , OlssonTP , et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. New England Journal of Medicine2011;365(14):1293‐303. O'ConnorPW , LublinFD , WolinskyJS , ConfavreuxC , ComiG , FreedmanMS , et al. Teriflunomide reduces relapse‐related neurological sequelae, hospitalizations and steroid use. Journal of Neurology2013;260(10):2472‐80. WolinksyJS , WangL , TruffinetP , NarayanaPA , NelsonF , O'ConnorP . Magnetic resonance imaging as a surrogate for clinical endpoints in multiple sclerosis. Multiple Sclerosis2012;18:470‐1. WolinskyJS , NarayanaPA , NelsonF , DattaS , O'ConnorP , ConfavreuxC , et al. Magnetic resonance imaging outcomes from a phase Ⅲ trial of teriflunomide. Multiple Sclerosis2013;19(10):1310‐9. ">O'Connor 2011</a> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>The proportion of participants with elevated ALT levels at 2 years</b> <br/> Follow‐up: 2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>67 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>143 per 1000</b> <br/> (90 to 226) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.14</b> <br/> (1.35 to 3.39) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>718<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>f</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The follow‐up periods were diverse in <a href="./references#CD009882-bbs2-0001" title="ComiG , FreedmanMS , KapposL , MillerA , OlssonTP , WolinskyJS , et al. Effect of teriflunomide on lymphocyte and neutrophil counts in patients with relapsing multiple sclerosis: results from the TOWER study. Journal of the Neurological Sciences2013;333:e376. ConfavreuxC , O'ConnorP , ComiG , FreedmanMS , MillerAE , OlssonTP , et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet Neurology2014;13(3):247‐56. KapposL , ComiG , ConfavreuxC , FreedmanMS , MillerAE , OlssonTP , et al. The efficacy and safety of teriflunomide in patients with relapsing MS: results from TOWER, a phase Ⅲ, placebo‐controlled study. Multiple Sclerosis2012;18:50‐1. MillerA , KapposL , ComiG , ConfavreuxC , FreedmanM , OlssonT , et al. Teriflunomide efficacy and safety in patients with relapsing multiple sclerosis: results from tower, a second, pivotal, phase 3 placebo‐controlled study. Neurology. 2013; Vol. 80. MillerAE , MacdonellR , ComiG , FreedmanMS , KapposL , MaurerM , et al. Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study. Journal of Neurology2014;261(9):1781‐8. MosesH , FreedmanM , KapposL , MillerA , OlssonT , WolinskyJ , et al. Pre‐defined subgroups analyses of tower, a placebo‐controlled phase 3 trial of teriflunomide in patients with relapsing multiple sclerosis. Proceedings of the American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). O'ConnorP , LublinF , WolinskyJ , ComiG , ConfavreuxC , FreedmanM , et al. Teriflunomide reduces relapse‐related sequelae, hospitalizations and corticosteroid use: a post‐HOC analysis of the phase 3 TOWER study. Proceedings of The American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). ">Confavreux 2014</a> and <a href="./references#CD009882-bbs2-0004" title="ComiG , BenzerdjebH , WangL , TruffinetP , O'ConnorP . Effect of teriflunomide on lymphocyte and neutrophil levels in patients with relapsing multiple sclerosis: results from the TEMSO study. Journal of Neurological Science2013;333(Suppl 1):e376. ComiG , O'ConnorP , WolinskyJ , ConfavreuxC , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: safety outcomes with up to 4 years of follow‐Up. Multiple Sclerosis2011;17:S182‐3. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Long‐term safety and efficacy of teriflunomide in patients with relapsing forms of multiple sclerosis in the TEMSO extension trial. Multiple Sclerosis2013;19:225. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Safety and efficacy of teriflunomide for up to 9 years in relapsing forms of multiple sclerosis: Update of the TEMSO extension trial. Neurology2014; Vol. 82, issue Suppl 10:3‐150. FreedmanMS , DelhayJL , BenamorM . Gastrointestinal symptoms infrequently lead to discontinuation of teriflunomide therapy. Multiple Sclerosis2012;18:S13. MillerA , LublinF , O'ConnorP , TaniouC , Dive‐PoulettyC . Impact of relapses with sequelae on disability, health‐related quality of life, and fatigue in a population with relapsing forms of multiple sclerosis using data from TEMSO, a pivotal phase Ⅲ teriflunomide trial. Neurology2012;78:P07.082. MillerA , LublinF , O'ConnorP , WolinskyJ , ComiG , KapposL , et al. Effect of teriflunomide on relapses with sequelae and relapse leading to hospitalization in a population with relapsing forms of multiple sclerosis: results from the TEMSO study. Neurology2012;78:S30.003. MillerA , O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , et al. Efficacy of oral teriflunomide in multiple sclerosis with relapses: cognitive outcomes from a phase Ⅲ trial (TEMSO). Multiple Sclerosis2011;17:S182. MillerAE , O'ConnorP , WolinskyJS , ConfavreuxC , KapposL , OlssonTP , et al. Pre‐specified subgroup analyses of a placebo‐controlled phase Ⅲ trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis. Multiple Sclerosis2012;18(11):1625‐32. O'ConnorP , BriggsA , CaritaP , Bego‐Le‐BagousseG . Impact on health‐related quality of life of teriflunomide treatment by estimating utilities in patients with relapsing multiple sclerosis: results from TEMSO post hoc analysis. Journal of Neurology2012;259:S107. O'ConnorP , BurrellA , WangL , WeiL , CaritaP , ZhangQ . Effect of teriflunomide on longitudinal patterns of relapse and relapse‐related hospitalization in multiple sclerosis. Multiple Sclerosis2011;17:S414. O'ConnorP , LublinF , WolinskyJ , ComiG , KapposL , FreedmanM , et al. Effect of teriflunomide on relapses leading to healthcare resource use: results from the TEMSO study. Multiple Sclerosis2011;17:S95‐6. O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: clinical and MRI data 5 years after initial randomization. Multiple Sclerosis2011;17:S414‐5. O'ConnorP , WolinskyJS , ConfavreuxC , ComiG , KapposL , OlssonTP , et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. New England Journal of Medicine2011;365(14):1293‐303. O'ConnorPW , LublinFD , WolinskyJS , ConfavreuxC , ComiG , FreedmanMS , et al. Teriflunomide reduces relapse‐related neurological sequelae, hospitalizations and steroid use. Journal of Neurology2013;260(10):2472‐80. WolinksyJS , WangL , TruffinetP , NarayanaPA , NelsonF , O'ConnorP . Magnetic resonance imaging as a surrogate for clinical endpoints in multiple sclerosis. Multiple Sclerosis2012;18:470‐1. WolinskyJS , NarayanaPA , NelsonF , DattaS , O'ConnorP , ConfavreuxC , et al. Magnetic resonance imaging outcomes from a phase Ⅲ trial of teriflunomide. Multiple Sclerosis2013;19(10):1310‐9. ">O'Connor 2011</a> (at least 48 weeks (<a href="./references#CD009882-bbs2-0001" title="ComiG , FreedmanMS , KapposL , MillerA , OlssonTP , WolinskyJS , et al. Effect of teriflunomide on lymphocyte and neutrophil counts in patients with relapsing multiple sclerosis: results from the TOWER study. Journal of the Neurological Sciences2013;333:e376. ConfavreuxC , O'ConnorP , ComiG , FreedmanMS , MillerAE , OlssonTP , et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet Neurology2014;13(3):247‐56. KapposL , ComiG , ConfavreuxC , FreedmanMS , MillerAE , OlssonTP , et al. The efficacy and safety of teriflunomide in patients with relapsing MS: results from TOWER, a phase Ⅲ, placebo‐controlled study. Multiple Sclerosis2012;18:50‐1. MillerA , KapposL , ComiG , ConfavreuxC , FreedmanM , OlssonT , et al. Teriflunomide efficacy and safety in patients with relapsing multiple sclerosis: results from tower, a second, pivotal, phase 3 placebo‐controlled study. Neurology. 2013; Vol. 80. MillerAE , MacdonellR , ComiG , FreedmanMS , KapposL , MaurerM , et al. Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study. Journal of Neurology2014;261(9):1781‐8. MosesH , FreedmanM , KapposL , MillerA , OlssonT , WolinskyJ , et al. Pre‐defined subgroups analyses of tower, a placebo‐controlled phase 3 trial of teriflunomide in patients with relapsing multiple sclerosis. Proceedings of the American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). O'ConnorP , LublinF , WolinskyJ , ComiG , ConfavreuxC , FreedmanM , et al. Teriflunomide reduces relapse‐related sequelae, hospitalizations and corticosteroid use: a post‐HOC analysis of the phase 3 TOWER study. Proceedings of The American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). ">Confavreux 2014</a>) and 108 weeks (<a href="./references#CD009882-bbs2-0004" title="ComiG , BenzerdjebH , WangL , TruffinetP , O'ConnorP . Effect of teriflunomide on lymphocyte and neutrophil levels in patients with relapsing multiple sclerosis: results from the TEMSO study. Journal of Neurological Science2013;333(Suppl 1):e376. ComiG , O'ConnorP , WolinskyJ , ConfavreuxC , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: safety outcomes with up to 4 years of follow‐Up. Multiple Sclerosis2011;17:S182‐3. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Long‐term safety and efficacy of teriflunomide in patients with relapsing forms of multiple sclerosis in the TEMSO extension trial. Multiple Sclerosis2013;19:225. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Safety and efficacy of teriflunomide for up to 9 years in relapsing forms of multiple sclerosis: Update of the TEMSO extension trial. Neurology2014; Vol. 82, issue Suppl 10:3‐150. FreedmanMS , DelhayJL , BenamorM . Gastrointestinal symptoms infrequently lead to discontinuation of teriflunomide therapy. Multiple Sclerosis2012;18:S13. MillerA , LublinF , O'ConnorP , TaniouC , Dive‐PoulettyC . Impact of relapses with sequelae on disability, health‐related quality of life, and fatigue in a population with relapsing forms of multiple sclerosis using data from TEMSO, a pivotal phase Ⅲ teriflunomide trial. Neurology2012;78:P07.082. MillerA , LublinF , O'ConnorP , WolinskyJ , ComiG , KapposL , et al. Effect of teriflunomide on relapses with sequelae and relapse leading to hospitalization in a population with relapsing forms of multiple sclerosis: results from the TEMSO study. Neurology2012;78:S30.003. MillerA , O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , et al. Efficacy of oral teriflunomide in multiple sclerosis with relapses: cognitive outcomes from a phase Ⅲ trial (TEMSO). Multiple Sclerosis2011;17:S182. MillerAE , O'ConnorP , WolinskyJS , ConfavreuxC , KapposL , OlssonTP , et al. Pre‐specified subgroup analyses of a placebo‐controlled phase Ⅲ trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis. Multiple Sclerosis2012;18(11):1625‐32. O'ConnorP , BriggsA , CaritaP , Bego‐Le‐BagousseG . Impact on health‐related quality of life of teriflunomide treatment by estimating utilities in patients with relapsing multiple sclerosis: results from TEMSO post hoc analysis. Journal of Neurology2012;259:S107. O'ConnorP , BurrellA , WangL , WeiL , CaritaP , ZhangQ . Effect of teriflunomide on longitudinal patterns of relapse and relapse‐related hospitalization in multiple sclerosis. Multiple Sclerosis2011;17:S414. O'ConnorP , LublinF , WolinskyJ , ComiG , KapposL , FreedmanM , et al. Effect of teriflunomide on relapses leading to healthcare resource use: results from the TEMSO study. Multiple Sclerosis2011;17:S95‐6. O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: clinical and MRI data 5 years after initial randomization. Multiple Sclerosis2011;17:S414‐5. O'ConnorP , WolinskyJS , ConfavreuxC , ComiG , KapposL , OlssonTP , et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. New England Journal of Medicine2011;365(14):1293‐303. O'ConnorPW , LublinFD , WolinskyJS , ConfavreuxC , ComiG , FreedmanMS , et al. Teriflunomide reduces relapse‐related neurological sequelae, hospitalizations and steroid use. Journal of Neurology2013;260(10):2472‐80. WolinksyJS , WangL , TruffinetP , NarayanaPA , NelsonF , O'ConnorP . Magnetic resonance imaging as a surrogate for clinical endpoints in multiple sclerosis. Multiple Sclerosis2012;18:470‐1. WolinskyJS , NarayanaPA , NelsonF , DattaS , O'ConnorP , ConfavreuxC , et al. Magnetic resonance imaging outcomes from a phase Ⅲ trial of teriflunomide. Multiple Sclerosis2013;19(10):1310‐9. ">O'Connor 2011</a>)). Treatment duration of participants in <a href="./references#CD009882-bbs2-0001" title="ComiG , FreedmanMS , KapposL , MillerA , OlssonTP , WolinskyJS , et al. Effect of teriflunomide on lymphocyte and neutrophil counts in patients with relapsing multiple sclerosis: results from the TOWER study. Journal of the Neurological Sciences2013;333:e376. ConfavreuxC , O'ConnorP , ComiG , FreedmanMS , MillerAE , OlssonTP , et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet Neurology2014;13(3):247‐56. KapposL , ComiG , ConfavreuxC , FreedmanMS , MillerAE , OlssonTP , et al. The efficacy and safety of teriflunomide in patients with relapsing MS: results from TOWER, a phase Ⅲ, placebo‐controlled study. Multiple Sclerosis2012;18:50‐1. MillerA , KapposL , ComiG , ConfavreuxC , FreedmanM , OlssonT , et al. Teriflunomide efficacy and safety in patients with relapsing multiple sclerosis: results from tower, a second, pivotal, phase 3 placebo‐controlled study. Neurology. 2013; Vol. 80. MillerAE , MacdonellR , ComiG , FreedmanMS , KapposL , MaurerM , et al. Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study. Journal of Neurology2014;261(9):1781‐8. MosesH , FreedmanM , KapposL , MillerA , OlssonT , WolinskyJ , et al. Pre‐defined subgroups analyses of tower, a placebo‐controlled phase 3 trial of teriflunomide in patients with relapsing multiple sclerosis. Proceedings of the American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). O'ConnorP , LublinF , WolinskyJ , ComiG , ConfavreuxC , FreedmanM , et al. Teriflunomide reduces relapse‐related sequelae, hospitalizations and corticosteroid use: a post‐HOC analysis of the phase 3 TOWER study. Proceedings of The American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). ">Confavreux 2014</a> was variable, ending 48 weeks after the last participant was included (a maximum treatment duration of 173 weeks). Actually, the data on adverse events in <a href="./references#CD009882-bbs2-0001" title="ComiG , FreedmanMS , KapposL , MillerA , OlssonTP , WolinskyJS , et al. Effect of teriflunomide on lymphocyte and neutrophil counts in patients with relapsing multiple sclerosis: results from the TOWER study. Journal of the Neurological Sciences2013;333:e376. ConfavreuxC , O'ConnorP , ComiG , FreedmanMS , MillerAE , OlssonTP , et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet Neurology2014;13(3):247‐56. KapposL , ComiG , ConfavreuxC , FreedmanMS , MillerAE , OlssonTP , et al. The efficacy and safety of teriflunomide in patients with relapsing MS: results from TOWER, a phase Ⅲ, placebo‐controlled study. Multiple Sclerosis2012;18:50‐1. MillerA , KapposL , ComiG , ConfavreuxC , FreedmanM , OlssonT , et al. Teriflunomide efficacy and safety in patients with relapsing multiple sclerosis: results from tower, a second, pivotal, phase 3 placebo‐controlled study. Neurology. 2013; Vol. 80. MillerAE , MacdonellR , ComiG , FreedmanMS , KapposL , MaurerM , et al. Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study. Journal of Neurology2014;261(9):1781‐8. MosesH , FreedmanM , KapposL , MillerA , OlssonT , WolinskyJ , et al. Pre‐defined subgroups analyses of tower, a placebo‐controlled phase 3 trial of teriflunomide in patients with relapsing multiple sclerosis. Proceedings of the American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). O'ConnorP , LublinF , WolinskyJ , ComiG , ConfavreuxC , FreedmanM , et al. Teriflunomide reduces relapse‐related sequelae, hospitalizations and corticosteroid use: a post‐HOC analysis of the phase 3 TOWER study. Proceedings of The American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). ">Confavreux 2014</a> were not at 2 years. There was a heterogeneity in follow‐up period between the studies. Therefore, we did not combine the data on adverse events in <a href="./references#CD009882-bbs2-0001" title="ComiG , FreedmanMS , KapposL , MillerA , OlssonTP , WolinskyJS , et al. Effect of teriflunomide on lymphocyte and neutrophil counts in patients with relapsing multiple sclerosis: results from the TOWER study. Journal of the Neurological Sciences2013;333:e376. ConfavreuxC , O'ConnorP , ComiG , FreedmanMS , MillerAE , OlssonTP , et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet Neurology2014;13(3):247‐56. KapposL , ComiG , ConfavreuxC , FreedmanMS , MillerAE , OlssonTP , et al. The efficacy and safety of teriflunomide in patients with relapsing MS: results from TOWER, a phase Ⅲ, placebo‐controlled study. Multiple Sclerosis2012;18:50‐1. MillerA , KapposL , ComiG , ConfavreuxC , FreedmanM , OlssonT , et al. Teriflunomide efficacy and safety in patients with relapsing multiple sclerosis: results from tower, a second, pivotal, phase 3 placebo‐controlled study. Neurology. 2013; Vol. 80. MillerAE , MacdonellR , ComiG , FreedmanMS , KapposL , MaurerM , et al. Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study. Journal of Neurology2014;261(9):1781‐8. MosesH , FreedmanM , KapposL , MillerA , OlssonT , WolinskyJ , et al. Pre‐defined subgroups analyses of tower, a placebo‐controlled phase 3 trial of teriflunomide in patients with relapsing multiple sclerosis. Proceedings of the American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). O'ConnorP , LublinF , WolinskyJ , ComiG , ConfavreuxC , FreedmanM , et al. Teriflunomide reduces relapse‐related sequelae, hospitalizations and corticosteroid use: a post‐HOC analysis of the phase 3 TOWER study. Proceedings of The American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). ">Confavreux 2014</a> and <a href="./references#CD009882-bbs2-0004" title="ComiG , BenzerdjebH , WangL , TruffinetP , O'ConnorP . Effect of teriflunomide on lymphocyte and neutrophil levels in patients with relapsing multiple sclerosis: results from the TEMSO study. Journal of Neurological Science2013;333(Suppl 1):e376. ComiG , O'ConnorP , WolinskyJ , ConfavreuxC , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: safety outcomes with up to 4 years of follow‐Up. Multiple Sclerosis2011;17:S182‐3. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Long‐term safety and efficacy of teriflunomide in patients with relapsing forms of multiple sclerosis in the TEMSO extension trial. Multiple Sclerosis2013;19:225. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Safety and efficacy of teriflunomide for up to 9 years in relapsing forms of multiple sclerosis: Update of the TEMSO extension trial. Neurology2014; Vol. 82, issue Suppl 10:3‐150. FreedmanMS , DelhayJL , BenamorM . Gastrointestinal symptoms infrequently lead to discontinuation of teriflunomide therapy. Multiple Sclerosis2012;18:S13. MillerA , LublinF , O'ConnorP , TaniouC , Dive‐PoulettyC . Impact of relapses with sequelae on disability, health‐related quality of life, and fatigue in a population with relapsing forms of multiple sclerosis using data from TEMSO, a pivotal phase Ⅲ teriflunomide trial. Neurology2012;78:P07.082. MillerA , LublinF , O'ConnorP , WolinskyJ , ComiG , KapposL , et al. Effect of teriflunomide on relapses with sequelae and relapse leading to hospitalization in a population with relapsing forms of multiple sclerosis: results from the TEMSO study. Neurology2012;78:S30.003. MillerA , O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , et al. Efficacy of oral teriflunomide in multiple sclerosis with relapses: cognitive outcomes from a phase Ⅲ trial (TEMSO). Multiple Sclerosis2011;17:S182. MillerAE , O'ConnorP , WolinskyJS , ConfavreuxC , KapposL , OlssonTP , et al. Pre‐specified subgroup analyses of a placebo‐controlled phase Ⅲ trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis. Multiple Sclerosis2012;18(11):1625‐32. O'ConnorP , BriggsA , CaritaP , Bego‐Le‐BagousseG . Impact on health‐related quality of life of teriflunomide treatment by estimating utilities in patients with relapsing multiple sclerosis: results from TEMSO post hoc analysis. Journal of Neurology2012;259:S107. O'ConnorP , BurrellA , WangL , WeiL , CaritaP , ZhangQ . Effect of teriflunomide on longitudinal patterns of relapse and relapse‐related hospitalization in multiple sclerosis. Multiple Sclerosis2011;17:S414. O'ConnorP , LublinF , WolinskyJ , ComiG , KapposL , FreedmanM , et al. Effect of teriflunomide on relapses leading to healthcare resource use: results from the TEMSO study. Multiple Sclerosis2011;17:S95‐6. O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: clinical and MRI data 5 years after initial randomization. Multiple Sclerosis2011;17:S414‐5. O'ConnorP , WolinskyJS , ConfavreuxC , ComiG , KapposL , OlssonTP , et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. New England Journal of Medicine2011;365(14):1293‐303. O'ConnorPW , LublinFD , WolinskyJS , ConfavreuxC , ComiG , FreedmanMS , et al. Teriflunomide reduces relapse‐related neurological sequelae, hospitalizations and steroid use. Journal of Neurology2013;260(10):2472‐80. WolinksyJS , WangL , TruffinetP , NarayanaPA , NelsonF , O'ConnorP . Magnetic resonance imaging as a surrogate for clinical endpoints in multiple sclerosis. Multiple Sclerosis2012;18:470‐1. WolinskyJS , NarayanaPA , NelsonF , DattaS , O'ConnorP , ConfavreuxC , et al. Magnetic resonance imaging outcomes from a phase Ⅲ trial of teriflunomide. Multiple Sclerosis2013;19(10):1310‐9. ">O'Connor 2011</a> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for <b>assumed risk</b> is the placebo group risk. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>ALT: a</b> lanine aminotransferase; <b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> <p>The assumed risk was defined as placebo group risk because only one study was evaluated.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> High risks of bias existed in <a href="./references#CD009882-bbs2-0001" title="ComiG , FreedmanMS , KapposL , MillerA , OlssonTP , WolinskyJS , et al. Effect of teriflunomide on lymphocyte and neutrophil counts in patients with relapsing multiple sclerosis: results from the TOWER study. Journal of the Neurological Sciences2013;333:e376. ConfavreuxC , O'ConnorP , ComiG , FreedmanMS , MillerAE , OlssonTP , et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet Neurology2014;13(3):247‐56. KapposL , ComiG , ConfavreuxC , FreedmanMS , MillerAE , OlssonTP , et al. The efficacy and safety of teriflunomide in patients with relapsing MS: results from TOWER, a phase Ⅲ, placebo‐controlled study. Multiple Sclerosis2012;18:50‐1. MillerA , KapposL , ComiG , ConfavreuxC , FreedmanM , OlssonT , et al. Teriflunomide efficacy and safety in patients with relapsing multiple sclerosis: results from tower, a second, pivotal, phase 3 placebo‐controlled study. Neurology. 2013; Vol. 80. MillerAE , MacdonellR , ComiG , FreedmanMS , KapposL , MaurerM , et al. Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study. Journal of Neurology2014;261(9):1781‐8. MosesH , FreedmanM , KapposL , MillerA , OlssonT , WolinskyJ , et al. Pre‐defined subgroups analyses of tower, a placebo‐controlled phase 3 trial of teriflunomide in patients with relapsing multiple sclerosis. Proceedings of the American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). O'ConnorP , LublinF , WolinskyJ , ComiG , ConfavreuxC , FreedmanM , et al. Teriflunomide reduces relapse‐related sequelae, hospitalizations and corticosteroid use: a post‐HOC analysis of the phase 3 TOWER study. Proceedings of The American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). ">Confavreux 2014</a> due to unblinded assessments for relapse and conflicts of interest. </p> <p><sup>b</sup> High risks of bias existed in <a href="./references#CD009882-bbs2-0004" title="ComiG , BenzerdjebH , WangL , TruffinetP , O'ConnorP . Effect of teriflunomide on lymphocyte and neutrophil levels in patients with relapsing multiple sclerosis: results from the TEMSO study. Journal of Neurological Science2013;333(Suppl 1):e376. ComiG , O'ConnorP , WolinskyJ , ConfavreuxC , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: safety outcomes with up to 4 years of follow‐Up. Multiple Sclerosis2011;17:S182‐3. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Long‐term safety and efficacy of teriflunomide in patients with relapsing forms of multiple sclerosis in the TEMSO extension trial. Multiple Sclerosis2013;19:225. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Safety and efficacy of teriflunomide for up to 9 years in relapsing forms of multiple sclerosis: Update of the TEMSO extension trial. Neurology2014; Vol. 82, issue Suppl 10:3‐150. FreedmanMS , DelhayJL , BenamorM . Gastrointestinal symptoms infrequently lead to discontinuation of teriflunomide therapy. Multiple Sclerosis2012;18:S13. MillerA , LublinF , O'ConnorP , TaniouC , Dive‐PoulettyC . Impact of relapses with sequelae on disability, health‐related quality of life, and fatigue in a population with relapsing forms of multiple sclerosis using data from TEMSO, a pivotal phase Ⅲ teriflunomide trial. Neurology2012;78:P07.082. MillerA , LublinF , O'ConnorP , WolinskyJ , ComiG , KapposL , et al. Effect of teriflunomide on relapses with sequelae and relapse leading to hospitalization in a population with relapsing forms of multiple sclerosis: results from the TEMSO study. Neurology2012;78:S30.003. MillerA , O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , et al. Efficacy of oral teriflunomide in multiple sclerosis with relapses: cognitive outcomes from a phase Ⅲ trial (TEMSO). Multiple Sclerosis2011;17:S182. MillerAE , O'ConnorP , WolinskyJS , ConfavreuxC , KapposL , OlssonTP , et al. Pre‐specified subgroup analyses of a placebo‐controlled phase Ⅲ trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis. Multiple Sclerosis2012;18(11):1625‐32. O'ConnorP , BriggsA , CaritaP , Bego‐Le‐BagousseG . Impact on health‐related quality of life of teriflunomide treatment by estimating utilities in patients with relapsing multiple sclerosis: results from TEMSO post hoc analysis. Journal of Neurology2012;259:S107. O'ConnorP , BurrellA , WangL , WeiL , CaritaP , ZhangQ . Effect of teriflunomide on longitudinal patterns of relapse and relapse‐related hospitalization in multiple sclerosis. Multiple Sclerosis2011;17:S414. O'ConnorP , LublinF , WolinskyJ , ComiG , KapposL , FreedmanM , et al. Effect of teriflunomide on relapses leading to healthcare resource use: results from the TEMSO study. Multiple Sclerosis2011;17:S95‐6. O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: clinical and MRI data 5 years after initial randomization. Multiple Sclerosis2011;17:S414‐5. O'ConnorP , WolinskyJS , ConfavreuxC , ComiG , KapposL , OlssonTP , et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. New England Journal of Medicine2011;365(14):1293‐303. O'ConnorPW , LublinFD , WolinskyJS , ConfavreuxC , ComiG , FreedmanMS , et al. Teriflunomide reduces relapse‐related neurological sequelae, hospitalizations and steroid use. Journal of Neurology2013;260(10):2472‐80. WolinksyJS , WangL , TruffinetP , NarayanaPA , NelsonF , O'ConnorP . Magnetic resonance imaging as a surrogate for clinical endpoints in multiple sclerosis. Multiple Sclerosis2012;18:470‐1. WolinskyJS , NarayanaPA , NelsonF , DattaS , O'ConnorP , ConfavreuxC , et al. Magnetic resonance imaging outcomes from a phase Ⅲ trial of teriflunomide. Multiple Sclerosis2013;19(10):1310‐9. ">O'Connor 2011</a> due to unblinded assessments for relapse and conflicts of interest. </p> <p><sup>c</sup> High risks of bias existed in <a href="./references#CD009882-bbs2-0001" title="ComiG , FreedmanMS , KapposL , MillerA , OlssonTP , WolinskyJS , et al. Effect of teriflunomide on lymphocyte and neutrophil counts in patients with relapsing multiple sclerosis: results from the TOWER study. Journal of the Neurological Sciences2013;333:e376. ConfavreuxC , O'ConnorP , ComiG , FreedmanMS , MillerAE , OlssonTP , et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet Neurology2014;13(3):247‐56. KapposL , ComiG , ConfavreuxC , FreedmanMS , MillerAE , OlssonTP , et al. The efficacy and safety of teriflunomide in patients with relapsing MS: results from TOWER, a phase Ⅲ, placebo‐controlled study. Multiple Sclerosis2012;18:50‐1. MillerA , KapposL , ComiG , ConfavreuxC , FreedmanM , OlssonT , et al. Teriflunomide efficacy and safety in patients with relapsing multiple sclerosis: results from tower, a second, pivotal, phase 3 placebo‐controlled study. Neurology. 2013; Vol. 80. MillerAE , MacdonellR , ComiG , FreedmanMS , KapposL , MaurerM , et al. Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study. Journal of Neurology2014;261(9):1781‐8. MosesH , FreedmanM , KapposL , MillerA , OlssonT , WolinskyJ , et al. Pre‐defined subgroups analyses of tower, a placebo‐controlled phase 3 trial of teriflunomide in patients with relapsing multiple sclerosis. Proceedings of the American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). O'ConnorP , LublinF , WolinskyJ , ComiG , ConfavreuxC , FreedmanM , et al. Teriflunomide reduces relapse‐related sequelae, hospitalizations and corticosteroid use: a post‐HOC analysis of the phase 3 TOWER study. Proceedings of The American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). ">Confavreux 2014</a> due to effects of the high attrition bias on progression disability and conflicts of interest. </p> <p><sup>d</sup> High risk of bias existed in <a href="./references#CD009882-bbs2-0004" title="ComiG , BenzerdjebH , WangL , TruffinetP , O'ConnorP . Effect of teriflunomide on lymphocyte and neutrophil levels in patients with relapsing multiple sclerosis: results from the TEMSO study. Journal of Neurological Science2013;333(Suppl 1):e376. ComiG , O'ConnorP , WolinskyJ , ConfavreuxC , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: safety outcomes with up to 4 years of follow‐Up. Multiple Sclerosis2011;17:S182‐3. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Long‐term safety and efficacy of teriflunomide in patients with relapsing forms of multiple sclerosis in the TEMSO extension trial. Multiple Sclerosis2013;19:225. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Safety and efficacy of teriflunomide for up to 9 years in relapsing forms of multiple sclerosis: Update of the TEMSO extension trial. Neurology2014; Vol. 82, issue Suppl 10:3‐150. FreedmanMS , DelhayJL , BenamorM . Gastrointestinal symptoms infrequently lead to discontinuation of teriflunomide therapy. Multiple Sclerosis2012;18:S13. MillerA , LublinF , O'ConnorP , TaniouC , Dive‐PoulettyC . Impact of relapses with sequelae on disability, health‐related quality of life, and fatigue in a population with relapsing forms of multiple sclerosis using data from TEMSO, a pivotal phase Ⅲ teriflunomide trial. Neurology2012;78:P07.082. MillerA , LublinF , O'ConnorP , WolinskyJ , ComiG , KapposL , et al. Effect of teriflunomide on relapses with sequelae and relapse leading to hospitalization in a population with relapsing forms of multiple sclerosis: results from the TEMSO study. Neurology2012;78:S30.003. MillerA , O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , et al. Efficacy of oral teriflunomide in multiple sclerosis with relapses: cognitive outcomes from a phase Ⅲ trial (TEMSO). Multiple Sclerosis2011;17:S182. MillerAE , O'ConnorP , WolinskyJS , ConfavreuxC , KapposL , OlssonTP , et al. Pre‐specified subgroup analyses of a placebo‐controlled phase Ⅲ trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis. Multiple Sclerosis2012;18(11):1625‐32. O'ConnorP , BriggsA , CaritaP , Bego‐Le‐BagousseG . Impact on health‐related quality of life of teriflunomide treatment by estimating utilities in patients with relapsing multiple sclerosis: results from TEMSO post hoc analysis. Journal of Neurology2012;259:S107. O'ConnorP , BurrellA , WangL , WeiL , CaritaP , ZhangQ . Effect of teriflunomide on longitudinal patterns of relapse and relapse‐related hospitalization in multiple sclerosis. Multiple Sclerosis2011;17:S414. O'ConnorP , LublinF , WolinskyJ , ComiG , KapposL , FreedmanM , et al. Effect of teriflunomide on relapses leading to healthcare resource use: results from the TEMSO study. Multiple Sclerosis2011;17:S95‐6. O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: clinical and MRI data 5 years after initial randomization. Multiple Sclerosis2011;17:S414‐5. O'ConnorP , WolinskyJS , ConfavreuxC , ComiG , KapposL , OlssonTP , et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. New England Journal of Medicine2011;365(14):1293‐303. O'ConnorPW , LublinFD , WolinskyJS , ConfavreuxC , ComiG , FreedmanMS , et al. Teriflunomide reduces relapse‐related neurological sequelae, hospitalizations and steroid use. Journal of Neurology2013;260(10):2472‐80. WolinksyJS , WangL , TruffinetP , NarayanaPA , NelsonF , O'ConnorP . Magnetic resonance imaging as a surrogate for clinical endpoints in multiple sclerosis. Multiple Sclerosis2012;18:470‐1. WolinskyJS , NarayanaPA , NelsonF , DattaS , O'ConnorP , ConfavreuxC , et al. Magnetic resonance imaging outcomes from a phase Ⅲ trial of teriflunomide. Multiple Sclerosis2013;19(10):1310‐9. ">O'Connor 2011</a> due to effects of the unclear attrition bias on progression disability and conflicts of interest. </p> <p><sup>e</sup> Serious indirectness existed in <a href="./references#CD009882-bbs2-0001" title="ComiG , FreedmanMS , KapposL , MillerA , OlssonTP , WolinskyJS , et al. Effect of teriflunomide on lymphocyte and neutrophil counts in patients with relapsing multiple sclerosis: results from the TOWER study. Journal of the Neurological Sciences2013;333:e376. ConfavreuxC , O'ConnorP , ComiG , FreedmanMS , MillerAE , OlssonTP , et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet Neurology2014;13(3):247‐56. KapposL , ComiG , ConfavreuxC , FreedmanMS , MillerAE , OlssonTP , et al. The efficacy and safety of teriflunomide in patients with relapsing MS: results from TOWER, a phase Ⅲ, placebo‐controlled study. Multiple Sclerosis2012;18:50‐1. MillerA , KapposL , ComiG , ConfavreuxC , FreedmanM , OlssonT , et al. Teriflunomide efficacy and safety in patients with relapsing multiple sclerosis: results from tower, a second, pivotal, phase 3 placebo‐controlled study. Neurology. 2013; Vol. 80. MillerAE , MacdonellR , ComiG , FreedmanMS , KapposL , MaurerM , et al. Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study. Journal of Neurology2014;261(9):1781‐8. MosesH , FreedmanM , KapposL , MillerA , OlssonT , WolinskyJ , et al. Pre‐defined subgroups analyses of tower, a placebo‐controlled phase 3 trial of teriflunomide in patients with relapsing multiple sclerosis. Proceedings of the American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). O'ConnorP , LublinF , WolinskyJ , ComiG , ConfavreuxC , FreedmanM , et al. Teriflunomide reduces relapse‐related sequelae, hospitalizations and corticosteroid use: a post‐HOC analysis of the phase 3 TOWER study. Proceedings of The American Academy of Neurology's 65th AAN Annual Meeting; 2013 Mar 16‐23; San Diego (CA). ">Confavreux 2014</a> or in <a href="./references#CD009882-bbs2-0004" title="ComiG , BenzerdjebH , WangL , TruffinetP , O'ConnorP . Effect of teriflunomide on lymphocyte and neutrophil levels in patients with relapsing multiple sclerosis: results from the TEMSO study. Journal of Neurological Science2013;333(Suppl 1):e376. ComiG , O'ConnorP , WolinskyJ , ConfavreuxC , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: safety outcomes with up to 4 years of follow‐Up. Multiple Sclerosis2011;17:S182‐3. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Long‐term safety and efficacy of teriflunomide in patients with relapsing forms of multiple sclerosis in the TEMSO extension trial. Multiple Sclerosis2013;19:225. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Safety and efficacy of teriflunomide for up to 9 years in relapsing forms of multiple sclerosis: Update of the TEMSO extension trial. Neurology2014; Vol. 82, issue Suppl 10:3‐150. FreedmanMS , DelhayJL , BenamorM . Gastrointestinal symptoms infrequently lead to discontinuation of teriflunomide therapy. Multiple Sclerosis2012;18:S13. MillerA , LublinF , O'ConnorP , TaniouC , Dive‐PoulettyC . Impact of relapses with sequelae on disability, health‐related quality of life, and fatigue in a population with relapsing forms of multiple sclerosis using data from TEMSO, a pivotal phase Ⅲ teriflunomide trial. Neurology2012;78:P07.082. MillerA , LublinF , O'ConnorP , WolinskyJ , ComiG , KapposL , et al. Effect of teriflunomide on relapses with sequelae and relapse leading to hospitalization in a population with relapsing forms of multiple sclerosis: results from the TEMSO study. Neurology2012;78:S30.003. MillerA , O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , et al. Efficacy of oral teriflunomide in multiple sclerosis with relapses: cognitive outcomes from a phase Ⅲ trial (TEMSO). Multiple Sclerosis2011;17:S182. MillerAE , O'ConnorP , WolinskyJS , ConfavreuxC , KapposL , OlssonTP , et al. Pre‐specified subgroup analyses of a placebo‐controlled phase Ⅲ trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis. Multiple Sclerosis2012;18(11):1625‐32. O'ConnorP , BriggsA , CaritaP , Bego‐Le‐BagousseG . Impact on health‐related quality of life of teriflunomide treatment by estimating utilities in patients with relapsing multiple sclerosis: results from TEMSO post hoc analysis. Journal of Neurology2012;259:S107. O'ConnorP , BurrellA , WangL , WeiL , CaritaP , ZhangQ . Effect of teriflunomide on longitudinal patterns of relapse and relapse‐related hospitalization in multiple sclerosis. Multiple Sclerosis2011;17:S414. O'ConnorP , LublinF , WolinskyJ , ComiG , KapposL , FreedmanM , et al. Effect of teriflunomide on relapses leading to healthcare resource use: results from the TEMSO study. Multiple Sclerosis2011;17:S95‐6. O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: clinical and MRI data 5 years after initial randomization. Multiple Sclerosis2011;17:S414‐5. O'ConnorP , WolinskyJS , ConfavreuxC , ComiG , KapposL , OlssonTP , et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. New England Journal of Medicine2011;365(14):1293‐303. O'ConnorPW , LublinFD , WolinskyJS , ConfavreuxC , ComiG , FreedmanMS , et al. Teriflunomide reduces relapse‐related neurological sequelae, hospitalizations and steroid use. Journal of Neurology2013;260(10):2472‐80. WolinksyJS , WangL , TruffinetP , NarayanaPA , NelsonF , O'ConnorP . Magnetic resonance imaging as a surrogate for clinical endpoints in multiple sclerosis. Multiple Sclerosis2012;18:470‐1. WolinskyJS , NarayanaPA , NelsonF , DattaS , O'ConnorP , ConfavreuxC , et al. Magnetic resonance imaging outcomes from a phase Ⅲ trial of teriflunomide. Multiple Sclerosis2013;19(10):1310‐9. ">O'Connor 2011</a> because disability progression was confirmed at 3 months of follow‐up. </p> <p><sup>f</sup> High risk of bias existed in <a href="./references#CD009882-bbs2-0004" title="ComiG , BenzerdjebH , WangL , TruffinetP , O'ConnorP . Effect of teriflunomide on lymphocyte and neutrophil levels in patients with relapsing multiple sclerosis: results from the TEMSO study. Journal of Neurological Science2013;333(Suppl 1):e376. ComiG , O'ConnorP , WolinskyJ , ConfavreuxC , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: safety outcomes with up to 4 years of follow‐Up. Multiple Sclerosis2011;17:S182‐3. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Long‐term safety and efficacy of teriflunomide in patients with relapsing forms of multiple sclerosis in the TEMSO extension trial. Multiple Sclerosis2013;19:225. FreedmanM , WolinskyJ , ComiG , KapposL , OlssonT , MillerA , et al. Safety and efficacy of teriflunomide for up to 9 years in relapsing forms of multiple sclerosis: Update of the TEMSO extension trial. Neurology2014; Vol. 82, issue Suppl 10:3‐150. FreedmanMS , DelhayJL , BenamorM . Gastrointestinal symptoms infrequently lead to discontinuation of teriflunomide therapy. Multiple Sclerosis2012;18:S13. MillerA , LublinF , O'ConnorP , TaniouC , Dive‐PoulettyC . Impact of relapses with sequelae on disability, health‐related quality of life, and fatigue in a population with relapsing forms of multiple sclerosis using data from TEMSO, a pivotal phase Ⅲ teriflunomide trial. Neurology2012;78:P07.082. MillerA , LublinF , O'ConnorP , WolinskyJ , ComiG , KapposL , et al. Effect of teriflunomide on relapses with sequelae and relapse leading to hospitalization in a population with relapsing forms of multiple sclerosis: results from the TEMSO study. Neurology2012;78:S30.003. MillerA , O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , et al. Efficacy of oral teriflunomide in multiple sclerosis with relapses: cognitive outcomes from a phase Ⅲ trial (TEMSO). Multiple Sclerosis2011;17:S182. MillerAE , O'ConnorP , WolinskyJS , ConfavreuxC , KapposL , OlssonTP , et al. Pre‐specified subgroup analyses of a placebo‐controlled phase Ⅲ trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis. Multiple Sclerosis2012;18(11):1625‐32. O'ConnorP , BriggsA , CaritaP , Bego‐Le‐BagousseG . Impact on health‐related quality of life of teriflunomide treatment by estimating utilities in patients with relapsing multiple sclerosis: results from TEMSO post hoc analysis. Journal of Neurology2012;259:S107. O'ConnorP , BurrellA , WangL , WeiL , CaritaP , ZhangQ . Effect of teriflunomide on longitudinal patterns of relapse and relapse‐related hospitalization in multiple sclerosis. Multiple Sclerosis2011;17:S414. O'ConnorP , LublinF , WolinskyJ , ComiG , KapposL , FreedmanM , et al. Effect of teriflunomide on relapses leading to healthcare resource use: results from the TEMSO study. Multiple Sclerosis2011;17:S95‐6. O'ConnorP , WolinskyJ , ConfavreuxC , ComiG , KapposL , OlssonT , et al. Extension of a phase Ⅲ trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: clinical and MRI data 5 years after initial randomization. Multiple Sclerosis2011;17:S414‐5. O'ConnorP , WolinskyJS , ConfavreuxC , ComiG , KapposL , OlssonTP , et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. New England Journal of Medicine2011;365(14):1293‐303. O'ConnorPW , LublinFD , WolinskyJS , ConfavreuxC , ComiG , FreedmanMS , et al. Teriflunomide reduces relapse‐related neurological sequelae, hospitalizations and steroid use. Journal of Neurology2013;260(10):2472‐80. WolinksyJS , WangL , TruffinetP , NarayanaPA , NelsonF , O'ConnorP . Magnetic resonance imaging as a surrogate for clinical endpoints in multiple sclerosis. Multiple Sclerosis2012;18:470‐1. WolinskyJS , NarayanaPA , NelsonF , DattaS , O'ConnorP , ConfavreuxC , et al. Magnetic resonance imaging outcomes from a phase Ⅲ trial of teriflunomide. Multiple Sclerosis2013;19(10):1310‐9. ">O'Connor 2011</a> due to an unclear attrition bias and conflicts of interest. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Teriflunomide compared to placebo for multiple sclerosis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009882.pub3/full#CD009882-tbl-0001">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD009882.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD009882-note-0001">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD009882-note-0003">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD009882-note-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="hr#CD009882-note-0002">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ja#CD009882-note-0004">日本語</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009882\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009882\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009882\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009882\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009882\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009882\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009882\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009882\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009882\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009882\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009882\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009882\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009882\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009882\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009882\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009882\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009882\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009882\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=9nGOjNGw&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009882.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD009882.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD009882.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD009882.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009882.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"/> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740724851419"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD009882.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"/> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740724851424"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD009882.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e6cead839f4ca',t:'MTc0MDcyNDg1MS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 